JPWO2020219748A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219748A5 JPWO2020219748A5 JP2021562914A JP2021562914A JPWO2020219748A5 JP WO2020219748 A5 JPWO2020219748 A5 JP WO2020219748A5 JP 2021562914 A JP2021562914 A JP 2021562914A JP 2021562914 A JP2021562914 A JP 2021562914A JP WO2020219748 A5 JPWO2020219748 A5 JP WO2020219748A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- linker
- binding
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims description 604
- 108090001123 antibodies Proteins 0.000 claims description 604
- 230000027455 binding Effects 0.000 claims description 316
- 239000000427 antigen Substances 0.000 claims description 254
- 108091007172 antigens Proteins 0.000 claims description 254
- 102000038129 antigens Human genes 0.000 claims description 254
- 101710009391 KIT Proteins 0.000 claims description 177
- 102100016985 KIT Human genes 0.000 claims description 177
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 104
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 125000000539 amino acid group Chemical group 0.000 claims description 35
- 230000001264 neutralization Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 description 310
- 210000004027 cells Anatomy 0.000 description 170
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 79
- -1 cell growth Proteins 0.000 description 78
- 230000035772 mutation Effects 0.000 description 78
- 235000001014 amino acid Nutrition 0.000 description 71
- 231100000599 cytotoxic agent Toxicity 0.000 description 70
- 239000002619 cytotoxin Substances 0.000 description 68
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 55
- 239000000203 mixture Substances 0.000 description 53
- 239000000562 conjugate Substances 0.000 description 52
- 150000001875 compounds Chemical class 0.000 description 45
- 201000010099 disease Diseases 0.000 description 45
- 101700027111 3SA0 Proteins 0.000 description 43
- 101700067609 ctx Proteins 0.000 description 43
- 239000000611 antibody drug conjugate Substances 0.000 description 42
- 108091008116 antibody drug conjugates Proteins 0.000 description 42
- 238000000034 method Methods 0.000 description 40
- 239000000126 substance Substances 0.000 description 40
- 108010004143 Alpha-amanitin Proteins 0.000 description 39
- 201000011510 cancer Diseases 0.000 description 37
- 125000001424 substituent group Chemical group 0.000 description 37
- 239000003814 drug Substances 0.000 description 36
- 231100000729 Amatoxin Toxicity 0.000 description 35
- 230000000694 effects Effects 0.000 description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 32
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 31
- 231100000765 Toxin Toxicity 0.000 description 31
- 239000003053 toxin Substances 0.000 description 31
- 108020003112 toxins Proteins 0.000 description 31
- 108010016626 Dipeptides Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- 238000006467 substitution reaction Methods 0.000 description 28
- 230000021615 conjugation Effects 0.000 description 27
- 229940079593 drugs Drugs 0.000 description 27
- 238000002560 therapeutic procedure Methods 0.000 description 27
- 210000000130 stem cell Anatomy 0.000 description 26
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 24
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 24
- 108010014709 amatoxin Proteins 0.000 description 23
- 238000004166 bioassay Methods 0.000 description 23
- 230000003750 conditioning Effects 0.000 description 23
- 230000004048 modification Effects 0.000 description 23
- 238000006011 modification reaction Methods 0.000 description 23
- 229940024606 Amino Acids Drugs 0.000 description 22
- 229920002574 CR-39 Polymers 0.000 description 22
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 108060005723 speA Proteins 0.000 description 22
- 102000018358 Immunoglobulins Human genes 0.000 description 21
- 108060003951 Immunoglobulins Proteins 0.000 description 21
- 108010079723 Shiga Toxin Proteins 0.000 description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 21
- 230000001363 autoimmune Effects 0.000 description 20
- 230000001472 cytotoxic Effects 0.000 description 20
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 20
- 150000002019 disulfides Chemical class 0.000 description 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 19
- 210000001772 Blood Platelets Anatomy 0.000 description 18
- 210000000138 Mast Cells Anatomy 0.000 description 18
- 230000003394 haemopoietic Effects 0.000 description 18
- 125000005842 heteroatoms Chemical group 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 125000004429 atoms Chemical group 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 16
- 102000004851 Immunoglobulin G Human genes 0.000 description 15
- 231100000433 cytotoxic Toxicity 0.000 description 15
- 210000001519 tissues Anatomy 0.000 description 15
- 206010003816 Autoimmune disease Diseases 0.000 description 14
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000001419 dependent Effects 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000002823 phage display Methods 0.000 description 13
- 150000003568 thioethers Chemical class 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 125000004450 alkenylene group Chemical group 0.000 description 12
- 235000018417 cysteine Nutrition 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 210000001616 Monocytes Anatomy 0.000 description 11
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 11
- 238000003127 radioimmunoassay Methods 0.000 description 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 108060001251 CD34 Proteins 0.000 description 10
- 102100016492 CD34 Human genes 0.000 description 10
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 10
- 210000003743 Erythrocytes Anatomy 0.000 description 10
- 230000035693 Fab Effects 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 10
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 10
- 125000004419 alkynylene group Chemical group 0.000 description 10
- 239000004007 alpha amanitin Substances 0.000 description 10
- 230000002860 competitive Effects 0.000 description 10
- 125000004404 heteroalkyl group Chemical group 0.000 description 10
- 230000003834 intracellular Effects 0.000 description 10
- 125000004430 oxygen atoms Chemical group O* 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 238000000159 protein binding assay Methods 0.000 description 10
- 230000002829 reduced Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- CIORWBWIBBPXCG-SXZCQOKQSA-N α-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 10
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 9
- 210000001185 Bone Marrow Anatomy 0.000 description 9
- 230000036499 Half live Effects 0.000 description 9
- 210000002540 Macrophages Anatomy 0.000 description 9
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 9
- 210000001744 T-Lymphocytes Anatomy 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 125000004432 carbon atoms Chemical group C* 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 125000004474 heteroalkylene group Chemical group 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 210000003719 B-Lymphocytes Anatomy 0.000 description 8
- 210000004443 Dendritic Cells Anatomy 0.000 description 8
- 229960004679 Doxorubicin Drugs 0.000 description 8
- 102000009490 IgG Receptors Human genes 0.000 description 8
- 108010073807 IgG Receptors Proteins 0.000 description 8
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 8
- 206010024324 Leukaemias Diseases 0.000 description 8
- 102000028664 Microtubules Human genes 0.000 description 8
- 108091022031 Microtubules Proteins 0.000 description 8
- 210000004688 Microtubules Anatomy 0.000 description 8
- 108010017898 Shiga Toxins Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- OFILNAORONITPV-ZUROAWGWSA-N ε-Amanitin Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 OFILNAORONITPV-ZUROAWGWSA-N 0.000 description 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 108010087819 Fc receptors Proteins 0.000 description 7
- 102000009109 Fc receptors Human genes 0.000 description 7
- 210000003714 Granulocytes Anatomy 0.000 description 7
- 210000004698 Lymphocytes Anatomy 0.000 description 7
- 208000008466 Metabolic Disease Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000000440 Neutrophils Anatomy 0.000 description 7
- 210000002997 Osteoclasts Anatomy 0.000 description 7
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 125000000732 arylene group Chemical group 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 102000024070 binding proteins Human genes 0.000 description 7
- 108091007650 binding proteins Proteins 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000004602 germ cell Anatomy 0.000 description 7
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000002025 microglial Effects 0.000 description 7
- 102000005614 monoclonal antibodies Human genes 0.000 description 7
- 108010045030 monoclonal antibodies Proteins 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 230000002148 osteoclast Effects 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 201000010874 syndrome Diseases 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 125000003396 thiol group Chemical class [H]S* 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- BOHCOUQZNDPURZ-MIBTZWEZSA-N Amaninamide Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=CC=C2N1 BOHCOUQZNDPURZ-MIBTZWEZSA-N 0.000 description 6
- 101800001350 Beta-amanitin Proteins 0.000 description 6
- 210000000601 Blood Cells Anatomy 0.000 description 6
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 6
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 6
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 6
- 210000003979 Eosinophils Anatomy 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 101700079793 NR13 Proteins 0.000 description 6
- 108010004258 amaninamide Proteins 0.000 description 6
- 239000004080 beta amanitin Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000000875 corresponding Effects 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 125000005549 heteroarylene group Chemical group 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
- 229920000023 polynucleotide Polymers 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000005017 substituted alkenyl group Chemical group 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 125000004426 substituted alkynyl group Chemical group 0.000 description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- IEQCUEXVAPAFMQ-JAXJKTSHSA-N β-Amanitin Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 IEQCUEXVAPAFMQ-JAXJKTSHSA-N 0.000 description 6
- WVHGJJRMKGDTEC-ZUROAWGWSA-N γ-Amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 WVHGJJRMKGDTEC-ZUROAWGWSA-N 0.000 description 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 5
- 210000003651 Basophils Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 5
- 210000004335 Megakaryocyte Progenitor Cells Anatomy 0.000 description 5
- 210000003593 Megakaryocytes Anatomy 0.000 description 5
- 108010091769 Shiga Toxin 1 Proteins 0.000 description 5
- 108010087748 Shiga toxin subunit A Proteins 0.000 description 5
- 241000607764 Shigella dysenteriae Species 0.000 description 5
- 208000006110 Wiskott-Aldrich Syndrome Diseases 0.000 description 5
- 102000001392 Wiskott-Aldrich Syndrome Protein Human genes 0.000 description 5
- 108010093528 Wiskott-Aldrich Syndrome Protein Proteins 0.000 description 5
- 230000002378 acidificating Effects 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 108010044540 auristatin Proteins 0.000 description 5
- 230000001580 bacterial Effects 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 230000011132 hemopoiesis Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002629 repopulating Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 4
- QCZXQEYEVLCQHL-MIBTZWEZSA-N Amanin Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=CC=C2N1 QCZXQEYEVLCQHL-MIBTZWEZSA-N 0.000 description 4
- 229960005261 Aspartic Acid Drugs 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 4
- 210000000987 Immune System Anatomy 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 4
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 4
- 108060009220 USE1 Proteins 0.000 description 4
- 102100003921 USE1 Human genes 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 125000002993 cycloalkylene group Chemical group 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000004059 degradation Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 229910003460 diamond Inorganic materials 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 150000007857 hydrazones Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 230000002147 killing Effects 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 210000004962 mammalian cells Anatomy 0.000 description 4
- 229960000060 monoclonal antibodies Drugs 0.000 description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VQZYZXLBKBUOHE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)butanoate Chemical compound C=1C=CC=NC=1SSC(C)CC(=O)ON1C(=O)CCC1=O VQZYZXLBKBUOHE-UHFFFAOYSA-N 0.000 description 3
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010071919 Bispecific Antibodies Proteins 0.000 description 3
- 102100013077 CD4 Human genes 0.000 description 3
- 101700022938 CD4 Proteins 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 229920001405 Coding region Polymers 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 229960000975 Daunorubicin Drugs 0.000 description 3
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 3
- 229960001904 EPIRUBICIN Drugs 0.000 description 3
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 3
- 102100015540 FCGR1A Human genes 0.000 description 3
- 101710003440 FCGR1A Proteins 0.000 description 3
- 201000004939 Fanconi anemia Diseases 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- 208000001284 Hemoglobinopathy Diseases 0.000 description 3
- 102100019441 ITGAM Human genes 0.000 description 3
- 101710006572 ITGAM Proteins 0.000 description 3
- 229960000908 Idarubicin Drugs 0.000 description 3
- 102000004854 Immunoglobulin M Human genes 0.000 description 3
- 108090001096 Immunoglobulin M Proteins 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 3
- 102000035443 Peptidases Human genes 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 3
- 229960005190 Phenylalanine Drugs 0.000 description 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102100018787 RPS19 Human genes 0.000 description 3
- 101710007829 RPS19 Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- 101700023970 SLT2 Proteins 0.000 description 3
- 108010084592 Saporins Proteins 0.000 description 3
- 208000002491 Severe Combined Immunodeficiency Diseases 0.000 description 3
- 108010090763 Shiga Toxin 2 Proteins 0.000 description 3
- 101700057439 TOXA Proteins 0.000 description 3
- 208000002903 Thalassemia Diseases 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 230000000735 allogeneic Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000002838 bio layer interferometry Methods 0.000 description 3
- 201000002393 blood protein disease Diseases 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- XZMCDFZZKTWFGF-UHFFFAOYSA-N carbodiimide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 230000002255 enzymatic Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 201000003923 hemoglobinopathy Diseases 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 230000000155 isotopic Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 230000002934 lysing Effects 0.000 description 3
- 230000003211 malignant Effects 0.000 description 3
- 201000011442 metachromatic leukodystrophy Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 230000000051 modifying Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 3
- 230000000269 nucleophilic Effects 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 235000014393 valine Nutrition 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 2
- 101700023105 3L21 Proteins 0.000 description 2
- 101700012833 3S11 Proteins 0.000 description 2
- 102000009914 Adenosine deaminases Human genes 0.000 description 2
- 108091022188 Adenosine deaminases Proteins 0.000 description 2
- 229940009456 Adriamycin Drugs 0.000 description 2
- 206010002967 Aplastic anaemia Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101710039869 BC_0920 Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 206010061590 Blood disease Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 101700034624 CASP3 Proteins 0.000 description 2
- 102100003814 CASP3 Human genes 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- 102100006435 CSF3 Human genes 0.000 description 2
- 101700083500 CTX1 Proteins 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 108010084740 Daclizumab Proteins 0.000 description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 2
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 101710044640 FCGR2A Proteins 0.000 description 2
- 101710044641 FCGR2B Proteins 0.000 description 2
- 102100015544 FCGR2C Human genes 0.000 description 2
- 101710044642 FCGR2C Proteins 0.000 description 2
- 102100015541 FCGR3A Human genes 0.000 description 2
- 101710044656 FCGR3A Proteins 0.000 description 2
- 101710044657 FCGR3B Proteins 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 206010018048 Gaucher's disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229960002989 Glutamic Acid Drugs 0.000 description 2
- 208000007345 Glycogen Storage Disease Diseases 0.000 description 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N Homoharringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 101700052785 Ly6a Proteins 0.000 description 2
- 206010049646 Lymphohistiocytosis Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 210000000479 Mitotic Spindle Apparatus Anatomy 0.000 description 2
- 208000002678 Mucopolysaccharidosis Diseases 0.000 description 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101700051754 NA11 Proteins 0.000 description 2
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 2
- 229950010159 Nemorubicin Drugs 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 208000002865 Osteopetrosis Diseases 0.000 description 2
- 206010025310 Other lymphomas Diseases 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960002340 Pentostatin Drugs 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 231100000654 Protein toxin Toxicity 0.000 description 2
- 101700068919 SCAL1 Proteins 0.000 description 2
- 101700052317 SLIT1 Proteins 0.000 description 2
- 101700008007 STX1A Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000009642 Severe combined immunodeficiency due to adenosine deaminase deficiency Diseases 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- 208000010346 Sphingolipidosis Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 108091008153 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100008333 THY1 Human genes 0.000 description 2
- 101700026084 THY1 Proteins 0.000 description 2
- 101700055586 TXT1 Proteins 0.000 description 2
- 206010043391 Thalassaemia beta Diseases 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 101700039798 VKT1 Proteins 0.000 description 2
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229930013930 alkaloids Natural products 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000006143 cell culture media Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 235000013477 citrulline Nutrition 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 101700041767 ctxA Proteins 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000006352 cycloaddition reaction Methods 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000002327 eosinophilic Effects 0.000 description 2
- 229930013356 epothilones Natural products 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 230000003899 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 229940020899 hematological Enzymes Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000002132 lysosomal Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 230000003458 metachromatic Effects 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 201000009251 multiple myeloma Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000005445 natural product Substances 0.000 description 2
- 229930014626 natural products Natural products 0.000 description 2
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 2
- 230000003448 neutrophilic Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 2
- 150000002891 organic anions Chemical class 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 101710031800 phtx Proteins 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 230000001743 silencing Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 201000001307 sphingolipidosis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 125000004434 sulfur atoms Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 201000009594 systemic scleroderma Diseases 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- HFQKBOPMAOTAIR-TZSVBWBLSA-N α-D-galactosyl-(1->4)-β-D-galactosyl-(1->4)-β-D-glucosylceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 HFQKBOPMAOTAIR-TZSVBWBLSA-N 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N (1S,2Z,4E,8E,12E)-5,9,13-trimethyl-2-propan-2-ylcyclotetradeca-2,4,8,12-tetraen-1-ol Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- GCPUVEMWOWMALU-HZMBPMFUSA-N (1S,3S)-1-hydroxy-8-methoxy-3-methyl-1,2,3,4-tetrahydrobenzo[a]anthracene-7,12-dione Chemical compound C1[C@H](C)C[C@H](O)C2=C1C=CC1=C2C(=O)C(C=CC=C2OC)=C2C1=O GCPUVEMWOWMALU-HZMBPMFUSA-N 0.000 description 1
- UFIVODCEJLHUTQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(1-phenylethyldisulfanyl)-2H-pyridine-1-carboxylate Chemical compound C=1C=CC=CC=1C(C)SSC1C=CC=CN1C(=O)ON1C(=O)CCC1=O UFIVODCEJLHUTQ-UHFFFAOYSA-N 0.000 description 1
- FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2E,4E,6E)-7-[(1R,5R,6S)-3-[[(2E,4E)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2E,4E,6Z,8E,10E,14E)-13-hydroxy-N-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- NOENHWMKHNSHGX-FAZSUBJTSA-N (2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@H](CCC1)C(=O)NC(C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-FAZSUBJTSA-N 0.000 description 1
- RCGXNDQKCXNWLO-YUHQQKLOSA-N (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@@H]1C)C(C)C)=C\C)C(C)C)[C@@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-YUHQQKLOSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2S)-2-[(3S,6S)-6-[2-[(1R,2R,4aS,8aS)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical group CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2S)-2-[[4-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2S)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N (2S)-2-amino-3-(5-hydroxypyridin-2-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- QXRNAOYBCYVZCD-BQBZGAKWSA-N (2S)-6-amino-2-[[(2S)-2-aminopropanoyl]amino]hexanoic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN QXRNAOYBCYVZCD-BQBZGAKWSA-N 0.000 description 1
- UUSZLLQJYRSZIS-GHRWIAHFSA-N (2S)-N-[(2R)-1-[[(3S,6R,8S,12S,13R,16R,17S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4- Chemical compound CN([C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)C(CC=2C=CC(OC)=CC=2)C(=O)O[C@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-GHRWIAHFSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- HWMMBHOXHRVLCU-QOUANJGESA-N (2S,4S,5S)-4-[(1E,3E,5E)-7-[(2R,6R)-6-[(2R,3S,4aR,12bS)-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxo-2,4-dihydrobenzo[a]anthracen-9-yl]-2-methyloxan-3-yl]oxy-7-oxohepta-1,3,5-trienyl]-2,5-dimethyl-1,3-dioxolane-2-carboxylic acid Chemical compound C[C@@H]1O[C@](C)(C(O)=O)O[C@H]1\C=C\C=C\C=C\C(=O)OC1[C@@H](C)O[C@@H](C=2C(=C3C(=O)C4=C([C@]5(C(=O)[C@H](O)[C@@](C)(O)C[C@@]5(O)C=C4)O)C(=O)C3=CC=2)O)CC1 HWMMBHOXHRVLCU-QOUANJGESA-N 0.000 description 1
- JSUANXYBLFQZGI-HDFWGNLJSA-N (2Z,4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-5-methyl-2-(6-oxocyclohexa-2,4-dien-1-ylidene)-1,3-oxazolidine-4-carboxamide Chemical compound O=C([C@H]1NC(/O[C@@H]1C)=C\1C(C=CC=C/1)=O)N(CCCNC(=O)C=1C(=C(O)C=CC=1)O)CCCCNC(=O)C1=CC=CC(O)=C1O JSUANXYBLFQZGI-HDFWGNLJSA-N 0.000 description 1
- UYRMXZIBPZVBNO-QPJJXVBHSA-N (4E)-4-[amino-(hydroxyamino)methylidene]-2-hydroxycyclohexa-2,5-dien-1-one Chemical compound ONC(/N)=C1\C=CC(=O)C(O)=C1 UYRMXZIBPZVBNO-QPJJXVBHSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'R)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- SLURUCSFDHKXFR-WWMWMSKMSA-N (7S,9S)-7-[[(1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyl-3,4,4a,6,7,9,9a,10a-octahydro-1H-pyrano[1,2][1,3]oxazolo[3,4-b][1,4]oxazin-3-yl]oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O=C1C2=CC=CC(OC)=C2C(=O)C(C(O)=C23)=C1C(O)=C3C[C@@](O)(C(=O)CO)C[C@@H]2O[C@H]1C[C@@H]2N3CCO[C@H](OC)[C@H]3O[C@@H]2[C@H](C)O1 SLURUCSFDHKXFR-WWMWMSKMSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (E)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2R,3S,4R,6S)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- DEPDDPLQZYCHOH-UHFFFAOYSA-N 1H-imidazol-2-amine Chemical compound NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 1
- NKUWPVYXJNSCQL-UHFFFAOYSA-L 2,2-bis(aminomethyl)propane-1,3-diol;cyclobutane-1,1-dicarboxylate;platinum(2+) Chemical compound [Pt+2].NCC(CN)(CO)CO.[O-]C(=O)C1(C([O-])=O)CCC1 NKUWPVYXJNSCQL-UHFFFAOYSA-L 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N 2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- JUNILAWHCDMYAE-HGJPKUQDSA-N 2-[(3E,7E,9E,17E)-14,19-dihydroxy-3,5,9,11,13,15,17-heptamethyl-12-oxononadeca-3,7,9,17-tetraenyl]-2,3-dihydropyran-6-one Chemical compound OC/C=C(C)/CC(C)C(O)C(C)C(=O)C(C)/C=C(\C)/C=C/CC(C)\C=C(/C)CCC1CC=CC(=O)O1 JUNILAWHCDMYAE-HGJPKUQDSA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3H-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- BMUXBWLKTHLRQC-UHFFFAOYSA-N 2-azanylethanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O BMUXBWLKTHLRQC-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 229920002652 28S ribosomal RNA Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 1
- XSCKKKKCZBNKQZ-UHFFFAOYSA-N 3-chloroquinoxaline-2-sulfonamide Chemical compound C1=CC=C2N=C(Cl)C(S(=O)(=O)N)=NC2=C1 XSCKKKKCZBNKQZ-UHFFFAOYSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- IBLSXJXHUXUHIM-UHFFFAOYSA-N 4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexane-1-carboxamide Chemical compound C1CC(C(=O)N)CCC1CN1C(=O)C=CC1=O IBLSXJXHUXUHIM-UHFFFAOYSA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N 4-acetamido-N-(2-aminophenyl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-ARQDHWQXSA-N 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(E)-5-[(1S)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N 5508-58-7 Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-(2,5-dioxopyrrol-1-yl)hexanoic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- MSNVESLISHTIRS-UHFFFAOYSA-N 9H-pyrrolo[2,1-c][1,4]benzodiazepine Chemical class N1=C2C=CC=CC2=CN2CC=CC2=C1 MSNVESLISHTIRS-UHFFFAOYSA-N 0.000 description 1
- 101710026914 AAG Proteins 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229960000583 Acetic Acid Drugs 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 241000948470 Amanita phalloides Species 0.000 description 1
- CIORWBWIBBPXCG-JZTFPUPKSA-N Amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 description 1
- 229950010949 Ambamustine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N Aminothiazole Chemical group NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- 229950003476 Aminothiazole Drugs 0.000 description 1
- 210000004381 Amniotic Fluid Anatomy 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N Anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-QPSYGYIJSA-N Andrographolide Natural products C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1\[C@H](O)COC1=O BOJKULTULYSRAS-QPSYGYIJSA-N 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 229940046836 Anti-estrogens Drugs 0.000 description 1
- 229940019746 Antifibrinolytic amino acids Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- ZCISRIHHEXSWIR-UHFFFAOYSA-L Antrin Chemical compound [Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 ZCISRIHHEXSWIR-UHFFFAOYSA-L 0.000 description 1
- IOASYARYEYRREA-LQAJYKIKSA-N Aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 229920002395 Aptamer Polymers 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229950006933 Atrimustine Drugs 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N Axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N Axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N Axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N Azasetron Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 229950005951 Azasetron Drugs 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N Azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 229950002370 BISNAFIDE Drugs 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N Balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 Batimastat Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N Betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- QGJZLNKBHJESQX-CASBDLHJSA-N Betulinic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2 QGJZLNKBHJESQX-CASBDLHJSA-N 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
- 229950009494 Bropirimine Drugs 0.000 description 1
- 229950002361 Budotitane Drugs 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N Buthionine sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 102100019453 CD7 Human genes 0.000 description 1
- 101700063101 CD7 Proteins 0.000 description 1
- 102100008191 CD8A Human genes 0.000 description 1
- 101700054655 CD8A Proteins 0.000 description 1
- 229950007258 CRISNATOL Drugs 0.000 description 1
- 101700017076 CTX2 Proteins 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N Carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 210000004252 Chorionic Villi Anatomy 0.000 description 1
- 229950000634 Cicaprost Drugs 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 Clomifene Drugs 0.000 description 1
- 229940107775 Clomiphene Drugs 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N Conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- TYVRUMCYJWCOOO-TVEJMLEISA-N Cypemycin Chemical compound C1S\C=C/NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(C(C)CC)NC(=O)C(=C\C)/NC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(\NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)N(C)C)=C/C)=C/C)=C/C)C(C)C)CC1=CC=CC=C1 TYVRUMCYJWCOOO-TVEJMLEISA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- 229960000605 Dexrazoxane Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229950005878 Dexverapamil Drugs 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical group OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- YWHLKYXPLRWGSE-UHFFFAOYSA-N Dimethyl trisulfide Chemical group CSSSC YWHLKYXPLRWGSE-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
- 229960002918 Doxorubicin Hydrochloride Drugs 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229950004203 Droloxifene Drugs 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 208000001848 Dysentery Diseases 0.000 description 1
- 229950011461 EDELFOSINE Drugs 0.000 description 1
- 229950010033 Ebselen Drugs 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselenum Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 229950005678 Ecomustine Drugs 0.000 description 1
- MHFRGQHAERHWKZ-UHFFFAOYSA-N Edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
- 229960001484 Edetic Acid Drugs 0.000 description 1
- 108010070635 Edrecolomab Proteins 0.000 description 1
- 229940087477 Ellence Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- QXRSDHAAWVKZLJ-TYFQHMATSA-N Epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@@]2(C)CCC[C@@H]([C@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-TYFQHMATSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 229950009537 Epristeride Drugs 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 229920001272 Exogenous DNA Polymers 0.000 description 1
- 231100000776 Exotoxin Toxicity 0.000 description 1
- 229950011548 FADROZOLE Drugs 0.000 description 1
- 229950005096 FAZARABINE Drugs 0.000 description 1
- 101710003435 FCGRT Proteins 0.000 description 1
- 102100014838 FCGRT Human genes 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 229950010404 FOSTRIECIN Drugs 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- 108091006004 Fc-tagged proteins Proteins 0.000 description 1
- 101700050236 Fcgr4 Proteins 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229950004217 Forfenimex Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229950004410 Galocitabine Drugs 0.000 description 1
- 108010089239 Gelonium multiflorum GEL protein Proteins 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108020005128 Glycosidases Proteins 0.000 description 1
- 210000002288 Golgi Apparatus Anatomy 0.000 description 1
- 210000002397 Granulocyte Precursor Cells Anatomy 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 210000000777 Hematopoietic System Anatomy 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N Hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 1
- 229950006905 ILMOFOSINE Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229940099279 Idamycin Drugs 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 229950002248 Idoxifene Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N Ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 108010027440 Immunoconjugates Proteins 0.000 description 1
- 102000018748 Immunoconjugates Human genes 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N Iobenguane Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- 229950010984 Irsogladine Drugs 0.000 description 1
- 229940045996 Isethionic Acid Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 101000188492 KIT Proteins 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- DSLZVSRJTYRBFB-ZNIBRBMXSA-N L-mannaric acid Chemical compound OC(=O)[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-ZNIBRBMXSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 101700046135 LEC2 Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700028593 LECH Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 229950005634 LOXORIBINE Drugs 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- ATHLLZUXVPNPAW-UHFFFAOYSA-N Lamellarin D Chemical compound C1=C(O)C(OC)=CC(C2=C3C4=CC(OC)=C(O)C=C4C=CN3C3=C2C=2C=C(OC)C(O)=CC=2OC3=O)=C1 ATHLLZUXVPNPAW-UHFFFAOYSA-N 0.000 description 1
- 210000001821 Langerhans Cells Anatomy 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229920001320 Leader sequence (mRNA) Polymers 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 206010068202 Leukodystrophy Diseases 0.000 description 1
- 206010024381 Leukodystrophy Diseases 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229950000909 Lometrexol Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 210000003712 Lysosomes Anatomy 0.000 description 1
- 101700067074 MAPK Proteins 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 229940041033 Macrolides Drugs 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960003951 Masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 102000001544 Maspin Human genes 0.000 description 1
- 241001441512 Maytenus serrata Species 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229950008541 Mirimostim Drugs 0.000 description 1
- 229960003539 Mitoguazone Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229950001745 Mitonafide Drugs 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N Motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- 206010028093 Mucopolysaccharidosis Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N,3,4-trihydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-Butylamine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N N-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 Chemical compound N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- FTJHKZQHQDKPFJ-UHFFFAOYSA-M NC(=O)NNC([O-])=O Chemical compound NC(=O)NNC([O-])=O FTJHKZQHQDKPFJ-UHFFFAOYSA-M 0.000 description 1
- 102100007544 NCAM1 Human genes 0.000 description 1
- 101700077124 NCAM1 Proteins 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- GYAVMUDJCHAASE-UHFFFAOYSA-M Nedaplatin Chemical compound [H][N]([H])([H])[Pt]1([N]([H])([H])[H])OCC(=O)O1 GYAVMUDJCHAASE-UHFFFAOYSA-M 0.000 description 1
- 229950007221 Nedaplatin Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- 229950008017 Ormaplatin Drugs 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N Palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N Palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N Panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- RDIMTXDFGHNINN-BRWVUGGUSA-N Panaxytriol Natural products CCCCCCC[C@@H](O)[C@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-BRWVUGGUSA-N 0.000 description 1
- 210000001819 Pancreatic Juice Anatomy 0.000 description 1
- 229940055726 Pantothenic Acid Drugs 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N Perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Natural products OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229940095574 Propionic acid Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108010077397 Pseudomonas aeruginosa toxA protein Proteins 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 108060007057 RIPPLY Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 108060007040 Rilpl Proteins 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 230000036141 SERUM STABILITY Effects 0.000 description 1
- 101700001720 SIX2 Proteins 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 210000000717 Sertoli cell Anatomy 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 229940007046 Shigella dysenteriae Drugs 0.000 description 1
- 241000446766 Shigella dysenteriae 1 Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229950004225 Sonermin Drugs 0.000 description 1
- 229950004796 Sparfosic Acid Drugs 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 229950006050 Spiromustine Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229960004274 Stearic acid Drugs 0.000 description 1
- 229960005137 Succinic Acid Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N Sulfanilic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- 102000002663 Surrogate Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010018324 Surrogate Immunoglobulin Light Chains Proteins 0.000 description 1
- 101700024472 TXAA2 Proteins 0.000 description 1
- 229940033123 Tannic Acid Drugs 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N Tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 229920000401 Three prime untranslated region Polymers 0.000 description 1
- 229950002376 Tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- TVPNFKRGOFJQOO-UHFFFAOYSA-N Topsentin B1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- 229950003873 Triciribine Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 240000004652 Vaccinium ovalifolium Species 0.000 description 1
- BNJNAEJASPUJTO-DUOHOMBCSA-N Vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 1
- 229950001694 Vadastuximab talirine Drugs 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 229960002110 Vincristine Sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229950003017 Zeniplatin Drugs 0.000 description 1
- ZMQRJWIYMXZORG-DSWNLJKISA-N [(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2R)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-DSWNLJKISA-N 0.000 description 1
- ZZWKZQDOSJAGGF-BVTJJHQYSA-N [(1S,2Z,7S,10Z,12R,13R,15S)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C/C(=O)O[C@@H](C)CCC\C=C/[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-BVTJJHQYSA-N 0.000 description 1
- NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2R,3S,4R,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3S)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
- NBLHOLNNKJBEDC-XOGQCRKLSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-5-[[(2S,3R)-1-[2-[4-[4-[4-(diaminomethylideneamino)butylcarbamoyl]-1,3-th Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCCN=C(N)N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C NBLHOLNNKJBEDC-XOGQCRKLSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8R,9S,13S,14S,17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000001270 agonistic Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000007854 aminals Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- OVMSOCFBDVBLFW-VHLOTGQHSA-N baccatin III derivatives Chemical class [H][C@]12[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](O)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 1
- 238000002819 bacterial display Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000000721 bacterilogical Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- JAPMJSVZDUYFKL-UHFFFAOYSA-N bicyclo[3.1.0]hexane Chemical compound C1CCC2CC21 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960004649 calcipotriene Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 229930016259 castanospermine Natural products 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 101700067277 chxA Proteins 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 201000002403 combined T cell and B cell immunodeficiency Diseases 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 230000001085 cytostatic Effects 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000000779 depleting Effects 0.000 description 1
- 230000027832 depurination Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940042396 direct acting antivirals Thiosemicarbazones Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229950006877 dodecanoic acid Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229930013349 epothilone B Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 230000001586 eradicative Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HWMJAPURZLIYQA-JPFZJSEDSA-L ethanolate;(Z)-3-oxo-1-phenylbut-1-en-1-olate;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)\C=C(/[O-])C1=CC=CC=C1.CC(=O)\C=C(/[O-])C1=CC=CC=C1 HWMJAPURZLIYQA-JPFZJSEDSA-L 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000000198 fluorescence anisotropy Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 210000004475 gamma-delta T lymphocyte Anatomy 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 201000002138 hematopoietic system disease Diseases 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 150000002374 hemiaminals Chemical class 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 230000003284 homeostatic Effects 0.000 description 1
- 102000020493 human KIT protein Human genes 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-O hydrazinium(1+) Chemical compound [NH3+]N OAKJQQAXSVQMHS-UHFFFAOYSA-O 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 230000000521 hyperimmunizing Effects 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229960003795 iobenguane (123I) Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 238000000111 isothermal titration calorimetry Methods 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000001868 lysosomic Effects 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 230000001002 morphogenetic Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N pantothenic acid Natural products OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 101710043201 phtx2 Proteins 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Chemical group 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 101710024887 rl Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000003530 single readout Methods 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 101710044770 sll1951 Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 101700045897 spk-1 Proteins 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- OJXASOYYODXRPT-UHFFFAOYSA-N sulfamoylurea Chemical group NC(=O)NS(N)(=O)=O OJXASOYYODXRPT-UHFFFAOYSA-N 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003555 thioacetals Chemical class 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- 150000003584 thiosemicarbazones Chemical class 0.000 description 1
- 230000002446 thrombocytic Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 108091015697 vadastuximab talirine Proteins 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Î-Lactam Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Description
ãã®åºé¡ã¯2019幎4æ24æ¥ã«åºé¡ãããç±³åœä»®åºé¡ç¬¬62/838,255å·ããã³2019幎5æ1æ¥ã«åºé¡ãããç±³åœä»®åºé¡ç¬¬62/841,739å·ã«å¯Ÿããåªå
æš©ã䞻匵ãããåè¿°ã®åã
ã®åªå
åºé¡ã®å
容ã¯åç
§ã«ããããã«çµã¿èŸŒãŸããã
åé
æ¬é瀺ã¯ãæCD117æäœãæäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCsïŒãããã³ãããã®æåçµåæ§æçããªãã³ã«ãé è¡çŽ°èãäŸãã°ãé è¡å¹¹çŽ°èãªã©ã®ãããªãã®ã«ãã£ãŠçºçŸãããæåã«çµåããèœåãããæäœããŸãã¯æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCïŒã®æäžã«ãã£ãŠãæ§ã ãªç ç¶ãäŸãã°ãè¡æ¶²çŸæ£ã代è¬é害ãçãããã³èªå·±å ç«çŸæ£ããªã©ã®ã»ãã«ãããããã®ãããªãã®ã«çœ¹æ£ããŠããæ£è ãåŠçœ®ããæ¹æ³ã«é¢ããã
æ¬é瀺ã¯ãæCD117æäœãæäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCsïŒãããã³ãããã®æåçµåæ§æçããªãã³ã«ãé è¡çŽ°èãäŸãã°ãé è¡å¹¹çŽ°èãªã©ã®ãããªãã®ã«ãã£ãŠçºçŸãããæåã«çµåããèœåãããæäœããŸãã¯æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCïŒã®æäžã«ãã£ãŠãæ§ã ãªç ç¶ãäŸãã°ãè¡æ¶²çŸæ£ã代è¬é害ãçãããã³èªå·±å ç«çŸæ£ããªã©ã®ã»ãã«ãããããã®ãããªãã®ã«çœ¹æ£ããŠããæ£è ãåŠçœ®ããæ¹æ³ã«é¢ããã
ã·ãŒã¯ãšã³ã¹ãªã¹ãã£ã³ã°
ãã®åºé¡ã«ã¯ãé»åçã«å¯èªãªåœ¢åŒã§ããã«æ·»ããŠæåºãããã·ãŒã¯ãšã³ã¹ãªã¹ãã£ã³ã°ãå«ãŸãããã·ãŒã¯ãšã³ã¹ãªã¹ãã£ã³ã°ãã¡ã€ã«ã¯2020幎4æ20æ¥ã«äœãåºãããM103034_2160WO_SL.txtãšåä»ããããããã³ãã®ãµã€ãºã¯76kbã§ãããsequencelisting.tetãã¡ã€ã«ã«ãããã·ãŒã¯ãšã³ã¹ãªã¹ãã£ã³ã°ã®å å®¹å šäœã¯åç §ã«ããããã«çµã¿èŸŒãŸããã
ããã¯ã°ã©ãŠã³ã
ãã®åºé¡ã«ã¯ãé»åçã«å¯èªãªåœ¢åŒã§ããã«æ·»ããŠæåºãããã·ãŒã¯ãšã³ã¹ãªã¹ãã£ã³ã°ãå«ãŸãããã·ãŒã¯ãšã³ã¹ãªã¹ãã£ã³ã°ãã¡ã€ã«ã¯2020幎4æ20æ¥ã«äœãåºãããM103034_2160WO_SL.txtãšåä»ããããããã³ãã®ãµã€ãºã¯76kbã§ãããsequencelisting.tetãã¡ã€ã«ã«ãããã·ãŒã¯ãšã³ã¹ãªã¹ãã£ã³ã°ã®å å®¹å šäœã¯åç §ã«ããããã«çµã¿èŸŒãŸããã
ããã¯ã°ã©ãŠã³ã
å»åŠæè¡ã§ã®é²æ©ã«ãããããããé è¡ç³»ã®ç
ç¶ãäŸãã°ããšããããç¹å®ã®è¡çã®çŸæ£ã代è¬é害ãçãããã³èªå·±å
ç«ç¶æ
ãªã©ã®ãããªãã®ãåŠçœ®ããããã®éèŠãæ®ã£ãŠãããé è¡å¹¹çŽ°èã«ã¯å€§ããªæ²»çäžã®å¯èœæ§ãããããã¯ãªããã¯ã§ã®ãããã®äœ¿çšã劚ããŠããå¶éã¯å®¿äž»ã§ã®é è¡å¹¹çŽ°è移æ€ã®ç¢ºå®ãªççã«é¢é£ããå°é£æ§ã§ãã£ãã
ç®äžãç¹å®ã®å
å æ§å¹¹çŽ°èãæšçãšããçµæç©ã«ã€ããŠã®å¿
èŠæ§ãååšããããã¯å€å æ§é è¡å¹¹çŽ°è移æ€çã®ççãä¿é²ããããã«ã³ã³ãã£ã·ã§ãã³ã°å€ãšããŠäœ¿çšããããšãã§ãããããã®çŽ°èã®å€èœæ§ããã³é è¡æ©èœã¯ç§»æ€åŸã®æ£è
ã«ãããŠä¿åãããããã«ãªãã
CD117ïŒc-ãããïŒc-kitïŒãŸãã¯å¹¹çŽ°èå åå容äœïŒStem Cell Factor ReceptorïŒïŒSCRFïŒãšãåŒã°ããïŒã¯ããªã¬ã³ã幹现èå åïŒSCFïŒã«çµåããåäžã®è貫éã®ãå容äœããã·ã³ãããŒãŒã§ãããSCFã¯cKITã®ãã¢äºéäœåãèªå°ããããã¯ãã®ããã·ã³ãããŒãŒæŽ»æ§ã掻æ§åããããã³PI3-AKTããã³MAPKçµè·¯ã®äž¡æ¹ãéããŠä¿¡å·äŒéããïŒKindblomïŒãã³ããã«ã ïŒet al., Am J. Path.ïŒã¢ã¡ãªã«ã³ã»ãžã£ãŒãã«ã»ãªãã»ããœããžãŒïŒ1998 152(5):1259ïŒã
CD117ã¯åæã«çéºäŒåãšããŠçºèŠãããããã³è
«çåŠã®åéã«ãããŠç 究ãããïŒäŸãã°ãStankovïŒã¹ã¿ã³ã³ãïŒet al. (2014) Curr Pharm Des.ïŒã«ã¬ã³ãã»ãã¡ãŒãã¹ãŒãã£ã«ã«ã»ãã¶ã€ã³ïŒ20(17):2849-80åç
§ïŒãCD117ã«åããããæäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒKTN0158ïŒã¯é£æ²»æ§æ¶å管é質è
«çïŒGISTïŒã®æ²»çã®ããã«ç®äžèª¿æ»äžã§ããïŒäŸã¯ããKTN0158, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cellsïŒKTN0158ãããåæKITã¢ãã¯ããŒãã«æäœã¯æ£åžžããã³æªæ§ã®ã€ãè¥æºçŽ°èã®äž¡æ¹ã«å¯ŸããŠçç©åŠç掻æ§ãè«èšŒããïŒãLondonïŒãã³ãã³ïŒet al. (2016) Clin Cancer ResïŒã¯ãªãã«ã«ã»ãã£ã³ãµãŒã»ãªãµãŒãïŒDOIïŒããžã¿ã«ãªããžã§ã¯ãèå¥åïŒ: 10.1158/1078-0432.CCR-16-2152ïŒã
CD117ã¯é è¡å¹¹çŽ°èïŒHSCsïŒã§é«åºŠã«çºçŸããããã®çºçŸãã¿ãŒã³ã«ããCD117ã¯å¹
åºãçŸæ£ã«ãããã³ã³ãã£ã·ã§ãã³ã°ã®ããã®æœåšçãªæšçã«ãªããããããªããã移æ€ãäŸãã°ã骚é«ç§»æ€ãªã©ã®ãããªãã®ã®ããã«æ£è
ãã³ã³ãã£ã·ã§ãã³ã°ããã®ã«å¹æçã§ããæCD117ããŒã¹çæ³ã«ã€ããŠã®å¿
èŠæ§ãæ®ã£ãŠããã
ãµããªãŒ
ãµããªãŒ
ããã«é瀺ããã®ã¯ãããCD117ïŒc-kitãšããŠãç¥ãããïŒã«ç¹ç°çã«çµåããæäœãããã³ãã®æåçµåéšåããªãã³ã«åèšæäœã䜿çšããçµæç©ããã³æ¹æ³ã§ãããç¹ã«ãããã«èšèŒããæäœããã³æçã¯æCD117æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCsïŒã«ãããŠäœ¿çšããããšãã§ããã
äžå®æœæ
æ§ã§ã¯ãæ¬é瀺ã¯ãé è¡ç³»ã®æ§ã
ãªé害ã代è¬é害ãã¬ã³ãããã³èªå·±å
ç«çŸæ£ãã»ãã«ããããããããã®çŽæ¥åŠçœ®ã®ããã®çµæç©ããã³æ¹æ³ãæäŸãããæ¬é瀺ã¯ããã«ãé è¡å¹¹çŽ°è移æ€çã®ççãä¿é²ããããã«ãé è¡å¹¹çŽ°è移æ€çæ³ãåããã®ã«å
ç«ã¡ããã€ã·ã§ã³ããäŸãã°ããããã€ã·ã§ã³ããªã©ã®ãããªãã®ã®ã³ã³ãã£ã·ã§ãã³ã°ã®ããã®æ¹æ³ãç¹é·ãšããããã€ã·ã§ã³ãã¯äžä»¥äžã®è¡æ¶²é害ãäŸãã°ãç°åžžãã¢ã°ããã³çãŸãã¯ä»ã®é è¡ç
æ
ïŒhematopoietic pathologyïŒãªã©ã®ãããªãã®ãæ£ããã®ã§ããåŸãããã³åŸã£ãŠé è¡å¹¹çŽ°è移æ€ã®å¿
èŠããããããã«èšèŒããããã«ãé è¡å¹¹çŽ°èã¯é è¡ç³»çµ±ã«ãããŠæ°å€ã现èã¿ã€ãã«ååããèœåããããããã³ãã€ã·ã§ã³ãã«ãããŠæ¬ æããŠãã现èã¿ã€ããéåãŸãã¯åå¢æ®ãããããã«ãã€ã·ã§ã³ãã«æœãããšãã§ãããæ¬é瀺ã¯é è¡çŽ°èãäŸãã°ãCD117ïŒäŸãã°ãGNNK+CD117ãå«ãïŒãªã©ã®ãããªãã®ã«ãã£ãŠçºçŸãããã¿ã³ãã¯è³ªã«çµåããèœåãããæäœããã³æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCsïŒãçšããŠãCD117ãçºçŸãã现èãäŸãã°ãç°åžžãªè¡æ¶²çŽ°èãã¬ã³çŽ°èããŸãã¯èªå·±å
ç«çŽ°èãªã©ã®ãããªãã®ã®éå£ãéžæçã«æžå°ãããããšã«ãã£ãŠãïŒiïŒçŸæ£ãäŸãã°ãããã«èšèŒããè¡æ¶²é害ã代è¬çŸæ£ãã¬ã³ããŸãã¯èªå·±å
ç«çŸæ£ãã»ãã«ããããããã®ãããªãã®ãçŽæ¥åŠçœ®ããããã³/ãŸãã¯ïŒiiïŒãã€ã·ã§ã³ãå
ã®å
å æ§é è¡å¹¹çŽ°èã®éå£ãæžå°ãããããã«ããã€ã·ã§ã³ããåŠçœ®ããæ¹æ³ã«ç¹è²ããããåè
ã®æŽ»æ§ã¯é è¡ç³»çµ±ã®çŽ°èã«é¢é£ããåºç¯å²ã®é害ã®çŽæ¥åŠçœ®ãå¯èœã«ããããã¯CD117ãã¬ã³æ§çŽ°èãäŸãã°ãçœè¡ç
现èãªã©ã®ãããªãã®ãèªå·±å
ç«ãªã³ãçãäŸãã°ãèªå·±æåãšäº€å·®åå¿ããT现èå容äœãçºçŸããT现èãã»ãã«ããããã现èã¿ã€ããªã©ã®ãããªãã®ã«ãã£ãŠçºçŸããåŸãããã§ãããåŸè
ã®æŽ»æ§ãé è¡å¹¹çŽ°èã®éžæçæžå°ã¯ã次ã«ããã®åŸãå€å æ§ïŒäŸãšããŠãèªå®¶ãåçš®ããŸãã¯åç³»ïŒé è¡å¹¹çŽ°è移æ€çã®ç§»æ€ã«ãã£ãŠæºããããšãã§ãã空æãäœãåºããæ¬é瀺ã¯ããããã«ãæ§ã
ãªé è¡æ§ç¶æ
ãäŸãã°ãéç¶èµ€è¡ç貧è¡ããµã©ã»ãã¢ããã¡ã³ã³ã貧è¡ïŒFanconi anemiaïŒããŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀ïŒWiskott-Aldrich syndromeïŒãã¢ããã·ã³ãã¢ãããŒãŒæ¬ æ-éçè€åå
ç«äžå
šãç°ææ§çœè³ªãžã¹ãããã£ãŒããã€ã¢ã¢ã³ã-ãã©ãã¯ãã¡ã³è²§è¡ïŒDiamond-Blackfan anemiaïŒããã³ã·ã¥ã¯ãããã³-ãã€ã¢ã¢ã³ãçå矀ïŒSchwachman-Diamond syndromeïŒãªã©ã®ãããªãã®ãããå
ç«äžå
šãŠã€ã«ã¹ææãããã³åŸå€©æ§å
ç«äžå
šçå矀ããªãã³ã«ã¬ã³ããã³èªå·±å
ç«çŸæ£ãã»ãã«ãããããããããªã©ã®ãããªãã®ãåŠçœ®ããæ¹æ³ãæäŸããã
äžæ
æ§ã§ã¯ãæ¬é瀺ã¯åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçãæäŸããããã§CD117ã«çµåãããšãããã®æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®ãã¡ã®å°ãªããšã2ã€ã«çµåãããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®ãã¡ã®å°ãªããšã3ã€ã«çµåãããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšã4ã€ã«çµåããããŸã å¥ã®å®æœæ
æ§ã«ãããŠãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšã5ã€ã«çµåãããäžå®ã®å®æœæ
æ§ã«ãããŠãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®åã
ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ããã³T279ã«çµåããã
äžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ80%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ80%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã80%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã80%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ85%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ85%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã85%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã85%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ90%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ90%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã90%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã90%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ95%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ95%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã95%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã95%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ96%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ96%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã96%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã96%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ97%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ97%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã97%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã97%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ98%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ98%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã98%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã98%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããäžå®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšçŽ99%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšçŽ99%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·2ãšå°ãªããšã99%åäžã§ããã¢ããé
žé
åãæããééå¯å€é åããã³é
åçªå·6ãšå°ãªããšã99%åäžã§ããã¢ããé
žé
åãæãã軜éå¯å€é åãå«ãã
å¥ã®æ
æ§ã§ã¯æ¬é瀺ã¯CD117ã«çµåããèœåãããæäœããŸãã¯ãã®æåçµåæ§æçã«é¢ä¿ããããã¯CD117ã«ããããšãããŒãã«çµåããé
åçªå·1ã®CD117ã®ã¢ããé
žæ®åºS236ãH238ãY244ãS273ãT277ããã³T279ã®ãã¡ãå°ãªããšã2ãå°ãªããšã3ãå°ãªããšã4ãå°ãªããšã5ããŸãã¯ãã¹ãŠã®6ã€ãå«ãŸããã
1ã€ã®æ
æ§ã«ãããŠãæ¬é瀺ã¯CD117ã«çµåããèœåãããåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçãæäŸããããã¯é
åçªå·1ã®å°ãªããšãã¢ããé
ž236-244ããã³273-279å
ã®æ®åºãæãããšãããŒãã«çµåããã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯CD117ã«çµåããèœåãããåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçãæäŸããããã¯é
åçªå·1ã«æããããCD117ã®ã¢ããé
žæ®åºS236ãH238ãY244ãS273ãT277ããã³T279ã®ãã¡ã®2ã€ã3ã€ã4ã€ã5ã€ããŸãã¯ãã¹ãŠãå«ãŸããCD117ã«ããããšãããŒãã«çµåããã
äžå®ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯CDRsãããã¯é
åçªå·2ããã³é
åçªå·6ã«èŠå®ãããå¯å€é åãå«ãã§ããªããå¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯CDRsãããã¯é
åçªå·32ããã³é
åçªå·33ã«èŠå®ãããå¯å€é åãå«ãã§ããªããå¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯CDRsãããã¯é
åçªå·34ããã³é
åçªå·35ã«èŠå®ãããå¯å€é åãå«ãã§ããªããå¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯CDRsãããã¯é
åçªå·36ããã³é
åçªå·37ã«èŠå®ãããå¯å€é åãå«ãã§ããªããå¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯CDRsãããã¯é
åçªå·38ããã³é
åçªå·39ã«èŠå®ãããå¯å€é åãå«ãã§ããªããå¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯CDRsãããã¯é
åçªå·40ããã³é
åçªå·41ã«èŠå®ãããå¯å€é åãå«ãã§ããªããããã«å¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯äžæ§æäœããŸãã¯ãã®æåçµåæ§æçã§ããã
å¥ã®æ
æ§ã«ãããŠãæ¬é瀺ã¯åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçãå«ãè¬å€çµæç©ãæäŸããããã§ãCD117ã«çµåãããšãããã®æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®ãã¡ã®å°ãªããšã2ã€ã«çµåãããäžå®æœæ
æ§ã«ãããŠããã®æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºT67ãK69ãT71ãS81ãY83ãT114ãT119ããŸãã¯K129ã®å°ãªããšã3ã€ã«çµåãããå¥ã®å®æœæ
æ§ã§ã¯ããã®æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšã4ã€ãšçµåãããããã«å¥ã®å®æœæ
æ§ã§ã¯ããã®æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšã5ã€ã«çµåãããäžå®ã®å®æœæ
æ§ã§ã¯ããã®æäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã«æããããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ããã³T279ã®åã
ã«çµåããã
ããå®æœæ
æ§ã«ãããŠãããã«èšèŒããçµæç©ããã³æ¹æ³ã«çšããããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ä»¥äžã®ã¢ããé
žæ®åºæ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ïŒåç
§é
åçªå·1ïŒã®å°ãªããšãäºã€ãå«ãããCD117ã§ã®ãšãããŒãã«çµåããããã§ãã®æäœããŸãã¯ãã®æåçµåæ§æçã¯Ab67ã®ééããã³è»œéCDRsãå«ãŸãªãã
äžå®æœæ
æ§ã§ã¯ãããã«èšèŒããçµæç©ããã³æ¹æ³ã«çšããããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ä»¥äžã®ã¢ããé
žæ®åºæ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ïŒåç
§é
åçªå·1ïŒã®å°ãªããšãäºã€ãå«ãããCD117ã§ã®ãšãããŒãã«çµåããããã§ãã®æäœããŸãã¯ãã®æåçµåæ§æçã¯Ab67ã®ééããã³è»œéå¯å€é åãå«ãŸãªãã
ããã«èšèŒãããã®ã¯ããCD117ã«çµåããåé¢ãããæCD117ããæäœã§ãããããã«æäŸããæäœã¯å¹¹çŽ°è移æ€ã®ããã®ãããã€ã·ã§ã³ãã®ã³ã³ãã£ã·ã§ãã³ã°æ¹æ³ãå«ããããããæ²»çã«æå©ãªãã®ã«ããå€ãã®ç¹æ§ãæãããäŸãã°ãããã«é瀺ãããæäœã¯ã¢ã«ã²ã¶ã«CD117ãšäº€å·®åå¿ããããã³ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ããã®ã«æèœã§ããããããã®ç¹é·ã®äž¡æ¹ã«ãããŸãããããã¯CD117çºçŸçŽ°èã«çŽ°èæ¯çŽ ãéãããã®ã³ã³ãžã¥ã²ãŒãã«ããã䜿çšã«ã€ããŠæå©ã«ãããã
ããã«èšèŒãããæäœã«ã¯ãäžæ§æäœãå«ãŸãããå
·äœçã«ã¯ãããã«æäŸãããã®ã¯æCD117æäœã¢ã³ãããã£ãŒïŒanti-CD117 antibody AntibodyïŒ67ïŒAb67ïŒã§ãããããã¯ããCD117ã®å€éšãã¡ã€ã³ã«ç¹ç°çã«çµåãããããæCD117æäœã§ãããAb67ã®çµåé åã¯ä»¥äžã«èšèŒããããããã«é瀺ãããæCD117æäœã«ã¯ãæCD117æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCsïŒãŸãããã§ã¯ã³ã³ãžã¥ã²ãŒããšããŠèšåãããïŒã«ãããŠå«ãŸããããšãã§ããã
ããã«èšèŒãããæCD117æäœããã³ADCsã¯æ§ã
ãªçŸæ£ãäŸãã°ãé è¡ç³»çµ±ã«ããã现èã¿ã€ãã®çŸæ£ãã¬ã³ãèªå·±å
ç«çŸæ£ã代è¬é害ãããã³å¹¹çŽ°èé害ãã»ãã«ãããããããããªã©ã®ãããªãã®ãåŠçœ®ããæ¹æ³ã«ãããŠäœ¿çšããããšãã§ãããããã«èšèŒãããçµæç©ããã³æ¹æ³ã¯ãïŒiïŒç
ç¶ãåŒãèµ·ãã现èãäŸãã°ãã¬ã³çŽ°èïŒäŸã¯ãçœè¡ç
现èïŒããã³èªå·±å
ç«çŽ°èïŒäŸã¯ãèªå·±åå¿æ§T现èïŒãªã©ã®ãããªãã®ã®éå£ãçŽæ¥çã«æžå°ãããããã³/ãŸãã¯ïŒiiïŒç§»æ€ãã现èãåž°å·£ãïŒhomeïŒåŸãããããæäŸããããšã«ãã£ãŠç§»æ€ããé è¡å¹¹çŽ°èã®ççãä¿é²ããããã«å
å æ§é è¡å¹¹çŽ°èã®éå£ãæžå°ããåŸããäžè¿°ã®æŽ»æ§ã¯ãå
å æ§çŸæ£ãåŒãèµ·ãã现èãŸãã¯é è¡å¹¹çŽ°èã«ãã£ãŠçºçŸãããæåãçµåããèœåãããADCãæäœããŸãã¯ãããã®æåçµåæ§æçã®æäžã«ãã£ãŠéæããããšãã§ãããçŸæ£ãçŽæ¥åŠçœ®ããå Žåããã®æäžã¯é¢å¿ãããç
ç¶ãçãã现èã®éã«ãããäœäžãåŒãèµ·ããããšãã§ãããé è¡å¹¹çŽ°è移æ€æ²»çã®ããã«ãã€ã·ã§ã³ããæºåããå Žåããã®æäžã¯å
å æ§é è¡å¹¹çŽ°èã®éå£ã®éžæçãªæ¯æžãåŒãèµ·ããããšãã§ããããã«ãã£ãŠé è¡çµç¹ã«ããã空éãäŸãã°ã移æ€ãããå€å æ§é è¡å¹¹çŽ°èã«ãã£ãŠåŒãç¶ããŠå
å¡«ããåŸã骚é«ã®ãããªãã®ãäœãåºãããšãã§ãããæ¬é瀺ã¯éšåçã«ã¯ãCD117ïŒäŸãã°ãGNK+D117ãªã©ã®ãããªãã®ïŒãçµåããèœåãããADCsãæäœããŸãã¯ãããã®æåçµåæ§æçããäžèšæŽ»æ§ã®äž¡æ¹ã«åœ±é¿ãäžããããã«ãã€ã·ã§ã³ãã«æœãããããšãã§ãããšããçºèŠã«åºã¥ããCD117ãçµåããADCsãæäœããŸãã¯ãããã®æåçµåæ§æçã¯ã¬ã³æ§çŽ°èãŸãã¯èªå·±å
ç«çŽ°èã®éå£ãçŽæ¥æ¯æžãããããã«ã¬ã³ãŸãã¯èªå·±å
ç«çŸæ£ãæ£ããã€ã·ã§ã³ãã«æœãããšãã§ããããã³ãŸã移æ€ãããé è¡å¹¹çŽ°èã®çåããã³ççèœãä¿é²ããããã«é è¡å¹¹çŽ°è移æ€çæ³ãå¿
èŠãšãããã€ã·ã§ã³ãã«æœãããšãã§ããã
æCD117 ADCsãæäœããŸãã¯ãããã®æåçµåæ§æçã®æäžã«ããé è¡å¹¹çŽ°è移æ€çµç¹ã®ççã¯æ§ã
ãªçµéšç枬å®ã«ãããŠæããã«ããããšãã§ãããäŸãšããŠã移æ€ãããé è¡å¹¹çŽ°èã®ççã¯CD117ãšçµåããèœåãããADCsãæäœããŸãã¯ãããã®æåçµåæ§æçã®æäžãããã³ãã®åŸã®é è¡å¹¹çŽ°è移æ€çµç¹ã®æäžã«ç¶ããŠãã€ã·ã§ã³ãã®éªšé«å
ã«ååšãã競åçåå¢æ®åäœïŒcompetitive repopulating unitsïŒïŒCRUïŒã®éãè©å®ããããšã«ãã£ãŠè©äŸ¡ããããšãã§ãããå ããŠãã¬ããŒã¿ãŒéºäŒåãäŸãã°ãèå
ãçºè²å£ããŸãã¯çºå
çç£ç©ãç£çããååŠåå¿ã觊åªããé
µçŽ ãªã©ã®ãããªãã®ããããŒã®é è¡å¹¹çŽ°èããã©ã³ã¹ãã§ã¯ãããããã¯ã¿ãŒäžã«çµã¿èŸŒãããšãããã³ãã®åŸé è¡å¹¹çŽ°èãåž°å·£ããïŒhave homedïŒçµç¹ãäŸãã°ã骚é«ãªã©ã®ãããªãã®ã«ãããŠå¯Ÿå¿ããä¿¡å·ãç£èŠããããšã«ãã£ãŠé è¡å¹¹çŽ°è移æ€çµç¹ã®ççã芳å¯ããããšãã§ããããŸããäŸãšããŠãæ¬æè¡ã«ãããŠç¥ãããèå
掻æ§å现èåé¡ïŒFACSïŒåææ³ã«ãã£ãŠæ±ºå®ãããããã«ãé è¡å¹¹ããã³åé§çŽ°èã®éããã³çåçã®è©äŸ¡ã«ãã£ãŠé è¡å¹¹çŽ°èççã芳å¯ããããšãã§ãããççã¯ãŸã移æ€åŸæéäžã®æ«æ¢¢è¡ã«ãããçœè¡çã«ãŠã³ãã枬å®ããããšãããã³/ãŸãã¯éªšé«åžåŒãµã³ãã«ã«ããããããŒçŽ°èã«ãã骚é«çŽ°èã®ååã枬å®ããããšã«ãã£ãŠæ±ºå®ããããšãã§ããã
以äžã®ã»ã¯ã·ã§ã³ã¯é è¡å¹¹çŽ°è移æ€çã®ççãä¿é²ããããã«ããã€ã·ã§ã³ããäŸãã°ãã¬ã³ïŒäŸãã°ãæ¥æ§éªšé«æ§çœè¡ç
ãŸãã¯éªšé«ç°åœ¢æçå矀ãªã©ã®ãããªãã®ïŒãŸãã¯èªå·±å
ç«çŸæ£ãæ£ããã€ã·ã§ã³ãããŸãã¯é è¡å¹¹çŽ°è移æ€æ²»çãå¿
èŠãšãããã€ã·ã§ã³ããªã©ã®ãããªãã®ã«æœãããšãã§ãããADCsãæäœããŸãã¯ãããã®æåçµåæ§æçããªãã³ã«ãã€ã·ã§ã³ãã«ãã®ãããªæ²»ççšç©è³ªãæœãæ¹æ³ïŒäŸã¯ãé è¡å¹¹çŽ°è移æ€ã«å
ç«ã€ïŒã®èª¬æãæäŸããã
å®çŸ©
å®çŸ©
ããã§çšãããããçŽããšããçšèªã¯èšèŒãããå€ããã10%äžãŸãã¯äžã®ç¯å²å
ã§ããå€ã«èšåãããäŸãã°ãçšèªãçŽ5nMãã¯4.5nMãã5.5nMãŸã§ã®ç¯å²ãæã瀺ãã
ããã§çšããããããã«ããã¢ãããã·ã³ããšããçšèªã¯Amanita phalloidesïŒã¢ããã¿ã»ãã¡ãã€ãã¹ãååïŒã¿ããŽãã³ã°ãã±ïŒããã³ïŒmushroomsãããã·ã¥ã«ãŒã ïŒã«ãã£ãŠçæãããããããã®ã¢ãããã·ã³ãã¡ããªãŒã®ã¡ã³ããŒããŸãã¯ãããã®å€çš®ïŒvariantïŒè¥ããã¯æŽŸçç©ïŒderivativeïŒãäŸãã°ãRNããªã¡ã©ãŒãŒII掻æ§ãæå¶ããèœåããããããã®å€çš®ãŸãã¯æŽŸçç©ãªã©ã®ãããªãã®ã«èšåãããããã«èšèŒãããçµæããã³æ¹æ³ãšé¢é£ããŠæçšãªã¢ãããã·ã³ã¯å¶éãããªãããåŒïŒIIIïŒã«åŸã£ãååç©ãå«ã¿ãα-ã¢ãããã³ãβ-ã¢ãããã³ãγ-ã¢ãããã³ãε-ã¢ãããã³ãã¢ããã³ãã¢ããã³ã¢ãããã¢ãããªã³ãã¢ãããªã³é
žããŸãã¯ããã¢ãããªã³ãå«ãŸãããããã«èšèŒãããããã«ãã¢ãããã·ã³ã¯äŸãšããŠãªã³ã«ãŒã¢ã€ãšãã£ïŒLïŒãçµç±ããŠïŒåŸã£ãŠADCã圢æããïŒããšã«ãããæäœããŸãã¯ãã®æåçµåæ§æçã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãåŸãããã®ãããªããã»ã¹ã«æçšãªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒã·ã§ã³ã®æš¡ç¯çæ¹æ³ããã³ãªã³ã«ãŒã以äžã«èšèŒãããçµæç©ããã³æ¹æ³ã«åŸã£ããæäœããŸãã¯æåçµåæ§æçãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«æçšãªæš¡ç¯çãªã³ã«ãŒãå«ãã¢ãããã·ã³ãããã«èšèŒããã
åŒïŒIIIïŒã¯æ¬¡ã®ããã§ããïŒ
åŒäžãR1ã¯HãOHããŸãã¯ORAã§ããïŒ
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãããéæã«çœ®æããã5-å¡ã®ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãŸãã¯RDã§ããïŒ
R4ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ããŸãã¯ORDã§ããïŒ
R9ã¯HãOHããŸãã¯OR Dã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
RDã¯éæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããã
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãããéæã«çœ®æããã5-å¡ã®ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãŸãã¯RDã§ããïŒ
R4ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ããŸãã¯ORDã§ããïŒ
R9ã¯HãOHããŸãã¯OR Dã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
RDã¯éæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããã
äŸãšããŠãããã«èšèŒãããçµæç©ããã³æ¹æ³ãšäœµããŠæçšãªã¢ãããã·ã³ã¯æ¬¡ã®åŒïŒIIIAïŒã«ããååç©ãå«ãïŒ
åŒäžãR1ã¯HãOHããŸãã¯ORAã§ããïŒ
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãããéæã«çœ®æããã5-å¡ã®ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãŸãã¯RDã§ããïŒ
R4ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ããŸãã¯ORDã§ããïŒ
R9ã¯HãOHããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããã
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãããéæã«çœ®æããã5-å¡ã®ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãŸãã¯RDã§ããïŒ
R4ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ããŸãã¯ORDã§ããïŒ
R9ã¯HãOHããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããã
ããã«èšèŒãããçµæç©ããã³æ¹æ³ãšäœµããŠæçšãªã¢ãããã·ã³ã¯ãŸãã次ã®åŒïŒIIIBïŒã«ããååç©ãå«ãã
åŒäžãR1ã¯ãHãOHããŸãã¯ORAã§ããïŒ
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãããéæã«çœ®æããã5-å¡ã®ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãŸãã¯RDã§ããïŒ
R4ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ããŸãã¯ORDã§ããïŒ
R9ã¯HãOHããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããã
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãããéæã«çœ®æããã5-å¡ã®ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãŸãã¯RDã§ããïŒ
R4ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORDããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ããŸãã¯ORDã§ããïŒ
R9ã¯HãOHããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããã
äŸãšããŠãäžå®æœæ
æ§ã§ã¯ãããã«èšèŒãããçµæããã³æ¹æ³ãšé¢é£ããŠæçšãªã¢ãããã·ã³ã«ã¯ãåŒïŒIIICïŒã«åŸã£ãååç©ãå«ãŸã
åŒäžãR4ãR5ãXãããã³R8ã¯ããããäžèšã§èŠå®ããããããªãã®ã§ããã
ããã«èšèŒãããããã«ãã¢ãããã·ã³ã¯ãäŸãšããŠããªã³ã«ãŒã¢ã€ãšãã£ïŒLïŒãçµç±ããŠãæäœããŸãã¯ãã®æåçµåæ§æçã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãåŸãïŒåŸã£ãŠADCã圢æãããïŒããã®ãããªããã»ã¹ã«æçšãªã¢ãããã·ã³ã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã®æš¡ç¯çæ¹æ³ããã³ãªã³ã«ãŒã¯ãè¡š1ãå«ããŠæ¬¡ã«è¿°ã¹ããããã«èšèŒãããçµæç©ããã³æ¹æ³ã«åŸã£ãŠãæäœããŸãã¯ãã®æåçµåæ§æçãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«æçšãªãªã³ã«ãŒãå«ãæš¡ç¯çã¢ãããã·ã³ã¯ãããã«åæãããæ§é åŒïŒIïŒãïŒIAïŒãïŒIBïŒãïŒIIïŒãïŒIIAïŒããŸãã¯ïŒIIBïŒã«ç€ºãããã
ããã§çšããããããã«ããæäœããšããçšèªã¯ç¹å®ã®æåã«ç¹ç°çã«çµåãããããŸãã¯ããã«å¯ŸããŠå
ç«åŠçã«åå¿æ§ã§ããå
ç«ã°ãããªã³ååã«èšåãããæäœã«ã¯ãå¶éãããªãããã¢ãã¯ããŒãã«æäœãããªã¯ããŒãã«æäœãå€ç¹ç°æ§æäœïŒäŸã¯ãäºéç¹ç°æ§æäœïŒbispecific antibodiesïŒïŒãæäœã®éºäŒåæäœããããããã³å¥ãªãµãã«ä¿®é£Ÿããã圢æ
ãå«ãŸããå¶éãããªãããè±å
ç«åæäœïŒde-immunized antibodiesïŒããã¡ã©æäœãããåæäœããããã³ã³ãžã¥ã²ãŒãæäœïŒäŸã¯ãã-ããª-ããã³ã¯ã¢ãã-ç¹ç°æ§æäœããã€ã¢ããã£ïŒdiabodiesïŒãããªã¢ããã£ïŒtriabodiesïŒãããã³ããã©ããã£ïŒtetrabodiesïŒïŒãããã³æäœæçïŒå³ã¡ãæäœã®æåçµåæ§æçïŒãå«ãŸããäŸãã°ãFab'ãF(ab')2ãFabãFvãrIgGãããã³scFvæçãå«ãŸãããããã¯æãŸããæåçµåæ§æŽ»æ§ã瀺ãéãã«ãããŠã§ããã
æ¬é瀺ã®æäœã¯æŠããŠãåé¢ããããŸãã¯çµæããããŠãããããã§çšãããšããåé¢ãã¯ãäŸã¯ããããçºçŸããã现èãŸãã¯çŽ°èå¹é€ç©ããèå¥ããã³åããããããã³/ãŸãã¯ååãããããªããããã«èšåãããéåžžãåé¢ãããæäœã¯å°ãªããšãäžã€ã®ç²Ÿè£œã¹ãããã«ãã£ãŠèª¿è£œãããããã®ããã«ããŠããåé¢ãããæäœãã¯ç°ãªãæåç¹ç°æ§ãæããä»ã®æäœãå®è³ªå«ãŸãªãæäœã«èšåãããäŸãšããŠãCD117ã«ç¹ç°çã«çµåããåé¢ãããæäœã¯ãCD117以å€ã®æåãç¹ç°çã«çµåããæäœã¯å®è³ªããªãŒã§ããã
ããã§çšãããããã¢ãã¯ããŒãã«æäœãïŒmAbïŒãšããçšèªã¯ãåœæè¡ã«ãããŠå©çšå¯èœãªããŸãã¯æ¢ç¥ã®ä»»æã®æ段ã«ãã£ãŠãä»»æã®çæ žãåæ žããŸãã¯ãã¡ãŒãžã¯ããŒã³ãå«ããåäžã¯ããŒã³ããå°ãåºãããæäœã«èšåããããã³ãã€ããªãããã¯ãããžãŒãéããŠçç£ãããæäœã«ã¯å¶éãããªããæ¬é瀺ã«ã€ããŠæçšãªã¢ãã¯ããŒãã«æäœã¯ãæ¬æè¡ã«ãããŠç¥ãããå€çš®å€æ§ãªæè¡ããã€ããªããŒããçµæããããã³ãã¡ãŒãžãã£ã¹ãã¬ã€æè¡ããŸãã¯ãããã®çµåãã®äœ¿çšãå«ããŠäœ¿çšããŠã調補ããããšãã§ããããã¢ãã¯ããŒãã«æäœããšããçšèªã¯ãæšçã¿ã³ãã¯è³ªã«ç¹ç°çã«çµåããèœåãããç¡å·ã®ååããªãã³ã«æäœæçïŒäŸãã°ãFabããã³F(ab')2ã®æçãå«ãïŒã®äž¡æ¹ãå«ãããšãæå³ãããããã§çšããããããã«ãFabããã³F(ab')2æçã¯ç¡å·ã®æäœã®Fcæçãæ¬ ãæäœæçã«èšåããããããã®æäœæçã®äŸã¯ããã«èšèŒããã
æŠããŠãæäœã¯æåçµåé åãå«ãŸããééããã³è»œéãå«ããåééã¯ééå¯å€é åïŒããã§ã¯HCVRãŸãã¯VHãšããŠç¥ãããïŒããã³ééå®åžžé åããæ§æããããééå®åžžé åã¯3ã€ã®ãã¡ã€ã³ãCH1ãCH2ããã³CH3ããæ§æããããå軜éã¯è»œéå¯å€é åïŒããã§ã¯LCVRãŸãã¯VLãšããŠç¥ãããïŒããã³è»œéå®åžžé åããæ§æãããã軜éå®åžžé åã¯äžã€ã®ãã¡ã€ã³ãCLããæ§æããããVHãããã³VLé åã¯ããã«ãçžè£æ§æ±ºå®é åïŒCDRïŒãšåŒã°ããè¶
å¯å€æ§ã®é åã«åããããããäžå±€å€ãä¿åããããã¬ãŒã ã¯ãŒã¯é åïŒFRïŒãšåŒã°ããé åã«æ£åšãããããšãã§ãããåVHããã³VLã¯3ã€ã®CDRsããã³4ã€ã®FRsããæ§æãããã¢ãã端ããã«ã«ããã·ã«ç«¯ãŸã§æ¬¡ã®é ïŒFR1ãCDR1ãFR2ãCDR2ãFR3ãCDR3ãFR4ã«äžŠã¹ããããééããã³è»œéã®å¯å€é åã«ã¯ãæåãšçžäºäœçšããçµåãã¡ã€ã³ãå«ãŸãããæäœã®å®åžžé åã¯ãå
ç«ç³»ã®çš®ã
ã®çŽ°èïŒäŸã¯ããšãã§ã¯ã¿ãŒçŽ°èïŒããã³å€å
žçè£äœç³»ã®ç¬¬äžæåïŒClqïŒãå«ãã宿䞻çµç¹ãŸãã¯å åãžã®å
ç«ã°ãããªã³ã®çµåãåªä»ããããšãã§ããã
ããã§çšãããããç¡å·ããŸãã¯ãå
šé·ãæäœã¯ããžã¹ã«ãã£ãçµåã«ãã£ãŠçžäºã«çµåãã2ã€ã®éïŒHïŒéããªããããããã³2ã€ã®è»œïŒLïŒéã®ããªãããããæããæäœã«èšåãããåééã¯ééå¯å€é åïŒããã§ã¯HCVRãŸãã¯VHãšç¥ãïŒããã³ééå®åžžé åããæ§æããããééå®åžžé åã¯CH1ãCH2ããã³CH3ã®3ã€ã®ãã¡ã€ã³ããæ§æããããå軜éã¯è»œéå¯å€é åïŒããã§ã¯LCVRãŸãã¯VLãšç¥ãïŒããã³è»œéå®åžžé åããæ§æãããã軜éå®åžžé åã¯äžã€ã®ãã¡ã€ã³ã§ããCLããæ§æããããVHãããã³VLé åã¯ããã«ãçžè£æ§æ±ºå®é åïŒCDRïŒãšåŒã°ããè¶
å¯å€æ§ã®é åã«åããããããäžå±€å€ãä¿åããããã¬ãŒã ã¯ãŒã¯é åïŒFRïŒãšåŒã°ããé åã«æ£åšãããããšãã§ãããåVHããã³VLã¯3ã€ã®CDRsããã³4ã€ã®FRsããæ§æãããã¢ãã端ããã«ã«ããã·ã«ç«¯ãŸã§æ¬¡ã®é ïŒFR1ãCDR1ãFR2ãCDR2ãFR3ãCDR3ãFR4ã«äžŠã¹ããããééããã³è»œéã®å¯å€é åã«ã¯ãæåãšçžäºäœçšããçµåãã¡ã€ã³ãå«ãŸãããæäœã®å®åžžé åã¯å
ç«ç³»ã®çš®ã
ã®çŽ°èïŒäŸã¯ããšãã§ã¯ã¿ãŒçŽ°èïŒããã³å€å
žçè£äœç³»ã®ç¬¬äžæåïŒClqïŒãå«ãã宿䞻çµç¹ãŸãã¯å åãžã®å
ç«ã°ãããªã³ã®çµåãåªä»ããããšãã§ããã
ããã§çšãããããFcãããFcé åããããã³ãFcãã¡ã€ã³ããšããçšèªã¯ãå
ç«ã°ãããªã³ã®éšåãäŸã¯ãIgGæäœååã®ããã€ã³æ¶åã«ãã£ãŠåŸãããçµæ¶æ§æçãšçžé¢ããIgGååã«èšåãããFcé åã¯ãžã¹ã«ãã£ãçµåã«ãã£ãŠé£çµãããIgGååã®2ã€ã®ééã®C-æ«ç«¯ååãæ§æãããããã¯æåçµåæ§æŽ»æ§ãæããªãããçæ°Žåç©ã¢ã€ãšãã£ããã³è£å®ç©ïŒcomplementïŒããã³Fcå容äœã«ã€ããŠã®çµåæ§éšäœãå«ã¿ãFcRnå容äœïŒä»¥äžåç
§ïŒãå«ãŸãããäŸãã°ãFcé åã«ã¯ã第äºã®å®åžžãã¡ã€ã³CH2ïŒäŸã¯ãIgG1ã®EUäœçœ®231-340ã§ã®æ®åºïŒããã³ç¬¬äžã®å®åžžãã¡ã€ã³CH3ïŒäŸã¯ãããIgG1ã®EUäœçœ®341-447ã§ã®æ®åºïŒãå«ãŸãããããã§çšããããããã«ãFcé åã«ã¯ãäžåŽãã³ãžé åãïŒäŸã¯ãIgG1ã®EUäœçœ®233-239ã§ã®æ®åºïŒãå«ãŸããã
Fcã¯åé¢ç¶æ
ã§ã®ãã®é åããŸãã¯æäœãæäœæçããŸãã¯Fcèåã¿ã³ãã¯è³ªã®é¢é£ã«ããããã®é åã«èšåãããå€åœ¢æ§ïŒPolymorphismsãããªã¢ã«ãã£ãºã ïŒã¯ãFcãã¡ã€ã³ã®ããã€ãã®äœçœ®ãå¶éãããªãããEUäœçœ®270ã272ã312ã315ã356ãããã³358ãå«ãã§èŠ³å¯ãããŠãããããã³åŸã£ãŠæ¬åºé¡ã«æ瀺ãããé
åããã³æ¬æè¡ã«ãããŠæ¢ç¥ã®é
åéã®ããããªå·®ã¯ååšããããšãã§ããããã®ããã«ããéçåIgG Fcãã¡ã€ã³ããŸãã¯ãWT IgG Fcãã¡ã€ã³ãã¯ä»»æã®èªç¶ã«çºçããIgG Fcé åïŒå³ã¡ãä»»æã®å¯Ÿç«éºäŒåïŒã«èšåãããããIgG1ãIgG2ãIgG3ããã³IgG4ã®ééã®é
åã¯ããã€ãã®é
åããŒã¿ããŒã¹ãäŸãã°ãUniprotïŒãŠããããïŒããŒã¿ããŒã¹ïŒwww.uniprot.orgïŒã«ãŠã¢ã¯ã»ãã·ã§ã³ïŒåå
¥ãïŒçªå·P01857ïŒIGHG1_HUMANïŒãP01859ïŒIGHG2_HUMANïŒãP01860ïŒIGHG3_HUMANïŒãããã³P01861ïŒIGHG1_HUMANïŒã«ãããŠããããèŠåºãããšãã§ããããWTãFcé åã®äŸã¯é
åçªå·10ã«ãããŠæäŸãããïŒããã¯Fcé åãå«ãééå®åžžé åãæäŸããïŒã
ããã§çšããããçšèªã修食ããFcé åããŸãã¯ãå€çš®Fcé åãã¯Fcé åå
ã®ä»»æã®äœçœ®ã«ãŠå°å
¥ããã1以äžã®ã¢ããé
žçœ®æãæ¬ å€±ãæ¿å
¥ãŸãã¯ä¿®é£Ÿãå«ãIgG Fcãã¡ã€ã³ã«èšåãããäžå®ã®æ
æ§ã«ãããŠãå€çš®IgG Fcãã¡ã€ã³ã¯1以äžã®ã¢ããé
žçœ®æåºãå«ãŸãªãéçåFcãã¡ã€ã³ãšæ¯èŒããŠFcã¬ã³ãRããã³/ãŸãã¯C1qã«ã€ããŠæžå°ãããŸãã¯ã¢ãã¬ãŒã·ã§ã³ïŒåé€ïŒããçµå芪åæ§ããããã1以äžã®ã¢ããé
žçœ®æåºãå«ããããã«ãFcçµåæ§çžäºäœçšã¯ãæ§ã
ãªãšãã§ã¯ã¿ãŒæ©èœããã³äžæµã·ã°ãã«äŒéäºè±¡ã«ã€ããŠãå¶éãããªãããæäœäŸåæ§çŽ°èåªä»æ§çŽ°èå·å®³ïŒADCCïŒããã³è£äœäŸåæ§çŽ°èå·å®³ïŒCDCïŒãå«ããŠå¿
é ã§ããããããã£ãŠãäžå®ã®æ
æ§ã«ãããŠãå€çš®Fcãã¡ã€ã³ïŒäŸã¯ãæäœãèåã¿ã³ãã¯è³ªãŸãã¯ã³ã³ãžã¥ã²ãŒãïŒãå«ãæäœã¯å¥ãªãµãã«åãã¢ããé
žé
åãæãããã1以äžã®ã¢ããé
žçœ®æãæ¬ å€±ãæ¿å
¥ãŸãã¯ä¿®é£ŸãäŸãã°ãFcé åã«ãããŠå¯Ÿå¿ããäœçœ®ã«ãŠèªç¶ã«èµ·ããã¢ããé
žæ®åºãå«ãæªä¿®é£ŸFcé åãªã©ã®ãããªãã®ãå«ãŸãªã察å¿ããã¢ããé
žã«é¢ããŠå°ãªããšã1以äžã®Fcé
äœåïŒäŸã¯ãFcã¬ã³ãRsïŒã«ã€ããŠå€åããçµå芪åæ§ãèŠããããšãã§ããã
å€çš®Fcãã¡ã€ã³ã¯ããããæ§æããã¢ããé
žä¿®é£Ÿã«åŸãèŠå®ããããFcé åã«é¢ããŠããã§è°è«ãããã¹ãŠã®ã¢ããé
žçœ®æã«ã€ããŠããã³ããªã³ã°ïŒæ°ãæ¹ïŒã¯åžžã«KabatïŒã«ãããïŒã§ã®ããã«EUã€ã³ããã¯ã¹ã«åŸãããããããäŸãã°ãD265Cã¯ã芪Fcãã¡ã€ã³ã«é¢ããŠã·ã¹ãã€ã³ïŒCïŒã§çœ®ãæããããEUäœçœ®265ã«ãŠã¢ã¹ãã©ã®ã³é
žïŒDïŒãæããFcå€çš®ã§ããã眮æãæäŸãããé åºã¯ä»»æã§ããããšã«æ³šç®ããããåæ§ã«ãäŸã¯ãD265C/L234A/L235Aã¯EUäœçœ®265ïŒDããCãŸã§ïŒã234ïŒLããAãŸã§ïŒãããã³235ïŒLããAãŸã§ïŒã«ãŠèŠªã®Fcãã¡ã€ã³ã«é¢ããŠçœ®æãæããå€çš®Fcããªã¢ã³ãïŒããªã¢ã³ãã¯å€çš®ãå€åœ¢ç©ãªã©ãšãèšãïŒãèŠå®ãããå€çš®ã¯ãŸããå€ç°EUã¢ããé
žäœçœ®ã«ããããã®æçµã¢ããé
žçµæã«åŸã£ãŠæå®ããããšãã§ãããäŸãã°ãL234A/L235Aå€ç°äœïŒmutantïŒã¯ãLALAããšç§°ãããããšãã§ããããããªãäŸãšããŠãE233P.L234V.L235A.delG236ïŒ236ã®æ¬ 倱ïŒå€ç°äœã¯ãEPLVLAdelGããšç§°ããããšãã§ããããŸãå¥ã®äŸãšããŠãI253A.H310A.H435Aå€ç°äœã¯ãIHHããšç§°ããããšãã§ããã眮æãæäŸãããé åºã¯ä»»æã§ããããšã泚ç®ãããã
ããã§çšããããçšèªãFcã¬ã³ãå容äœããŸãã¯ãFcã¬ã³ãRãã¯IgGæäœFcé åãçµåããããã³Fcã¬ã³ãRéºäŒåã«ãã£ãŠã³ãŒããããã¿ã³ãã¯è³ªã®ãã¡ããªãŒã®ä»»æã®ã¡ã³ããŒã«èšåãããããã«ãããŠããã®ãã¡ããªãŒã¯ãå¶éãããªãããFcã¬ã³ãRIïŒCD64ïŒã§ãã¢ã€ãœãã©ãŒã ã®Fcã¬ã³ãRIaãFcã¬ã³ãRIbãããã³Fcã¬ã³ãRicãå«ããã®ïŒFcã¬ã³ãRIIïŒCD32ïŒã§ãã¢ã€ãœãã©ãŒã ã®Fcã¬ã³ãRIIaïŒã¢ãã¿ã€ãã®H131ããã³R131ãå«ãŸããïŒãFcã¬ã³ãRIIbïŒFcã¬ã³ãRIIb-1ããã³Fcã¬ã³ãRIIb-2ãå«ãŸããïŒãããã³Fcã¬ã³ãRIIcãå«ããã®ïŒããã³Fcã¬ã³ãRIIIïŒCD16ïŒã§ãã¢ã€ãœãã©ãŒã ã®Fcã¬ã³ãRIIIaïŒã¢ãã¿ã€ãã®V158ããã³F158ãå«ãŸããïŒããã³Fcã¬ã³ãRIIIbïŒã¢ãã¿ã€ãã®Fcã¬ã³ãRIIIb-NA1ããã³Fcã¬ã³ãRIIIb-NA2ãå«ãŸããïŒãå«ããã®ããªãã³ã«ä»»æã®æªçºèŠã®ããFcã¬ã³ãRsãŸãã¯Fcã¬ã³ãRã¢ã€ãœãã©ãŒã ãŸãã¯ã¢ãã¿ã€ããå«ããFcã¬ã³ãRã¯ãå¶éãããªããããããããŠã¹ãã©ããããŠãµã®ãããã³ãµã«ãå«ãä»»æã®ææ©äœããã®ãã®ã§ããããšãã§ãããããŠã¹Fcã¬ã³ãRsã«ã¯ãå¶éãããªãããFcã¬ã³ãRIïŒCD64ïŒãFcã¬ã³ãRIIïŒCD32ïŒãFcã¬ã³ãRIIIïŒCD16ïŒãããã³Fcã¬ã³ãRIII-2ïŒCD16-2ïŒããªãã³ã«ä»»æã®æªçºèŠã®ããŠã¹Fcã¬ã³ãRsãŸãã¯Fcã¬ã³ãRã¢ã€ãœãã©ãŒã ãŸãã¯ã¢ãã¿ã€ããå«ãŸããã
ããã§çšããããããšãã§ã¯ã¿ãŒæ©èœããšããçšèªã¯ãFcå容äœãšã®Fcãã¡ã€ã³ã®çžäºäœçšããããããããçååŠçäºè±¡ã«èšåããããšãã§ã¯ã¿ãŒæ©èœã«ã¯ãå¶éãããªãããADCCãADCPãããã³CDCãå«ãŸãããããã§çšãããããããªããšãã§ã¯ã¿ãŒçŽ°èãã«ãã£ãŠã1以äžã®Fcå容äœãçºçŸãïŒexpresses or one or more Fc receptorsïŒãããã³1以äžã®ãšãã§ã¯ã¿ãŒæ©èœã仲ä»ããå
ç«ç³»ã®çŽ°èãæå³ãããããšãã§ã¯ã¿ãŒçŽ°èã¯å¶éãããªãããåçããã¯ããã¡ãŒãžã奜äžçãæš¹ç¶çŽ°èã奜é
žçããã¹ã现èïŒè¥æºçŽ°èãšãèšãïŒãè¡å°æ¿ãB现èã倧åé¡ç²ãªã³ãçãã©ã³ã²ã«ãã³ã¹çŽ°èãããã¥ã©ã«ãã©ãŒïŒNKïŒçŽ°èãããã³ã¬ã³ããã«ã¿T现èãå«ã¿ãããã³ä»»æã®ææ©äœãå¶éãããªããããããããŠã¹ãã©ããããŠãµã®ãããã³ãµã«ããã®ãã®ãå«ãããšãã§ããã
ããµã€ã¬ã³ãããããµã€ã¬ã³ã·ã³ã°ãããããŸãã¯ããµã€ã¬ã³ã·ã³ã°ããšããçšèªã¯ãããã«ãããŠçšããããããã«ãæªä¿®é£ŸFcé åãå«ãåäžæäœã®Fcã¬ã³ãå容äœïŒFcγRïŒãžã®çµåã«é¢ããŠFcγRãžã®çµåãæžå°ããïŒäŸã¯ãBLIã«ãã£ãŠæž¬å®ãããããã«ãæªä¿®é£ŸFcé åãå«ãåäžæäœã®FcγRãžã®çµåã«é¢ããŠå°ãªããšã70%ãå°ãªããšã80%ãå°ãªããšã90%ãå°ãªããšã95%ãå°ãªããšã98%ãå°ãªããšã99%ããŸãã¯100%ã«ãã£ãŠã®FcγRãžã®çµåã«ãããæžå°ïŒãããã«èšèŒãã修食Fcé åãæããæäœã«èšåãããããã€ãã®æ
æ§ã«ãããŠãFcãµã€ã¬ã³ã·ã³ã°ããæäœã¯FcγRãžã®æ€åºå¯èœãªçµåãæããªãã修食Fcé åãæããæäœã®FcγRãžã®çµåã¯æ¬æè¡ã«ãããŠæ¢ç¥ã®æ§ã
ãªæè¡ãäŸãã°ãå¶éãããªããã平衡æ³ïŒequilibrium methodsïŒïŒäŸã¯ãé
µçŽ çµåå
ç«åžçæ€å®æ³ïŒenzyme-linked immunoabsorbent assayïŒïŒELISAïŒïŒKinExA, RathanaswamiïŒã©ã¿ãã¹ã¯ãïŒãAnalytical BiochemistryïŒã¢ããªãã£ã«ã«ã»ãã€ãªã±ãã¹ããªãŒïŒ, Vol. 373ïŒç¬¬373å·»ïŒ:52-60, 2008ïŒãŸãã¯æŸå°å
ç«æ€å®ïŒã©ãžãªã€ã ãã¢ãã»ã€ïŒïŒRIAïŒïŒãçšããŠããŸãã¯è¡šé¢ãã©ãºã¢ã³å
±é³Žã¢ãã»ã€ãŸãã¯ä»ã®åååŠã«åºã¥ãã¢ãã»ã€ïŒäŸã¯ãBIACORETMïŒãã¢ã³ã¢TMïŒåæãŸãã¯OctetTMïŒãªã¯ãããTMïŒåæïŒforteBIOïŒãã©ã«ããã€ãªïŒïŒïŒã®æ©æ§ãããã³ä»ã®æ¹æ³ãäŸãã°ãéæ¥çµåã¢ãã»ã€ã競äºçµåã¢ãã»ã€èå
å
±é³Žãšãã«ã®ãŒç§»åïŒFRETïŒïŒcompetitive binding assays fluorescence resonance energy transfer (FRET)ïŒãã²ã«é»æ°æ³³åæ³ããã³ã¯ãããã°ã©ãã£ãŒïŒäŸã¯ãã²ã«ãéïŒãªã©ã®ãããªãã®ã«ãã£ãŠæ±ºå®ããããšãã§ããããããããã³ä»ã®æ¹æ³ã¯æ€æ»ããŠããæåã®äžä»¥äžã§ã®ã©ãã«ãå©çšããããã³/ãŸãã¯å€æ§ãªæ€åºæ¹æ³ãå¶éãããªãããçºè²æ§ãèå
ãçºå
ããŸãã¯åäœäœæšèãå«ããã®ãæ¡çšãåŸããçµå芪åæ§ããã³åååŠã«ã€ããŠã®è©³çŽ°ãªèšè¿°ã¯PaulïŒããŒã«ïŒ, W. E., ed.ïŒç·šéïŒ, Fundamental Immunology,4th Ed.ïŒåºç€å
ç«åŠã第4çïŒ, Lippincott-RavenïŒãªããã³ã³ãã-ã¬ãŒãã³ïŒ, PhiladelphiaïŒãã£ã©ãã«ãã£ã¢ïŒ(1999)ã«ãããŠèŠåºãããšãã§ããããã¯æäœ-å
ç«åçžäºäœçšã«çŠç¹ãåœãŠãã競åçµåã¢ãã»ã€ã®äžäŸã¯å¢å€§ããéã®éæšèæåã®ååšäžã§ã®æšèæåãšç®çã®æäœãšã®ã€ã³ãã¥ããŒã·ã§ã³ããã³æšèæåã«çµåããæäœã®æ€åºãå«ãã©ãžãªã€ã ãã¢ãã»ã€ã§ãããç¹å®ã®æåã«å¯Ÿããèå³ãããæäœã®èŠªåæ§ããã³çµåãªãã¬ãŒãïŒbinding off-ratesïŒã¯ã¹ãã£ããã£ãŒãããããåæïŒscatchard plot analysisïŒã«ãã£ãŠããŒã¿ãã決å®ããããšãã§ããããŸããäºæ¬¡æäœãšã®ç«¶åã¯ã©ãžãªã€ã ãã¢ãã»ã€ãçšããŠå®ããããšãã§ããããã®å Žåãæåã¯éæšè第äºæäœã®å¢å éã®ååšäžã«æšèååç©ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããèå³ãããæäœãšå
±ã«ã€ã³ãã¥ããŒããããã
ããã§çšããããããã«ããé修食Fcé åãå«ãåäžæäœããšããçšèªã¯åæãããã¢ããé
žçœ®æïŒäŸã¯ãD265CãH435AãL234Aãããã³/ãŸãã¯L235AïŒãæ¬ ãããå¥ãªãµãã«Fc修食æäœãæ¯èŒãããŠããã®ãšåãã¢ããé
žé
åãæããæäœã«èšåããã
ãæäœäŸåæ§çŽ°èåªä»æ§çŽ°èå·å®³ïŒantibody-dependent cell-mediated cytotoxicityïŒããŸãã¯ãADCCããšããçšèªã¯ã现èå·å®³ã®åœ¢æ
ã«èšåããããã§ã¯Fcãã¡ã€ã³ãå«ãããªãããããäŸã¯ãæäœã¯ãäžå®ã®çŽ°èå·å®³æ§çŽ°èïŒcytotoxic cellsïŒïŒäŸã¯ããã©ã€ããªãŒNK现èã奜äžçãããã³ãã¯ããã¡ãŒãžïŒã«ãŠååšããFcå容äœïŒFcRsïŒäžã«çµåãããã®ã§ãããããã³ãããã®çŽ°èå·å®³æ§ãšãã§ã¯ã¿ãŒçŽ°èãæåãã¢ãªã³ã°ïŒantigen-bearingïŒãæšç现èãã«ç¹ç°çã«çµåããããã³ç¶ããŠæšç现èã现èæ¯çŽ ã§æ®ºãããšãå¯èœã«ãããïŒHogarthïŒãã¬ãŒã¹ïŒã, Nature review Drug DiscoveryïŒãã€ãã£ãŒã»ã¬ãã¥ãŒãºïŒãã©ãã°ã»ãã£ã¹ã«ããªãŒïŒ2012, 11:313ïŒããã¯æäœããã³ãã®æçã«å ããŠãFcãã¡ã€ã³ãå«ãä»ã®ããªãããããäŸã¯ãFcèåã¿ã³ãã¯è³ªããã³Fcã³ã³ãžã¥ã²ãŒã·ã§ã³ã¿ã³ãã¯è³ªã§ãããæåãã¢ãªã³ã°æšç现èã«ç¹ç°çã«çµåããèœåãæãããã®ã现èåªä»æ§çŽ°èå·å®³ãäœçšãããããšãã§ãããšèããããã
åçŽåã®ããã«ãFcãã¡ã€ã³ãå«ãããªããããã®æŽ»æ§ãããããããã现èåªä»æ§çŽ°èå·å®³ã¯ãŸãããã§ã¯ADCC掻æ§ãšã称ãããADCCã«ãã£ãŠæšç现èã®æº¶è§£ãåªä»ããæ¬é瀺ã®ä»»æã®ç¹å®ã®ããªããããã®èœåã¯ãã¢ãã»ã€ããããšãã§ãããADCC掻æ§ãè©å®ããããã«ãèå³ãããããªããããïŒäŸã¯ãæäœïŒã¯ãæšç现èã«å
ç«ãšãã§ã¯ã¿ãŒçŽ°èãšçµã¿åãããŠå ããããæšç现èã®çŽ°è溶解ãããããããã现è溶解ã¯å€§æµãæšèïŒäŸã¯ãæŸå°æ§åºè³ªãèå
è²çŽ ãŸãã¯èªç¶ãªçŽ°èå
ã¿ã³ãã¯è³ªïŒã溶解ãã现èããæŸåºããããšã«ãã£ãŠæ€åºãããããã®ãããªã¢ãã»ã€ã«ã€ããŠã®æçšãªãšãã§ã¯ã¿ãŒçŽ°èã«ã¯ãåšèŸºè¡æ¶²åæ žçŽ°èïŒPBMCïŒããã³ããã¥ã©ã«ãã©ãŒïŒNKïŒçŽ°èãå«ãŸãããã€ã³ãããADCCã¢ãã»ã€ã®ç¹å®ã®äŸã¯BruggemannïŒãã«ãããã³ïŒã, J. Exp. Med.ïŒã¶ã»ãžã£ãŒãã«ã»ãªãã»ãšã¯ã¹ããªã¡ã³ã¿ã«ã»ã¡ãã£ã·ã³ïŒ166:1351 (1987)ïŒWilkinsonïŒãŠã£ã«ãã³ãœã³ïŒã, J. Immunol. MethodsïŒãžã£ãŒãã«ã»ãªãã»ã€ã ãããžã«ã«ã»ã¡ãœãã
ïŒ258:183 (2001)ïŒPatelïŒããã«ïŒã, J. Immunol. Methods 184:29 (1995)ã«èšèŒãããããããã¯ãŸãããŸãã¯è¿œå çã«ãé¢å¿ãããæäœã®ADCC掻æ§ã¯ãã€ã³ãããäŸã¯ãåç©ã¢ãã«ãäŸãã°ãClynesïŒã¯ã©ã€ã³ãºïŒã, Proc. Natl. Acad. Sci. USAïŒããã·ãŒãã£ã³ã°ã¹ã»ãªãã»ã¶ã»ãã·ã§ãã«ã»ã¢ã«ãããŒã»ãªãã»ãµã€ãšã³ã·ãŒãºã»ãªãã»ã¶ã»ãŠãã€ãããã»ã¹ããŒãã»ãªãã»ã¢ã¡ãªã«ïŒ95:652(1998)ã«é瀺ãããŠãããã®ãªã©ã®ãããªãã®ã«ãããŠè©å®ããããšãã§ããã
ããã§çšãããããæåçµåæ§æçããšããçšèªã¯ãæšçæåã«ç¹ç°çã«çµåããèœåãä¿æãã1以äžã®éšåã®æäœã«èšåãããæäœã®æåçµåæ§æ©èœã¯å
šé·æäœã®æçã«ãã£ãŠå®è¡ããããšãã§ãããæäœæçã¯äŸãã°ãFabãF(ab')2ãscFvããã€ã¢ããã£ãããªã¢ããã£ãã¢ãã£ããã£ïŒaffibodyïŒãããããã£ãã¢ãã¿ããŒããŸãã¯ãã¡ã€ã³æäœã§ããããšãã§ãããæäœã®ãæåçµåæ§æçããšããçšèªãå
å«ããçµåæ§æçã®äŸã¯ãå¶éãããªããã次ã®ïŒïŒiïŒFabæçãVLãVHãCLãããã³CH1ãã¡ã€ã³ãããªã1䟡æçïŒïŒiiïŒF(ab')2æçããã³ãžé åã«ãŠãžã¹ã«ãã£ãæ¶æ©ã«ãã£ãŠé£çµããã2ã€ã®Fabæçãå«ã2䟡æçïŒïŒiiiïŒVHããã³CH1ãã¡ã€ã³ãããªãFdæçïŒïŒivïŒæäœã®åäžã¢ãŒã ã®VLããã³VHãã¡ã€ã³ãããªãFvæçãïŒvïŒVHããã³VLãã¡ã€ã³ãå«ãdAbïŒïŒviïŒVHãã¡ã€ã³ãããªãdAbæçïŒäŸã¯ãWardïŒãŠã©ãŒãïŒã, NatureïŒãã€ãã£ãŒïŒ341:544-546, 1989ãåç
§ïŒïŒïŒviiïŒVHãŸãã¯VLãã¡ã€ã³ãããªãdAbïŒïŒviiiïŒåé¢çžè£æ§æ±ºå®é åïŒCDRïŒïŒããã³ïŒixïŒ2以äžã®çµåãïŒäŸã¯ã2ã3ã4ã5ããŸãã¯6ïŒã®åé¢CDRsã§åæãªã³ã«ãŒã«ãã£ãŠéæã«æ¥åããïŒjoinedïŒåŸããã®ãå«ããããã«ãFvæçã®2ã€ã®ãã¡ã€ã³ãVLããã³VHã¯å¥ã
ã®éºäŒåã«ãã£ãŠã³ãŒãããããããããã¯çµæãæ³ãçšããŠããªã³ã«ãŒã«ãã£ãŠæ¥åããããšãã§ããããã¯ããããåäžã®ã¿ã³ãã¯è³ªéãšããŠäœãããããšãå¯èœã«ããããã§ã¯VLããã³VHé åã¯äžäŸ¡ååïŒåäžéFvïŒscFvïŒãšããŠç¥ãããïŒäŸãã°ãBirdïŒããŒãïŒã, ScienceïŒãµã€ãšã³ã¹ïŒ242:423-426, 1988ããã³HustonïŒãã¥ãŒã¹ãã³ïŒã, Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988ãåç
§ïŒã圢æããããã«å¯Ÿåœ¢æããããããã®æäœæçã¯æ¬æè¡ã«ãããçç·Žã®è
ã«ç¥ãããæ
£ç¿çæè¡ã䜿çšããŠåŸãããšãã§ããããã³æçã¯ç¡å·ã®æäœãšåãæ§åŒã§æçšæ§ã«ã€ããŠã¹ã¯ãªãŒãã³ã°ããããšãã§ãããæåçµåæ§æçã¯çµæãDNAæè¡ãç¡å·ã®å
ç«ã°ãããªã³ã®é
µçŽ ã«ããããŸãã¯ååŠçãªéè£ã«ãã£ãŠããŸãã¯ããå Žåã«ã¯ãæ¬æè¡ã«ãããŠç¥ãããååŠããããåææé ã«ãã£ãŠçç£ããããšãã§ããã
ããã§çšããããããã«ããæCD117æäœããŸãã¯ãCD117ã«çµåããæäœããšããçšèªã¯ãæäœãCD117ãæšçãšããéã«èšºæããã³/ãŸãã¯æ²»çå€ãšããŠæçšã§ãããããªååãªèŠªåæ§ã䌎ãCD117ã«çµåããèœåãããæäœã«èšåããã
ããã§çšããããããã«ããäºéç¹ç°æ§æäœããšããçšèªã¯æäœãäŸãã°ã¢ãã¯ããŒãã«ãããã®ããŸãã¯ããåã®æäœã«èšåããããã¯åãããŸãã¯çš®ã
ã®æåäžã«ããããšãã§ããå°ãªããšã2ã€ã®ç°ãªãæåãŸãã¯2ã€ã®ç°ãªããšãããŒããçµåããèœåããããäŸãšããŠãçµåç¹ç°æ§ã®1ã€ã¯é è¡å¹¹çŽ°èè¡šé¢æåäžã®ãšãããŒããäŸãã°ãCD117ïŒäŸã¯ãGNNK+CD117ïŒãªã©ã®ãããªãã®ã«åããããããšãã§ããããã³ä»ã®ãã®ã¯ç°ãªãé è¡å¹¹çŽ°èè¡šé¢æåãŸãã¯ä»ã®çŽ°èè¡šé¢ã¿ã³ãã¯è³ªäžã§ã®ãšãããŒããäŸãã°ã现èæé·ãã»ãã«ããããããããã匷åã«ããã·ã°ãã«äŒéçµè·¯ã«é¢äžããå容äœãŸãã¯å容äœãµããŠããããªã©ã®ãããªãã®ãç¹ç°çã«çµåããããšãã§ãããããããã®å®æœæ
æ§ã«ãããŠãçµåç¹ç°æ§ã¯åãæšçæåäžã®ãŠããŒã¯ãªãéè€ããŠããªããšãããŒãïŒå³ã¡ããã€ãã©ãããã¯æäœïŒbiparatopic antibodyïŒïŒã«åããããšãã§ããã
ããã§çšãããããè±å
ç«åããããŸãã¯ãè±å
ç«åããšããçšèªã¯å
ã®éçåæ§ç¯ç©ïŒãŸãã¯èŠªã®æäœïŒã®ä¿®é£Ÿã«é¢ããåèšéçåæ§ç¯ç©ïŒãŸãã¯èŠªã®æäœïŒãããã«ãããŠéå
ç«æ§ãŸãã¯ããäžå±€åŒ±ãå
ç«æ§ã§ããããã«ããããšã«ãããè±å
ç«åããæäœã¯éšåïŒãã®è€æ°åœ¢ïŒïŒpart(s)ïŒãäŸã¯ãéããèµ·æºã®ããã¬ãŒã ã¯ãŒã¯é åïŒãã®è€æ°åœ¢ïŒããã³/ãŸãã¯CDR(s)ãå«ããããã§çšããããããã«ãè±å
ç«åããæäœããšããçšèªã¯å¯Ÿè±¡ã®å
ç«ç³»ã掻æ§åãããªãããã«å€ç°ã«ãã£ãŠè±å
ç«åãããæäœã«èšåããïŒäŸãã°ãNanusïŒããã¹ïŒã, J. UrologyïŒã¶ã»ãžã£ãŒãã«ã»ãªãã»ãŠãããžãŒïŒ170: S84-S89, 2003ïŒåœéå
¬éWO98/52976ïŒWO00/34317ïŒã
ããã§çšããããããã«ãçžè£æ§æ±ºå®é åãïŒCDRïŒãšããçšèªã¯æäœã®è»œéããã³ééã®å¯å€ãã¡ã€ã³ã®äž¡æ¹ã«èŠåºãããè¶
å¯å€é åã«èšåãããå¯å€ãã¡ã€ã³ã®ããäžå±€é«åºŠã«ä¿åãããéšåã¯ãã¬ãŒã ã¯ãŒã¯é åïŒFRsïŒãšç§°ããããæäœã®è¶
å¯å€é åãç·åŒãããã¢ããé
žäœçœ®ã¯ãåœæè¡ã«ãããæ¢ç¥ã®ç¶æ³ããã³çš®ã
ã®èŠå®ã«å¿ããŠå€åããããšãã§ãããå¯å€ãã¡ã€ã³å
ã®ããã€ãã®äœçœ®ã¯ãã€ããªããè¶
å¯å€äœçœ®ïŒhybrid hypervariable positionsïŒãšã¿ãŠãããããã§ã¯ãããã®äœçœ®ã¯1çµã®åºæºã®äžã§è¶
å¯å€é åå
ã§ãããšã¿ãªããåŸãäžæ¹ãç°ãªã1çµã®åºæºã®äžã§ã¯è¶
å¯å€é åå€ã§ãããšã¿ãªãããšãã§ããããããã®äœçœ®ã®ãã¡ã®1以äžã¯ãŸãæ¡å€§ãããè¶
å¯å€é åã«ãèŠãã ãããšãã§ãããããã«èšèŒãããæäœã¯ãããã®ãã€ããªããè¶
å¯å€äœçœ®ã«ãããŠä¿®é£Ÿãå«ã¿åŸããèªç¶ãªééããã³è»œéã®å¯å€ãã¡ã€ã³ã¯ãããã4ã€ã®ãã¬ãŒã ã¯ãŒã¯é åãå«ãã§ãããããã¯äž»ã«Î²ã·ãŒãé
眮ïŒÎ²-sheet configurationïŒãæ¡çšããŠããã3ã€ã®CDRsã«ãã£ãŠæ¥ç¶ããããããã¯æ¥ç¶ãããã«ãŒãã圢æããããã³å Žåã«ãã£ãŠã¯Î²ã·ãŒãæ§é ã®éšåã圢æãããåãã§ãŒã³ã§ã®CDRsã¯é FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4ã§ã®ãã¬ãŒã ã¯ãŒã¯é åã«ãã£ãŠå¯æ¥ããŠäžç·ã«ä¿ãããããã³ä»ã®æäœéããã®CDRsãšå
±ã«ãæäœã®æšççµåéšäœã®åœ¢æã«å¯äžããïŒKabatãïŒet al.ïŒ, Sequences of Proteins of Immunological InterestïŒå
ç«åŠçé¢å¿ãããããã±ã質ã®é
åïŒ, National Institute of HealthïŒç±³åœåœç«è¡çç 究æïŒãBethesdaïŒãã»ãºãïŒãMDïŒç±³åœã¡ãªãŒã©ã³ãå·ïŒã1987ãåç
§ïŒãäžå®ã®å®æœæ
æ§ã§ã¯ãå¥ãªãµãã«æ瀺ãããªãéããKabatãã®å
ç«ã°ãããªã³ã¢ããé
žæ®åºã®ãã³ããªã³ã°ã¯ïŒä»»æã®æäœãã³ããªã³ã°ã¹ããŒã ãå¶éãããªããIMGTããã³ChothiaïŒãã§ãŒã·ã¢ïŒãå«ããŠå©çšããããšãã§ãããïŒå
ç«ã°ãããªã³ã¢ããé
žæ®åºçªå·ã¥ãã·ã¹ãã ã«åŸã£ãŠè¡ãããã
ããã§çšããããããã«ããã³ã³ãã£ã·ã§ã³ãããã³ãã³ã³ãã£ã·ã§ãã³ã°ããšããçšèªã¯ãã€ã·ã§ã³ãã移æ€ãäŸã¯ãé è¡å¹¹çŽ°èãå«ã移æ€ã®åå
¥ãã®ããã«æºåãããããã»ã¹ã«èšåããããã®ãããªæé ã¯é è¡å¹¹çŽ°è移æ€çµç¹ã®ççãä¿é²ããïŒäŸãšããŠãã³ã³ãã£ã·ã§ãã³ã°æé ããã³ãã®åŸã®é è¡å¹¹çŽ°è移æ€ã«ç¶ããŠãã€ã·ã§ã³ãããåé¢ãããè¡æ¶²ãµã³ãã«å
ã®çåå¯èœãªé è¡å¹¹çŽ°èã®éã«ãããæç¶çå¢å ããæšæž¬ãããïŒãããã«èšèŒã®æ¹æ³ã«ããã°ããã€ã·ã§ã³ãã¯ãADCãé è¡å¹¹çŽ°èã«ãã£ãŠçºçŸãããæåãäŸãã°ãCD117ïŒäŸã¯ãGNNK+CD117ïŒãªã©ã®ãããªãã®ã«çµåããèœåãããæäœããŸãã¯ãã®æåçµåæ§æçã®ãã€ã·ã§ã³ããžã®æäžã«ãã£ãŠé è¡å¹¹çŽ°è移æ€æ²»çã®ããã«ã³ã³ãã£ã·ã§ãã³ã°ããåŸããããã«èšèŒããããã«ãæäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCïŒã圢æããããã«ãæäœã¯çŽ°èæ¯çŽ ãšå
±æçµåã«ããã³ã³ãžã¥ã²ãŒã·ã§ã³ãåŸããé è¡å¹¹çŽ°è移æ€æ²»çãå¿
èŠãšãããã€ã·ã§ã³ãã«äžèšã®æåã®ãã¡ã®1以äžãçµåããèœåããããæäœããã®æåçµåæ§æçããŸãã¯ADCã®æäžã¯ãäŸãã°ãå
å æ§ã®é è¡å¹¹çŽ°èãéžæçã«æžå°ãããããšã«ãã£ãŠãé è¡å¹¹çŽ°è移æ€çã®ççãä¿é²ããããšãã§ããããã«ãã£ãŠå€å æ§ã®é è¡å¹¹çŽ°è移æ€ã«ãã£ãŠæºããããããŒã«ã³ã·ãŒïŒvacancyã空çœïŒãäœãåºãããã
ããã§çšããããçšèªãã³ã³ãžã¥ã²ãŒãããŸãã¯ãæäœè¬ç©ã³ã³ãžã¥ã²ãŒãããŸãã¯ãADCãã¯çŽ°èæ¯çŽ ïŒcytotoxinïŒã«é£çµãããæäœã«èšåãããADCã¯ããååãäŸãã°ãæäœãŸãã¯ãã®æåçµåæ§æçãªã©ã®ãããªãã®ãšã®åå¿æ§ã®æ©èœçåºãšãå¥ã®ååãäŸãã°ãããã«è¿°ã¹ã现èæ¯çŽ ãªã©ã®ãããªãã®ã®é©åã«åå¿æ§ã®ããæ©èœçåºãšã®éã®ååŠççµåã«ãã£ãŠåœ¢æããããã³ã³ãžã¥ã²ãŒãã«ã¯ãäºãã«çµåãã2ã€ã®ååéãäŸã¯ãæäœããã³çŽ°èæ¯çŽ éã®ãªã³ã«ãŒãå«ãŸãåŸããã³ã³ãžã¥ã²ãŒãã®åœ¢æã«äœ¿çšããããšãã§ãããªã³ã«ãŒã®äŸã«ã¯ããããããå«ããªã³ã«ãŒãäŸãã°ãèªç¶ã«çºçããããããã¯éèªç¶çºçããã¢ããé
žãäŸãã°ãD-ã¢ããé
žãªã©ã®ãããªãã®ãå«ãããããªã©ã®ãããªãã®ãå«ãŸããããªã³ã«ãŒã¯ããã«èšèŒãããããã³æ¬æè¡ã«ãããŠç¥ãããæ§ã
ãªæŠç¥ãçšããŠèª¿è£œããããšãã§ãããããã§ã®åå¿æ§æåã«å¿ããŠããªã³ã«ãŒã¯ãäŸãã°ãé
µçŽ ã«ããå æ°Žå解ãå
å解ãé
žæ§æ¡ä»¶äžã§ã®å æ°Žå解ãå¡©åºæ§æ¡ä»¶äžã§ã®å æ°Žå解ãé
žåããžã¹ã«ãã£ãéå
ãæ±æ žæ§éè£ããŸãã¯ææ©éå±éè£ïŒäŸãã°ãLericheïŒã¬ãªãã§ïŒã, Bioorg. Med. Chem.ïŒãã€ãªãªãŒã¬ããã¯ïŒã¡ãã£ã·ãã«ã»ã±ãã¹ããªãŒïŒ, 20:571-582ã2012ãåç
§ïŒã«ãã£ãŠéè£ããåŸããäžè¿°ã®ã³ã³ãžã¥ã²ãŒãã¯ãŸããããã§ã¯ããè¬ç©æäœã³ã³ãžã¥ã²ãŒããããæäœè¬ç©ã³ã³ãžã¥ã²ãŒããããã³ãADCããšã亀æå¯èœã«ç§°ãããã
ããã§çšããããããã«ããã«ãããªã³ã°åå¿ããšããçšèªã¯ããããã®çœ®æäœã«çµåããååæçãæ¥åããïŒäŸã¯ãå
±æçµåã«ããïŒååŠçã¢ã€ãšãã£ã圢æããããã«äºããšã®åå¿ã«é©ãã2以äžã®çœ®æåºãåå¿ããååŠåå¿ã«èšåãããã«ãããªã³ã°åå¿ã«ã¯ã现èæ¯çŽ ãäŸãã°ãåœæè¡ã§ç¥ããããŸãã¯ããã«èšèŒããã现èæ¯çŽ ãªã©ã®ãããªãã®ã§ããæçã«çµåããåå¿æ§çœ®æåºããæäœããŸãã¯ãã®æåçµåæ§æçãäŸãã°ãåœæè¡ã§ç¥ããããŸãã¯ããã«èšèŒããCD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒã«ç¹æãªãæäœããŸãã¯ãã®æåçµåæ§æçãªã©ã®ãããªãã®ã§ããæçã«çµåããé©åã«åå¿æ§ããã眮æåºãšåå¿ãããã®ãå«ããé©åã«åå¿æ§ããã眮æåºã®äŸã«ã¯ãæ±æ žå€/æ±é»åå€å¯ŸïŒäŸã¯ãããªãŒã«/ããã¢ã«ãã«ãã¢ãã¢ãã³/ã«ã«ããã«ãã¢ããŸãã¯ããªãŒã«/αãβäžé£œåã«ã«ããã«ãã¢ãã»ãã«ããããïŒããžãšã³/æ±ãžãšã³äœãã¢ïŒäŸã¯ãã¢ãžã/ã¢ã«ãã³ãã¢ãã»ãã«ããããïŒãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸãããã«ãããªã³ã°åå¿ã¯ãå¶éãããªãããããªãŒã«ã¢ã«ãã«åãããããã·ã«ã¢ã«ãã«åãã¢ãã³ã¢ã«ãã«åãã¢ãã³çž®åãã¢ããåããšã¹ãã«åããžã¹ã«ãã£ã圢æãä»å ç°åïŒäŸã¯ã[4+2]Diels-AlderïŒãã£ãŒã«ã¹-ã¢ã«ããŒïŒä»å ç°åã[3+2]HuisgenïŒãã¥ã¹ã²ã³ïŒä»å ç°åãã»ãã«ããããïŒãæ±æ žè³éŠæ眮æãæ±é»åè³éŠæ眮æãããã³æ¬æè¡ã«ãããæ¢ç¥ã®ãŸãã¯ããã«èšèŒãããä»ã®åå¿æ§ã¢ããªãã£ãŒãå«ãã
ããã§çšãããããCRUïŒcompetitive repopulating unitã競åçåå¢æ®åäœïŒãã¯é·æçç幹现èã®æž¬å®åäœã«èšåããããã¯ã€ã³ãã移æ€åŸã«æ€åºããããšãã§ããã
ããã§çšããããããã«ãè¬ç©å¯Ÿæäœæ¯ïŒdrug-to-antibody ratioïŒããŸãã¯ãDARãã¯çŽ°èæ¯çŽ ãäŸã¯ãã¢ãããã·ã³ã§ãADCã®æäœã«ä»çãããã®ã®æ°ã«èšåãããADCã®DARã¯1ãã8ãŸã§ã«åã¶ããšãã§ããããããäžå±€é«ãè² è·ããŸãæäœäžã®é£çµéšäœã®æ°ã«ãã£ãŠå¯èœã§ããããããããäžå®ã®å®æœæ
æ§ã«ãããŠãããã«èšèŒãããADCã¯ã1ã2ã3ã4ã5ã6ã7ããŸãã¯8ã®DARãæããã
ããã§çšããããããã«ãããããŒããšããçšèªã¯ãããŸãã¯åç©ã«èšåãããããã1以äžã®çŽ°èãã¬ã·ããšã³ãäžãžã®çŽ°èããŸãã¯ãã®ç¶ä»£ã®æäžã«å
ç«ã£ãŠåé¢ãããã1以äžã®çŽ°èã¯äŸãã°ãé è¡å¹¹çŽ°èã®éå£ã§ããåŸãã
ããã§çšããããããã«ãããã€ã¢ããã£ããšããèªã¯2ã€ã®ããªããããéãå«ãäºäŸ¡æäœã«èšåããããã§ã¯åããªããããéã¯åãããããéäžã®VHããã³VLãã¡ã€ã³ã®ååå
äŒåãå¯èœã«ããã«ã¯çããããªã³ã«ãŒïŒäŸã¯ã5ã€ã®ã¢ããé
žããæ§æããããªã³ã«ãŒïŒã«ãã£ãŠæ¥åãããVHããã³VLãã¡ã€ã³ãå«ãããã®é
眮ã«ãã£ãŠãåãã¡ã€ã³ã¯å¥ã®ããªããããéäžã®çžè£çãªãã¡ã€ã³ãšå¯Ÿã«ãªãããã¢äºéäœã®æ§é ã圢æããããšã«ãªãããããã£ãŠããããªã¢ããã£ããšããçšèªã¯3ã€ã®ããããéãå«ãäžäŸ¡ã®æäœã«èšåãããããã®åã
ã¯åãããããéå
ã§VHããã³VLãã¡ã€ã³ã®ååå
çµåãå¯èœã«ããéåžžã«çããªã³ã«ãŒïŒäŸã¯ã1-2ã¢ããé
žããæ§æããããªã³ã«ãŒïŒã«ãã£ãŠæ¥åãã1ã€ã®VHãã¡ã€ã³ããã³1ã€ã®VLãã¡ã€ã³ãå«ãããããã®èªç¶ãªæ§é ã«æãç³ãããã«ããã®ããã«æ§æãããããããã¯ãé£æ¥ããããããéã®VHããã³VLãã¡ã€ã³ã空éçã«äºãã«è¿æ¥ããããã«äœçœ®ä»ããããã«å
žåçã«äžéäœåœ¢æãããïŒäŸãã°ãHolligerïŒããªã¬ãŒïŒã, Proc. Natal. Acad. Sci. USA 90:6444-48, 1993ãåç
§ïŒã
ããã§çšããããããã«ããäºéå¯å€ãã¡ã€ã³ïŒdual variable domainïŒå
ç«ã°ãããªã³ãïŒãDVD-IgãïŒã¯ãå䟡ãäºéã¿ãŒã²ãã£ã³ã°åå€ïŒdual-targeting single agentïŒãäœãåºãããã«ãªã³ã«ãŒãä»ããŠ2ã€ã®ã¢ãã¯ããŒãã«æäœã®å€æ°é åã®æšççµåå¯å€ãã¡ã€ã³ãçµã¿åãããæäœã«èšåããïŒäŸãã°ãGuïŒã°ãŒïŒã, Meth. Enzymol.ïŒã¡ãœãã
ã»ã€ã³ã»ãšã³ã¶ã€ã¢ããžãŒïŒ, 502:25-41, 2012ãåç
§ïŒã
ããã§çšããããããã«ããå
å æ§ããšããèªã¯ç©è³ªãäŸãã°ãååã现èãçµç¹ããŸãã¯åšå®ãªã©ã®ãããªãã®ïŒäŸã¯ãé è¡å¹¹çŽ°èãŸãã¯é è¡ç³»çµ±ã®çŽ°èãäŸãã°ãå·šæ žçãæ çïŒthrombocyteïŒãè¡å°æ¿ïŒplateletïŒãèµ€è¡çããã¹ã现èãçèœçŽ°èïŒmyeoblastãããšãªãã©ã¹ãïŒã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢çŽ°èãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ãã©ãŒçŽ°èãTãªã³ãçããŸãã¯Bãªã³ãçãªã©ã®ãããªãã®ïŒãèšèŒããããã¯ç¹å®ã®ææ©äœãäŸãã°ããããã€ã·ã§ã³ããªã©ã®ãããªãã®ã«ãããŠèªç¶ã«èŠåºãããã
ããã§çšããããããã«ããççèœããšããçšèªã¯é è¡å¹¹çŽ°èããã³åé§çŽ°èãçµç¹ãåå¢æ®ããïŒrepopulateïŒèœåã«èšåããããã«ããã®ãããªçŽ°èãèªç¶ã«åŸªç°ããŠãããããŸãã¯ç§»æ€ã«ãã£ãŠæäŸããããã«é¢ä¿ãªãçšãããããçšèªã¯ççãåãå·»ãããŸãã¯ãããŸã§ã«è³ããã¹ãŠã®äºè±¡ãäŸãã°ã现èã®çµç¹åž°å·£ïŒtissue homingïŒããã³èå³ãããçµç¹å
ã§ã®çŽ°èã®ã³ãããŒåœ¢æãªã©ã®ãããªãã®ãå
å«ãããççå¹çãŸãã¯ççã®é床ã¯åœæè¡ã«ãããçç·Žã®è
ã«ç¥ããããããªèšåºçã«èš±å®¹å¯èœãªä»»æã®ãã©ã¡ãŒã¿ãçšããŠè©äŸ¡ãŸãã¯å®éåããããšãã§ããããã³äŸãã°ã競ååå¢æ®åäœïŒCRUïŒã®è©å®ïŒå¹¹çŽ°èãåž°å·£ããã³ãããŒåãããŸãã¯ççãããããšã«ãªã£ãïŒbecome engraftedïŒçµç¹ïŒãã®è€æ°åœ¢ïŒã«ãããããŒã«ãŒã®çµèŸŒã¿ãŸãã¯çºçŸïŒãŸãã¯çŸæ£ã®é²è¡ãéãã察象ã®é²æïŒprogressïŒã®è©äŸ¡ã«ãã£ãŠãé è¡å¹¹ããã³åé§çŽ°èã®çåããŸãã¯ã¬ã·ããšã³ãã®çåãå«ãããšãã§ãããççã¯ç§»æ€æéåŸã®éã«æ«æ¢¢è¡ã«ãããŠçœè¡çã«ãŠã³ãã枬å®ããããšã«ãã£ãŠã決ããããšãã§ãããççã¯ãŸãã骚é«åžåŒãµã³ãã«ã«ããããããŒçŽ°èã«ãã骚é«çŽ°èã®å埩ã枬å®ããããšã«ãã£ãŠãè©å®ããããšãã§ããã
ããã§çšããããããã«ãçšèªããšãããŒããã¯çµåã¿ã³ãã¯è³ªãäŸã¯ãæäœãŸãã¯ãã®æåçµåéšåã«ç¹ç°çã«çµåããèœåãããä»»æã®ããªãããã決å®åºãå«ããäžå®ã®å®æœæ
æ§ã«ãããŠããšãããŒã決å®åºã¯ååãäŸãã°ãã¢ããé
žãç³åŽéããã¹ããªã«ããŸãã¯ã¹ã«ããã«ãªã©ã®ãããªãã®ã®ååŠçã«æŽ»æ§ãªè¡šé¢ã°ã«ãŒãã³ã°ãå«ã¿ãããã³äžå®ã®å®æœæ
æ§ã«ãããŠãç¹å®ã®äžæ¬¡å
æ§é ç¹æ§ãããã³/ãŸãã¯ç¹å®ã®é»è·ç¹æ§ãæãåŸããæ§ã
ãªå®æœæ
æ§ã«ãããŠããšãããŒãã¯æåãå³ã¡ãCD117ã®äžæ¬¡æ§é ã®ãç·åœ¢ãŸãã¯é£ç¶ãããšãããŒããå³ã¡ãã¢ããé
žã®ç·åœ¢é
åã§ããåŸãããããã¯ãŸããä»ã®å®æœæ
æ§ã«ãããŠããšãããŒãã¯æåããã®äºæ¬¡æ§é ããšããšãã«ç¹å®ã®äžæ¬¡å
圢ç¶ãæããç«äœæ§é ãšãããŒãã§ããåŸããäŸãã°ãç«äœæ§é ãšãããŒãã¯æåã®éç·ç¶ãå³ã¡ãéé£ç¶çãªã¢ããé
žããæ§æããåŸãã
ç¹å®ã®å®æœæ
æ§ã«ãããŠããšãããŒãã¯çµåã¿ã³ãã¯è³ªãäŸã¯ãæäœãŸãã¯ãã®æåçµåéšåã«ãã£ãŠçµåãããæåã®é åã§ãããäžå®ã®å®æœæ
æ§ã§ã¯ãçµåã¿ã³ãã¯è³ªãäŸã¯ãæäœãŸãã¯ãã®æåçµåéšåã¯ãããã¿ã³ãã¯è³ªããã³/ãŸãã¯é«ååã®è€éãªæ··åç©ã«ãããŠãã®æšçæåãåªå
çã«èªèãããšããæåãç¹ç°çã«çµåãããšèšããããç¹å®ã®å®æœæ
æ§ã§ã¯ãæåã®ãšãããŒããå³ã¡ãCD117ã¯ãçµåã¿ã³ãã¯è³ªãæåã«çµåããŠãããšãã«çµåã¿ã³ãã¯è³ªãäŸã¯ãæäœãŸãã¯ãã®æåçµåéšåã®çŽ4ãªã³ã°ã¹ãããŒã ïŒâ«ïŒä»¥å
ã«ãããããã®ã¢ããé
žæ®åºãå«ãã
ããã§çšããããããã«ãçšèªãå€å æ§ãã¯ãç©è³ªãäŸãã°ååã现èãçµç¹ããŸãã¯åšå®ãªã©ã®ãããªãã®ïŒäŸã¯ïŒé è¡å¹¹çŽ°èãŸãã¯é è¡ç³»çµ±ã®çŽ°èãäŸãã°ãå·šæ žçãæ çãè¡å°æ¿ãèµ€è¡çããã¹ã现èã骚é«èœçïŒmyeoblastãããšãªãã©ã¹ãïŒã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢çŽ°èãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ãã©ãŒçŽ°èãTãªã³ãçããŸãã¯Bãªã³ãçãªã©ã®ãããªãã®ïŒãèšèŒããããã¯ç¹å®ã®ææ©äœãäŸãã°ããããã€ã·ã§ã³ããªã©ã®ãããªãã®ã«ãããŠèªç¶ã«èŠåºãããªããã¬ã·ããšã³ãææ©äœãäŸãã°ãã¬ã·ããšã³ããã€ã·ã§ã³ãã«å¯ŸããŠå€å æ§ã§ããç©è³ªã¯ããããŒææ©äœãäŸã¯ããã®ç©è³ªãç±æ¥ãããããŒå¯Ÿè±¡ã«ãããŠèªç¶ã«ååšãåŸããäŸãã°ãå皮现è移æ€çµç¹ã¯ã¬ã·ããšã³ãã«å¯Ÿãå€å æ§ã§ãããããããŒã«ã¯èªç¶ã§ãã现èãå«ããå€å æ§ç©è³ªã«ã¯ãå€éšäŸçµŠæºããææ©äœã«ãŸãã¯ããããæœåºãããå¹é€ç©ã«äŸçµŠããããã®ãå«ãŸããã
ããã§çšããããããã«ãããã¬ãŒã ã¯ãŒã¯é åããŸãã¯ãFWé åããšããçšèªã¯æäœãŸãã¯ãã®æåçµåæ§æçã®CDRsã«é£æ¥ããã¢ããé
žæ®åºãå«ããFWé åæ®åºã¯ãäŸãã°ãããæäœãããåæäœãã¢ãã¯ããŒãã«æäœãæäœæçãFabæçãåéæäœæçãscFvæçãæäœãã¡ã€ã³ãããã³äºéç¹ç°æ§æäœãã»ãã«ããããããããã«ååšãåŸãã
ãŸããæäŸããã®ã¯ãããã«èª¬æããé
åçªå·ïŒSEQ ID NOsïŒã«èŠå®ããé
åã®ãä¿åçé
å修食ïŒconservative sequence modificationsïŒããå³ã¡ããã¯ã¬ãªããé
åã«ãã£ãŠã³ãŒããããæäœã®æåãžã®çµåãŸãã¯ã¢ããé
žé
åã®å«æãæãªããªãïŒabrogateïŒãã¯ã¬ãªããããã³ã¢ããé
žé
å修食ã§ããããã®ãããªä¿åçé
å修食ã«ã¯ãä¿åçãã¯ã¬ãªããããã³ã¢ããé
žçœ®æããªãã³ã«ããã¯ã¬ãªããããã³ã¢ããé
žã®ä»å ããã³æ¬ 倱ãå«ãŸãããäŸãã°ã修食ã¯ãåœæè¡ã«ãããŠæ¢ç¥ã®æšæºçãªæè¡ãäŸãã°ãéšäœç¹ç°çå€ç°èªçºããã³PCRåªä»å€ç°èªçºãªã©ã®ãããªãã®ã«ãã£ãŠããã«èšèŒã®é
åçªå·ã«å°å
¥ããããšãã§ãããä¿åçé
å修食ã«ã¯ãä¿åçã¢ããé
žçœ®æãå«ãŸããããã§ã¯ãã¢ããé
žæ®åºã¯äŒŒãåŽéãæããã¢ããé
žæ®åºãšçœ®æããããé¡äŒŒã®åŽéãæããã¢ããé
žæ®åºã®ãã¡ããªãŒã¯åœæè¡ã«ãããŠå®çŸ©ãããŠããããããã®ãã¡ããªãŒã«ã¯ãå¡©åºæ§åŽéïŒäŸã¯ããªãžã³ãã¢ã«ã®ãã³ããã¹ããžã³ïŒãé
žæ§åŽéïŒäŸã¯ãã¢ã¹ãã©ã®ã³é
žãã°ã«ã¿ãã³é
žïŒãéè·é»æ¥µæ§åŽéïŒäŸã¯ãã°ãªã·ã³ãã¢ã¹ãã©ã®ã³ãã°ã«ã¿ãã³ãã»ãªã³ãã¹ã¬ãªãã³ãããã·ã³ãã·ã¹ãã€ã³ãããªãããã¡ã³ïŒãé極æ§åŽéïŒäŸã¯ãã¢ã©ãã³ãããªã³ããã€ã·ã³ãã€ãœãã€ã·ã³ããããªã³ããã§ãã«ã¢ã©ãã³ãã¡ããªãã³ïŒãããŒã¿åæåŽéïŒäŸã¯ãã¹ã¬ãªãã³ãããªã³ãã€ãœãã€ã·ã³ïŒããã³è³éŠæåŽéïŒäŸã¯ãããã·ã³ããã§ãã«ã¢ã©ãã³ãããªãããã¡ã³ããã¹ããžã³ïŒãæããã¢ããé
žãå«ãŸããããããããæCD117æäœã«ãããäºæž¬ãããéå¿
é ã¢ããé
žæ®åºã¯ãªãã¹ããªããåãåŽéãã¡ããªãŒããã®å¥ã®ã¢ããé
žæ®åºã§çœ®æããããæåçµåãæé€ããªããã¯ã¬ãªããããã³ã¢ããé
žã®ä¿åç眮æãèå¥ããæ¹æ³ã¯ãåœæè¡ã§ããç¥ãããŠããïŒäŸã¯ãBrummellïŒãã©ã³ã¡ã«ïŒã, Biochem.ïŒãã€ãªã±ãã¹ããªãŒïŒ32:1180-1187 (1993)ïŒKobayashiïŒã³ãã€ã·ïŒã Protein Eng.ïŒãããã€ã³ã»ãšã³ãžãã¢ãªã³ã°ïŒ12(10):879-884 (1999)ïŒããã³BurksïŒããŒã¯ã¹ïŒã Proc. Natl. Acad. Sci. USA 94:412-417 (1997)åç
§ïŒã
ããã§çšããããããã«ãçšèªãåæžæãã¯äœå
ã§ã®æäœè¬ç©ã®è¡ãããæ¿åºŠã«ã€ããŠå¯Ÿè±¡ãäŸã¯ããã察象ã«ãããŠååãŸãã¯50ïŒ
ãŸã§æžå°ããã®ã«èŠãããæéã«èšåããããã®50ïŒ
ã®è¡æž
æ¿åºŠã§ã®æžå°ã¯åŸªç°ããŠããè¬ç©ã®éãåæ ããã
ããã§çšããããããã«ãçšèªãé è¡å¹¹çŽ°èãïŒãHSCsãïŒã¯èªå·±åçããããã³å€æ§ãªç³»çµ±ãå«ãæçè¡æ¶²çŽ°èãå¶éãããªãããé¡ç²çïŒäŸã¯ãå骚é«çã奜äžçã奜é
žçã奜塩åºçïŒãèµ€è¡çïŒäŸã¯ã網ç¶èµ€è¡çãèµ€è¡çïŒãæ çïŒäŸã¯ãå·šæ žèœçãè¡å°æ¿ç£çå·šæ žèœçãè¡å°æ¿ïŒãåçïŒäŸã¯ãåçããã¯ããã¡ãŒãžïŒãæš¹ç¶çŽ°èããã¯ãã°ãªã¢çŽ°èãç ŽéªšçŽ°èãããã³ãªã³ãçïŒäŸã¯ãNK现èãB现èããã³T现èïŒãå«ãŸãããã®ã«ååããèœåãæããæªçè¡æ¶²çŽ°èã«èšåããããã®ãããªçŽ°èã¯CD34+现èãå«ã¿åŸããCD34+现èã¯CD34现èè¡šé¢ããŒã«ãŒãçºçŸããæªçãªçŽ°èã§ãããããã§ã¯ãCD34+现èã¯äžèšã«èŠå®ããã幹现èç¹æ§ãæãã现èã®äºéå£ãå«ããšèããããŠãããããã®äžæ¹ããŠã¹ã§ã¯ãHSCsã¯CD34-ã§ãããå ããŠãHSCsã¯ãŸãé·æåå¢æ®HSCsïŒLT-HSCïŒããã³çæåå¢æ®HSCsïŒST-HSCïŒã«ãèšåãããLT-HSCsããã³ST-HSCsã¯æ©èœçå¯èœæ§ã«ããã³çŽ°èè¡šé¢ããŒã«ãŒçºçŸã«åºã¥ãååãããäŸãã°ãããHSCsã¯ãCD34+ãCD38-ãCD45RA-ãCD90+ãCD49F+ãããã³lin-ïŒCD2ãCD3ãCD4ãCD7ãCD8ãCD10ãCD11BãCD19ãCD20ãCD56ãCD235Aãå«ãæç系統ããŒã«ãŒã«ã€ããŠã¯é°æ§ïŒã§ãããããŠã¹ã§ã¯ã骚é«LT-HSCsã¯ãCD34-ãSCA-1+ãC-kitïŒC-ãããïŒ+ãCD135-ãSlamfl/CD150+ãCD48-ãããã³lin-ïŒTer119ãCD11bãGr1ãCD3ãCD4ãCD8ãB220ãIL7raãå«ãæç系統ããŒã«ãŒã«ã€ããŠã¯é°æ§ïŒã§ããããã®äžæ¹ãST-HSCsã¯ãCD34+ãSCA-1+ãC-kit+ãCD135-ãSlamfl/CD150+ãããã³lin-ïŒTer119ãCD11bãGr1ãCD3ãCD4ãCD8ãB220ãIL7raãå«ãæç系統ããŒã«ãŒã«ã€ããŠã¯é°æ§ïŒã§ãããããã«ãST-HSCsã¯æåžžæ§æ¡ä»¶ã®äžã§LT-HSCsãããéæ¢ç¶æ
ãå°ãªããããã³å¢æ®æ§ãé«ããããããLT-HSCã¯èªå·±åçèœåïŒself renewal potentialïŒãããäžå±€é«ãïŒå³ã¡ããããã¯æäœæãŸã§çåããããã³é£ç¶ããïŒsuccessiveïŒã¬ã·ããšã³ããéããŠé£ç¶çã«ïŒseriallyïŒç§»æ€ããããšãã§ããïŒããã®äžæ¹ãST-HSCsã¯èªå·±åçã«éçãããïŒå³ã¡ããããã¯æéã®éãããæéããçåãããããã³é£ç¶ç§»æ€ã®å¯èœæ§ã¯ãªãïŒããããã®HSCsã®ãããããããã«èšèŒãããæ¹æ³ã«äœ¿çšããããšãã§ãããST-HSCsã¯ãããããé«åºŠã«å¢æ®æ§ã§ãããããã³ããããããäžå±€è¿
éã«ååããåå«ãçããããããšãã§ããããç¹ã«æçšã§ããã
ããã§çšããããããã«ããé è¡å¹¹çŽ°èæ©èœçèœåïŒhematopoietic stem cell functional potentialïŒããšããçšèªã¯é è¡å¹¹çŽ°èã®æ©èœçç¹æ§ã«èšåããããã«ã¯ã1ïŒå€èœæ§ïŒããã¯è€æ°ã®ç°ãªãè¡æ¶²ç³»çµ±ã«ååããèœåã«èšåããå¶éãããªãããé¡ç²çïŒäŸã¯ãå骚é«çã奜äžçã奜é
žçã奜塩åºçïŒãèµ€è¡çïŒäŸã¯ã網ç¶èµ€è¡çãèµ€è¡çïŒãæ çïŒäŸã¯ãå·šæ žèœçãè¡å°æ¿ç£çå·šæ žèœçãè¡å°æ¿ïŒãåçïŒäŸã¯ãåçããã¯ããã¡ãŒãžïŒãæš¹ç¶çŽ°èããã¯ãã°ãªã¢çŽ°èãç ŽéªšçŽ°èãããã³ãªã³ãçïŒäŸã¯ãNK现èãB现èããã³T现èïŒã2ïŒèªå·±åçïŒããã¯é è¡å¹¹çŽ°èãæ¯çŽ°èãšåçã®èœåãæããåšçŽ°èãçã¿åºãèœåãããã³ããã«ãã®èœåãåäœã®äžçã®éãã£ãšæ¯æžããããšãªãç¹°ãè¿ãèµ·ããããšã«èšåããïŒãããã³3ïŒé è¡å¹¹çŽ°èãŸãã¯ãã®åå«ã移æ€ã¬ã·ããšã³ãã«åå°å
¥ããããã®ããã§ãããã¯é è¡å¹¹çŽ°èãããã«åž°å·£ããããã³çç£çã§æç¶çãªé è¡ãå確ç«ããèœåãå«ãŸããã
ããã§çšããããããã«ããããæäœããšããçšèªã¯ããçæ®ç³»åå
ç«ã°ãããªã³é
åã«ç±æ¥ããå¯å€é åããã³å®åžžé åãæããæäœãå«ãããšãæå³ããŠãããããæäœã¯ããçæ®ç³»åå
ç«ã°ãããªã³é
åã«ãã£ãŠã³ãŒããããªãã¢ããé
žæ®åºïŒäŸã¯ãã€ã³ãããã§ã®ã©ã³ãã ãŸãã¯éšäœç¹ç°çå€ç°èªçºã«ãã£ãŠããŸãã¯éºäŒååé
åã®éã«ããŸãã¯ã€ã³ããã§ã®äœçŽ°èå€ç°ã«ãã£ãŠå°å
¥ãããå€ç°ïŒãå«ã¿åŸããããããªãããããã§çšãããããããæäœããšããçšèªã¯å¥ã®åºä¹³é¡çš®ãäŸãã°ãããŠã¹ãªã©ã®ãããªãã®ã®çæ®ç³»åã«ç±æ¥ããCDRé
åããããã¬ãŒã ã¯ãŒã¯é
åã«ç§»æ€ãããæäœãå«ãããšã¯æå³ããŠããªããããæäœã¯ãã现èã«ãããŠïŒäŸãã°ãçµæãçºçŸã«ãã£ãŠïŒããããã¯éããåç©ããŸãã¯æ©èœçã«åé
åãããããå
ç«ã°ãããªã³ïŒäŸãã°ãééããã³/ãŸãã¯è»œéãªã©ã®ãããªãã®ïŒã®éºäŒåãçºçŸããèœåãããåæ žçŽ°èãããã¯çæ žçŽ°èã«ãã£ãŠçç£ããããšãã§ãããããæäœãäžæ¬éæäœïŒsingle chain antibodyïŒã§ãããšããããã¯èªç¶ãªããæäœã«ã¯èŠãããªããªã³ã«ãŒãããããå«ãããšãã§ãããäŸãã°ãFvã¯ãªã³ã«ãŒãããããäŸãã°ã2ããçŽ8ãŸã§ã®ã°ãªã·ã³ãŸãã¯ä»ã®ã¢ããé
žæ®åºãªã©ã®ãããªãã®ãå«ãããšãã§ããããã¯ééã®å¯å€é åããã³è»œéã®å¯å€é åãé£çµããããã®ãããªãªã³ã«ãŒããããã¯ããç±æ¥ã§ãããšèãããããããæäœã¯ããå
ç«ã°ãããªã³é
åã«ç±æ¥ããæäœã©ã€ãã©ãªãŒãçšãããã¡ãŒãžãã£ã¹ãã¬ã€æ³ãå«ããŠåœæè¡ã§æ¢ç¥ã®æ§ã
ãªæ¹æ³ã«ãã£ãŠäœãããšãã§ãããããæäœã¯ãŸããæ©èœçãªå
å æ§å
ç«ã°ãããªã³ãçºçŸäžèœã§ããããããå
ç«ã°ãããªã³éºäŒåãçºçŸããããšãã§ãããã©ã³ã¹ãžã§ããã¯ããŠã¹ãçšããŠçç£ããããšãã§ããïŒäŸãã°ãPCT Publication Nos.ïŒPCTåœéå
¬éçªå·ïŒWO 1998/24893ïŒWO 1992/01047ïŒWO 1996/34096ïŒWO 1996/33735ïŒU.S. Patent Nos.ïŒç±³åœç¹èš±çªå·ïŒç¬¬5,413,923å·æ现æžïŒç¬¬5,625,126å·ïŒç¬¬5,633,425å·ïŒç¬¬5,569,825å·ïŒç¬¬5,661,016å·ïŒç¬¬5,545,806å·ïŒç¬¬5,814,318å·ïŒç¬¬5,885,793å·ïŒç¬¬5,916,771å·ïŒããã³ç¬¬5,939,598å·ãåç
§ïŒã
éããïŒäŸã¯ãããºããŸãã¯ã©ããïŒæäœã®ãããåã圢æ
ã¯éããå
ç«ã°ãããªã³ã«ç±æ¥ããæå°éé
åãå«ãå
ç«ã°ãããªã³ã§ãããæŠããŠãããåæäœã¯å°ãªããšã1ã€ãããã³å
žåçã«ã¯2ã€ã®å¯å€ãã¡ã€ã³ã®å®è³ªãã¹ãŠãå«ã¿ãããã§ã¯CDRé åã®ãã¹ãŠãŸãã¯å®è³ªãã¹ãŠãéããå
ç«ã°ãããªã³ã®ãã®ã«å¯Ÿå¿ããããã³FRé åã®ãã¹ãŠãŸãã¯å®è³ªãã¹ãŠãããå
ç«ã°ãããªã³é
åã®ãã®ã§ãããããåæäœã¯ãŸããå
ç«ã°ãããªã³å®åžžé åïŒFcïŒãå
žåçã«ã¯ããå
ç«ã°ãããªã³ã®ã³ã³ã»ã³ãµã¹é
åã®ãã®ã®å°ãªããšãäžéšåãå«ãããšãã§ãããæäœããåã®æ¹æ³ã¯åœæè¡ã§ç¥ãããããã³äŸãã°ãRiechmannïŒã©ã€ããã³ïŒã, Nature 332:323-7, 1988ïŒQueenïŒã¯ã€ãŒã³ïŒããžã®U.S. Patent Nos: 5,530,101ïŒ5,585,089ïŒ5,693,761ïŒ5,693,762ïŒããã³6,180,370ïŒEPïŒæ¬§å·ç¹èš±ïŒ239400ïŒPCT publication WO 91/09967ïŒU.S. Pat. No. 5,225,539å·ïŒEP592106å·ïŒEP519596å·ïŒPadlanïŒããã©ã³ïŒ, 1991, Mol. Immunol.ïŒã¢ã¬ãã¥ã©ãŒã»ã€ã ãããžãŒïŒ, 28: 489-498ïŒStudnickaïŒã¹ã¿ããããã«ïŒã, 1994, Prot. Eng.ïŒãããã€ã³ã»ãšã³ãžãã¢ãªã³ã°ïŒ7: 805-814ïŒRoguskaïŒãã°ã¹ã«ïŒã, 1994, Proc. Natl. Acad. Sci. 91:969-973ïŒããã³U.S. Pat. No. 5,565,332ã«èšèŒãããŠããã
ããã§çšããããããã«ãé è¡å¹¹çŽ°è移æ€ãã®å¿
èŠãããããã€ã·ã§ã³ãã«ã¯ã1以äžã®è¡æ¶²çŽ°èã¿ã€ãã®æ¬ æãŸãã¯æ¬ ä¹ïŒdefect or deficiencyïŒãèŠãããã€ã·ã§ã³ãããªãã³ã«å¹¹çŽ°èé害ãèªå·±å
ç«çŸæ£ãã¬ã³ããŸãã¯ããã«èšèŒã®ä»ã®ç
ç¶ãæãããã€ã·ã§ã³ããå«ããé è¡å¹¹çŽ°èã¯æŠããŠã1ïŒå€èœæ§ãããã³åŸã£ãŠè€æ°ã®ç°ãªãè¡æ¶²ç³»çµ±ã«ååããããšãã§ããå¶éãããªãããé¡ç²çïŒäŸã¯ãå骚é«çã奜äžçã奜é
žçã奜塩åºçïŒãèµ€è¡çïŒäŸã¯ã網ç¶èµ€è¡çãèµ€è¡çïŒãæ çïŒäŸã¯ãå·šæ žèœçãè¡å°æ¿ç£çå·šæ žçãè¡å°æ¿ïŒãåçïŒäŸã¯ãåçããã¯ããã¡ãŒãžïŒãæš¹ç¶çŽ°èããã¯ãã°ãªã¢çŽ°èãç ŽéªšçŽ°èãããã³ãªã³ãçïŒäŸã¯ãNK现èãB现èããã³T现èïŒãå«ãŸãã2ïŒèªå·±åçãããã³åŸã£ãŠæ¯çŽ°èãšåçã®èœåãæããåšçŽ°èãçã¿åºãããšãã§ããããã³3ïŒç§»æ€ã¬ã·ããšã³ãã«åå°å
¥ããããã®ããã§ãããã¯é è¡å¹¹çŽ°èãããã«åž°å·£ããããã³çç£çã§æç¶çãªé è¡ãå確ç«ããèœåãèŠãããããããã«ãé è¡å¹¹çŽ°èã¯ãæ¬ æãããŸãã¯æ¬ ä¹æ§ã®çŽ°èã®éå£ãã€ã³ããã§åæ§æããããã«é è¡ç³»çµ±ã®1以äžã®çŽ°èã¿ã€ãã«ãããŠæ¬ æãããŸãã¯æ¬ ä¹æ§ããããã€ã·ã§ã³ãã«æäžããããšãã§ãããäŸãã°ããã€ã·ã§ã³ãã¯ã¬ã³ãæ£ããã®ã§ããåŸãããã³æ¬ æã¯ã¬ã³æ§çŽ°èéå£ãéžæçãŸãã¯éç¹ç°çã«ã®ããããã«æžå°ãããååŠçæ³å€ãŸãã¯ä»ã®è¬ã®æäžã«ãã£ãŠåŒãèµ·ãããåŸããè¿œå ã§ãŸãã¯ä»£æ¿çã«ããã€ã·ã§ã³ãã¯ãç°åžžãã¢ã°ããã³çïŒäŸã¯ãéæªæ§ãã¢ã°ããã³çïŒãäŸãã°ãéç¶èµ€è¡ç貧è¡ããµã©ã»ãã¢ããã¡ã³ã³ããŒè²§è¡ãåçäžè¯æ§è²§è¡ïŒaplastic anemiaïŒããŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀ãªã©ã®ãããªãã®ãæ£ãåŸãã察象ã¯ã¢ããã·ã³ãã¢ãããŒãŒæ¬ æ-éçè€åå
ç«äžå
šïŒadenosine deaminase severe combined immunodeficiencyïŒïŒADA SCIDïŒãHIV/AIDSãç°ææ§çœè³ªãžã¹ãããã£ãŒããã€ã¢ã¢ã³ã-ãã©ãã¯ãã¡ã³è²§è¡ïŒDiamond-Blackfan anemiaïŒããã³ã·ã¥ã¯ãããã³-ãã€ã¢ã¢ã³ãçå矀ïŒSchwachman-Diamond syndromeïŒãæ£ã£ãŠãããã®ã§ããåŸãã察象ã¯éºäŒæ§è¡æ¶²çŸæ£ïŒäŸã¯ãéç¶èµ€è¡ç貧è¡ïŒãŸãã¯èªå·±å
ç«çŸæ£ãæãããããŸãã¯ãããã«ãã£ãŠåœ±é¿ãåãåŸããè¿œå ã§ãŸãã¯ä»£æ¿çã«ã察象ã¯æªæ§è
«çãäŸãã°ãç¥çµèœè
«ãŸãã¯è¡æ¶²åŠçã¬ã³ãªã©ã®ãããªãã®ãæãããããŸãã¯ãããã«ãã£ãŠåœ±é¿ããåŸããäŸãšããŠã察象ã¯çœè¡ç
ããªã³ãè
«ããŸãã¯éªšé«è
«ãæãåŸããããããã®å®æœæ
æ§ã§ã¯ã察象ã¯æ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«ããŸãã¯éããžãã³ãªã³ãè
«ãæãããããããã®å®æœæ
æ§ã§ã¯ã察象ã¯éªšé«ç°åœ¢æçå矀ãæãããããããã®å®æœæ
æ§ã§ã¯ã察象ã¯ãèªå·±å
ç«çŸæ£ãäŸãã°ã硬ç®ïŒåŒ·ç®ïŒçãå€çºæ§ç¡¬åçã朰çæ§å€§è
žçãã¯ããŒã³ç
ã1åç³å°¿ç
ããŸãã¯ããã«èšèŒã®å¥ã®èªå·±å
ç«ç
æ
ãªã©ã®ãããªãã®ãæãããããããã®å®æœæ
æ§ã§ã¯ã察象ã¯ãã¡ã©æåå容äœT现èïŒCARTïŒçæ³ã®å¿
èŠããããããããã®å®æœæ
æ§ã§ã¯ã察象ã¯ä»£è¬æ§èç©ïŒè²¯èµïŒé害ïŒmetabolic storage disorderïŒãæãããããŸãã¯ããã«ãã£ãŠå¥ãªãµãã«åœ±é¿ãåããŠããã察象ã¯ç³åç
ïŒglycogen storage diseasesãã°ãªã³ãŒã²ã³è²¯èµçŸæ£ïŒãã ã³å€ç³çïŒmucopolysaccharidosesãã ã³å€ç³æ²çïŒããŽãŒã·ã§ç
ïŒGaucher's DiseaseïŒãããŒã©ãŒç
ïŒHurlers DiseaseïŒãã¹ãã£ã³ãŽãªããçïŒsphingolipidosesïŒãç°ææ§çœè³ªãžã¹ãããã£ãŒïŒmetachromatic leukodystrophyãã¡ã¿ã¯ãããã£ãã¯çœè³ªãžã¹ãããã£ãŒïŒããŸãã¯ããã«é瀺ãããåŠçœ®ããã³çæ³ããå©çãåŸããåŸãä»»æã®ä»ã®çŸæ£ãããã¯é害ãããªã矀ããéžã°ãã代è¬æ§é害ã«èŠãããããŸãã¯ããã«ãã£ãŠå¥ãªãµãã«åœ±é¿ãåãåŸãããã³å¶éã䌎ããã«éçè€åå
ç«äžå
šããŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀ãé«å
ç«ã°ãããªã³MïŒIgMïŒçå矀ïŒhyper immunoglobulin M (lgM) syndromeïŒããã§ãã£ã¢ãã¯-æ±ç
ïŒChediak-Higashi diseaseïŒãéºäŒæ§ãªã³ãçµç¹ççïŒhereditary lymphohistiocytosisïŒã倧çç³éªšç
ïŒosteopetrosisïŒã骚圢æäžå
šãèç©çïŒstorage diseaseãæ²ççïŒããµã©ã»ãã¢ã¡ãžã£ãŒãéç¶èµ€è¡ççïŒsickle cell diseaseïŒãå
šèº«æ§ç¡¬åçãå
šèº«æ§ãšãªããããŒãã¹ãå€çºæ§ç¡¬åçãè¥å¹Žæ§é¢ç¯ãªãŠãããããã³ãBone Marrow Transplantation for Non-Malignant DiseaseïŒéæªæ§çŸæ£ã«ã€ããŠã®éªšé«ç§»æ€ïŒãASH Education BookïŒASHæè²ããã¯ïŒ, 1; 319-338(2000)ã«èšèŒãããŠãããããã®çŸæ£ããŸãã¯é害ãå«ãŸãããã®é瀺ã¯ãããé è¡å¹¹çŽ°è移æ€çæ³ã®ç®¡çã«ãã£ãŠåŠçœ®ããåŸãç
æ
ã«é¢é£ãããã®ãšããŠãã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸãããè¿œå çã«ãŸãã¯ä»£æ¿çã«ãé è¡å¹¹çŽ°è移æ€ãã®å¿
èŠãããããã€ã·ã§ã³ãã¯åè¿°ã®ç
æ
ã®1ã€ã«çœ¹æ£ããŠãããããŸãã¯çœ¹æ£ããŠããªãã§ãããããã§ãäœäžããã¬ãã«ïŒäŸã¯ãå¥ãªãµãã«å¥åº·ãªå¯Ÿè±¡ã®ãã®ãšæ¯ã¹ããã®ïŒã®ãé è¡ç³»çµ±å
ã®1以äžã®å
å æ§çŽ°èåã®ãã®ãäŸãã°ãå·šæ žçãæ çïŒthrombocytesïŒãè¡å°æ¿ãèµ€è¡çããã¹ã现èã骚é«èœçïŒmyeoblastãããšãªãã©ã¹ãïŒã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢çŽ°èãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ãã©ãŒçŽ°èãTãªã³ãçããŸãã¯Bãªã³ãçãªã©ã®ãããªãã®ãèŠãããåœæè¡ã«ãããçç·Žã®è
ã¯ãäŸãšããŠããããŒãµã€ãã¡ããªãŒããã³èå
掻æ§å现èéžå¥ïŒFACSïŒæ³ãã»ãã«ããããæ¬æè¡ã«ãããŠæ¢ç¥ã®ææ³ãçµç±ããåè¿°ã®çŽ°èã¿ã€ãã®1以äžããŸãã¯ä»ã®è¡æ¶²çŽ°èã¿ã€ãã®ãã®ã¬ãã«ããä»ã®å¥åº·ãªå¯Ÿè±¡ã«é¢ããŠäœäžããŠãããã©ããã簡䟿ã«å®ããããšãã§ããã
ããã§çšããããããã«ããäžæ§æäœãã¯ç¹å®ã®ãŸãã¯ç¹å®ããæšçïŒäŸã¯ãCD117ïŒã®æŽ»æ§ããªã¬ã³ããžã®å容äœã®çµåãŸãã¯é
µçŽ ã®åºè³ªãšã®çžäºäœçšãå«ãããã®ãèããäžåãé®æãæå¶ãææ¢ãäœæžãŸãã¯å¹²æžããããšãäžå¯èœã§ããæäœããŸãã¯ãã®æåçµåæçã«èšåãããäžå®æœæ
æ§ã§ã¯ãäžæ§æCD117æäœããŸãã¯ãã®æçã¯ãSCFäŸåæ§çŽ°èå¢æ®ãå®è³ªæå¶ãããããã³CD117ãžã®SCFçµåãã¯ãã¹ãããã¯ããªãæCD117æäœã§ãããäžæ§æäœã®äŸã¯Ab67ïŒãŸãã¯Ab67ã®çµåé åãæããæäœïŒã§ããã察ç
§çã«ããã¢ã³ã¿ãŽãã¹ããæCD117æäœã¯SCFäŸåæ§å¢æ®ãæå¶ããããã³CD117ãžã®SCFçµåãã¯ãã¹ãããã¯ããããšãã§ãããã¢ã³ã¿ãŽãã¹ãæäœã®äŸã¯Ab55ïŒãŸãã¯Ab55ã®çµåé åãæããæäœïŒã§ããã
ããã§çšããããããã«ãçšèªãã¬ã·ããšã³ããã¯ç§»æ€çãäŸãã°ãé è¡å¹¹çŽ°èã®éå£ãå«ã移æ€çãªã©ã®ãããªãã®ãåãããã€ã·ã§ã³ãã«èšåãããã¬ã·ããšã³ãã«æäžããã移æ€çŽ°èã¯ãäŸã¯ãèªå·±ç±æ¥ãåç³»ããŸãã¯å皮现èã§ããåŸãã
ããã§çšããããããã«ãçšèªããµã³ãã«ãã¯å¯Ÿè±¡ããæ¡åããæšæ¬ïŒäŸã¯ãè¡æ¶²ãè¡æ¶²æåïŒäŸã¯ãè¡æž
ãŸãã¯è¡ãããïŒãå°¿ãåŸæ¶²ãçŸæ°Žãè³èé«æ¶²ãçµç¹ïŒäŸã¯ãèç€ãŸãã¯ç®èïŒãèµæ¶²ã絚æ¯è絚æ¯ãµã³ãã«ãããã³çŽ°èïŒã«èšåããã
ããã§çšããããããã«ãçšèªãscFvãã¯æäœããã®ééããã³è»œéã®å¯å€ãã¡ã€ã³ã1ã€ã®éã圢æããããã«æ¥åããæäœã圢æããåéFvæäœã«èšåããscFvãã©ã°ã¡ã³ãïŒãã©ã°ã¡ã³ãã¯æçãšãããïŒã¯æäœè»œéã®å¯å€é åïŒVLïŒïŒäŸã¯ãCDR-L1ãCDR-L2ãããã³/ãŸãã¯CDR-L3ïŒããã³ãªã³ã«ãŒãä»ããŠæ¥ç¶ãããæäœééã®å¯å€é åïŒVHïŒïŒäŸã¯ãCDR-H1ãCDR-H2ãããã³/ãŸãã¯CDR-H3ïŒãå«ãåäžã®ããªããããéãå«ããscFvæçã®VLé åããã³VHé åãæ¥åãããªã³ã«ãŒã¯ã¿ã³ãã¯è³ªåæ§ã¢ããé
žããæ§æããããããããªã³ã«ãŒã§ããããšãã§ããã代æ¿ãªã³ã«ãŒã¯scFvæçã®ã¿ã³ãã¯è³ªå解ã«å¯Ÿããèæ§ãå¢å€§ãããããã«ïŒäŸãã°ãD-ã¢ããé
žãå«ããªã³ã«ãŒïŒãscFvæçã®æº¶è§£æ§ãé«ããããã«ïŒäŸãã°ã芪氎æ§ãªã³ã«ãŒãäŸãã°ãããªãšãã¬ã³ã°ãªã³ãŒã«å«æãªã³ã«ãŒãŸãã¯ã°ãªã·ã³ããã³ã»ãªã³æ®åºã®ç¹°è¿ããå«ãããªãããããªã©ã®ãããªãã®ïŒãååã®çç©ç©çåŠçå®å®æ§ãåäžãããããã«ïŒäŸãã°ãååå
ãŸãã¯ååéã®ãžã¹ã«ãã£ãçµåã圢æããã·ã¹ãã€ã³æ®åºãå«ããªã³ã«ãŒïŒããŸãã¯scFvæçã®å
ç«åæ§ãæžåŒ±ãããããã«ïŒäŸãã°ãã°ãªã³ã·ã«åéšäœãå«ããªã³ã«ãŒïŒäœ¿çšããããšãã§ããããŸããããã«èšèŒãããscFvååã®å¯å€é åã¯æäœååããã®ã¢ããé
žé
åã«ãããŠãããããããããç±æ¥ããŠãããããããå€åããããã«ä¿®é£Ÿãããããšãã§ããããšã¯ãåœæè¡ã«ãããéåžžã®æéã®è
ïŒåœæ¥è
ãšãèšãïŒã«ã¯ç解ãããã§ããããäŸãã°ã察å¿ããæäœã«ãã£ãŠèªèãããæåã«çµåããscFvã®èœåãç¶æãŸãã¯åŒ·åããããã«ãã¢ããé
žæ®åºã§ã®ä¿åç眮æãŸãã¯å€åããããããã¯ã¬ãªãããŸãã¯ã¢ããé
žçœ®æãè¡ãããšãã§ããïŒäŸã¯ãCDRããã³/ãŸãã¯ãã¬ãŒã ã¯ãŒã¯æ®åºã«ãããŠïŒã
ããã§çšãããããç¹ç°ççµåããŸãã¯ãç¹ç°çã«çµåããããšããçšèªã¯ãã¿ã³ãã¯è³ªäžè¬ã§ã¯ãªããç¹å®ã®ã¿ã³ãã¯è³ªæ§é ïŒãšãããŒãïŒãèªèããããã³çµåããæäœïŒãŸãã¯ADCïŒã®èœåã«èšåãããæäœããšãããŒããAãã«ç¹ç°çã§ããå ŽåãæšèãAãããã³æäœãå«ãåå¿ã«ãããŠããšãããŒãAãå«ãååïŒãŸãã¯éé¢ã®ãæªæšèAïŒã®ååšã¯ãæäœã«çµåããæšèAã®éãæžå°ããããäŸãšããŠãæäœã¯ãæäœããæšèããããšãã察å¿ããéæšèæäœã«ãã£ãŠãã®æšçããé¢ããŠç«¶åããããšãã§ããå Žåãæšçã«ãç¹ç°çã«çµåããããäžå®æœæ
æ§ã§ã¯ãæäœã¯ãæäœãå°ãªããšãçŽ10-4Mã10-5Mã10-6Mã10-7Mã10-8Mã10-9Mã10-10Mã10-11Mã10-12MããŸãã¯ããäžå±€å°ãªãæšçã«å¯ŸããKDïŒããäžå±€å°ãªãã¯10-12æªæºã§ããæ°ãäŸã¯ã10-13ãæå³ããïŒãæããŠããå ŽåãæšçãäŸã¯ãCD117ã«ç¹ç°çã«çµåãããäžå®æœæ
æ§ã§ã¯ãããã§çšãããããCD117ãžã®ç¹ç°ççµåããŸãã¯ãCD117ã«ç¹ç°çã«çµåããããšããçšèªã¯ãCD117ã«çµåããããã³è¡šé¢ãã©ãºã¢ã³å
±é³Žã«ãã£ãŠå®ãããã1.0Ã10-7MãŸãã¯ããæªæºã®è§£é¢å®æ°ïŒKDïŒãæããæäœïŒãŸãã¯ADCïŒã«èšåãããäžå®æœæ
æ§ã«ãããŠãKDïŒMïŒã¯æšæºçãªçäœå±€å¹²æžæ³ïŒbio-layer interferometeryïŒïŒBLIïŒã«åŸã£ãŠå®ãããããäžå®æœæ
æ§ã§ã¯ãKoffïŒ1/sïŒã¯æšæºçãªçäœå±€å¹²æžæ³ïŒBLIïŒã«åŸã£ãŠå®ãããããããããªãããæäœã¯é
åã«é¢é£ãã2以äžã®æåã«ç¹ç°çã«çµåããããšãå¯èœã§ããåŸãããšãç解ãããã¹ãã§ãããäŸãã°ãäžå®æœæ
æ§ã§ã¯ãæäœã¯CD117ã®ããããã³éããïŒäŸã¯ãããŠã¹ãŸãã¯éããéé·é¡ïŒãªã«ãœãã°ã®äž¡æ¹ã«ç¹ç°çã«çµåããããšãã§ãããäŸãã°ãäžå®æœæ
æ§ã§ã¯ãæäœã¯CD117ã®ããããã³éããïŒäŸãã°ãããŠã¹ãŸãã¯éããéé·é¡ïŒã®äž¡æ¹ã®ãªã«ãœãã°ã«ç¹ç°çã«çµåããããšãã§ããã
ããã§çšããããã察象ãããã³ããã€ã·ã§ã³ãïŒäººéã§èšããšãæ£è
ïŒããšããçšèªã¯ããã«èšèŒãããããã«ç¹å®ã®çŸæ£ãŸãã¯ç¶æ
ã«ã€ããŠåŠçœ®ãåããææ©äœãäŸãã°ããããªã©ã®ãããªãã®ã«èšåãããäŸãšããŠããã€ã·ã§ã³ããäŸãã°ããããã€ã·ã§ã³ããªã©ã®ãããªãã®ã¯å€å æ§é è¡å¹¹çŽ°èã®ççãä¿é²ããããã«é è¡å¹¹çŽ°è移æ€çæ³ã«å
ç«ã£ãŠåŠçœ®ãåãåŸãã
ããã§çšããããããã«ããè¡æ¶²ããå®è³ªçã«åãé€ãããšããèªå¥ã¯ãã€ã·ã§ã³ããžã®æ²»çäžè¬å€ïŒäŸãã°ãæCD117æäœããã®æåçµåæ§æçããŸãã¯äžã®æCD117 ADCãªã©ã®ãããªãã®ïŒã®æäžåŸã«ããã€ã·ã§ã³ãããåé¢ãããè¡æ¶²ãµã³ãã«ã«ãããŠæ²»çäžè¬å€ã®æ¿åºŠãæ²»çäžè¬å€ãæ
£ç¿çãªæ段ã«ãã£ãŠæ€åºããããšãã§ããªããããªãã®ã§ãããšãïŒäŸãšããŠãæ²»çäžè¬å€ã®æ€åºã®ããã«äœ¿çšããè£
眮ãŸãã¯ã¢ãã»ã€ã®ãã€ãºéŸå€ãè¶
ããŠæ€åºå¯èœã§ãªããããªãã®ïŒã®æç¹ã®ããšã«èšåãããåœæè¡ã«ãããŠæ¢ç¥ã®æ§ã
ãªæè¡ã¯ãæäœãæåçµåæ§æçãããã³ADCsãæ€åºããããã«ãäŸãã°ãåœæè¡ã«ãããŠæ¢ç¥ã®ããŸãã¯ããã«èšèŒã®ELISAããŒã¹ã®æ€åºã¢ãã»ã€ãªã©ã®ãããªãã®ã䜿çšããããšãã§ãããæäœããŸãã¯æäœæçãæ€åºããããã«äœ¿çšããããšãã§ããè¿œå ã®ã¢ãã»ã€ã«ã¯ãå
ç«æ²éæè¡ããã³ã€ã ãããããã¢ãã»ã€ãã»ãã«ããããåœæè¡ã§æ¢ç¥ã®ãã®ãå«ãã
ããã§çšããããããã«ãã幹现èé害ããšããèªå¥ã¯å¯Ÿè±¡ã®æšççµç¹ãã³ã³ãã£ã·ã§ãã³ã°ããããšïŒæ¡ä»¶ä»ããããšïŒã«ãã£ãŠãããã³/ãŸãã¯æšççµç¹ã«ãããå
å æ§å¹¹çŽ°èéå£ãåé€ããããšã«ãã£ãŠïŒäŸã¯ã察象ã®éªšé«çµç¹ããå
å æ§é è¡å¹¹çŽ°èãŸãã¯åé§çŽ°èéå£ãåé€ããããšïŒããã³/ãŸãã¯å¯Ÿè±¡ã®æšççµç¹ã«å¹¹çŽ°èãççãŸãã¯ç§»æ€ããããšã«ãã£ãŠåŠçœ®ãŸãã¯æ²»çãåŸãä»»æã®çŸæ£ãé害ããŸãã¯ç¶æ
ãåºç¯ã«æå³ãããäŸãã°ãIåç³å°¿ç
ã¯é è¡å¹¹çŽ°è移æ€ã«ãã£ãŠæ²»çãããããšã瀺ãããŠãããããã³ããã«èšèŒã®çµæç©ããã³æ¹æ³ã«åŸã£ãŠã³ã³ãã£ã·ã§ãã³ã°ããå©çãåŸããåŸããããã«èšèŒã®çµæç©ããã³æ¹æ³ãçšããŠåŠçœ®ããããšãã§ããè¿œå ã®é害ã«ã¯ãå¶éãããªãããéç¶èµ€è¡ç貧è¡ããµã©ã»ãã¢ããã¡ã³ã³ããŒè²§è¡ãåçäžè¯æ§è²§è¡ããŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀ãADA SCIDãHIV/AIDSãç°ææ§çœè³ªãžã¹ãããã£ãŒå€è²æ§çœè¡ç
ããã€ã€ã¢ã³ã-ãã©ãã¯ãã¡ã³è²§è¡ãããã³ã·ã¥ã¯ãã¯ãã³-ãã€ã¢ã¢ã³ãçå矀ãå«ãŸãããããã«èšèŒã®ãã€ã·ã§ã³ãã³ã³ãã£ã·ã§ãã³ã°ããã³/ãŸãã¯é è¡å¹¹çŽ°è移æ€æ¹æ³ãçšããŠåŠçœ®ããåŸãè¿œå ã®çŸæ£ã¯ãéºäŒæ§è¡æ¶²çŸæ£ïŒäŸã¯ãéç¶èµ€è¡ç貧è¡ïŒããã³èªå·±å
ç«çŸæ£ãäŸãã°ã硬ç®çãå€çºæ§ç¡¬åçã朰çæ§å€§è
žçãããã³ã¯ããŒã³ç
ãªã©ã®ãããªãã®ãææãããïŒinfludeïŒãããã«èšèŒã®ã³ã³ãã£ã·ã§ãã³ã°ããã³/ãŸãã¯ç§»æ€æ¹æ³ãçšããŠåŠçœ®ããåŸãè¿œå ã®çŸæ£ã«ã¯ãæªæ§è
«çãäŸãã°ãç¥çµèœè
«ãªã©ã®ãããªãã®ããŸãã¯è¡æ¶²åŠçã¬ã³ãäŸãã°ãçœè¡ç
ããªã³ãè
«ãããã³éªšé«è
«ãªã©ã®ãããªãã®ãå«ãŸãããäŸãšããŠãã¬ã³ã¯æ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«ããŸãã¯éããžãã³ãªã³ãè
«ã§ããåŸããããã«èšèŒã®ã³ã³ãã£ã·ã§ãã³ã°ããã³/ãŸãã¯ç§»æ€æ¹æ³ãçšããŠåŠçœ®å¯èœãªè¿œå ã®çŸæ£ã«ã¯ã骚é«ç°åœ¢æçå矀ãå«ãŸãããããããã®å®æœæ
æ§ã§ã¯ã察象ã¯ä»£è¬æ§èç©é害ãæãããããŸãã¯ããã«ãã£ãŠå¥ãªãµãã«åœ±é¿ãåããŠãããäŸãã°ã察象ã¯ç³åç
ãã ã³å€ç³çããŽãŒã·ã§ç
ãããŒã©ãŒç
ãã¹ãã£ã³ãŽãªããçãç°ææ§çœè³ªãžã¹ãããã£ãŒããŸãã¯ããã«é瀺ãããåŠçœ®ããã³çæ³ããå©çãåŸããåŸãä»»æã®ä»ã®çŸæ£ãããã¯é害ãããªã矀ããéžã°ãã代è¬æ§é害ã«èŠãããããŸãã¯ããã«ãã£ãŠå¥ãªãµãã«åœ±é¿ãåãåŸãããã³å¶éã䌎ããã«éçè€åå
ç«äžå
šããŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀ãé«å
ç«ã°ãããªã³MïŒIgMïŒçå矀ããã§ãã£ã¢ãã¯-æ±ç
ãéºäŒæ§ãªã³ãçµç¹ççã倧çç³éªšç
ã骚圢æäžå
šãèç©çããµã©ã»ãã¢ã¡ãžã£ãŒãéç¶èµ€è¡ççãå
šèº«æ§ç¡¬åçãå
šèº«æ§ãšãªããããŒãã¹ãå€çºæ§ç¡¬åçãè¥å¹Žæ§é¢ç¯ãªãŠãããããã³ãéæªæ§çŸæ£ã«ã€ããŠã®éªšé«ç§»æ€ããASH Education BookïŒASHæè²ããã¯ïŒ, 1; 319-338(2000)ã«èšèŒãããŠãããããã®çŸæ£ããŸãã¯é害ãå«ãŸãããã®é瀺ã¯ãããé è¡å¹¹çŽ°è移æ€çæ³ã®ç®¡çã«ãã£ãŠåŠçœ®ããåŸãç
æ
ã«é¢é£ãããã®ãšããŠãã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸããã
ããã§çšããããããã«ãçšèªããã©ã³ã¹ãã§ã¯ã·ã§ã³ãã¯åæ žçç©ãŸãã¯çæ žçç©å®¿äž»çŽ°èäžãžã®å€å æ§DNAã®å°å
¥ã«ã€ããŠæ®éã«äœ¿çšããå€çš®å€æ§ãªæè¡ãäŸãã°ããšã¬ã¯ãããã¬ãŒã·ã§ã³ããªããã§ã¯ã·ã§ã³ããªã³é
žã«ã«ã·ãŠã -æ²æ®¿ãDEAE-ããã¹ãã©ã³ãã©ã³ã¹ãã§ã¯ã·ã§ã³ããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ã®ãããªãã®ã®ããããã«èšåããã
ããã§çšããããããã«ãçšèªãåŠçœ®ããããŸãã¯ãåŠçœ®ãã¯çŸæ£çç¶ã®éç床ããã³/ãŸãã¯é »åºŠãäœæžããããšãçŸæ£çç¶ããã³/ãŸãã¯åèšçç¶ã®æ ¹æ¬åå ãæé€ããããšãçŸæ£çç¶ããã³/ãŸãã¯ãã®æ ¹æ¬åå ã®é »åºŠãŸãã¯å¯èœæ§ãäœæžããããšãããã³çŸæ£ã«ãã£ãŠçŽæ¥çãŸãã¯éæ¥çã«åŒãèµ·ããããæå·ãæ¹åãŸãã¯æ¯æ£ããããšãçŸæ£ã®ä»»æã®çµæãäŸãã°ã延åœïŒprolonged survivalïŒãç
çç¶æ
ã®è»œæžïŒless morbidityïŒãããã³/ãŸãã¯ä»£æ¿æ²»çæ§çžïŒalternative therapeutic modalityïŒã®å¯ç£ç©ã§ããå¯äœçšã軜æžããããšãªã©ã®ãããªãã®ã®ä»»æã®æ¹åã«èšåãïŒåœæè¡ã«ãããŠå®¹æã«ç解ãããããã«ãçŸæ£ã®ååãªæ ¹çµ¶ã¯å¥œãŸãããããšã¯ããåŠçœ®è¡çºã«ã€ããŠã®èŠä»¶ã§ã¯ãªããæçãªãŸãã¯æãŸããèšåºçµæã«ã¯ãå¶éãããªãããããã«èšèŒã®ãããªæäœã³ã³ãã£ã·ã§ãã³ã°çæ³ããã³ãã®åŸã®é è¡å¹¹çŽ°è移æ€çæ³åŸã®ãã€ã·ã§ã³ãã«ãããå€å æ§é è¡çŽ°èã®ççãä¿é²ããããšãå«ãŸãããè¿œå ã®æçãªçµæã«ã¯ãã³ã³ãã£ã·ã§ãã³ã°çæ³ããã³ãã®åŸã®ãã€ã·ã§ã³ããžã®å€å æ§é è¡å¹¹çŽ°è移æ€çã®æäžã«ç¶ãé è¡å¹¹çŽ°è移æ€ã®å¿
èŠããããã€ã·ã§ã³ãã«ãããé è¡å¹¹çŽ°èã®çŽ°èæ°ãŸãã¯çžå¯Ÿæ¿åºŠã«ãããŠã®å¢å€§ãå«ãŸãããããã«èšèŒã®çæ³ã®æçãªçµæã«ã¯ãŸããé è¡ç³»çµ±ãäŸãã°ãå·šæ žçãæ çãè¡å°æ¿ãèµ€è¡çããã¹ã现èãããšãªãã©ã¹ãã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢çŽ°èãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ãã©ãŒçŽ°èãTãªã³ãçããŸãã¯Bãªã³ãçãªã©ã®ãããªãã®ã®ã1以äžã®çŽ°èã®çŽ°èã«ãŠã³ããŸãã¯çžå¯Ÿæ¿åºŠã«ãããŠã®ã³ã³ãã£ã·ã§ãã³ã°çæ³ããã³ãã®åŸã®é è¡å¹¹çŽ°è移æ€çæ³ã«ç¶ããŠã®å¢å ãå«ãŸãåŸããè¿œå ã®æçãªçµæã«ã¯ãçŸæ£ãåŒãèµ·ãã现èéå£ãäŸãã°ãã¬ã³çŽ°èïŒäŸãã°ãCD117+çœè¡ç
现èïŒãŸãã¯èªå·±å
ç«çŽ°èïŒäŸã¯ãCD117+èªå·±å
ç«ãªã³ãçãäŸãã°ãèªå·±æåãšäº€å·®åå¿ããT现èå容äœãçºçŸããCD117+T现èãªã©ã®ãããªãã®ïŒã®éå£ãªã©ã®ãããªãã®ã®éã«ãããŠã®æžå°ãå«ã¿åŸããæ¬é瀺ã®æ¹æ³ãé害ãé²æ¢ããããšã«åããããéãããé²æ¢ããããšããçšèªã¯çŸæ£ç¶æ
ãå®å
šã«åŠšå®³ãããããšãå¿
èŠãšããªãããšãç解ããããããããããã§çšããããããã«ãé²æ¢ãšããçšèªã¯æ¬é瀺ã®ååç©ã®æäžãçŸæ£ã®çºçã«å
ç«ã¡èµ·ããåŸãããã«ãçç·Žããè·äººãé害ã«æåæ§ãããéå£ãèå¥ããèœåã«èšåãããçšèªã¯çŸæ£ç¶æ
ãå®å
šã«åé¿ãããããšãæå³ãããã®ã§ã¯ãªãã
ããã§çšããããããã«ããå€çš®ãããã³ã掟çç©ããšããçšèªã¯äºæçã«äœ¿çšãããããã³ããã«èšèŒããååç©ããããããã¿ã³ãã¯è³ªããŸãã¯ä»ã®ç©è³ªã®èªç¶ã«çºçãããåæã®ãããã³ååæã®é¡çžäœã«èšåãããããã«èšèŒããååç©ããããããã¿ã³ãã¯è³ªããŸãã¯ä»ã®ç©è³ªã®å€çš®ãŸãã¯æŽŸçç©ã¯å
ã®ç©è³ªã®çç©åŠç掻æ§ãä¿æãŸãã¯æ¹åãåŸãã
ããã§çšããããããã«ãçšèªããã¯ã¿ãŒãã¯æ žé
žãã¯ã¿ãŒãäŸãã°ããã©ã¹ãããDNAãã¯ã¿ãŒããã©ã¹ãããRNAãã¯ã¿ãŒããŠã€ã«ã¹ããŸãã¯ä»ã®é©åãªã¬ããªã³ã³ãªã©ã®ãããªãã®ãå«ããããã«èšèŒã®çºçŸãã¯ã¿ãŒã¯ããªãã¯ã¬ãªããé
åããªãã³ã«äŸãã°ãã¿ã³ãã¯è³ªã®çºçŸããã³/ãŸãã¯ãããã®ããªãã¯ã¬ãªããé
åã®åºä¹³åç©çŽ°èã®ã²ãã ãžã®çµèŸŒã¿ã«çšããããè¿œå ã®é
åèŠçŽ ãå«ã¿åŸããæ¬é瀺ã®æäœããã³æäœæçã®çºçŸã«ã€ããŠäœ¿çšããããšãã§ããäžå®ã®ãã¯ã¿ãŒã«ã¯ã調ç¯é
åãäŸãã°ãããã¢ãŒã¿ãŒããã³ãšã³ãã³ãµãŒé åãªã©ã®ãããªãã®ãå«ããã©ã¹ãããå«ãŸãããããã¯éºäŒå転åãæ瀺ãããæäœããã³æäœæçã®çºçŸã«æçšãªä»ã®ãã¯ã¿ãŒã¯ããããã®éºäŒåã®ç¿»èš³é床ãåäžããããŸãã¯éºäŒåã®è»¢åããçããmRNAã®å®å®æ§ãããã¯æ žå€èŒžéãåäžãããããªãã¯ã¬ãªããé
åãå«ãããããã®é
åèŠçŽ ã¯ãçºçŸãã¯ã¿ãŒäžã§éã°ããéºäŒåã®å¹ççãªè»¢åãæ瀺ããããã«ãäŸãã°ã5'ããã³3'é翻蚳é åããã³ããªã¢ããã«åã·ã°ãã«éšäœãå«ã¿åŸããããã«èšèŒã®çºçŸãã¯ã¿ãŒã¯ãŸãããã®ãããªãã¯ã¿ãŒãå«ã现èãéžæããããã®ããŒã«ãŒãã³ãŒãããããªãã¯ã¬ãªãããå«ãããšãã§ããã奜é©ãªããŒã«ãŒã®äŸã«ã¯ãæçç©è³ªãäŸãã°ãã¢ã³ãã·ãªã³ãã¯ãã©ã ãã§ãã³ãŒã«ãã«ããã€ã·ã³ãããã³ããŒã»ãªããªã·ã³ïŒnourseothricinïŒãªã©ã®ãããªãã®ã«å¯Ÿããèæ§ãã³ãŒãããéºäŒåãå«ãŸããã
ããã§çšããããçšèªãã¢ã·ã«ãã¯ã-C(=O)Rã«èšåããåŒäžRã¯æ°ŽçŽ ïŒãã¢ã«ããããïŒãã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã«ã«ãã·ã¯ãªã«ãã¢ãªãŒã«ããããã¢ãªãŒã«ããŸãã¯ãããã·ã¯ãªã«ã§ãããããã«èŠå®ããããã§ãããéå¶éçãªäŸã«ã¯ããã«ãã«ãã¢ã»ãã«ãããããã€ã«ããã³ãŸã€ã«ãããã³ã¢ã¯ãªãã€ã«ãå«ãŸããã
ããã§çšããããããã«ãçšèªãã¢ã«ãã«ãã¯ãäŸãã°ãéã«ãããŠ1ãã20åãŸã§ã®ççŽ ååãæããçŽéãŸãã¯åæéã®ã¢ã«ãã«åºã«èšåãããã¢ã«ãã«åºã®äŸã«ã¯ãã¡ãã«ããšãã«ãn-ãããã«ãã€ãœãããã«ãããã«ãã€ãœããã«ãsec-ããã«ãtert-ããã«ããã³ãã«ãã€ãœãã³ãã«ãtert-ãã³ãã«ãããã·ã«ãã€ãœããã·ã«ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªãã¢ã«ãã¬ã³ãã¯çŽéãŸãã¯åæéã®äºäŸ¡ã®ã¢ã«ãã«åºãæå³ãããäºäŸ¡ã®äœçœ®ã¯ã¢ã«ãã«éå
ã®åãããŸãã¯ç°ãªãååäžã§ãã£ãŠããããã¢ã«ãã¬ã³ã®äŸã«ã¯ãã¡ãã¬ã³ããšãã¬ã³ããããã¬ã³ãã€ãœãããã¬ã³ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªããããã¢ã«ãã«ãã¯ãäŸãã°ãéã«ãããŠ1ãã20åãŸã§ã®ççŽ ååãæããçŽéãŸãã¯åæéã¢ã«ãã«åºã«èšåããããã³éã«ãããŠ1以äžã®ãããååïŒäŸã¯ãé
žçŽ ãçªçŽ ããŸãã¯ç¡«é»ãã»ãã«ãããïŒãããã«å«ãŸããã
ããã§çšããããããã«ãçšèªããããã¢ã«ãã¬ã³ãã¯çŽéãŸãã¯åæéã®äºäŸ¡ã®ãããã¢ã«ãã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯ãããã¢ã«ãã«éå
ã®åãããŸãã¯ç°ãªãååäžã§ãã£ãŠããããäºäŸ¡ã®äœçœ®ã¯1以äžã®ãããååã§ãã£ãŠãããã
ããã§çšããããããã«ãçšèªãã¢ã«ã±ãã«ãã¯ãäŸãã°ãéã«ãããŠ2ãã20åãŸã§ã®ççŽ ååãæããçŽéãŸãã¯åæéã®ã¢ã«ã±ãã«åºã«èšåãããã¢ã«ã±ãã«åºã®äŸã«ã¯ãããã«ãããããã«ãã€ãœããããã«ããããã«ãtert-ããã¬ãã«ãããã»ãã«ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªãã¢ã«ã±ãã¬ã³ãã¯çŽéãŸãã¯åæéã®äºäŸ¡ã®ã¢ã«ã±ãã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯ã¢ã«ã±ãã«éå
ã®åãããŸãã¯ç°ãªãååäžã§ããåŸããã¢ã«ã±ãã¬ã³ã®äŸã«ã¯ããšããã¬ã³ãããããã¬ã³ãã€ãœããããã¬ã³ããããã¬ã³ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªããããã¢ã«ã±ãã«ãã¯ãäŸãã°ãéã«ãããŠ2ãã20åãŸã§ã®ççŽ ååãæããçŽéãŸãã¯åæéã¢ã«ã±ãã«åºã«èšåããããã³éã«ãããŠ1以äžã®ãããååïŒäŸã¯ãé
žçŽ ãçªçŽ ããŸãã¯ç¡«é»ãã»ãã«ãããïŒãããã«å«ãŸããã
ããã§çšããããããã«ãçšèªããããã¢ã«ã±ãã¬ã³ãã¯çŽéãŸãã¯åæéã®äºäŸ¡ã®ãããã¢ã«ã±ãã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯ãããã¢ã«ã±ãã«éå
ã®åãããŸãã¯ç°ãªãååäžã§ããåŸãã2䟡ã®äœçœ®ã¯1以äžã®ãããååã§ããåŸãã
ããã§çšããããããã«ãçšèªãã¢ã«ããã«ãã¯ãäŸãã°ãéã«ãããŠ2ãã20åãŸã§ã®ççŽ ååãæããçŽéãŸãã¯åæéã®ã¢ã«ããã«åºã«èšåãããã¢ã«ããã«åºã®äŸã«ã¯ããããã«ã®ã«ããããã«ããã³ããã«ãããã·ãã«ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªãã¢ã«ããã¬ã³ãã¯çŽéãŸãã¯åæéã®äºäŸ¡ã®ã¢ã«ããã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯ã¢ã«ããã«éå
ã®åãããŸãã¯ç°ãªãååäžã§ããåŸãã
ããã§çšããããããã«ãçšèªããããã¢ã«ããã«ãã¯ãäŸãã°ãéã«ãããŠ2ãã20åãŸã§ã®ççŽ ååãæããããã³éã«ãããŠ1以äžã®ãããååïŒäŸã¯ãé
žçŽ ãçªçŽ ããŸãã¯ç¡«é»ãã»ãã«ãããïŒãããã«å«ãçŽéãŸãã¯åæéã®ã¢ã«ããã«åºã«èšåããã
ããã§çšããããããã«ãçšèªããããã¢ã«ããã¬ã³ãã¯çŽéãŸãã¯åæéã®2䟡ã®ãããã¢ã«ããã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯ãããã¢ã«ããã«éå
ã®åãååäžã§ãç°ãªãååäžã§ããããäºäŸ¡ã®äœçœ®ã¯1以äžã®ãããååã§ãã£ãŠãããã
ããã§çšããããããã«ãçšèªãã·ã¯ãã¢ã«ãã«ãã¯ã飜åããããã³äŸãã°3ãã12åãŸã§ã®ççŽ ç°ååãæããåç°åŒããŸãã¯çž®åãæ¶æ©ããŸãã¯ã¹ããå€ç°åŒã®ç°æ§é ã®ãã®ã«èšåãããã·ã¯ãã¢ã«ãã«åºã®äŸã«ã¯ãã·ã¯ããããã«ãã·ã¯ãããã«ãã·ã¯ããã³ãã«ãã·ã¯ãããã·ã«ãã·ã¯ããããã«ãã·ã¯ããªã¯ãã«ããã·ã¯ã[3.1.0]ãããµã³ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªãã·ã¯ãã¢ã«ãã¬ã³ãã¯äºäŸ¡ã®ã·ã¯ãã¢ã«ãã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯ç°æ§é å
ã®åãããŸãã¯ç°ãªãååäžã§ãã£ãŠããããã·ã¯ãã¢ã«ãã¬ã³ã®äŸã«ã¯ãã·ã¯ããããã¬ã³ãã·ã¯ãããã¬ã³ãã·ã¯ããã³ãã¬ã³ãã·ã¯ãããã·ã¬ã³ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªããããã·ãã¢ã«ãã«ïŒheterocyloalkylïŒãã¯ã飜åããäŸãã°ãççŽ ååããã³äŸã¯ãçªçŽ ãé
žçŽ ãããã³ç¡«é»ãã»ãã«ãããããéžã°ãããããååããéžã°ããç°æ§é ããã3ãã12ãŸã§ã®ç°ååãæããåç°ããŸãã¯çž®åãæ¶æ©ãŸãã¯ã¹ããå€ç°åŒç°æ§é ã®ãã®ã«èšåãããç°æ§é ã¯ãäŸãã°ãççŽ ãçªçŽ ããŸãã¯ç¡«é»ã®ç°ç¶ã¡ã³ããŒïŒring membersïŒäžã«1以äžã®ãªããœåºãå«ãã§ãããããããã·ã¯ãã¢ã«ãã«ã®äŸã«ã¯ãäŸãçµç±ããŠãããã³å¶éãããªããããžãããããªãžã«ïŒdihydroypyridylïŒãããã©ãããããªãžã«ïŒãããªãžã«ïŒãããã©ãããããªãã§ãã«ããããªãžãã«ã4-ãããªããã«ããããªãžãã«ã2-ãããªããã«ïŒããã©ããããã©ãã«ãããã©ããããã©ãã«ããã¹ããã©ããããã©ãã«ãããã©ããããããªãã«ãããã©ãããã€ãœãããªãã«ããã«ããããããªãã«ããªã¯ã¿ãããã€ãœãããªãã«ãããã©ãžãã«ãããã¯ãªãžãã«ãããã³ã¢ã«ããªãã«ãå«ãŸããã
ããã§çšããããããã«ãçšèªããããã·ã¯ãã¢ã«ãã¬ã³ãã¯äºäŸ¡ã®ãããã·ã¯ãã¢ã«ãã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯ç°æ§é å
ã®åãããŸãã¯ç°ãªãååäžã§ãã£ãŠãããã
ããã§çšããããããã«ãçšèªãã¢ãªãŒã«ãã¯ãäŸãã°ã6ãã19åãŸã§ã®ççŽ ååãå«ãåç°åŒãŸãã¯å€ç°åŒã®è³éŠç°ç³»ã®ãã®ã«èšåãããã¢ãªãŒã«åºã«ã¯ãå¶éãããªããããã§ãã«ããã«ãªã¬ãã«ããããã«ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã2䟡ã®äœçœ®ã¯1以äžã®ãããååã§ãã£ãŠãããã
ããã§çšããããããã«ãçšèªãã¢ãªãŒã¬ã³ãã¯2䟡ã®ã¢ãªãŒã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯åãããŸãã¯ç°ãªãååäžã§ãã£ãŠãããã
ããã§çšããããããã«ãçšèªããããã¢ãªãŒã«ãã¯åç°åŒè€çŽ è³éŠæããŸãã¯1以äžã®ç°ååããããååãäŸã¯ãçªçŽ ãé
žçŽ ããŸãã¯ç¡«é»ã§ããäºç°åŒãããã¯äžç°åŒçž®åç°åŒè€çŽ è³éŠæåºã«èšåããããããã¢ãªãŒã«åºã«ã¯ãããªãžã«ããããªã«ãããªã«ãããšãã«ãã€ãããŸãªã«ããªããµãŸãªã«ãã€ãœãªããµãŸãªã«ããã¢ãŸãªã«ãã€ãœãã¢ãŸãªã«ããã©ãŸãªã«ã1,2,3-ããªã¢ãŸãªã«ã1,2,4-ããªã¢ãŸãªã«ã1,2,3-ãªããµãžã¢ãŸãªã«ã1,2,4-ãªããµãžã¢-ãŸãªã«ã1,2,5-ãªããµãžã¢ãŸãªã«ã1,3,4-ãªããµãžã¢ãŸãªã«ã1,3,4-ããªã¢ãžãã«ã1,2,3-ããªã¢ãžãã«ããã³ãŸããªã«ã[2,3-ãžããã]ãã³ãŸããªã«ãã€ãœãã³ãŸããªã«ããã³ãŸããšãã«ããã³ãŸããªã¢ãŸãªã«ãã€ãœãã³ãŸããšãã«ãã€ã³ããªã«ãã€ãœã€ã³ããªã«ã3H-ã€ã³ããªã«ããã³ãºã€ãããŸãªã«ãã€ãããŸ[1,2-a]ããªãžã«ããã³ãŸãã¢ãŸãªã«ããã³ãŸãªããµãŸãªã«ããããªãžãã«ããããŸãªãã«ããã¿ã©ãžãã«ïŒpthalazinylããã¿ã©ãžãã«ïŒãããããµãªãã«ïŒquinoxalinylïŒãã·ããªãã«ãããããªãžãã«ïŒnapthyridinylãããããªãžãã«ïŒãããªã[3,4-b]ããªãžã«ãããªã[3.2-b]ããªãžã«ãããªã[4,3-b]ããªãžã«ããããªã«ãã€ãœãããªã«ãããã©ãŸãªã«ã5,6,7,8-ããã©ããããããªã«ã5,6,7,8-ããã©ãããã€ãœãããªã«ãããªãã«ããããªãžãã«ãã«ã«ããŸãªã«ãããµã³ããã«ïŒxanthenylãããµã³ã»ãã«ïŒããã³ãŸãããªã«ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããã
ããã§çšããããããã«ãçšèªããããã¢ãªãŒã¬ã³ãã¯äºäŸ¡ã®ãããã¢ãªãŒã«åºã«èšåãããäºäŸ¡ã®äœçœ®ã¯åãããŸãã¯ç°ãªãååäžã«ãã£ãŠããããäºäŸ¡ã®äœçœ®ã¯1以äžã®ãããååã§ãã£ãŠãããã
åã
ã®çœ®æåºã®èŠå®ã«ãã£ãŠå¥ãªãµãã«å¶çŽãããªãéããåè¿°ã®ååŠçã¢ã€ãšãã£ãäŸãã°ããã¢ã«ãã«ãããã¢ã«ãã¬ã³ããããããã¢ã«ãã«ããããããã¢ã«ãã¬ã³ãããã¢ã«ã±ãã«ãããã¢ã«ã±ãã¬ã³ããããããã¢ã«ã±ãã«ããããããã¢ã«ã±ãã¬ã³ãããã¢ã«ããã«ãããã¢ã«ããã¬ã³ããããããã¢ã«ããã«ããããããã¢ã«ããã¬ã³ãããã·ã¯ãã¢ã«ãã«ãããã·ã¯ãã¢ã«ãã¬ã³ããããããã·ã¯ãã¢ã«ãã«ãããããã·ã¯ãã¢ã«ãã¬ã³ãããã¢ãªãŒã«ãããã¢ãªã¬ã³ïŒaryleneïŒããããããã¢ãªãŒã«ããããã³ããããã¢ãªã¬ã³ãåºãªã©ã®ãããªãã®ã¯ãäŸãã°ãã¢ã«ãã«ãã¢ã«ã±ãã«ãã¢ã«ããã«ãã·ã¯ãã¢ã«ãã«ããããã·ã¯ãã¢ã«ãã«ãã¢ã«ãã«ã¢ãªãŒã«ãã¢ã«ãã«ãããã¢ãªãŒã«ãã¢ã«ãã«ã·ã¯ãã¢ã«ãã«ãã¢ã«ãã«ãããã·ã¯ãã¢ã«ãã«ãã¢ãããã¢ã³ã¢ããŠã ãã¢ã·ã«ãã¢ã·ã«ãªãã·ãã¢ã·ã«ã¢ãããã¢ããã«ã«ããã«ãã¢ã«ã³ãã·ã«ã«ããã«ããŠã¬ã€ããã«ã«ãããŒããã¢ãªãŒã«ããããã¢ãªãŒã«ããµã«ãã£ãã«ãã¹ã«ããã«ãã¢ã«ã³ãã·ããµã«ãã¡ãã«ãããã²ã³ãã«ã«ããã·ãããªããã¡ãã«ãã·ã¢ããããããã·ãã¡ã«ã«ãããããããããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãããªã矀ããéžã°ãã1ãã5åãŸã§ã®çœ®æåºã«ããéæã«çœ®æãããããšãã§ãããå
žåçãªçœ®æåºã«ã¯ãå¶éãããªããã-Xã-Rã-OHã-ORã-SHã-SRãNH2ã-NHRã-N(R)2ã-N+(R)3ã-CX3ã-CNã-OCNã-SCNã-NCOã-NCSã-NOã-NO2ã-N3ã-NC(=O)Hã-NC(=O)Rã-C(=O)Hã-C(=O)Rã-C(=O)NH2ã-C(=O)N(R)2ã-SO3-ã-SO3Hã-S(=O)2Rã-OS(=O)2ORã-S(=O)2NH2ã-S(=O)2N(R)2ã-S(=O)Rã-OP(=O)(OH)2ã-OP(=O)(OR)2ã-P(=O)(OR)2ã-PO3ã-PO3H2ã-C(=O)Xã-C(=S)Rã-CO2Hã-CO2Rã-CO2-ã-C(=S)ORã-C(=O)SRã-C(=S)SRã-C(=O)NH2ã-C(=O)N(R)2ã-C(=S)NH2ã-C(=S)N(R)2ã-C(=NH)NH2ãããã³-C(=NR)N(R)2ãå«ãŸãïŒåŒäžãåXã¯FãClãBrãããã³Iããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒããã³åRã¯ã¢ã«ãã«ãã¢ãªãŒã«ããããã·ã¯ãã¢ã«ãã«ãŸãã¯ãããã¢ãªãŒã«ãä¿è·åºããã³ãããã©ãã°ã¢ã€ãšãã£ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãããåºããéæã«çœ®æãããŠããããšèšèŒãããŠããã©ã®ãããªå Žåã§ãããã®åºã¯åå Žé¢ã«ã€ããŠç¡é¢ä¿ã«1以äžã®äžèšã®çœ®æåºã«ãã眮æããåŸãã眮æã«ã¯ãäŸãã°ãé£æ¥ãã眮æåºãè¿æ¥ããå®èœæ§çœ®æåºã®éç°ãªã©ã®ãããªãã®ãçµãŠãäŸãšããŠãäŸãã°ãä¿è·åºãäžããããã«éç°ã«ãã£ãŠåœ¢æãããã©ã¯ã¿ã ãã©ã¯ãã³ãç°ç¶ç¡æ°Žç©ãã¢ã»ã¿ãŒã«ãããã¢ã»ã¿ãŒã«ãããªã¢ã»ã¿ãŒã«ãã¢ãããŒã«ãããã³ããã¢ãããŒã«ãªã©ã®ãããªãã®ã圢æããããã«éç°ãåããç¶æ³ãå«ã¿åŸãã
äžå®ã®ã©ãžã«ã«ã®åœåèŠåã¯æèã«å¿ããŠã¢ãã©ãžã«ã«ãŸãã¯ãžã©ãžã«ã«ã®ãããããå«ãããšãã§ããããšãç解ãããã¹ãã§ãããäŸãã°ã眮æåºãååã®æ®äœãžã®2ã€ã®ä»çç¹ãå¿
èŠãšããå Žåã眮æåºã¯ãžã©ãžã«ã«ã§ãããšç解ããããäŸãã°ãã¢ã«ãã«ãšããŠèå¥ããã眮æåºã§ã2ç¹ã®ä»çãå¿
èŠãªãã®ã«ã¯ããžã©ãžã«ã«ãäŸãã°ã-CH2-ã-CH2CH2-ã-CH2CH(CH3)CH2-ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ã®ãããªãã®ãå«ãŸãããä»ã®ã©ãžã«ã«åœåèŠåã¯ã©ãžã«ã«ããžã©ãžã«ã«ãäŸãã°ããã¢ã«ãã¬ã³ãããã¢ã«ã±ãã¬ã³ãããã¢ãªãŒã¬ã³ããããããã·ã¯ãã¢ã«ãã¬ã³ããããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ã®ãããªãã®ã§ããããšãæ確ã«æã瀺ãã
眮æåºããžã©ãžã«ã«ãšããŠæãããŠããã©ã®ãããªå Žåã§ãïŒå³ã¡ãååã®æ®äœã«å¯ŸããŠ2ã€ã®ä»çç¹ãæããïŒãå¥ãªãµãã«æã瀺ãããªãéãã眮æåºã¯ä»»æã®æ¹åã®é
眮ã«ãããŠä»çããããšãã§ãããšç解ãããã¹ãã§ããã
ãç°æ§ãã¯åååŒãåãã§ãããããããã®ååã®çµåã®é åºã«ãããŠãŸãã¯ç©ºéã«ããããããã®ååã®é
眮ã«ãããŠç°ãªãååç©ãæå³ããããããã®ååã®ç©ºéã«ãããé
眮ã«ãããŠç°ãªãç°æ§äœã¯ãç«äœç°æ§äœããšåŒã¶ãäºãã«é¡åã§ãªãç«äœç°æ§äœãããžã¢ã¹ãã¬ãªç°æ§äœããããã³ãäºãã®éé¡åã§ããç«äœç°æ§äœãããšãã³ããªããŒãããŸãã¯æã«ã¯ãå
åŠç°æ§äœããšåŒã¶ã
4ã€ã®éåäžçœ®æåºã«çµåããççŽ ååã¯ããã©ã«äžå¿ããšç§°ããããããã©ã«ç°æ§äœãã¯å°ãªããšã1ã€ã®ãã©ã«äžå¿ãæããååç©ãæå³ããã1ãããå€ãã®ãã©ã«äžå¿ãæããååç©ã¯ãåã
ã®ãžã¢ã¹ãã¬ãªããŒãšããŠããŸãã¯ããžã¢ã¹ãã¬ãªããŒæ··åç©ããšåŒã°ãããžã¢ã¹ãã¬ãªããŒã®æ··åç©ãšããŠã®ããããã§ååšãåŸãã1ã€ã®ãã©ã«äžå¿ãååšãããšããç«äœç°æ§äœã¯ãã®ãã©ã«äžå¿ã®çµ¶å¯Ÿé
眮ïŒRãŸãã¯SïŒã«ãã£ãŠç¹åŸŽä»ãããåŸãã絶察é
眮ã¯ãã©ã«äžå¿ã«ä»çããŠãã眮æåºã®ç©ºéã«ãããé
眮ã«èšåãããèæ
®äžã®ãã©ã«äžå¿ã«ä»çãã眮æåºã¯CahnïŒã«ãŒã³ïŒãIngoldïŒã€ã³ãŽãŒã«ãïŒããã³PrelogïŒãã¬ããŒã°ïŒã®ã·ãŒã±ã³ã¹ã»ã«ãŒã«ïŒSequence RuleïŒã«åŸã£ãŠã©ã³ã¯ä»ããããïŒCahn ã, Angew. Chem. Inter. Edit.ïŒã¢ã³ã²ãŽã¡ã³ãã»ã±ããŒã»ã€ã³ã¿ãŒãã·ã§ãã«ã»ãšãã£ã·ã§ã³ïŒ1966, 5, 385; errataïŒæ£èª€è¡šïŒ511; CahnãAngew. Chem. 1966, 78, 413; Cahnããã³Ingold, J. Chem. Soc.ïŒãžã£ãŒãã«ã»ãªãã»ã¶ã»ã±ãã«ã«ã»ãœãµãšãã£ïŒ1951 (LondonïŒãã³ãã³ïŒ), 612; Cahnã, ExperientiaïŒãšã¯ã¹ããªãšã³ãã£ã¢ïŒ1956, 12, 81; Cahn, J. Chem. Educ.ïŒãžã£ãŒãã«ã»ãªãã»ã±ãã«ã«ã»ãšãã¥ã±ãŒã·ã§ã³ïŒ1964, 41, 116ïŒãå察ã®ãã©ãªãã£ãŒã®åã
ã®ãšãã³ããªããŒåœ¢æ
ïŒenantiomeric formsãé¡åç°æ§äœåœ¢æ
ãªã©ãšãèšãïŒãçéå«ãæ··åç©ã¯ãã©ã»ãæ··åç©ããšåŒã°ããã
ãã®æ现ã«ãããŠããã³è«æ±ã®ç¯å²ã«ãããŠé瀺ããååç©ã¯ã1以äžã®é察称äžå¿ãå«ãã§ããŠããããããã³åã
ã®ååç©ã®ç°ãªããžã¢ã¹ãã¬ãªããŒããã³/ãŸãã¯ãšãã³ããªããŒãååšããŠãããããã®æ现ã«ãããããã³è«æ±ã®ç¯å²ã«ãããä»»æã®ååç©ã®èšè¿°ã¯ãå¥ãªãµãã«è¿°ã¹ãªãéãããã¹ãŠã®ãšãã³ããªããŒããžã¢ã¹ãã¬ãªããŒãããã³ãããã®æ··åç©ãå«ãããšãæå³ãããè¿œå çã«ããã®æ现ã«ãããããã³è«æ±ã®ç¯å²ã«ãããä»»æã®ååç©ã®èšèŒã¯ãå¥ãªãµãã«è¿°ã¹ãªãéããåã
ã®ãšãã³ããªããŒãããã³ãšãã³ããªããŒã®ã©ã»ããŸãã¯å¥ãªãµãã«ä»»æã®æ··åç©ã®äž¡æ¹ãå«ãããšãæå³ãããååç©ã®æ§é ãç¹å®ã®ãšãã³ããªããŒãšããŠæãããŠãããšããæ¬åºé¡ã®é瀺ã¯ãã®ç¹å®ã®ãšãã³ããªããŒã«å¶éãããªããšç解ãããããããã£ãŠãæ¬é瀺ã®åã
ã®æ§é åŒã®ãšãã³ããªããŒãå
åŠç°æ§äœãããã³ãžã¢ã¹ãã¬ãªããŒãããã«ãããŠäŒå³ããããæ¬æ现ã«ãããŠãååç©ã®æ§é åŒã¯ããããã®å Žåã«ãããŠäŸ¿å®äžäžå®ã®ç°æ§äœã代衚ããããæ¬é瀺ã¯ãã¹ãŠã®ç°æ§äœãäŸãã°ã幟äœç°æ§äœãé察称ççŽ ã«åºã¥ãå
åŠç°æ§äœãç«äœç°æ§äœãäºå€ç°æ§äœãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ã®ãããªãã®ãå«ã¿ããã¹ãŠã®ç°æ§äœãåãã¬ãã«ã®æŽ»æ§ãæãããšã¯éããªãããšãç解ããããååç©ã¯ç°ãªãäºå€ç°æ§åœ¢æ
ã§çºçããŠããããæ¬é瀺ã«ããååç©ã¯å¥ãªãµãã«è¿°ã¹ãªãéãããã¹ãŠã®äºå€ç°æ§äœãå«ãããšãæå³ãããååç©ã®æ§é ãç¹å®ã®äºå€ç°æ§äœãšããŠæããããšããæ¬åºé¡ã®é瀺ã¯ãã®ç¹å®ã®äºå€ç°æ§äœã«å¶éãããªãããšãç解ãããã
ããã«èšèŒããä»»æã®åŒã®ååç©ã¯ãååç©ãããèªäœããªãã³ã«ãããã®å¡©ãããã³è©²åœããå Žåã«ã¯ãããã®æº¶åªåç©ãå«ããå¡©ã¯ãäŸãã°ãã¢ããªã³ããã³æ¬é瀺ã®ååç©äžã®æ£ã«åž¯é»ããåºïŒäŸã¯ãã¢ããïŒéã§åœ¢æããããšãã§ãããé©åãªã¢ããªã³ã«ã¯ãå¡©åç©ãèåç©ããšãŠåç©ãç¡«é
žå¡©ãéç¡«é
žå¡©ãã¹ã«ãã¡ãã³é
žå¡©ãç¡é
žå¡©ããªã³é
žå¡©ãã¯ãšã³é
žå¡©ãã¡ã¿ã³ã¹ã«ãã³é
žå¡©ãããªãã«ãªãé
¢é
žå¡©ãã°ã«ã¿ãã³é
žå¡©ãã°ã«ã¯ãã³é
žå¡©ãã°ã«ã¿ã«é
žå¡©ããªã³ãŽé
žå¡©ããã¬ã€ã³é
žå¡©ããã¯ãé
žå¡©ãããã«é
žå¡©ãé
ç³é
žå¡©ããã·ã©ãŒãïŒãã«ãšã³ã¹ã«ãã³é
žå¡©ïŒããµãªãã«é
žå¡©ãä¹³é
žå¡©ãããã¿ã¬ã³ã¹ã«ãã³é
žå¡©ãããã³é
¢é
žå¡©ïŒäŸã¯ãããªãã«ãªãé
¢é
žå¡©ïŒãå«ãŸãããçšèªã調å€äžèš±å®¹å¯èœãªã¢ããªã³ãã¯èª¿å€äžèš±å®¹å¯èœãªå¡©ã圢æããã®ã«é©ããã¢ããªã³ã«èšåãããåæ§ã«ãå¡©ã¯ãŸããã«ããªã³ããã³æ¬é瀺ã®ååç©äžã®è² ã«åž¯é»ããåºïŒäŸã¯ãã«ã«ãã³é
žå¡©ïŒéã§ã圢æããããšãã§ããã奜é©ãªã«ããªã³ã«ã¯ããããªãŠã ã€ãªã³ãã«ãªãŠã ã€ãªã³ããã°ãã·ãŠã ã€ãªã³ãã«ã«ã·ãŠã ã€ãªã³ãããã³ã¢ã³ã¢ããŠã ã«ããªã³ãäŸãã°ãããã©ã¡ãã«ã¢ã³ã¢ããŠã ã€ãªã³ãªã©ã®ãããªãã®ãå«ãŸãããããã€ãã®å¥œé©ãªçœ®æã¢ã³ã¢ããŠã ã€ãªã³ã®äŸã¯ã以äžïŒãšãã«ã¢ãã³ããžãšãã«ã¢ãã³ããžã·ã¯ãããã·ã«ã¢ãã³ãããªãšãã«ã¢ãã³ãããã«ã¢ãã³ããšãã¬ã³ãžã¢ãã³ããšã¿ããŒã«ã¢ãã³ããžãšã¿ããŒã«ã¢ãã³ãããã©ãžã³ããã³ãžã«ã¢ãã³ããã§ãã«ãã³ãžã«ã¢ãã³ãã³ãªã³ãã¡ã°ã«ãã³ãããã³ããã¡ã¿ãã³ããªãã³ã«ã¢ããé
žãäŸãã°ããªãžã³ããã³ã¢ã«ã®ãã³ãªã©ã®ãããªãã®ããèªå°ããããã®ã§ããããŸããæ¬é瀺ã®ååç©ã«ã¯ã4çŽçªçŽ ååãå«ããããã®å¡©ãå«ãŸããã
奜é©ãªç¡æ©ã¢ããªã³ã®äŸã«ã¯ãå¶éãããªããã以äžã®ç¡æ©é
žïŒå¡©é
žãèåæ°ŽçŽ é
žããšãŠåæ°ŽçŽ é
žãç¡«é
žãäºç¡«é
žãç¡é
žãäºç¡é
žããªã³é
žãããã³äºãªã³é
žããå°ãåºããããã®ãå«ãŸãããé©åãªææ©ã¢ããªã³ã®äŸã«ã¯ãå¶éãããªããã以äžã®ææ©é
žïŒ2-ã¢ã»ããªãã·å®æ¯éŠé
žãé
¢é
žãã¢ã¹ã³ã«ãã³é
žãã¢ã¹ãã©ã®ã³é
žãå®æ¯éŠé
žãã«ã³ãã¡ãŒã¹ã«ãã³é
žãæ¡ç®é
žãã¯ãšã³é
žããšããé
žããšã¿ã³ãžã¹ã«ãã³é
žããšã¿ã³ã¹ã«ãã³é
žãããã«é
žãã°ã«ã³ãããã³é
žãã°ã«ã³ã³é
žïŒgluconicïŒãã°ã«ã¿ãã³é
žãã°ãªã³ãŒã«é
žãããããã·ãã¬ã€ã³é
žãããããã·ããã¿ã¬ã³ã«ã«ãã³é
žãã€ã»ããªã³é
žãä¹³é
žãã©ã¯ãããªã³é
žãã©ãŠãªã³é
žããã¬ã€ã³é
žããªã³ãŽé
žãã¡ã¿ã³ã¹ã«ãã³é
žãã ãã³é
žããªã¬ã€ã³é
žãã·ã¥ãŠé
žããã«ããã³é
žããã¢é
žããã³ããã³é
žããã§ãã«é
¢é
žããã§ãã«ã¹ã«ãã³é
žãããããªã³é
žããã«ãã³é
žããµãªãã«é
žãã¹ãã¢ãªã³é
žããã¯ãé
žãã¹ã«ãã¡ãã«é
žãé
ç³é
žããã«ãšã³ã¹ã«ãã³é
žãããã³åèé
žããèªå°ããããã®ãå«ãŸãããé©åãªé«ååææ©ã¢ããªã³ã®äŸã«ã¯ãå¶éãããªããã以äžã®é«ååé
žïŒã¿ã³ãã³é
žãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ããå°ãåºããããã®ãå«ãŸããã
è¿œå çã«ãæ¬é瀺ã®ååç©ãäŸãã°ããã®ååç©ã®å¡©ã¯ãæ°Žåç©ãŸãã¯ç¡æ°Žåç©ïŒç¡æ°Žç©ïŒã®ããããã®åœ¢æ
ã«ãããŠããŸãã¯ä»ã®æº¶åªååãšã®æº¶åªåç©ãšããŠååšããããšãã§ãããæ°Žåç©ã®éå¶éçãªäŸã«ã¯ãäžæ°Žåç©ãäºæ°Žåç©ããªã©ãå«ãŸããã溶åªåç©ã®éå¶éçãªäŸã«ã¯ããšã¿ããŒã«æº¶åªåç©ãã¢ã»ãã³æº¶åªåç©ããªã©ãå«ãŸãããã溶åªåç©ãã¯ååŠéè«çãŸãã¯éååŠéè«çã®ãããããšããŠã®éã®æº¶åªãå«ã溶åªä»å 圢æ
ãæå³ãããããããã®ååç©ã¯çµæ¶æ§åºåœ¢ç¶æ
ã«ãããŠæº¶åªååãäžå®ã®ã¢ã«æ¯ã§ææãããããã溶åªåç©ã圢æãããåŸåãããã溶åªãæ°Žã®å Žåã圢æããã溶åªåç©ã¯æ°Žåç©ã§ããïŒããã³æº¶åªãã¢ã«ã³ãŒã«ã®å Žåã圢æããã溶åªåç©ã¯ã¢ã«ã³ã©ãŒãïŒã¢ã«ã³ãŒã«åç©ïŒã§ãããæ°Žåç©ã¯1åå以äžã®æ°Žããã³1ååã®ç©è³ªã®çµåãã«ãã£ãŠåœ¢æãããããã§ã¯æ°Žã¯H2OãšããŠã®ãã®ååç¶æ
ãä¿æãããæ°Žåç©ã¯ãäŸãã°ãäžæ°Žåç©ãäºæ°Žåç©ãäžæ°Žåç©ããªã©ã«èšåããã
å ããŠãçµæ¶å€åœ¢ã¯ãããã«é瀺ãããåŒã«ãã£ãŠè¡šãããååç©ãŸãã¯ãã®å¡©ã«ã€ããŠååšãåŸããä»»æã®çµæ¶åœ¢æ
ãçµæ¶åœ¢æ
æ··åç©ããŸãã¯ãã®ç¡æ°Žç©ãããã¯æ°Žåç©ã¯æ¬é瀺ã®ç¯å²ã«ãããŠå«ãŸããããšã«æ³šç®ãããã
æCD117æäœ
æCD117æäœ
æ¬é瀺ã¯ãæ²»çç®çã«æçšãªæ°èŠãªæCD117æäœããã³ãã®æåçµåæ§éšåïŒantigen binding portionsïŒã®çºèŠã«éšåçã«åºã¥ããæ¬é瀺ã¯ãŸããCD117ãäŸãã°ãGNNKïŒCD117ãªã©ã®ãããªãã®ãçµåããããšãå¯èœãªæäœãŸãã¯ãã®æåçµåæ§æçããïŒiïŒCD117ïŒçŽ°èã«ãã£ãŠç¹åŸŽä»ããããã¬ã³ïŒäŸãã°ãæ¥æ§éªšé«æ§çœè¡ç
ãŸãã¯éªšé«ç°åœ¢æçå矀ãªã©ã®ãããªãã®ïŒããã³èªå·±å
ç«çŸæ£ãåŠçœ®ããããã³ïŒiiïŒç§»æ€æ²»çãå¿
èŠãšããŠãããã€ã·ã§ã³ãã«ããã移æ€é è¡å¹¹çŽ°èã®ççä¿é²ããããã«åç¬ã§æ²»çå€ãšããŠãŸãã¯ADCsãšããŠäœ¿çšã§ããããšãçºèŠããããšã«éšåçã«åºã¥ãããããã®æ²»ç掻æ§ã¯äŸãšããŠã现èãäŸãã°ãã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èãªã©ã®ãããªãã®ã®è¡šé¢ã«çºçŸããCD117ïŒäŸã¯ãGNNK+CD117ïŒã«å¯ŸããŠæCD117æäœãŸãã¯ãã®æåçµåæ§æçïŒantigen-binding fragmentsïŒãçµåããããã³ãã®åŸã«çŽ°èæ»ãèªå°ãããããšã«ãã£ãŠåŒãèµ·ããããšãã§ãããå
å æ§é è¡å¹¹çŽ°èãæ¯æžããããšã§ã移æ€ãããé è¡å¹¹çŽ°èãåž°å·£ããããšãã§ããããããæäŸããããã³ãã®åŸã«çç£çãªé è¡ã確ç«ããããšãã§ããããã®ããã«ããŠã移æ€ãããé è¡å¹¹çŽ°èã¯ããã«èšèŒã®å¹¹çŽ°èäžèª¿ãæ£ããã€ã·ã§ã³ããäŸãã°ããããã€ã·ã§ã³ããªã©ã®ãããªãã®ã«ãããŠéŠå°ŸããççãåŸãã
ããCD117ïŒãŸãc-KitãmRNA NCBI Reference SequenceïŒåç
§é
åïŒïŒNM_000222.2ãã¿ã³ãã¯è³ªNCBIåç
§é
åïŒNP_000213.1ãšã称ãããïŒãçµåããããšãå¯èœãªæäœããã³æåçµåæ§æçã¯GNNK+CD117ã«çµåããããšãå¯èœãªãã®ãå«ããé è¡å¹¹çŽ°è移æ€çæ³ã®ããã«ãã€ã·ã§ã³ããã³ã³ãã£ã·ã§ãã³ã°ããããã«ãããã«èšèŒã®çµæç©ããã³æ¹æ³ãšçµã¿åãããŠäœ¿çšããããšãã§ãããæ¯éå£ã®ããªãã®å²åã«ãããŠCD117ã®ã³ãŒãé åãŸãã¯çŽ°èå€ãã¡ã€ã³ã«åœ±é¿ãåãŒãå€åã¯ãéãªã³ã³ããžãŒé©å¿ïŒnon-oncology indicationsïŒã«ãããŠç®äžããç¥ãããŠã¯ããªããCD117ã«ã¯å°ãªããšã4ã€ã®ã¢ã€ãœãã©ãŒã ãèå¥ãããŠãããè
«ç现èã«ãããŠçºçŸããè¿œå ã®ã¢ã€ãœãã©ãŒã ãååšããå¯èœæ§ãæãããCD117ã¢ã€ãœãã©ãŒã ã®ãã¡2ã€ã¯ã¿ã³ãã¯è³ªã®çŽ°èå
ãã¡ã€ã³äžã«äœçœ®ãããããã³2ã€ã¯å€éšèè¿åé åïŒexternal juxtamembrane regionïŒã«ååšããã现èå€ã®2ã€ã®ã¢ã€ãœãã©ãŒã ãGNNK+ããã³GNNK-ã¯ã4ã€ã®ã¢ããé
žé
åã®ååšïŒGNNK+ïŒãŸãã¯äžååšïŒGNNK-ïŒã®éãã§ç°ãªãããããã®ã¢ã€ãœãã©ãŒã ã¯ãªã¬ã³ãïŒSCFïŒã«å¯Ÿãã芪åæ§ã¯åãã§ããããGNNK-ã¢ã€ãœãã©ãŒã ã«ãªã¬ã³ããçµåãããšãã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ããã³å解ãä¿é²ãããããšãå ±åãããŠããããã®ã¢ã€ãœãã©ãŒã ã«å¯ŸããŠçæãããæäœã¯GNNK+ããã³GNNK-ã¿ã³ãã¯è³ªãå
å«ããããšã«ãªãã®ã§ãCD117ãšçµåå¯èœãªæäœãçæããããã«ãGNNK+ã¢ã€ãœãã©ãŒã ãå
ç«åãšããŠäœ¿çšããããšãã§ããã
ããã€ãã®å®æœæ
æ§ã§ã¯ãæäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã®ã¢ããé
žæ®åºå
ã«äœçœ®ãããšãããŒãã«ãŠããCD117ãšçµåãããé
åçªå·1ã¯ããCD117æåã«å¯Ÿå¿ããããã³ä»¥äžã®ã¢ããé
žé
åãæããïŒ
QPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTHHHHHH (é åçªå·1).
QPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKLQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGGTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPHTHHHHHH (é åçªå·1).
PCT/US2018/057172ïŒãã®é瀺å
容ã¯ãã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸããïŒã«èšèŒãããŠããããã«ãæ²»ççšéãæããæ°èŠãªæCD117æäœãããã³ãã®æçãèå¥ããããã«ããæäœã®é
µæ¯ã©ã€ãã©ãªã¹ã¯ãªãŒãã³ã°ãå®è¡ããããã»ãã«ããããæäœ67ïŒAb67ïŒã¯ãã®ã¹ã¯ãªãŒã³ã«ãããŠèå¥ãããã
Ab67ã®ééå¯å€é åïŒVHïŒã¢ããé
žé
åã¯é
åçªå·2ãšããŠä»¥äžã«æäŸãããAb67ã®VH CDRã¢ããé
žé
åã¯äžã«äžç·ãåŒããããã³æ¬¡ã®ããã§ããïŒFTFSDADMDïŒVH CDR1ïŒé
åçªå·3ïŒïŒRTRNKAGSYTTEYAASVKGïŒVH CDR2ïŒé
åçªå·4ïŒïŒããã³AREPKYWIDFDLïŒVH CDR3ïŒé
åçªå·5ïŒã
Ab67ã®è»œéå¯å€é åïŒVLïŒã¢ããé
žé
åã¯é
åçªå·6ãšããŠä»¥äžã«æäŸãããAb67ã®VL CDRã¢ããé
žé
åã¯äžã«äžç·ãåŒããããã³æ¬¡ã®ããã§ããïŒ
RASQSISSYLN (VL CDR1; é åçªå·7)ïŒAASSLQS (VL CDR2; é åçªå·8)ïŒããã³QQSYIAPYT (VL CDR3; é åçªå·9)ã
RASQSISSYLN (VL CDR1; é åçªå·7)ïŒAASSLQS (VL CDR2; é åçªå·8)ïŒããã³QQSYIAPYT (VL CDR3; é åçªå·9)ã
ããã«èšèŒãããæCD117æäœã®ãã¡ã®ãããã®ã¯ãCD117çºçŸçŽ°èäžã®CD117掻æ§ãå®è³ªæå¶ããªãç¹ã§ãäžæ§æäœã§ãããäžæ§æäœã¯ãäŸãã°ãã€ã³ããã幹现èå åïŒSCFïŒäŸåæ§çŽ°èå¢æ®ã¢ãã»ã€ïŒäŸã¯ãããã«èšèŒã®äŸ1åç
§ïŒãçšããŠèå¥ããããšãã§ãããSCFäŸåæ§çŽ°èå¢æ®ã¢ãã»ã€ã§ã¯ãäžæ§CD117æäœã¯ãCD117掻æ§ãæå¶ããããã«SCFãCD117ã«çµåããããšããããã¯ããªãã®ã§ãåè£ããããã«SCFã«äŸåããŠããCD34+现èã殺ããªãã§ãããã
äžæ§æäœã¯ãããCD117ã«ç¹ç°çã«çµåããèœåãæããããšããã蚺æç®çã«äœ¿çšããããšãã§ãããã现èæ¯çŽ ãäŸãã°ãããã«èšèŒããããªã©ã®ãããªãã®ã«ã³ã³ãžã¥ã²ãŒãããããšããCD117çºçŸçŽ°èã殺å·ããããã«ãæå¹ã§ãããå
žåçã«ãã³ã³ãžã¥ã²ãŒãã«çšããããæäœã¯ããã®æäœã«ç¹æã®ã¢ãŽãã¹ã掻æ§ãŸãã¯ã¢ã³ã¿ãŽãã¹ã掻æ§ãæãããããããªãããããã«èšèŒãããã®ã¯ãã³ã³ãžã¥ã²ãŒãã«å¯Ÿããç¹ã«ã³ã³ãžã¥ã²ãŒãã幹现è移æ€ã«ã³ã³ãã£ã·ã§ãã³ã°å€ïŒconditioning agentïŒãšããŠäœ¿çšãããŠããç¶æ³ã«ãããŠãç¹æãªã¢ãããŒãã§ãããã¢ã³ã¿ãŽãã¹ãæäœåç¬ãŸãã¯ã³ã³ãžã¥ã²ãŒããšããŠã®çŽ°èæ¯çŽ ãšã®çµåãã¯ã现èæ¯çŽ ã«å ããŠæäœåç¬ã®æ®ºå·èœåãèãããšå¹æçã§ããããšãã§ããäžæ¹ã§ãäžæ§æCD117æäœãå«ãã³ã³ãžã¥ã²ãŒãã«ããã³ã³ãã£ã·ã§ãã³ã°ã¯ãæäœã®æŽ»æ§ã现èæ¯çŽ ã®å¹æã«å¯ŸããŠäºæ¬¡çã§ããããæäœã®ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ããã³èŠªåç¹æ§ãäŸã¯ã解é¢é床ã现èæ¯çŽ ã®æå¹ãªããªããªãŒã«éèŠã§ãã代æ¿æŠç¥ã瀺ãã
ãã®ããã«ããŠãäžå®ã®å®æœæ
æ§ã«ãããŠãæCD117æäœã«ã¯ãé
åçªå·3ã4ãããã³5ã«èšèŒã®CDRã»ããïŒCDR1ãCDR2ãããã³CDR3ïŒãå«ãééããªãã³ã«é
åçªå·7ã8ãããã³9ã«èšèŒã®CDRã»ãããå«ã軜éãå«ãŸããããã³CD117ãçºçŸããŠãã现èã«ãããŠã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ããã
ããã«èšèŒã®æCD117æäœã¯ãå
šé·æäœãäºéç¹ç°æ§æäœãäºéå¯å€ãã¡ã€ã³æäœãå€éãŸãã¯åéæäœãããã³/ãŸãã¯ããCD117ãšç¹ç°çã«çµåããçµåæ§æçã®æ
æ§ã§ããããšãã§ããå¶éãããªãããFabãFab'ã(Fab')2ãFvïŒãscFvïŒåéFvïŒããµã«ããã£ïŒsurrobodiesïŒïŒä»£æ¿è»œéïŒsurrogate light chainïŒæ§ç¯ç©ãå«ãïŒãåäžãã¡ã€ã³æäœããã£ã¡ã«åæäœïŒcamelized antibodiesïŒããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸããããŸãããããã¯ä»»æã®ã¢ã€ãœã¿ã€ãã§ãã£ããããŸãã¯ããããèªå°ããããããããšãã§ããäŸãã°ãIgAïŒäŸã¯ãIgA1ãŸãã¯IgA2ïŒãIgDãIgEãIgGïŒäŸã¯ãIgG1ãIgG2ãIgG3ãŸãã¯IgG4ïŒããŸãã¯IgMãå«ãŸãããããããã®å®æœæ
æ§ã§ã¯ãæCD117æäœã¯ãIgGïŒäŸã¯ãIgG1ãIgG2ãIgG3ãŸãã¯IgG4ïŒã§ããã
ããã«èšèŒã®æ¹æ³ãšçµã¿åãããŠäœ¿çšããããã®æäœã«ã¯ãäžèšã®ãããã®æäœã®å€çš®ãäŸãã°ãFcãã¡ã€ã³ãå«ãããŸãã¯æ¬ ãæäœæçã䞊ã³ã«ããã«èšèŒã®éããæäœã®ããåå€çš®ãããã³ããã«èšèŒã®æäœããŸãã¯æäœæçã®CDRsãŸãã¯ãã®ç䟡é åã®äžä»¥äžããŸãã¯ãã¹ãŠãå«ãæäœæ§ã¿ã³ãã¯è³ªã¹ãã£ãã©ãŒã«ãïŒäŸã¯ã10Fn3ãã¡ã€ã³ïŒãªã©ã®ãããªãã®ãå«ãŸãããåè¿°ã®æäœã®æš¡ç¯çãªæåçµåæ§æçã«ã¯ãäºéå¯å€å
ç«ã°ãããªã³ãã¡ã€ã³ãåéFvååïŒscFvïŒããã€ã¢ããã£ãããªã¢ããã£ãããããã£ãæäœæ§ã¿ã³ãã¯è³ªã¹ãã£ãã©ãŒã«ããFvæçãFabæçãF(ab')2ååãããã³ã¿ã³ãã ãžscFvããã»ãã«ãããããå«ãŸããã
äžå®æœæ
æ§ã§ã¯ãäžä»¥äžã®æŸå°æ§æšèã¢ããé
žãå«ãæCD117æäœãæäŸãããæŸå°æ§æšèãããæCD117æäœã¯ã蚺æããã³æ²»çã®äž¡æ¹ã®ç®çã§äœ¿çšããåŸãïŒæŸå°æ§æšèååãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ããŸãå¥ã®å¯èœãªç¹é·ã§ããïŒãããªããããã®ããã®æšèã®éå¶éçãªäŸã«ã¯ãéãããªããã3Hã14Cã15Nã35Sã90Yã99Tcãããã³125Iã131Iãããã³186Reãå«ãŸãããæŸå°æ§æšèã¢ããé
žããã³é¢é£ããããèªå°äœã調補ããæ¹æ³ã¯ãåœæè¡ã«ãããŠç¥ãããïŒäŸãšããŠãJunghansïŒãŠã³ãã³ã¹ïŒããCancer Chemotherapy and BiotherapyïŒçååŠçæ³ããã³çç©çæ³ïŒ655-686 (2d edition, ChafnerïŒã·ã£ãããŒïŒããã³LongoïŒãã³ãŽïŒ, eds.ïŒç·šïŒ, Lippincott RavenïŒãªããã³ã³ããã»ã¬ãŒãŽã³ïŒ(1996))ããã³U.S. Pat. No. 4,681,581ãU.S. Pat. No. 4,735,210ãU.S. Pat. No. 5,101,827ãU.S. Pat. No. 5,102,990 (U.S. RE35,500)ãU.S. Pat. No. 5,648,471ããã³U.S. Pat. No. 5,697,902åç
§ãäŸãã°ãã¯ãã©ãã³Tæ³ã«ãã£ãŠæŸå°æ§åäœå
çŽ ãå
±åœ¹ããåŸãã
ããã«èšèŒã®æCD117æäœãŸãã¯çµåæ§æçã¯ãåœæè¡ã§ç¥ãããŠããããã«ãæäœããã³/ãŸãã¯æçã®ç¹æ§ãå€åããããã®ãäŸãã°ãåæžæãå¢å ãããADCCãçãå¢å ãŸãã¯æžå°ããããã®ãªã©ã®ãããªãã®ã®ä¿®é£Ÿããã³/ãŸãã¯å€åœ¢ãå«ã¿åŸãã
äžå®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®çµåæ§æçã¯ãå€çš®ïŒãŸãã¯ä¿®é£ŸïŒFcé åãå«ã¿ãããã§åèšå€çš®Fcé åã¯åèšååãFcã¬ã³ãRã«å¯Ÿããå€åãã芪åæ§ãæããããã«ãéçåFcé åãšæ¯èŒããŠå°ãªããšãäžã®ã¢ããé
žä¿®é£Ÿãå«ããFcé åå
ã®äžå®ã®ã¢ããé
žäœçœ®ã¯FcγRãšçŽæ¥æ¥è§Šããããšãçµæ¶åŠçç 究ã«ãã£ãŠç¥ãããŠãããå
·äœçã«ã¯ãã¢ããé
ž234-239ïŒãã³ãžé åïŒãã¢ããé
ž265-269ïŒB/Cã«ãŒãïŒãã¢ããé
ž297-299ïŒC'/Eã«ãŒãïŒãããã³ã¢ããé
ž327-332ïŒF/GïŒã«ãŒãã§ããã(SondermannïŒãŸã³ããŒãã³ïŒã, 2000 Nature, 406ïŒ267-273ãåç
§ïŒãäŸãã°ãFcé åã®ã¢ããé
žäœçœ®234ããã³235ã«ãããã¢ããé
žçœ®æã¯ãFcå容äœãç¹ã«Fcã¬ã³ãå容äœïŒFcγRïŒã«çµåããããã®IgGæäœã®èŠªåæ§ãäœäžããããã®ãšããŠèå¥ããããäžå®æœæ
æ§ã§ã¯ãããã«èšèŒã®æCD117æäœã¯L234ããã³/ãŸãã¯L235ãäŸã¯ãL234Aããã³L235AïŒEUã€ã³ããã¯ã¹ïŒã«ãããã¢ããé
žçœ®æãå«ãŸããFcé åãå«ããããããã®å®æœæ
æ§ã§ã¯ãããã«èšèŒã®æCD117æäœã¯æ§é ããã³çµæ¶åŠç解æã«åºã¥ããŠFcγRãšçŽæ¥æ¥è§Šããå°ãªããšã1ã€ã®æ®åºã®ä¿®é£Ÿãå«ãŸããå€çš®Fcé åãå«ã¿åŸããäžå®æœæ
æ§ã§ã¯ãæCD117æäœïŒãŸãã¯ãã®Fcå«ææçïŒã®Fcé åã¯ãåç
§ã«ããããã«æ瀺çã«çµã¿èŸŒãŸãããKabatããSequences of Proteins of Immunological Interest, 5th Ed.ïŒç¬¬5çïŒPublic Health ServiceïŒå
¬è¡è¡çå±ïŒ, NH1, MD (1991)ãã«ããããããªEUã€ã³ããã¯ã¹ã«åŸã£ãŠã¢ããé
ž265ã§ã®ã¢ããé
žçœ®æãå«ãããKabatã«ãããEUã€ã³ããã¯ã¹ããŸãã¯ãEUã€ã³ããã¯ã¹ãã¯ããIgG1 EUæäœã®ãã³ããªã³ã°ã«èšåããããã³å¥ãªãµãã«æã瀺ããªãéãFcã¢ããé
žäœçœ®ã«é¢ããŠããã§çšããããã
äžå®æœæ
æ§ã§ã¯ãFcé åã¯D265Aå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯D265Cå€ç°ãå«ãã
ããããã®å®æœæ
æ§ã§ã¯ãæCD117æäœïŒãŸãã¯ãã®æçïŒã®Fcé åã¯Kabatã®ãããªEUã€ã³ããã¯ã¹ã«åŸã£ãŠã¢ããé
ž234ã«ãŠã¢ããé
žçœ®æãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯L234Aå€ç°ãå«ããããããã®å®æœæ
æ§ã§ã¯ãæCD117æäœïŒãŸãã¯ãã®æçïŒã®Fcé åã¯Kabatã«ããããããªEUã€ã³ããã¯ã¹ã«åŸã£ãŠã¢ããé
ž235ã«ãŠã¢ããé
žçœ®æãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯L235Aå€ç°ãå«ããããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯L234Aããã³L235Aå€ç°ãå«ãããããªãå®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234Aãããã³L235Aå€ç°ãå«ãã
ããããã®å®æœæ
æ§ã§ã¯ãæCD117æäœïŒãŸãã¯ãã®æçïŒã®Fcé åã¯Kabatã®ãããªEUã€ã³ããã¯ã¹ã«åŸã£ãŠã¢ããé
ž239ã«ãããã¢ããé
žçœ®æãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯S239Cå€ç°ãå«ãã
äžå®æœæ
æ§ã§ã¯ãFcé åã¯D265ãV205ãH435ãI253ãããã³/ãŸãã¯H310ã®ã¢ããé
žäœçœ®ã§ã®å€ç°ãå«ããäŸãã°ããããã®äœçœ®ã«ãããç¹å®ã®å€ç°ã¯D265CãV205CãH435AãI253Aãããã³/ãŸãã¯H310Aãå«ãã
äžå®æœæ
æ§ã§ã¯ãFcé åã¯L234Aå€ç°ãå«ããããå®æœæ
æ§ã§ã¯ãæCD117æäœïŒãŸãã¯ãã®æçïŒã®Fcé åã¯Kabatã®ãããªEUã€ã³ããã¯ã¹ã«åŸã£ãŠã¢ããé
ž235ã«ãŠã¢ããé
žçœ®æãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯L235Aå€ç°ãå«ããããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯L234Aããã³L235Aå€ç°ãå«ãããããªãå®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234Aãããã³L235Aå€ç°ãå«ããããã«ãããªãå®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234AãL235Aãããã³H435Aå€ç°ãå«ãããããªãå®æœæ
æ§ã§ã¯ãFcé åã¯D265Cããã³H435Aå€ç°ãå«ãã
ããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯L234Aããã³L235Aå€ç°ïŒããã§ã¯ãL234A.L235AããšããŠãŸãã¯ãLALAããšã称ãããïŒãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯L234Aããã³L235Aå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãã§ããªãããããªãå®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234Aãããã³L235Aå€ç°ïŒããã§ã¯ãD265C.L234A.L235Aããšã称ãããïŒãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234Aãããã³L235Aå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãŸãªããããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234AãL235Aãããã³H435Aå€ç°ïŒããã§ã¯ãD265C.L234A.L235A.H435Aããšã称ããïŒãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234AãL235Aãããã³H435Aå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãŸãªãããããªãå®æœæ
æ§ã§ã¯ãFcé åã¯D265Cããã³H435Aå€ç°ïŒããã§ã¯ãD265C.H435AããšãåŒã°ããïŒãå«ããããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯D265AãS239CãL234Aãããã³L235Aå€ç°ïŒããã§ã¯ãD265A.S239C.L234A.L235Aããšã称ããïŒãå«ããããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯D265AãS239CãL234Aãããã³L235Aå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãŸãªããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯D265CãN297Gãããã³H435Aå€ç°ïŒããã§ã¯ãD265C.N297G.H435AããšãåŒã°ããïŒãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯D265CãN297Qãããã³H435Aå€ç°ïŒããã§ã¯ãD265C.N297Q.H435AããšãåŒã°ããïŒãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯E233PãL234VãL235Aããã³delG236ïŒ236ã®æ¬ 倱ïŒå€ç°ïŒããã§ã¯ããE233P.L234V.L235A.delG236ããšããŠãŸãã¯ãEPLVLAdelGããšããŠãèšåãããïŒãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯E233PãL234VãL235Aããã³delG236ïŒ236ã®æ¬ 倱ïŒå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãŸãªããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯E233PãL234VãL235AãdelG236ïŒ236ã®æ¬ 倱ïŒããã³H435Aå€ç°ïŒããã§ã¯ãE233P.L234V.L235A.delG236.H435AããšããŠãŸãã¯ãEPLVLAdelG.H435AããšããŠãèšåããïŒãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯E233PãL234VãL235AãdelG236ïŒ236ã®æ¬ 倱ïŒããã³H435Aå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãŸãªããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯L234AãL235AãS239Cããã³D265Aå€ç°ãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯L234AãL235AãS239Cããã³D265Aå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãŸãªããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯H435AãL234AãL235Aãããã³D265Cå€ç°ãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯H435AãL234AãL235Aãããã³D265Cå€ç°ãå«ã¿ãããã§Fcé åã¯P329Gå€ç°ãå«ãŸãªãã
ããããã®å®æœæ
æ§ã«ãããŠãæäœã¯ä¿®é£ŸFcé åãæããæCD117æäœã¯Fcå容äœïŒFc RïŒãžã®çµåã§ã®æžå°ã«ãããFcRãžã®é修食Fcé åãå«ãåäžã®æäœã®çµåãšæ¯èŒããŠãã€ã³ãããã®ãšãã§ã¯ã¿ãŒæ©èœã¢ãã»ã€ã«ãããŠãšãã§ã¯ã¿ãŒæ©èœãäœäžããããããªãã®ã§ãããããããã®å®æœæ
æ§ã§ã¯ãæäœã¯ä¿®é£ŸFcé åãæããæCD117æäœã¯Fcγå容äœïŒFcγRïŒãžã®çµåã§ã®æžå°ã«ãããFcγRãžã®é修食Fcé åãå«ãåäžã®æäœã®çµåãšæ¯èŒããŠãã€ã³ãããã®ãšãã§ã¯ã¿ãŒæ©èœã¢ãã»ã€ã«ãããŠãšãã§ã¯ã¿ãŒæ©èœãäœäžããããããªãã®ã§ãããããããã®å®æœæ
æ§ã§ã¯ãFcγRã¯FcγR1ã§ãããããã€ãã®å®æœæ
æ§ã§ã¯ãFcγRã¯FcγR2Aã§ãããããã€ãã®å®æœæ
æ§ã§ã¯ãFcγRã¯FcγR2Bã§ãããä»ã®å®æœæ
æ§ã§ã¯ãFcγRã¯FcγR2Cã§ãããããã€ãã®å®æœæ
æ§ã§ã¯ãFcγRã¯FcγR3Aã§ãããããã€ãã®å®æœæ
æ§ã§ã¯ãFcγRã¯FcγR3Bã§ãããä»ã®å®æœæ
æ§ã§ã¯ãçµåã§ã®æžå°ã¯ãé修食Fcé åãå«ãåäžã®æäœã®FcγRãžã®çµåãšæ¯èŒããŠãFcγRãžã®æäœçµåã§ã®å°ãªããšã70ïŒ
ã®æžå°ãå°ãªããšã80ïŒ
ã®æžå°ãå°ãªããšã90ïŒ
ã®æžå°ãå°ãªããšã95ïŒ
ã®æžå°ãå°ãªããšã98ïŒ
ã®æžå°ãå°ãªããšã99ïŒ
ã®æžå°ããŸãã¯100ïŒ
ã®æžå°ã§ãããä»ã®å®æœæ
æ§ã§ã¯ãçµåã§ã®æžå°ã¯ãæªä¿®é£Ÿã®Fcé åãå«ãåäžã®æäœã®FcγRãžã®çµåãšæ¯èŒããŠãFcγRãžã®æäœçµåã§ã®å°ãªããšã70ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã80ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã90ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã95ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ããŸãã¯å°ãªããšã98ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãæCD117æäœã¯ä¿®é£ŸFcé åãæããæäœã¯ã€ã³ããããµã€ãã«ã€ã³æŸåºã¢ãã»ã€ã«ãããŠãé修食Fcé åãå«ãåäžã®æäœã®ãµã€ãã«ã€ã³æŸåºã«å¯ŸããŠå°ãªããšã50ïŒ
ã®ãµã€ãã«ã€ã³æŸåºã§ã®æžå°ã䌎ã£ãŠãµã€ãã«ã€ã³æŸåºãæžå°ããããããªãã®ã§ãããããããã®å®æœæ
æ§ã§ã¯ããµã€ãã«ã€ã³æŸåºã§ã®æžå°ã¯é修食Fcé åãå«ãåäžã®æäœã®ãµã€ãã«ã€ã³æŸåºã«å¯ŸããŠãµã€ãã«ã€ã³æŸåºã«ãããŠå°ãªããšã70ïŒ
ã®æžå°ãå°ãªããšã80ïŒ
ã®æžå°ãå°ãªããšã90ïŒ
ã®æžå°ãå°ãªããšã95ïŒ
ã®æžå°ãå°ãªããšã98ïŒ
ã®æžå°ãå°ãªããšã99ïŒ
ã®æžå°ããŸãã¯100ïŒ
ã®æžå°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããµã€ãã«ã€ã³æŸåºã§ã®æžå°ã¯é修食ã®Fcé åãå«ãåäžã®æäœã®ãµã€ãã«ã€ã³æŸåºã«å¯ŸããŠãµã€ãã«ã€ã³æŸåºã«ãããŠå°ãªããšã70ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã80ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã90ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã95ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ã§ãããäžå®ã®å®æœæ
æ§ã«ãããŠããµã€ãã«ã€ã³æŸåºã¯å
ç«çŽ°èã«ãããã®ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ãæCD117æäœã¯ãæäœãã€ã³ãããã®ãã¹ã现èè±é¡ç²ã¢ãã»ã€ã«ãããŠãé修食Fcé åãå«ãåäžã®æäœã®ãã¹ã现èè±é¡ç²ã«å¯ŸããŠå°ãªããšã50ïŒ
ã®ãã¹ã现èè±é¡ç²ã§ã®æžå°ã䌎ããã¹ã现èè±é¡ç²ãæžå°ãããããã«ä¿®é£ŸFcé åãæãããããããã®å®æœæ
æ§ã§ã¯ããã¹ã现èè±é¡ç²ã§ã®æžå°ã¯ãé修食Fcé åãå«ãåäžã®æäœã®ãã¹ã现èè±é¡ç²ã«å¯ŸããŠå°ãªããšã70ïŒ
ã®æžå°ãå°ãªããšã80ïŒ
ã®æžå°ãå°ãªããšã90ïŒ
ã®æžå°ãå°ãªããšã95ïŒ
ã®æžå°ãå°ãªããšã98ïŒ
ã®æžå°ãå°ãªããšã99ïŒ
ã®æžå°ããŸãã¯100ïŒ
ã®æžå°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããã¹ã现èè±é¡ç²ã§ã®æžå°ã¯ãé修食Fcé åãå«ãåäžã®æäœã®ãã¹ã现èè±é¡ç²ã«å¯Ÿããå°ãªããšã70ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã80ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ãå°ãªããšã90ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ããŸãã¯å°ãªããšã95ïŒ
ãã100ïŒ
ãŸã§ã®æžå°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ãæCD117æäœã¯ãæäœãã€ã³ãããã®æäœäŸåæ§çŽ°è貪é£ã¢ãã»ã€ã«ãããŠæäœäŸåæ§çŽ°è貪é£ïŒADCPïŒãé修食Fcé åãå«ãŸããåäžã®æäœã®ADCPã«å¯ŸããŠå°ãªããšã50ïŒ
ã®ADCPã§ã®æžå°ãšå
±ã«æžå°ãŸãã¯é²æ¢ããããã«ä¿®é£ŸFcé åãæãããããããã®å®æœæ
æ§ã§ã¯ãADCPã§ã®æžå°ã¯ãé修食Fcé åãå«ãåäžã®æäœã®ãµã€ãã«ã€ã³æŸåºã«å¯ŸããŠå°ãªããšã70ïŒ
ã®æžå°ãå°ãªããšã80ïŒ
ã®æžå°ãå°ãªããšã90ïŒ
ã®æžå°ãå°ãªããšã95ïŒ
ã®æžå°ãå°ãªããšã98ïŒ
ã®æžå°ãå°ãªããšã99ïŒ
ã®æžå°ããŸãã¯100ïŒ
ã®æžå°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ãããã«èšèŒã®ããã«ãæCD117æäœã¯ä»¥äžã®ä¿®é£ŸãŸãã¯ä¿®é£Ÿã®çµåãïŒD265AãD265CãD265C/H435AãD265C/LALAãD265C/LALA/H435AãD265A/S239C/L234A/L235A/H435AãD265A/S239C/L234A/L235AãD265C/N297GãD265C/N297G/H435AãD265C (EPLVLAdelG*)ãD265C (EPLVLAdelG)/H435AãD265C/N297Q/H435AãD265C/N297QãEPLVLAdelG/H435AãEPLVLAdelG/D265CãEPLVLAdelG/D265AãN297AãN297GããŸãã¯N297Qã®ãã¡ã®1ã€ãå«ãŸããFcé åãå«ããããããã®å®æœæ
æ§ã§ã¯ãããã§ã®æCD117æäœã¯ã以äžã®ä¿®é£ŸãŸãã¯ä¿®é£Ÿã®çµåãïŒD265AãD265CãD265C/H435AãD265C/LALAãD265C/LALA/H435AãD265C/N297GãD265C/N297G/H435AãD265C (IgG2*)ãD265C (IgG2)/H435AãD265C/N297Q/H435AãD265C/N297QãEPLVLAdelG/H435AãN297AãN297GããŸãã¯N297Qã®1ã€ãå«ãŸããFcé åãå«ãã
修食Fcé åããã³Fcã¬ã³ãã¬ã»ãã¿ãŒéã®çµåãŸãã¯èŠªåæ§ã¯åœæè¡ã«ãããŠæ¢ç¥ã®æ§ã
ãªæè¡ãäŸãã°ãå¶éãããªããã平衡æ³ïŒäŸã¯ãé
µçŽ çµåå
ç«åžçæ€å®æ³ïŒELISAïŒïŒKinExA, Rathanaswamiã Analytical Biochemistry, Vol. 373: 52-60, 2008ïŒãŸãã¯æŸå°å
ç«æ€å®ïŒRIAïŒïŒãçšããŠããŸãã¯è¡šé¢ãã©ãºã¢ã³å
±é³Žã¢ãã»ã€ãŸãã¯ä»ã®åååŠã«åºã¥ãã¢ãã»ã€ïŒäŸã¯ãBIACORE.RTM.åæãŸãã¯OctetTMåæïŒforteBIOïŒïŒã®æ©æ§ãããã³ä»ã®æ¹æ³ãäŸãã°ãéæ¥çµåã¢ãã»ã€ã競äºçµåã¢ãã»ã€èå
å
±é³Žãšãã«ã®ãŒç§»åïŒFRETïŒãã²ã«é»æ°æ³³åæ³ããã³ã¯ãããã°ã©ãã£ãŒïŒäŸã¯ãã²ã«ãéïŒãªã©ã®ãããªãã®ã«ãã£ãŠæ±ºå®ããããšãã§ããããããããã³ä»ã®æ¹æ³ã¯æ€æ»ããŠããæåã®äžä»¥äžã§ã®ã©ãã«ãå©çšããããã³/ãŸãã¯å€æ§ãªæ€åºæ¹æ³ãå¶éãããªãããçºè²æ§ãèå
ãçºå
ããŸãã¯åäœäœæšèãå«ããã®ãæ¡çšãåŸããçµå芪åæ§ããã³åååŠã«ã€ããŠã®è©³çŽ°ãªèšè¿°ã¯Paul, W. E., ed., Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999)ã«ãããŠèŠåºãããšãã§ããããã¯æäœ-å
ç«åçžäºäœçšã«çŠç¹ãåœãŠãã競åçµåã¢ãã»ã€ã®äžäŸã¯å¢å€§ããéã®éæšèæåã®ååšäžã§ã®æšèæåãšèå³ãããæäœãšã®ã€ã³ãã¥ããŒã·ã§ã³ããã³æšèæåã«çµåããæäœã®æ€åºãå«ãã©ãžãªã€ã ãã¢ãã»ã€ã§ãããç¹å®ã®æåã«ã€ããŠã®èå³ãããæäœã®èŠªåæ§ããã³çµåãªãã¬ãŒãã¯ã¹ãã£ããã£ãŒãããããåæã«ãã£ãŠããŒã¿ãã決å®ããããšãã§ããããŸãã第äºã®æäœãšã®ç«¶åã¯ã©ãžãªã€ã ãã¢ãã»ã€ãçšããŠå®ããããšãã§ããããã®å Žåãæåã¯éæšè第äºæäœã®å¢å éã®ååšäžã«æšèååç©ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããèå³ãããæäœãšå
±ã«ã€ã³ãã¥ããŒããããã
äžå®æœæ
æ§ã§ã¯ãããã«èšèŒããFc修食ãæããæäœïŒäŸã¯ãD265CãL234AãL235Aãããã³/ãŸãã¯H435AïŒã¯é修食Fcé åãå«ãåäžã®æäœã®Fcã¬ã³ãå容äœãžã®çµåãšæ¯èŒããŠFcã¬ã³ãå容äœãžã®çµåã«ãããå°ãªããšã70ïŒ
ã®æžå°ãå°ãªããšã80ïŒ
ã®æžå°ãå°ãªããšã90ïŒ
ã®æžå°ãå°ãªããšã95ïŒ
ã®æžå°ãå°ãªããšã98ïŒ
ã®æžå°ãå°ãªããšã99ïŒ
ã®æžå°ããŸãã¯100ïŒ
ã®æžå°ïŒäŸã¯ãçç©å±€å¹²æžæ³ïŒbiolayer interferometryïŒïŒBLIïŒã«ãã£ãŠè©äŸ¡ãããããªãã®ïŒãæããã
ãããªãçè«ã«ãææãããããšãæããã®ã§ã¯ãªãããFcé åãšFcã¬ã³ãå容äœãšã®çµåçžäºäœçšã¯æ§ã
ãªãšãã§ã¯ã¿ãŒæ©èœããã³äžæµã·ã°ããªã³ã°äºè±¡ã§ãå¶éãããªãããæäœäŸåæ§çŽ°èåªä»æ§çŽ°èå·å®³ïŒADCCïŒããã³è£äœäŸåæ§çŽ°èå·å®³ïŒCDCïŒãå«ãŸãããã®ã«å¿
é ã§ãããšèããããããããã£ãŠãäžå®ã®æ
æ§ã«ãããŠã修食ãããFcé åïŒäŸã¯ãL234AãL235Aãããã³/ãŸãã¯D265Cå€ç°ãå«ãïŒãå«ãæäœã¯ãšãã§ã¯ã¿ãŒæ©èœãå®è³ªçã«æžå°ãŸãã¯æ¶å€±ãããããšãã§ã¯ã¿ãŒæ©èœã¯åœæè¡ã§æ¢ç¥ã®æ§ã
ãªæ¹æ³ãçšããŠãäŸãã°ãèå³ãããæäœã«å¿çãã现èå¿çïŒäŸã¯ããã¹ã现èè±é¡ç²ãŸãã¯ãµã€ãã«ã€ã³æŸåºïŒã枬å®ããããšã«ãããã¢ãã»ã€ããããšãã§ãããäŸãã°ãåœæè¡ã«ãããæšæºçãªæ¹æ³ãçšããŠãFc修食æäœã¯ãµã€ãã«ã€ã³æŸåºãèªçºãããããã®èœåã«ãããŠããŸãã¯ããã«ã€ããŠãã¹ã现èè±é¡ç²ãèªçºãããããã®èœåã«ã€ããŠãäŸã¯ãããæ«æ¢¢è¡åæ žçŽ°èã«ãã£ãŠã¢ãã»ã€ããããšãã§ããã
äžå®ã®æ
æ§ã«ãããŠãå€çš®IgG Fcãã¡ã€ã³ã¯1以äžã®ã¢ããé
žçœ®æãå«ãŸãªãéçåFcãã¡ã€ã³ãšæ¯èŒããŠãFcã¬ã³ãRïŒFcgammaRïŒããã³/ãŸãã¯C1qã«ã€ããŠæžå°ãŸãã¯ã¢ãã¬ãŒã·ã§ã³ããïŒablatedïŒçµå芪åæ§ããããã1以äžã®ã¢ããé
žçœ®æåºãå«ããFcçµåçžäºäœçšã¯ãæ§ã
ãªãšãã§ã¯ã¿ãŒæ©èœããã³äžæµã·ã°ãã«äŒéäºè±¡ã§ãå¶éãããªãããæäœäŸåæ§çŽ°èåªä»æ§çŽ°èå·å®³ïŒADCCïŒããã³è£äœäŸåæ§çŽ°èå·å®³ïŒCDCïŒãå«ããã®ã«å¿
é ã§ããããããã£ãŠãäžå®ã®æ
æ§ã«ãããŠã修食ãããFcé åïŒäŸã¯ãL234AãL235Aãããã³D265Cå€ç°ãå«ãïŒãå«ãæäœã¯ãšãã§ã¯ã¿ãŒæ©èœãå®è³ªæžå°ãŸãã¯æ¶å€±ããŠããïŒabolishedïŒã
Fcé åãžã®èŠªåæ§ã¯åœæè¡ã§ç¥ãããæ§ã
ãªæè¡ã䜿çšããŠæ±ºå®ããããšãã§ããäŸãã°ãå¶éãããªããã平衡æ³ïŒäŸã¯ãé
µçŽ çµåå
ç«åžçæ³ïŒELISAïŒïŒKinExA, Rathanaswamiã Analytical Biochemistry, Vol. 373: 52-60, 2008ïŒãŸãã¯ã©ãžãªã€ã ãã¢ãã»ã€ïŒRIAïŒïŒããŸãã¯è¡šé¢ãã©ãºã¢ã³å
±é³Žã¢ãã»ã€ãŸãã¯ä»ã®åååŠã«åºã¥ãã¢ãã»ã€ïŒäŸã¯ãBIACORETMïŒTMã¯ç±³åœçã§ã®ãã¬ãŒãããŒã¯è¡šç€ºïŒåæãŸãã¯OctetTMåæïŒforteBIOïŒïŒã®æ©æ§ãããã³ä»ã®æ¹æ³ãäŸãã°ãéæ¥çµåã¢ãã»ã€ã競äºçµåã¢ãã»ã€èå
å
±é³Žãšãã«ã®ãŒç§»åïŒFRETïŒãã²ã«é»æ°æ³³åæ³ããã³ã¯ãããã°ã©ãã£ãŒïŒäŸã¯ãã²ã«ãéïŒãªã©ã®ãããªãã®ã§ããããããããã³ä»ã®æ¹æ³ã¯æ€æ»ããŠããæåã®1以äžã§ã®ã©ãã«ãå©çšããããã³/ãŸãã¯å€æ§ãªæ€åºæ¹æ³ã§ãå¶éãããªãããçºè²æ§ãèå
ãçºå
ããŸãã¯åäœäœæšèãå«ããã®ãæ¡çšãåŸããçµå芪åæ§ããã³åååŠã«ã€ããŠã®è©³çŽ°ãªèšè¿°ã¯Paul, W. E., ed., Fundamental Immunology, 4th Ed., Lippincott-Raven, Philadelphia (1999)ã«ãããŠèŠåºãããšãã§ããããã¯æäœ-å
ç«åçžäºäœçšã«çŠç¹ãåœãŠãã競åçµåã¢ãã»ã€ã®äžäŸã¯å¢å€§ããéã®éæšèæåã®ååšäžã§ã®æšèæåãšèå³ãããæäœãšã®ã€ã³ãã¥ããŒã·ã§ã³ããã³æšèæåã«çµåããæäœã®æ€åºãå«ãã©ãžãªã€ã ãã¢ãã»ã€ã§ãããç¹å®ã®æåã«ã€ããŠã®èå³ãããæäœã®èŠªåæ§ããã³çµåãªãã¬ãŒãã¯ã¹ãã£ããã£ãŒãããããåæã«ãã£ãŠããŒã¿ãã決å®ããããšãã§ããããŸãã第äºã®æäœãšã®ç«¶åã¯ã©ãžãªã€ã ãã¢ãã»ã€ãçšããŠå®ããããšãã§ããããã®å Žåãæåã¯éæšè第äºæäœã®å¢å éã®ååšäžã«æšèååç©ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããèå³ãããæäœãšå
±ã«ã€ã³ãã¥ããŒããããã
äžå®æœæ
æ§ã§ã¯ãããã«èšèŒã®æCD117æäœã¯L235AãL235Aãããã³D265CïŒEUã€ã³ããã¯ã¹ïŒãå«ãŸããFcé åãå«ããæ¬é瀺ã®æäœã¯ããã«è¿œå Fcå€ç°ãäŸãã°ãïŒDall'AcquaïŒãã©ãŒã¯ã¢ïŒã (2006) J Biol ChemïŒã¶ã»ãžã£ãŒãã«ã»ãªãã»ãã€ãªããžã«ã«ã»ã±ãã¹ããªãŒïŒ281ïŒ23514-24ïŒãïŒZalevskyïŒã¶ã¬ãã¹ããŒïŒã(2010) Nat BiotechnolïŒãã€ãã£ãŒã»ãã€ãªãã¯ãããžãŒïŒ28: 157-9ïŒãïŒHintonïŒãã³ãã³ïŒã (2004) J Biol Chem 279ïŒ6213-6ïŒãïŒHintonã (2006) J ImmunolïŒã¶ã»ãžã£ãŒãã«ã»ãªãã»ã€ã ãããžãŒïŒ176: 346-56ïŒãïŒShieldsïŒã·ãŒã«ãºattaïŒã (2001) J Biol Chem 276: 6591-604ïŒãïŒPetkovaïŒããã³ã¯ïŒã (2006) Int ImmunolïŒã€ã³ã¿ãŒãã·ã§ãã«ã»ã€ã ãããžãŒïŒ18: 1759-69ïŒãïŒDatta-MannanïŒããã¿-ãã³ãã³ïŒã (2007) Drug Metab DisposïŒãã©ãã°ã»ã¡ã¿ããªãºã ã»ã¢ã³ãã»ãã£ã¹ããžã·ã§ã³ïŒ35: 86-94ïŒãïŒVaccaroïŒããã«ãŒãïŒã (2005) Nat Biotechnol 23: 1283-8ïŒãïŒYeungïŒã€ã³ïŒã (2010) Cancer ResïŒãã£ã³ãµãŒã»ãªãµãŒãïŒ70: 3269-77ïŒããã³ïŒKimïŒãã ïŒã (1999) Eur J ImmunolïŒãšãŒããã¢ã³ã»ãžã£ãŒãã«ã»ãªãã»ã€ã ãããžãŒïŒ29: 2819-25ïŒã«èšèŒããããã®ã®ãããªãã®ã®å°å
¥ã«ãã£ãŠæäœåæžæãããã«ã¢ãžã¥ã¬ãŒãããããã«å·¥åŠçã«äœãåºãããšãã§ããããã³äœçœ®250ã252ã253ã254ã256ã257ã307ã376ã380ã428ã434ããã³435ãå«ãŸãããåæ°ãŸãã¯çµã¿åãããŠè¡ãåŸãæš¡ç¯çãªå€ç°ã¯T250QãM252Yã1253AãS254TãT256EãP2571ãT307AãD376VãE380AãM428LãH433KãN434SãN434AãN434HãN434FãH435Aããã³H435Rã®å€ç°ã§ããã
ãããã£ãŠãäžå®æœæ
æ§ã«ãããŠãFcé åã¯åæžæã§ã®æžå°ãããããå€ç°ãå«ããçãåæžæãæããæäœã¯æäœãçåœã®æ²»çè¬ãšããŠæ©èœããããšãæåŸ
ãããäžå®ã®äŸãäŸã¯ãæäœãHSCsã«ç¶ããŠæäžãããããã«èšèŒã®ã³ã³ãã£ã·ã§ãã³ã°ã¹ãããã«ãããŠæå©ãšãªãåŸããçæ³çã«ã¯ãæäœã¯å
å æ§å¹¹çŽ°èãšã¯ç°ãªããæŠããŠCD117ãçºçŸãããæCD117æäœã®æšçã§ã¯ãªãHSCsãéãåã«å®è³ªã¯ãªã¢ãããã§ããããäžå®æœæ
æ§ã§ã¯ãFcé åã¯435äœïŒKabatã«ããEUã€ã³ããã¯ã¹ïŒã«ãŠå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãå€ç°ã¯H435Aå€ç°ã§ããã
äžå®æœæ
æ§ã§ã¯ãããã«èšèŒã®æCD117æäœã¯çŽ24æéã«çãããããŸãã¯ããæªæºïŒçãããããŸãã¯ããæªæºã¯ã以äžããšèšãïŒãçŽ22æé以äžãçŽ20æé以äžãçŽ18æé以äžãçŽ16æé以äžãçŽ14æé以äžãçŽ13æé以äžãçŽ12æé以äžããŸãã¯çŽ11æé以äžã®åæžæãæãããäžå®æœæ
æ§ã§ã¯ãæäœã®åæžæã¯çŽ11æéããçŽ24æéãŸã§ïŒçŽ12æéããçŽ22æéãŸã§ïŒçŽ10æéããçŽ20æéãŸã§ïŒçŽ8æéããçŽ18æéãŸã§ïŒãŸãã¯çŽ14æéããçŽ24æéãŸã§ã§ããã
ããã«èšèŒã®ãã€ã·ã§ã³ãã³ã³ãã£ã·ã§ãã³ã°æ¹æ³ãšçµã¿åãããŠäœ¿çšããããšãã§ããæCD117æäœã«ã¯ãäŸãšããŠãATCCã¢ã¯ã»ãã·ã§ã³çªå·10716ïŒBA7.3C.9ãšããŠå¯èšïŒããçç£ããã³æŸåºãããæäœãäŸãã°ãSR-1æäœã§ãç±³åœç¹èš±ç¬¬5,489,516å·ã«èšèŒã®ãã®ãªã©ã®ãããªãã®ãå«ãŸãããã®é瀺ãæCD117æäœã«é¢ãããã®ãšããŠåç
§ã«ããããã«çµã¿èŸŒãã
äžå®æœæ
æ§ã§ã¯ãããã«èšèŒã®æCD117æäœã¯L235AãL235AãD265Cãããã³H435AïŒEUã€ã³ããã¯ã¹ïŒãå«ãŸããFcé åãå«ãã
ããããã®æ
æ§ã«ãããŠãFcé åã¯æžå°ããåæžæãä»äžããããã³æäœã®ãšãã§ã¯ã¿ãŒæ©èœã倧å¹
ã«æžããããŸãã¯ååã«æ¶å€±ãã2以äžã®å€ç°ãå«ããããããã®å®æœæ
æ§ã§ã¯ãFcé åã¯åæžæã§ã®æžå°ãããããå€ç°ããã³FcγRãšçŽæ¥æ¥è§Šããããšãã§ããå°ãªããšã1ã®æ®åºã®å€ç°ãå«ãã§ããïŒäŸã¯ãæ§é ããã³çµæ¶åŠçåæã«åºã¥ããããªãã®ïŒãäžå®æœæ
æ§ã§ã¯ãFcé åã¯H435Aå€ç°ãL234Aå€ç°ãããã³L235Aå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯H435Aå€ç°ããã³D265Cå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯H435Aå€ç°ãL234Aå€ç°ãL235Aå€ç°ãããã³D265Cå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯S239Cå€ç°ãå«ãã
ããããã®å®æœæ
æ§ã§ã¯ãæCD117æäœãŸãã¯ãã®æåçµåæ§æçã¯æäœãŸãã¯ãã®æåçµåæ§æçã®Fcãã¡ã€ã³ã§ã®ã·ã¹ãã€ã³æ®åºãä»ããŠçŽ°èæ¯çŽ ïŒäŸã¯ãã¢ãããã·ã³ïŒã«ã³ã³ãžã¥ã²ãŒãããããããããã®å®æœæ
æ§ã§ã¯ãã·ã¹ãã€ã³æ®åºã¯æäœãŸãã¯ãã®æåçµåæ§æçã§ã®Fcãã¡ã€ã³ã«ãããå€ç°ãä»ããŠå°å
¥ããããäŸãšããŠãã·ã¹ãã€ã³æ®åºã¯Cys118ãCys239ïŒäŸã¯ãS239CïŒãããã³Cys265ãããªã矀ããéžã°ãåŸããäžå®æœæ
æ§ã§ã¯ãæCD117æäœïŒãŸãã¯ãã®æçïŒã®Fcé åã¯Kabatã§ã®ãããªEUã€ã³ããã¯ã¹ã«åŸãã¢ããé
ž265ã«ãŠã¢ããé
žçœ®æãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯D265Cå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯D265Cããã³H435Aå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234Aãããã³L235Aå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯D265CãL234AãL235Aãããã³H435Aå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã®Fcé åã¯Kabatã§ã®ãããªEUã€ã³ããã¯ã¹ã«åŸãã¢ããé
ž239ã§ã®ã¢ããé
žçœ®æãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯S239Cå€ç°ãå«ããäžå®æœæ
æ§ã§ã¯ãFcé åã¯L234Aå€ç°ãL235Aå€ç°ãS239Cå€ç°ããã³D265Aå€ç°ãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯S239Cããã³H435Aå€ç°ãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯L234Aå€ç°ãL235Aå€ç°ãããã³S239Cå€ç°ãå«ããããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯H435Aå€ç°ãL234Aå€ç°ãL235Aå€ç°ãããã³S239Cå€ç°ãå«ããããã«å¥ã®å®æœæ
æ§ã§ã¯ãFcé åã¯H435Aå€ç°ãL234Aå€ç°ãL235Aå€ç°ãS239Cå€ç°ãããã³D265Aå€ç°ãå«ãã
泚ç®ãã¹ãããšã«ãFcã¢ããé
žã®äœçœ®ã¯å¥ãªãµãã«ç€ºããªãéãEUãã³ããªã³ã°ã€ã³ããã¯ã¹ãåç
§ããã
ãããã®æ
æ§ã®ããããã®å®æœæ
æ§ã«ãããŠãã·ã¹ãã€ã³æ®åºã¯æäœãŸãã¯ãã®æåçµåæ§æçã®Fcãã¡ã€ã³ã«èªç¶ã«çºçãããäŸãšããŠãFcãã¡ã€ã³ã¯IgG Fcãã¡ã€ã³ãäŸãã°ãããIgG1 Fcãã¡ã€ã³ãªã©ã®ãããªãã®ã§ããåŸãããã³ã·ã¹ãã€ã³æ®åºã¯Cys261ãCsy321ãCys367ãããã³Cys425ãããªã矀ããéžã°ãåŸãã
äŸãã°ãäžå®æœæ
æ§ã§ã¯ãæäœ67ã®Fcé åã¯D265Cå€ç°ïŒäŸã¯ãé
åçªå·20ïŒãå«ãããã«ä¿®é£Ÿããããå¥ã®å®æœæ
æ§ã§ã¯ãæäœ67ã®Fcé åã¯D265CãL234Aãããã³L235Aå€ç°ïŒäŸã¯ãé
åçªå·18ïŒãå«ãããã«ä¿®é£Ÿããããããã«å¥ã®å®æœæ
æ§ã§ã¯ãæäœ67ã®Fcé åã¯D265Cããã³H435Aå€ç°ïŒäŸã¯ãé
åçªå·21ïŒãå«ãããã«ä¿®é£Ÿãããããããªãå®æœæ
æ§ã§ã¯ãæäœ67ã®Fcé åã¯D265CãL234AãL235Aãããã³H435Aå€ç°ïŒäŸã¯ãé
åçªå·19ïŒãå«ãããã«ä¿®é£Ÿãããã
ããã«èšèŒãããå€çš®Fcãã¡ã€ã³ã¯ããããæ§æããã¢ããé
žä¿®é£Ÿã«åŸã£ãŠèŠå®ããããFcé åã«é¢ããŠããã§è«ãããã¹ãŠã®ã¢ããé
žçœ®æã«ã€ããŠããã³ããªã³ã°ã¯åžžã«EUã€ã³ããã¯ã¹ã«ãããããããã«ãäŸãã°ãD265Cã¯èŠªFcãã¡ã€ã³ã«é¢ãã·ã¹ãã€ã³ïŒCïŒã«ãã眮æãããEUäœçœ®265ã§ã®ã¢ã¹ãã©ã®ã³é
žïŒDïŒãæããFcå€çš®ã§ãããåæ§ã«ãäŸãã°ãD265C/L234A/L235Aã¯èŠªFcãã¡ã€ã³ã«å¯ŸããŠEUäœçœ®265ïŒDããCïŒã234ïŒLããAïŒãããã³235ïŒLããAïŒã«çœ®æãæããå€çš®Fcããªã¢ã³ããèŠå®ãããå€çš®ã¯ãŸããå€ç°ããEUã¢ããé
žäœçœ®ã«ããããã®æçµçãªã¢ããé
žçµæã«åŸã£ãŠæå®ããããšãã§ãããäŸãã°ãL234A/L235Aå€ç°äœã¯LALAãšç§°ããããšãã§ããã眮æãæäŸãããé åºã¯ä»»æã§ããããšã«æ³šç®ãããã
äžå®ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæçã¯ãã³ã³ãžã¥ã²ãŒãã®äžéšãšããŠäœ¿çšãããšãã«ç¹ã«æå©ã§ããäžå®ã®è§£é¢é床ãæãããäŸãã°ãæCD117æäœã¯ãäžå®ã®å®æœæ
æ§ã«ãããŠãçäœå±€å¹²æžæ³ïŒBLIïŒã¢ãã»ã€ã«ãã£ãŠæž¬å®ãããããã«ã1Ã10-2ãã1Ã10-3ãŸã§ã1Ã10-3ãã1Ã10-4ãŸã§ã1Ã10-5ãã1Ã10-6ãŸã§ã1Ã10-6ãã1Ã10-7ãŸã§ãŸãã¯1Ã10-7ãã1Ã10-8ãŸã§ã®ããCD117ããã³/ãŸãã¯ã¢ã«ã²ã¶ã«CD117ã«å¯Ÿãããªãã¬ãŒãå®æ°ïŒKoffïŒãæãããããããã®å®æœæ
æ§ã§ã¯ãæäœãŸãã¯ãã®æåçµåæ§æçã¯CD117ïŒäŸã¯ãããCD117ããã³/ãŸãã¯ã¢ã«ã²ã¶ã«CD117ïŒã«çäœå±€å¹²æžæ³ïŒBLIïŒã¢ãã»ã€ã«ãã£ãŠæ±ºå®ãããããã«çŽ100nMãŸãã¯ããæªæºïŒä»¥äžãšãèšãïŒãçŽ90nM以äžãçŽ80nM以äžãçŽ70nM以äžãçŽ60nM以äžãçŽ50nM以äžãçŽ40nM以äžãçŽ30nM以äžãçŽ20nM以äžãçŽ10nM以äžãçŽ8nM以äžãçŽ6nM以äžãçŽ4nM以äžãçŽ2nM以äžãçŽ1nM以äžã®KDã«ããçµåããã
ããã«é瀺ãããæäœããŸãã¯ãã®æåçµåæ§æçã¯ã以äžã«ããäžå±€è©³çŽ°ã«èª¬æããããã«ãã³ã³ãžã¥ã²ãŒãã«ãããŠäœ¿çšããããšãã§ããã
åã
ã®åè¿°ã®åè¡ç©ã®é瀺ã¯æCD117æäœã«é¢é£ãããã®ãšããŠåç
§ã«ããããã«çµã¿èŸŒããããã«èšèŒã®çµæç©ããã³æ¹æ³ãšçµã¿åãããŠäœ¿çšããããšãã§ããæäœããã³æåçµåæ§æçã«ã¯ãäžè¿°ã®æäœããã³ãã®æåçµåæ§æçããªãã³ã«äžè¿°ã®ãããã®éããæäœããã³æåçµåæ§æçã®ããåå€çš®ãããã³äŸãšããŠç«¶åCD117çµåã¢ãã»ã€ãä»ããŠè©äŸ¡ãããããªãäžè¿°ã®ãã®ãšåããšãããŒããçµåããæäœãŸãã¯æåçµåæ§æçãå«ãŸããã
åè¿°ã®æäœã®äŸç€ºçãªæåçµåæ§æçã«ã¯ãäºéå¯å€å
ç«ã°ãããªã³ãã¡ã€ã³ãåéFvååïŒscFvïŒããã€ã¢ããã£ãããªã¢ããã£ãããããã£ãæäœæ§ã¿ã³ãã¯è³ªã¹ãã£ãã©ãŒã«ãïŒantibody-like protein scaffoldïŒãFvæçãFabæçãF(ab')2ååãããã³ã¿ã³ãã ãžscFvãã»ãã«ãããããå«ãŸããã
æäœã¯çµæãæ¹æ³ããã³çµæç©ãçšããŠçç£ãåŸãäŸã¯ãUS. Pat. No. 4,816,567å·ã«èšèŒãããŠãããäžå®æœæ
æ§ã§ã¯ãããã«èšèŒãããæCD117æäœãã³ãŒãããåé¢ãããæ žé
žãæäŸãããããã®ãããªæ žé
žã¯æäœã®VLãå«ãŸããã¢ããé
žé
åããã³/ãŸãã¯VHãå«ãŸããã¢ããé
žé
åïŒäŸã¯ãæäœã®è»œéããã³/ãŸãã¯ééïŒãã³ãŒããåŸãããããªãå®æœæ
æ§ã§ã¯ããã®ãããªæ žé
žãå«ã1以äžã®ãã¯ã¿ãŒïŒäŸã¯ãçºçŸãã¯ã¿ãŒïŒãæäŸãããããããªãå®æœæ
æ§ã§ã¯ããã®ãããªæ žé
žãå«ã宿䞻现èãæäŸãããã1ã€ã®ãã®ãããªå®æœæ
æ§ã§ã¯ã宿䞻现èã¯æ¬¡ã®ãã®ãå«ãïŒäŸã¯ã次ã®ãã®ã«ãã圢質転æãããŠããïŒïŒïŒ1ïŒæäœã®VLãå«ãŸããã¢ããé
žé
åããã³æäœã®VHãå«ãŸããã¢ããé
žé
åãã³ãŒãããæ žé
žãå«ããã¯ã¿ãŒããŸãã¯ïŒ2ïŒæäœã®VLãå«ãŸããã¢ããé
žé
åãã³ãŒãããæ žé
žãå«ãŸãã第1ã®ãã¯ã¿ãŒããã³æäœã®VHãå«ãŸããã¢ããé
žé
åãã³ãŒãããæ žé
žãå«ãŸãã第2ã®ãã¯ã¿ãŒãäžå®æœæ
æ§ã§ã¯ã宿䞻现èã¯çæ žçç©ãäŸã¯ããã£ã€ããŒãºãã ã¹ã¿ãŒåµå·£ïŒCHOïŒçŽ°èãŸãã¯ãªã³ãç系现èïŒäŸã¯ãY0ãNS0ãSp20现èïŒã§ãããäžå®æœæ
æ§ã§ã¯ãæCLL-1æäœãäœæããæ¹æ³ãæäŸãããããã§ã¯æ¹æ³ã¯äžèšã§æäŸãããããã«ãæäœãã³ãŒãããæ žé
žãå«ãŸãã宿䞻现èãæäœã®çºçŸã«é©ããæ¡ä»¶äžã§å¹é€ããããšãããã³éæã«å®¿äž»çŽ°èïŒãŸãã¯å®¿äž»çŽ°èå¹é€å¹å°ïŒããæäœãååããããšãå«ãã
æCD117æäœã®çµæãçç£ã®ããã«ãæäœãã³ãŒãããæ žé
žãäŸã¯ãäžèšã®ãããªãã®ã¯ãåé¢ãããããã³å®¿äž»çŽ°èã«ããããããªãã¯ããŒãã³ã°ããã³/ãŸãã¯çºçŸã®ããã«1以äžã®ãã¯ã¿ãŒã«æ¿å
¥ãããããã®ãããªæ žé
žã¯æ
£ç¿çãªæé ãçšããŠïŒäŸã¯ãæäœã®ééããã³è»œéãã³ãŒãããéºäŒåã«ç¹ç°çã«çµåããããšãå¯èœãªãªãªãŽãã¯ã¬ãªãããããŒããçšããããšã«ãã£ãŠïŒå®¹æã«åé¢ããã³é
å決å®ããåŸãã
æäœã³ãŒãåãã¯ã¿ãŒïŒantibody-encoding vectorsïŒã®ã¯ããŒãã³ã°ãŸãã¯çºçŸã«é©ãã宿䞻现èã«ã¯ãããã«èšèŒã®åæ žçŽ°èãŸãã¯çæ žçŽ°èãå«ãŸãããäŸãã°ãæäœã¯ãç¹ã«ã°ãªã³ã·ã«åããã³Fcãšãã§ã¯ã¿ãŒæ©èœãå¿
èŠã§ãªããšãã现èã«ãããŠçç£ãåŸãã现èã«ãããæäœæçããã³ããªããããã®çºçŸã«ã€ããŠãäŸã¯ãU.S. Pat. Nos. 5,648,237ã5,789,199ãããã³5,840,523å·åïŒãŸããCharltonïŒãã£ãŒã«ãã³ïŒãMethods in Molecular BiologyïŒã¡ãœããºã»ã€ã³ã»ã¢ã¬ãã¥ã©ãŒã»ãã€ãªããžãŒïŒãVol. 248 (B.K.C. LoïŒããŒïŒ, ed., Humana PressïŒãããã»ãã¬ã¹ïŒ, TotowaïŒããã¯ïŒ, N.J.ïŒç±³åœãã¥ãŒãžã£ãŒãžãŒå·ïŒ, 2003), pp.245-254, described of antibody fragments in E. coli.ïŒãšã·ã§ãªãã¢ã»ã³ãªã«ãããæäœæçã®èšèŒïŒãåç
§ïŒãçºçŸåŸãæäœã¯å¯æº¶æ§ç»åã«ãããŠãã¯ããªã¢çŽ°èããŒã¹ãããåé¢ãåŸãããã³ããã«ç²Ÿè£œããããšãã§ããã
ãŸãèæ€åç©ã®çŽ°èã宿䞻ãšããŠäœ¿çšããŠãããäŸãã°ãæžæ¿ç©ã«ãããŠå¢æ®ããããã«é©åãããåºä¹³é¡çŽ°èç³»ã¯æçšã§ããåŸããæçšãªåºä¹³é¡å®¿äž»çŽ°èç³»ã®ä»ã®äŸã¯SV40ã«ãã£ãŠåœ¢è³ªè»¢æããããµã«è
èCV1ç³»ïŒCOS-7ïŒïŒããèæ§è
èç³»ïŒäŸã¯ãGrahamïŒã°ã¬ã¢ã ïŒã, J. Gen Virol.ïŒã¶ã»ãžã£ãŒãã«ã»ãªãã»ãžã§ãã©ã«ã»ãã€ãããžãŒïŒ36:59 (1977)ã«èšèŒã®ãããª293ãŸãã¯293现èïŒïŒãããŒãã ã¹ã¿ãŒè
è现èïŒBHKïŒïŒããŠã¹ã»ã«ããªçŽ°èïŒäŸã¯ãMatherïŒãã¶ãŒïŒ, Biol. Reprod.ïŒãã€ãªããžãŒã»ãªãã»ãªãããã¯ã·ã§ã³ïŒ23:243-251 (1980)ã«èšèŒã®ãããªTM4现èïŒïŒãµã«è
è现èïŒCV1ïŒïŒã¢ããªã«ãããªã¶ã«è
è现èïŒVERO-76ïŒïŒããé žéšã¬ã³è
«çŽ°èïŒHELAïŒïŒã€ãè
è现èïŒMDCKïŒãããã¡ããŒã©ããèè现èïŒBRL 3AïŒïŒããèºçŽ°èïŒW138ïŒïŒããèè现èïŒHep G2ïŒïŒããŠã¹ä¹³è
ºè
«çïŒMMT 060562ïŒïŒTRI现èãäŸã¯ãMatherããAnnals N.Y. Acad. Sci.ïŒã¢ããŒã«ãºã»ãªãã»ã¶ã»ãã¥ãŒã»ãšãŒã¯ã»ã¢ã«ãããŒã»ãªãã»ãµã€ãšã³ã·ãŒãºïŒ383:44-68 (1982)ã«èšèŒããããããªãã®ïŒMRC5现èïŒããã³FS4现èã§ãããä»ã®æçšãªåºä¹³åç©å®¿äž»çŽ°èç³»ã«ã¯ããã£ã€ããŒãºãã ã¹ã¿ãŒåµå·£ïŒCHOïŒçŽ°èã§ãDHFR- CHO现èãå«ããã®ïŒUrlaubïŒãŠã«ã©ãŠãïŒã, Proc. Natl. Acad. Sci. USA 77:4216 (1980))ïŒããã³éªšé«è
«çŽ°èç³»ãäŸãã°ãY0ãNS0ããã³Sp2/0ãªã©ã®ãããªãã®ãå«ãŸãããæäœçç£ã«é©ããäžå®ã®åºä¹³é¡å®¿äž»çŽ°èç³»ã®æŠèª¬ã«ã€ããŠãäŸã¯ãYazakiïŒã€ã¶ãïŒããã³WuïŒãŠãŒïŒ, Methods in Molecular Biology, Vol. 248 (B. K. C. Lo, ed., Humana Press, Totowa, N.J.), pp.255-268 (2003)ãåç
§ã
äžå®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ãããã«é瀺ãããé
åçªå·ãšå°ãªããšãçŽ80%ãçŽ85%ãçŽ90%ãçŽ91%ãçŽ92%ãçŽ93%ãçŽ94%ãçŽ95%ãçŽ96%ãçŽ97%ãçŽ98%ãçŽ99%ãŸãã¯ããããããå€ãåäžã®ã¢ããé
žé
åãæããå¯å€é åãå«ãããããã¯ãŸããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ãããã«é瀺ãããé
åçªå·ãšå°ãªããšãçŽ80ïŒ
ãçŽ85ïŒ
ãçŽ90ïŒ
ãçŽ91ïŒ
ãçŽ92ïŒ
ãçŽ93ïŒ
ãçŽ94ïŒ
ãçŽ95ïŒ
ãçŽ96ïŒ
ãçŽ97ïŒ
ãçŽ98ïŒ
ãçŽ99ïŒ
ãŸãã¯ããããããå€ãåäžã§ããã¢ããé
žé
åãæããããã«èšèŒã®å¯å€é åã®ãã¬ãŒã ã¯ãŒã¯é åã䌎ãããã«é瀺ãããé
åçªå·ãå«ãŸããCDRsãå«ãã
äžå®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ããã«é瀺ãããã¢ããé
žé
åãæããééå¯å€é åããã³ééå®åžžé åãå«ããå¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ããã«é瀺ãããã¢ããé
žé
åãæãã軜éå¯å€é åããã³è»œéå®åžžé åãå«ããããã«å¥ã®å®æœæ
æ§ã§ã¯ãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ããã«é瀺ãããã¢ããé
žé
åãæããééå¯å€é åã軜éå¯å€é åãééå®åžžé åããã³è»œéå®åžžé åãå«ãã
æCD117æäœã®èå¥æ¹æ³
æCD117æäœã®èå¥æ¹æ³
ããã§æäŸãããã®ã¯ãäŸãã°ã幹现è移æ€ã®ããã®ã³ã³ãã£ã·ã§ãã³ã°æ³ã«ãããŠäœ¿çšããåŸãæ°èŠãªæCD117æäœã§ãããããã§ã®é瀺ã«éã¿ãŠãä»ã®æCD117æäœãäŸã¯ãäžæ§æäœïŒneutral antibodiesïŒãèå¥ããããšãã§ããã
CD117ïŒäŸã¯ãGNNKïŒCD117ïŒãçµåããããšãå¯èœãªååã«ã€ããŠã®æäœããŸãã¯æäœæçãã©ã€ãã©ãªãŒã®ãã€ã¹ã«ãŒãããã¹ã¯ãªãŒãã³ã°ã®ããã®æ¹æ³ã¯ã¬ã³ãèªå·±å
ç«çŸæ£ã®åŠçœ®ãããã³ããã«èšèŒã®ãããªé è¡å¹¹çŽ°èçæ³ã®å¿
èŠããããã€ã·ã§ã³ãïŒäŸã¯ããããã€ã·ã§ã³ãïŒã®ã³ã³ãã£ã·ã§ãã³ã°ã«åœ¹ç«ã€æäœãèå¥ããã³èŠªåæ§æçãããïŒaffinity matureïŒã®ã«äœ¿çšããããšãã§ããããã®ãããªæ¹æ³ã«ã¯ãåœæè¡ã§æ¢ç¥ã®ã€ã³ããããã£ã¹ãã¬ã€æè¡ãäŸãã°ããã¡ãŒãžãã£ã¹ãã¬ã€ã现èãã£ã¹ãã¬ã€ãé
µæ¯ãã£ã¹ãã¬ã€ãåºä¹³é¡çŽ°èãã£ã¹ãã¬ã€ããªããœãŒã ãã£ã¹ãã¬ã€ãmRNAãã£ã¹ãã¬ã€ãããã³cDNAãã£ã¹ãã¬ã€ãªã©ã®ãããªãã®ãã»ãã«ããããå«ãŸãããçç©åŠçã«é¢é£ããååãçµåãããªã¬ã³ããåé¢ããããã®ãã¡ãŒãžãã£ã¹ãã¬ã€ã®äœ¿çšã¯ãäŸãã°ãFeliciïŒãã§ãªã·ïŒã, Biotechnol. Annual Rev.ïŒãã€ãªãã¯ãããžãŒã»ã¢ãã¥ã¢ã«ã»ã¬ãã¥ãŒïŒ1:149-183, 1995ïŒKatzïŒã«ããïŒãAnnual Rev. Biophys. Biomol. Struct.ïŒã¢ãã¥ã¢ã«ã»ã¬ãã¥ãŒã»ãªãã»ãã€ãªãã£ãžãã¯ã¹ã»ã¢ã³ãã»ãã€ãªã¢ã¬ãã¥ã©ãŒã»ã¹ãã©ã¯ãã£ãŒïŒ26:27-45, 1997ïŒããã³HoogenboomïŒããŒãã³ããŒã ïŒã, ImmunotechnologyïŒã€ã ããã¯ãããžãŒïŒ4:1-20, 1998ã«ãããŠæŠèª¬ãããŠããããããã®åã
ã®é瀺ã¯ããããã€ã³ããããã£ã¹ãã¬ã€æè¡ã«é¢é£ãããã®ãšããŠåç
§ã«ãã£ãŠããã«çµã¿èŸŒãŸãããã©ã³ãã åã³ã³ããããªã¢ã«ããããã©ã€ãã©ãªãŒïŒRandomized combinatorial peptide librariesïŒã¯çŽ°èè¡šé¢æåã«çµåããããªãããããéžå®ããããã«æ§ç¯ãããŠãããKayïŒã±ã€ïŒ, Perspect. Drug Discovery Des.ïŒããŒã¹ãã¯ãã£ããºã»ã€ã³ã»ãã©ãã°ã»ãã£ã¹ã«ããªãŒã»ã¢ã³ãã»ãã¶ã€ã³ïŒ2:251-268, 1995ããã³KayããMol. Divers.ïŒã¢ã¬ãã¥ã©ãŒã»ãã€ããŒã·ãã£ïŒ1:139-140, 1996ã«èšèŒãããŠãããããªãã®ã§ããããããã®åã
ã®é瀺ã¯æåçµåååã®çºèŠã«é¢ãããã®ãšããŠåç
§ã«ãã£ãŠããã«çµã¿èŸŒãŸãããã¿ã³ãã¯è³ªãäŸãã°ãå€éäœã¿ã³ãã¯è³ªãªã©ã®ãããªãã®ã¯æ©èœæ§ååãšããŠå¥œéŠå°Ÿã«ãã¡ãŒãžãã£ã¹ãã¬ã€ãããïŒäŸãã°ãEP 0349578ïŒEP 4527839; ããã³EP 0589877ããªãã³ã«ChiswellïŒãã¹ãŠã§ã«ïŒããã³McCaffertyïŒããã«ãã¡ãã£ïŒ, Trends Biotechnol.ïŒãã¬ã³ã
ã»ã€ã³ã»ãã€ãªãã¯ãããžãŒïŒ10:80-84 1992ãåç
§ããããã®åã
ã®é瀺ã¯ããããæåçµåæ§ååã®çºèŠã®ããã®ã€ã³ããããã£ã¹ãã¬ã€æè¡ã®äœ¿çšã«é¢é£ãããã®ãšããŠåç
§ã«ãã£ãŠããã«çµã¿èŸŒãŸããïŒãå ããŠãæ©èœçæäœæçãäŸãã°ãFabããã³scFvæçãªã©ã®ãããªãã®ã¯ã€ã³ããããã£ã¹ãã¬ã€åœ¢åŒã«ãããŠã§çºçŸãããŠããïŒäŸãã°ãMcCaffertyããNature 348:552- 554, 1990ïŒBarvasïŒãã«ãã¹ïŒã, Proc. Natl. Acad. Sci. USA 88:7978-7982, 1991ïŒããã³ClacksonïŒã¯ã©ãã¯ãœã³ïŒã, Nature 352:624-628, 1991ãåç
§ããããã®åã
ã®é瀺ã¯ããããæåçµåæ§ååã®çºèŠã®ããã®ã€ã³ããããã£ã¹ãã¬ã€ãã©ãããã©ãŒã ã«é¢é£ãããã®ãšããŠåç
§ã«ãã£ãŠããã«çµã¿èŸŒãŸããïŒããããã®æè¡ã¯ãšããããé è¡å¹¹çŽ°è移æ€çæ³ãå¿
èŠãªãã€ã·ã§ã³ãïŒäŸã¯ããããã€ã·ã§ã³ãïŒã«ãããŠå
å æ§é è¡å¹¹çŽ°èãæžå°ãããããã«é ã«çšããããšãã§ããCD117ïŒäŸã¯ãGNNK+CD117ïŒãšçµåããæäœã®èŠªåæ§ãèå¥ããã³æ¹åããããã«çšããããšãã§ããã
ã€ã³ããããã£ã¹ãã¬ã€æè¡ã«å ããŠãCD117ïŒäŸã¯ãGNNKïŒCD117ïŒã«çµåããæäœããŸãã¯æäœæçãã€ã³ã·ãªã³ã§èšèšããã³èå¥ããããã«ãèšç®ã¢ããªã³ã°æè¡ïŒcomputational modeling techniquesïŒã䜿çšããããšãã§ãããäŸãã°ãèšç®ã¢ããªã³ã°æè¡ã䜿çšããŠãæ¬æè¡ã«ãããçç·Žã®è
ïŒåœæ¥è
ãšãèšãïŒã¯ç¹å®ã®ãšãããŒããäŸãã°ããã®æåã®çŽ°èå€ãšãããŒããªã©ã®ãããªãã®ãçµåããããšãå¯èœãªååã«ã€ããŠãæäœããŸãã¯æäœæçã®ã©ã€ãã©ãªãŒãã€ã³ã·ãªã³ã§ã¹ã¯ãªãŒãã³ã°ããããšãã§ããããããã®èšç®æè¡ã«ãã£ãŠèå¥ãããæäœããŸãã¯ãã®æåçµåæ§æçã¯ãããã«èšèŒã®æ²»çæ¹æ³ãäŸãã°ãããã«èšèŒã®ã¬ã³ããã³èªå·±å
ç«çŸæ£ã®åŠçœ®æ¹æ³ããªãã³ã«ããã«èšèŒã®ãã€ã·ã§ã³ãã³ã³ãã£ã·ã§ãã³ã°æé ãªã©ã®ãããªãã®ãšçµã¿åãããŠäœ¿çšããããšãã§ããã
è¿œå ã®æè¡ã¯ã现èïŒäŸã¯ãã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èïŒã®è¡šé¢äžã®CD117ïŒäŸã¯ãGNNKïŒCD117ïŒã«çµåããããã³çŽ°èã«ãã£ãŠãäŸãšããŠãå容äœåªä»ãšã³ããµã€ããŒã·ã¹ã«ãã£ãŠã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ããæäœããŸãã¯ãã®æåçµåæ§æçãèå¥ããããã«äœ¿çšããããšãã§ãããäŸãã°ãäžèšã®ã€ã³ããããã£ã¹ãã¬ã€æè¡ã¯ãã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èã®è¡šé¢äžã®CD117ïŒäŸã¯ãGNNK+CD117ïŒã«çµåããããã³ãã®åŸã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ããæäœããŸãã¯ãã®æåçµåæ§æçã«ã€ããŠã¹ã¯ãªãŒãã³ã°ããããã«é©å¿ãããããšãã§ããããã¡ãŒãžãã£ã¹ãã¬ã€ã¯ãã®ã¹ã¯ãªãŒãã³ã°ãã©ãã€ã ãšçµã¿åãããŠäœ¿çšããããšãã§ãããã®ãããªæè¡ã®1ã€ã代衚ãããCD117ïŒäŸã¯ãGNNKïŒCD117ïŒã«çµåããããã³ãã®åŸãã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èã«ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãããæäœãŸãã¯ãã®æçãèå¥ããããã«ãæ¬æè¡ã«ãããçç·Žã®è
ã¯ãäŸãã°ãWilliamsïŒãŠã£ãªã¢ã ãºïŒã, LeukemiaïŒã«ãŒããŒãã¢ïŒ19:1432-1438, 2005ã«èšèŒã®ãã¡ãŒãžãã£ã¹ãã¬ã€æè¡ãé©çšããããšãã§ãããã®é瀺ãåç
§ã«ããå
šäœãšããŠããã«çµã¿èŸŒãŸãããäŸãã°ãåœæè¡ã§æ¢ç¥ã®å€ç°èªçºæ³ãçšããŠçµæããã¡ãŒãžã©ã€ãã©ãªãŒãçç£ããããšãã§ããããã¯ã©ã³ãã åã¢ããé
žã«ã»ãããå«ãæäœãæäœæçãäŸãã°scFvæçãFabæçããã€ã¢ããã£ããã©ã€ã¢ããã£ãããã³10Fn3ãã¡ã€ã³ãªã©ã®ãããªãã®ãã»ãã«ãããããã³ãŒãããïŒäŸã¯ããã®CDRsãŸãã¯ãã®ç䟡ã®é åã®1以äžããŸãã¯ãã¹ãŠããŸãã¯æäœãŸãã¯æäœæçã«ãããŠïŒãæäœãŸãã¯æäœæçã®ãã¬ãŒã ã¯ãŒã¯é åããã³ãžãFcãã¡ã€ã³ãããã³ä»ã®é åã¯äŸãšããŠãããçæ®ç³»åæäœé
åãŸãã¯ããçæ®ç³»åæäœã«å¯ŸããŠããããªå€ç°ããèŠããªãé
åãæãããããã§ãããããããã«ãããŠéå
ç«åæ§ã§ããããã«èšèšãåŸãã
ããã«èšèŒããããŸãã¯åœæè¡ã«ãããŠæ¢ç¥ã®ãã¡ãŒãžãã£ã¹ãã¬ã€æè¡ã䜿çšãããã¡ãŒãžç²åã«å
±æçµåããã©ã³ãã åæäœããŸãã¯æäœæçãå«ããã¡ãŒãžã©ã€ãã©ãªãŒã¯ãCD117ïŒäŸã¯ãGNNK+CD117ïŒæåãšãäŸãšããŠãæåã«ãã¡ãŒãžã©ã€ãã©ãªãŒãããããã³ã°å€ïŒäŸãã°ãäŸãšããŠãéç¹ç°çã¿ã³ãã¯è³ªçµåã瀺ãæäœãŸãã¯ãã®æçãã³ãŒããããã¡ãŒãžããã³Fcãã¡ã€ã³ãçµåããæäœãŸãã¯ãã®æçãã³ãŒããããã¡ãŒãžãé€å»ããããã«ä¹³ã¿ã³ãã¯è³ªããŠã·è¡æž
ã¢ã«ããã³ãããã³/ãŸãã¯IgGãªã©ã®ãããªãã®ïŒãšã€ã³ãã¥ããŒã·ã§ã³ããããã³æ¬¡ãã§ãã¡ãŒãžã©ã€ãã©ãªãŒãé è¡å¹¹çŽ°èã®éå£ãšã€ã³ãã¥ããŒã·ã§ã³ããããšã«ãã£ãŠãã€ã³ãã¥ããŒã·ã§ã³ããããšãã§ããããã¡ãŒãžã©ã€ãã©ãªãŒã¯ãCD117ç¹ç°çæäœããŸãã¯ãã®æåçµåæ§æçïŒäŸã¯ãGNNK+ CD117ç¹ç°çæäœããŸãã¯ãã®æåçµåæ§æçïŒã现èè¡šé¢CD117ïŒäŸã¯ã现èè¡šé¢GNNK+CD117ïŒæåãšçµåããããã³ãã®åŸã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èã«ãã£ãŠã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãããã®ã«ååãªæéãæšç现èãäŸãã°ãã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èãªã©ã®ãããªãã®ãšã€ã³ãã¥ããŒã·ã§ã³ããããšãã§ããïŒäŸã¯ã4âã§30åãã6æéãŸã§ãäŸãã°ã4âã§1æéãªã©ã®ãããªãã®ïŒãã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èãžã®çµåããã³ãããã«ããã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãå¯èœã«ããããã«ããããã®æåã®1以äžã«ã€ããŠååãªèŠªåæ§ã瀺ããªãæäœããŸãã¯ãã®æçãå«ããã¡ãŒãžã¯ããã®åŸãäŸãšããŠãpH2.8ã§ã®å·ïŒ4âïŒ0.1Mã°ãªã·ã³ç·©è¡å€ã«ãã现èãæŽæµããããšã«ãã£ãŠé€å»ããããšãã§ãããæäœãŸãã¯ãã®æçã«çµåãããã¡ãŒãžã¯ããããã¯ã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èã«ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ããŠãäŸãšããŠã现èã溶解ããããšãããã³çŽ°èå¹é€åªäœããã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãããã¡ãŒãžãååããããšã«ãã£ãŠèå¥ããããšãã§ããã次ãã§ããã¡ãŒãžã¯äŸãã°ã现è现èãååãããã¡ãŒãžãš2xYTå¹å°ã«ãããŠåœæè¡ã§æ¢ç¥ã®æ¹æ³ãçšããŠã€ã³ãã¥ããŒãããããšã«ãã£ãŠã现è现èã«ãããŠå¢å¹
ãããããšãã§ããããã®å¹å°ããååããããã¡ãŒãžã¯æ¬¡ã«ãäŸãšããŠããã¡ãŒãžã²ãã å
ã«æ¿å
¥ãããæäœããŸãã¯ãã®æçãã³ãŒãããéºäŒåïŒãã®è€æ°åœ¢ïŒã®æ žé
žé
åã決å®ããããšã«ãã£ãŠç¹åŸŽä»ããããšãã§ãããã³ãŒãåãããæäœããŸãã¯ãã®æçããããã¯ãã®åŸãååŠåæã«ãã£ãŠïŒäŸãšããŠãæäœæçãäŸãã°ãscFvæçãªã©ã®ãããªãã®ã®ïŒãŸãã¯çµæãçºçŸïŒäŸã¯ãå
šé·æäœã®ïŒã«ãã£ãŠæ°ãã«èª¿è£œããããšãã§ããã
ããã«èšèŒã®çµæç©ããã³æ¹æ³ãšå
±ã«äœ¿çšããããã®æCD117ïŒäŸã¯ãæGNNKïŒCD117ïŒæäœã®ã€ã³ãããå±éïŒevolutionïŒã®ããã®æš¡ç¯çãªæ¹æ³ã¯ãã¡ãŒãžãã£ã¹ãã¬ã€ã§ããããã¡ãŒãžãã£ã¹ãã¬ã€ã©ã€ãã©ãªãŒã¯æäœã®CDRsãŸãã¯æäœæ§ã¹ãã£ãã©ãŒã«ãã®é¡äŒŒé åïŒäŸã¯ã10Fn3ãã¡ã€ã³ã®BCãCDãããã³DEã«ãŒãïŒã«ã€ããŠã®ã³ãŒãã£ã³ã°é
åå
ã§èšèšãããäžé£ã®å€ç°ãŸãã¯å€åœ¢ãè¡ãããšã«ãã£ãŠäœãåºãããšãã§ããããããã®å€ç°ãå°å
¥ãããé³åã®æäœã³ãŒãé
åã¯äŸãã°ããã€ãŒããªããçæ®ç³»åé
åã§ããåŸãããããã®å€ç°ã¯åœæè¡ã§ç¥ãããæšæºçãªå€ç°èªçºæè¡ãçšããŠå®è¡ããããšãã§ããããã®ããã«ããŠãåå€ç°é
åã¯1以äžã®ã¢ããé
žå€åœ¢ãé€ããŠã¯é³åã«å¯Ÿå¿ããæäœãã³ãŒããããã¬ãããŠã€ã«ã¹ããã³ãã¡ãŒãžãã£ã¹ãã¬ã€ãã¯ã¿ãŒã¯åœæè¡ã§ç¥ãããæšæºçãªãã¯ã¿ãŒæ§ç¯æè¡ã䜿çšããŠå·¥åŠçã«äœãåºãããšãã§ãããP3ãã¡ãŒãžãã£ã¹ãã¬ã€ãã¯ã¿ãŒã¯é©åæ§ãããã¿ã³ãã¯è³ªçºçŸãã¯ã¿ãŒãšãšãã«æäœå€æ§åã®ããã®ãã¡ãŒãžãã£ã¹ãã¬ã€ãã¯ã¿ãŒãçæããããã«äœ¿çšããããšãã§ããã
å€ç°ããDNAã¯é
åã®å€æ§æ§ãæäŸããããã³å圢質転æãã¡ãŒãžã¯DNAã«ãã£ãŠã³ãŒããããåæã®ãã³ãã¬ãŒãã¢ããé
žé
åã®1ã€ã®å€çš®ã衚瀺ããç°ãªããæ§é çã«é¢é£ããèšå€§ãªæ°ã®ã¢ããé
žé
åã衚瀺ãããã¡ãŒãžéå£ïŒã©ã€ãã©ãªãŒïŒããããããããã¯ã£ãããšèŠå®ãããæäœã®è¶
å¯å€é åã®ããããã¡ãŒãžãã£ã¹ãã¬ã€ã¹ã¯ãªãŒã³ã«ãããŠå°å
¥ãããã¢ããé
žã®å€åœ¢ã¯ãã®å
šäœçãªååæ§é ã倧ããå€ããããšãªãçµåãããããŸãã¯ãã¡ã€ã³ã®çµåç¹æ§ãå€ããããšãæåŸ
ãããã
å
žåçãªã¹ã¯ãªãŒãã³ã°ã§ã¯ããã¡ãŒãžã©ã€ãã©ãªãŒã¯åè¿°ã®æåãŸãã¯ãã®ãšãããŒãã®1ã€ãšæ¥è§Šãããããã³çµåãããããšãå¯èœã«ããåŸãããã€ã³ããŒïŒbindersïŒããã³éãã€ã³ããŒïŒnon-bindersïŒã®åé¢ã容æã«ããããã«ãæšçãåºåœ¢æ¯æäœäžã«åºå®åããããšã䟿å©ã§ãããCD117çµåæ§ã¢ã€ãšãã£ïŒCD117-binding moietyïŒã垯ã³ããã¡ãŒãžã¯åºåœ¢æ¯æäœäžã®æšçãšè€åäœã圢æããããšãã§ããããéçµåãã¡ãŒãžã¯æº¶æ¶²ãããŠæ®ããããã³éå°ã®ç·©è¡å€ã§æŽãæµãããšãã§ããã次ãã§çµåãããã¡ãŒãžã¯ç·©è¡å€ã極端ãªpHïŒpH2ãŸãã¯pH10ïŒã«å€ããããšãç·©è¡å€ã®ã€ãªã³åŒ·åºŠãå€ããããšãå€æ§å€ãå ããããšããŸãã¯ä»ã®æ¢ç¥ã®æ段ã«ãã£ãŠæšçããéé¢ãããããšãã§ããã
ååããããã¡ãŒãžã¯æ¬¡ã«ã现è现èã®ææãéããŠå¢å¹
ããããšãã§ããããã³ã¹ã¯ãªãŒãã³ã°ããã»ã¹ã¯ãä»ãéçµåæäœã«ãããŠæ¯æžãããããã³CD117ïŒäŸã¯ãGNNKïŒCD117ïŒãçµåããæäœã«ã€ããŠæ¿çž®ãããæ°ããããŒã«ãçšããŠç¹°ãè¿ãããšãã§ãããã»ãã®å°ãã®ïŒfewã2ã3ã®ïŒçµåãã¡ãŒãžããã®ååã¯ãã®åŸã®ã¹ã¯ãªãŒãã³ã°ã®å埩ïŒiterationïŒã«ã€ããŠãã¡ãŒãžãå¢å¹
ãããã®ã«ååã§ãããã»ãã®å°ãã®ã©ãŠã³ãã®éžå®ã®åŸãçµåããŒã«ã«ãããéžã°ãããã¡ãŒãžã¯ããŒã³ããå°ãåºãããæäœãŸãã¯ãã®æåçµåæ§æçãã³ãŒãããéºäŒåé
åã¯æ
£ç¿çãªæ¹æ³ã«ãã£ãŠæ±ºå®ãããããã«ãããã¡ãŒãžã®æšçãžã®çµå芪åæ§ãä»äžããïŒimpartsïŒããããé
åãæããã«ããããããã³ã°ããã»ã¹ïŒpanning processïŒã®éãéå£ã®é
åå€æ§æ§ã¯æãŸããããããçµåæäœãæ®ããŸã§éžå®ã®åã©ãŠã³ããšå
±ã«æžãããããé
åã¯å°æ°ã®ïŒsmall number ofïŒé¢é£ããæäœãŸãã¯ãã®æåçµåæ§æçã«åæãïŒconvergeïŒåŸããéžå®ã®åã©ãŠã³ãã«ãŠååããããã¡ãŒãžã®æ°ã§ã®å¢å ã¯ã©ã€ãã©ãªãŒã®åæãã¹ã¯ãªãŒã³ã§èµ·ãã£ãããšã®ææšã§ããã
æCD117æäœãèå¥ããããã®å¥ã®æ¹æ³ã«ã¯ãäŸãšããŠã以äžã®æé ã«åŸã£ãŠãCD117ïŒäŸã¯ãGNNK+CD117ïŒã«çµåããããåéããæäœãçšããããšãå«ãŸãããã³ã³ã»ã³ãµã¹ããæäœééããã³è»œéé
åã¯åœæè¡ã§ç¥ãããïŒäŸã¯ããVBASEãããçæ®ç³»åé
åããŒã¿ããŒã¹ïŒKabatã, Sequences of Proteins of Immunological Interest, Fifth EditionïŒç¬¬äºçïŒ, U.S. Department of Health and Human ServicesïŒç±³åœä¿å¥çŠç¥çïŒ, NIH PublicationïŒNIHåè¡ç©ïŒNo. 91 -3242, 1991ïŒTomlinsonïŒãã ãªã³ãœã³ïŒã, J. Mol. Biol.ïŒãžã£ãŒãã«ã»ãªãã»ã¢ã¬ãã¥ã©ãŒã»ãã€ãªããžãŒïŒ227:776-798, 1992ïŒããã³CoxïŒã³ãã¯ã¹ïŒã, Eur. J. Immunol. 24:827- 836, 1994ãåç
§ãããããã®åã
ã®é瀺ã¯ããããã³ã³ã»ã³ãµã¹ããæäœééããã³è»œéé
åã«é¢é£ãããã®ãšããŠåç
§ã«ããããã«çµã¿èŸŒãŸããã確ç«ãããæé ãçšããŠãåœæè¡ã«ãããçç·Žã®è
ã¯ã³ã³ã»ã³ãµã¹æäœé
åã®å¯å€ãã¡ã€ã³ãã¬ãŒã ã¯ãŒã¯æ®åºããã³CDRsãïŒäŸã¯ãé
åã¢ã©ã€ã¡ã³ãã«ãã£ãŠïŒèå¥ããããšãã§ããããããã®ã¯ããåæäœãçç£ããããã«ã³ã³ã»ã³ãµã¹ããæäœã®ééããã³/ãŸãã¯è»œéå¯å€ãã¡ã€ã³ã®1以äžã®CDRsãããã«èšèŒã®ãããªCD117ïŒäŸã¯ãGNNK+CD117ïŒã«çµåããéããæäœã®1以äžã®å¯Ÿå¿ããCDRsãšçœ®æããããšãã§ããããã®CDR亀æã¯ããã«èšèŒããããŸãã¯åœæè¡ã§æ¢ç¥ã®éºäŒåç·šéæè¡ãçšããŠå®è¡ããããšãã§ããã
ããåæäœãçç£ããããã«ããããã®ã¯1以äžã®å¯å€é åCDRsãCD117ïŒäŸã¯ãGNNK+CD117ïŒãšçµåããéããæäœã®1ã€ä»¥äžã®å¯å€é åCDRé
åãšçœ®æãããäžèšã®ã³ã³ã»ã³ãµã¹é
åãã³ãŒãããããªãã¯ã¬ãªãããçµæãçºçŸãããããšãã§ãããé è¡å¹¹çŽ°èæåã«ã€ããŠã®æäœã®èŠªåæ§ã¯äž»ã«CDRé
åã«ãã£ãŠæ±ºå®ããããããçµæãšããŠåŸãããããåæäœã¯ããåæäœãå°ãåºãããéããæäœãšã»ãŒåãé è¡å¹¹çŽ°èæåã«ã€ããŠã®èŠªåæ§ãèŠãããšäºæ³ããããæäœã®æšçæåã«ã€ããŠã®èŠªåæ§ã決å®ããæ¹æ³ã«ã¯äŸãšããŠãããã«èšèŒããããã³åœæè¡ã§æ¢ç¥ã®ELISAã«åºã¥ãæè¡ããªãã³ã«è¡šé¢ãã©ãºã¢ã³å
±é³Žãèå
ç°æ¹æ§ãããã³ç枩滎å®ã«ããªã¡ããªãŒãªã©ã»ãã«ããããå«ãŸããã
調補ãããæäœããŸãã¯ãã®æçã®ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³èœåã¯ãäŸãšããŠãåœæè¡ã§æ¢ç¥ã®æŸå°æ§æ žçš®ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ã¢ãã»ã€ãçšããŠè©äŸ¡ããããšãã§ãããäŸãã°ãããã«èšèŒããããŸãã¯åœæè¡ã«ãããŠæ¢ç¥ã®ã€ã³ããããã£ã¹ãã¬ã€æè¡ãçšããŠèå¥ãããæäœããŸãã¯ãã®æçã¯æŸå°æ§åäœå
çŽ ãäŸãã°ã18Fã75Brã77Brã122Iã123Iã124Iã125Iã129Iã131Iã211Atã67Gaã111Inã99Tcã169Ybã186Reã64Cuã67Cuã177Luã77Asã72Asã86Yã90Yã89Zrã212Biã213BiããŸãã¯225Acãªã©ã®ãããªãã®ã®çµèŸŒã¿ã«ãã£ãŠæ©èœåããããšãã§ãããäŸãšããŠãæŸå°æ§ããã²ã³ãäŸãã°ã18Fã75Brã77Brã122Iã123Iã124Iã125Iã129Iã131Iã211Atãªã©ã®ãããªãã®ã¯ããŒãºãäŸãã°ãããªã¹ãã¬ã³ããŒãºãªã©ã®ãããªãã®ã§ãæ±é»åæ§ããã²ã³è©Šè¬ïŒäŸã¯ãIodination BeadsïŒãšãŠçŽ åããŒãºïŒ, Thermo Fisher Scientific, IncïŒãµãŒã¢ãã£ãã·ã£ãŒç€ŸïŒ, CambridgeïŒã±ã³ããªããžïŒ, MAïŒç±³åœããµãã¥ãŒã»ããå·ïŒïŒãå«ããã®ãçšããŠæäœããŸãã¯ãã®æçäžã«çµã¿èŸŒãããšãã§ãããæŸå°æ§æšèæäœããŸãã¯ãã®æçã¯ã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ïŒinternalizationãå
é¢åãšãèšãïŒãå¯èœã«ããã®ã«ååãªæéïŒäŸã¯ã4âã§30åãã6æéãŸã§ãäŸãã°ã4âã§1æéãªã©ã®ãããªãã®ïŒãã¬ã³çŽ°èãèªå·±å
ç«çŽ°èããŸãã¯é è¡å¹¹çŽ°èãšãšãã«ã€ã³ãã¥ããŒã·ã§ã³ããããšãã§ããã次ãã§ãéã€ã³ã¿ãŒããªãŒãŒã·ã§ã³åæäœããŸãã¯ãã®æçãé€å»ããããã«çŽ°èãæŽæµããããšãã§ããïŒäŸã¯ãpH2.8ã§ã®å·ïŒ4âïŒ0.1Mã°ãªã·ã³ç·©è¡å€ã䜿çšããïŒãçµæãšããŠåŸãããã¬ã³çŽ°èãèªå·±å
ç«çŽ°èãé è¡å¹¹çŽ°èã®æŸåºæŸå°ç·ïŒäŸã¯ãγç·ïŒãååããæŽæµç·©è¡å€ã®æŸåºæŸå°ç·ïŒäŸã¯ãγç·ïŒãšæ¯èŒããŠæ€åºããããšã«ãã£ãŠã€ã³ã¿ãŒããªãŒãŒã·ã§ã³æäœããŸãã¯ãã®æçãèå¥ããããšãã§ããã
CD117ãšãããŒã
CD117ãšãããŒã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯CD117ãçµåããããšãå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã«ããããã®ã§ãã£ãŠãããã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®å°ãªããšã2ãå°ãªããšã3ãå°ãªããšã4ãå°ãªããšã5ããŸãã¯ãã¹ãŠã®6ã€ãå«ãCD117ã§ã®ãšãããŒãã«çµåãããäžå®æœæ
æ§ã§ã¯ãCD117ãšçµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®å°ãªããšã2ã€ãå«ãCD117ã§ã®ãšãããŒãã«çµåãããäžå®æœæ
æ§ã§ã¯ãCD117ãšçµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®å°ãªããšã3ã€ãå«ãCD117ã§ã®ãšãããŒãã«çµåãããäžå®æœæ
æ§ã§ã¯ãCD117ãšçµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®å°ãªããšã4ã€ãå«ãCD117ã§ã®ãšãããŒãã«çµåãããäžå®æœæ
æ§ã§ã¯ãCD117ãšçµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®å°ãªããšã5ã€ãå«ãCD117ã§ã®ãšãããŒãã«çµåãããäžå®æœæ
æ§ã§ã¯ãCD117ãšçµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®åã
ã®6ã€ãå«ãCD117ã§ã®ãšãããŒãã«çµåãããå¥ã®å®æœæ
æ§ã§ã¯ãCD117ãšçµåå¯èœãªçµåã¿ã³ãã¯è³ªãäŸã¯ãæäœããŸãã¯ãã®æåçµåæ§æçã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®ãã¹ãŠãå«ãCD117ã§ã®ãšãããŒãã«çµåããã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯CD117ã§ã®ãšãããŒãã«çµåããCD117ãçµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã«ããããããã§ã¯ãšãããŒãã¯é
åçªå·1ã®ã¢ããé
žæ®åºS236ãH238ãY244ãS273ãT277ããã³T279ã®å°ãªããšã2ãå°ãªããšã3ãå°ãªããšã4ãå°ãªããšã5ããŸãã¯åã
ã®6ã€ãããªã矀ããéžã°ããã¢ããé
žæ®åºãå«ãã
å¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯é
åçªå·1ã®å°ãªããšãã¢ããé
ž236-244ããã³273-279å
ã®æ®åºãæãããšãããŒãã«çµåããCD117ã«çµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã«ãããã
äžå®ã®å®æœæ
æ§ã§ã¯ãããã«èšè¿°ãããçµæç©ããã³æ¹æ³ã«ãããŠçšããããæCD117æäœããŸãã¯ãã®æåçµåæçã¯ãAb67ãšåãããCD117äžã®ãšãããŒãã«çµåããããAb67ãšç°ãªãCDRããã³/ãŸãã¯å¯å€é åãæãããäŸãã°ãããã«èšè¿°ãããçµæç©ããã³æ¹æ³ã§çšããããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ã以äžã®ã¢ããé
žæ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ïŒé
åçªå·1ãåç
§ïŒã®å°ãªããšã2ã€ãå«ãããCD117äžã®ãšãããŒãã«çµåãåŸãããã§æäœããŸãã¯ãã®æåçµåæ§æçã¯Ab67ã®ééããã³è»œéCDRsãå«ãã§ããªãããããã¯ãŸããããã«èšèŒãããçµæç©ããã³æ¹æ³ã«ãããŠçšããããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ã以äžã®ã¢ããé
žæ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®ãã¡ã®å°ãªããšã2ã€ãå«ãããCD117äžã®ãšãããŒãã«çµåãåŸïŒé
åçªå·1åç
§ïŒãããã§ãã®æäœããŸãã¯ãã®æåçµåæ§æçã¯ãAb67ã®éããã³è»œéå¯å€é åãå«ãã§ããªãã
Protein Data BankïŒã¿ã³ãã¯è³ªããŒã¿ãã³ã¯ïŒïŒPDBïŒã«ãããŠåç
§çªå·P10721ã§èšèŒãããããã«ïŒhttps://www.rcsb.org/pdb/protein/P10721ïŒ2019幎4æ24æ¥æç¹ïŒåç
§ïŒãCD117ã®çŽ°èå€éšåã¯Igæ§C2å1ãã¡ã€ã³ïŒa.k.a. D1ïŒD1ãšããŠãç¥ãããïŒïŒãIgæ§C2å2ãã¡ã€ã³ïŒa.k.a. D2ïŒãIgæ§C2å3ãã¡ã€ã³ïŒa.k.a. D3ïŒãIgæ§C2å4ãã¡ã€ã³ïŒa.k.a. D4ïŒãããã³Igæ§C2å5ãã¡ã€ã³ïŒa.k.a. D5ïŒãšããŠèšåããã5ã€ã®ãã¡ã€ã³ãå«ããå¥ã®æ
æ§ã«ãããŠãæ¬é瀺ã¯CD117ã®Igæ§C2å3ãã¡ã€ã³å
ã®ãšãããŒãã«çµåããCD117ãçµåå¯èœãªæäœããŸãã¯ãã®æåçµåæ§æçã«ãããã
å¥ã®æ
æ§ã«ãããŠãããã«èšèŒãããæäœã¯äžæ§æCD117æäœã§ãããããããã«ãæ¬é瀺ã«å«ãŸããã®ã¯æäœAb67ã«ãã£ãŠèªèããããšãããŒãã«çµåããæäœã§ãããç¹å®ã®å®æœæ
æ§ã§ã¯ãæ¬é瀺ã¯åé¢ãããæäœããŸãã¯ãã®æåçµåæ§æçãå«ã¿ãããã§åèšæäœããŸãã¯ãã®æåçµåæ§æçã¯ãåèšæäœããŸãã¯ãã®æåçµåæ§æçãšå
±ã«é
åçªå·1ã®ããã°ã©ãã£ãŒé åS236-Y244ããã³/ãŸãã¯S273-T279ã«ãã£ãŠèŠå®ããããšãããŒããšçµåããããã«ããCD117ãçµåãããå¥ã®æ
æ§ã§ã¯ãæ¬é瀺ã¯é
åçªå·1ã®S236ãH238ãY244ãS273ãT277ããã³T279ã®ã¢ããé
žæ®åºã®2ã€ã3ã€ã4ã€ã5ã€ããŸãã¯ãã¹ãŠãå«ãããCD117ã§ã®ãšãããŒãã«çµåããããCD117ã«çµåå¯èœãªæäœãŸãã¯ãã®æåçµåæ§æçã«ãããã
æäœè¬ç©ã³ã³ãžã¥ã²ãŒãé¡ïŒADCsïŒ
现èæ¯çŽ
æäœè¬ç©ã³ã³ãžã¥ã²ãŒãé¡ïŒADCsïŒ
现èæ¯çŽ
ããã«èšèŒã®æCD117æäœãããã³ãã®æåçµåæ§æçã¯çŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãïŒé£çµïŒãããããšãã§ãããç¹ã«ãæCD117 ADCsã¯çŽ°èæ¯æ§ã¢ã€ãšãã£ïŒãŸãã¯çŽ°èæ¯çŽ ïŒã«ã³ã³ãžã¥ã²ãŒããããïŒå³ã¡ããªã³ã«ãŒã«ãã£ãŠå
±æçµåãããïŒæäœïŒãŸãã¯ãã®æåçµåæ§æçïŒãå«ããçš®ã
ã®å®æœæ
æ§ã«ãããŠã现èæ¯æ§ã¢ã€ãšãã£ã¯ã³ã³ãžã¥ã²ãŒãïŒè€åäœãšãèšãïŒã«ãããŠçµåããŠãããšã现èæ¯æ§ãæžå°ãããããŸãã¯ãŸã£ããèŠããªããããªã³ã«ãŒããéè£ãããåŸã«çŽ°èå·å®³æ§ãåéããããçš®ã
ã®å®æœæ
æ§ã«ãããŠã现èå·å®³æ§ã¢ã€ãšãã£ã¯ãªã³ã«ãŒããéè£ãããããšãªã现èå·å®³æ§ãç¶æãããããããã®å®æœæ
æ§ã§ã¯ã现èå·å®³æ§ååã¯ãæäœããŸãã¯ãã®æçã®çŽ°èãžã®å蟌ã¿ã«ç¶ããŠã现èæ¯çŽ ããã®çŽ°èå
æšçã«ã¢ã¯ã»ã¹ããäŸã¯ãT现èæ»ãåªä»ãåŸãããã«ããã«é瀺ãããããã«ã现èã€ã³ã¿ãŒããªãŒãŒã·ã§ã³æäœããŸãã¯ãã®æåçµåæ§æçã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããã
ããã«èšèŒã®æäœãããã³ãã®æåçµåæ§æçïŒäŸã¯ãCD117ãèªèãããã³çµåããæäœãããã³ãã®æåçµåæ§æçïŒã¯çŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãïŒãŸãã¯é£çµïŒããããšãã§ããã
ãããã£ãŠãæ¬é瀺ã®ADCsã¯äžè¬åŒAb-(Z-L-D)nã®ãã®ã§ãã£ãŠããããåŒäžæäœãŸãã¯ãã®æåçµåæ§æçïŒAbïŒã¯ãååŠçã¢ã€ãšãã£ïŒZïŒãéããŠãªã³ã«ãŒïŒLïŒã«ã现èå·å®³æ§ã¢ã€ãšãã£ïŒãè¬ç©ããDïŒã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ïŒå
±æçµåïŒããããnãã¯æäœã«é£çµãããè¬ç©ã®æ°ãè¡šããããã³æŠããŠ1ãã8ãŸã§ã«åã¶ã
ãããã£ãŠãæäœãŸãã¯ãã®æåçµåæ§æçã¯æŽæ°nã«ãã£ãŠæã瀺ããããããªè€æ°ã®è¬ç©ã¢ã€ãšãã£ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããŠããããããã¯æäœãããã®çŽ°èæ¯æ§éšåã®å¹³åæ°ãè¡šããããã¯äŸã¯ãçŽ1ããçŽ20ãŸã§ã«åã³åŸããããããã®å®æœæ
æ§ã§ã¯ãnã¯1ãã4ãŸã§ã§ãããããããã®å®æœæ
æ§ã§ã¯ãnã¯2ã§ãããããããã®å®æœæ
æ§ã§ã¯ãnã¯1ã§ãããã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿ããã®ADCã®èª¿è£œç©ã«ãããæäœãããã®è¬ç©ã¢ã€ãšãã£ã®å¹³åæ°ã¯ãæ
£ç¿çãªæ段ãäŸãã°ã質éåæãELISAã¢ãã»ã€ããã³HPLCãªã©ã®ãããªãã®ã«ãã£ãŠç¹åŸŽä»ãåŸããnã«é¢ããŠADCã®å®éçååžããŸã決å®ããåŸããããããã®å®äŸã«ãããŠãnãããå€ã§ããå質ãªADCã®ãä»ã®è¬ç©è² è·éãæããADCããã®åé¢ã粟補ãããã³ç¹åŸŽä»ãã¯ãéçžHPLCãŸãã¯é»æ°æ³³åãªã©ã®ãããªæ段ã«ãã£ãŠéæããåŸãã
ããããã®æCD117 ADCsã«ã€ããŠãæäœãããã®çŽ°èæ¯çŽ ã®å¹³åæ°ã¯æäœäžã®ä»çéšäœã®æ°ã«ãã£ãŠå¶éããåŸããäŸãã°ãä»çãã·ã¹ãã€ã³ããªãŒã«ã§ããå Žåãæäœã¯1ã€ãŸãã¯ããã€ãã®ã·ã¹ãã€ã³ããªãŒã«åºã ããæããŠããããŸãã¯ãªã³ã«ãŒããã³ååŠçã¢ã€ãšãã£ãä»çãåŸãååã«åå¿æ§ã®ããªãŒã«åºã1ã€ãŸãã¯ããã€ãæããã ãã§ãã£ãŠãããã倧æµãæäœã¯è¬ç©ã¢ã€ãšãã£ã«é£çµããåŸãå€ãã®éé¢ããã³åå¿æ§ã®ã·ã¹ãã€ã³ããªãŒã«åºãå«ãŸãïŒäž»ã«ãæäœã«ãããã·ã¹ãã€ã³ããªãŒã«æ®åºã¯ãžã¹ã«ãã£ãæ©ãšããŠååšãããäžå®ã®å®æœæ
æ§ã§ã¯ãæäœã¯ãžããªã¹ã¬ã€ããŒã«ïŒDTTïŒãŸãã¯ããªã«ã«ããã«ãã«ãã¹ãã£ã³ïŒTCEPïŒãªã©ã®ãããªéå
å€ã«ãããéšåãŸãã¯åèšã®éå
æ¡ä»¶äžã§éå
ãããŠåå¿æ§ã·ã¹ãã€ã³ããªãŒã«åºãçæããåŸãã
äžå®ã®å®æœæ
æ§ã§ã¯ãè¬ç©ã¢ã€ãšãã£ã®çè«çæ倧å€ãããå°ãªãæ°ã¯ãã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿ã®éãæäœã«ã³ã³ãžã¥ã²ãŒãããããæäœã¯äŸãã°ãåŸè¿°ããããã«ãè¬ç©-ãªã³ã«ãŒäžéäœãŸãã¯ãªã³ã«ãŒè©Šè¬ãšåå¿ããªããªãžã³æ®åºãå«ã¿åŸããæãåå¿æ§ãé«ããªãžã³åºã ããã¢ãã³åå¿æ§ãªã³ã«ãŒè©Šè¬ãšåå¿ãåŸããäžå®ã®å®æœæ
æ§ã§ã¯ãæäœã¯ãªãžã³ãŸãã¯ã·ã¹ãã€ã³ã®ãããªåå¿æ§æ±æ žåºãæããã«ããããã«å€æ§æ¡ä»¶ã«ããããããã
ADCã®ããŒãã£ã³ã°ïŒè¬ç©/æäœæ¯ïŒã¯ç°ãªãä»æ¹ãäŸã¯ã以äžã«ãã£ãŠå¶åŸ¡ãåŸãïŒïŒiïŒæäœã«é¢ããŠè¬ç©-ãªã³ã«ãŒäžéäœãŸãã¯ãªã³ã«ãŒè©Šè¬ã®ã¢ã«éå°ãå¶éããããšãïŒiiïŒã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿æéãŸãã¯æž©åºŠãå¶éããããšãïŒiiiïŒã·ã¹ãã€ã³ããªã³ä¿®é£Ÿã«ã€ããŠã®éå
æ¡ä»¶ãäžéšåãŸãã¯å¶éããããšãïŒivïŒãªã³ã«ãŒ-è¬ç©ä»çã®æ°ããã³/ãŸãã¯äœçœ®ã®ã³ã³ãããŒã«ã«ã€ããŠã·ã¹ãã€ã³æ®åºã®æ°ããã³äœçœ®ã修食ããããã«æäœã®ã¢ããé
žé
åãçµæãæè¡ã«ãã£ãŠå·¥åŠçã«äœãåºãããšã§ããã
ããããã®å®æœæ
æ§ã§ã¯ã现èå·å®³æ§ååã¯ãããã«é瀺ãããããªçŽ°èã€ã³ã¿ãŒããªãŒãŒã·ã§ã³æäœããŸãã¯ãã®æåçµåæ§æçã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããããã§æäœããŸãã¯ãã®æåçµåæ§æçã®çŽ°èãžã®å蟌ã¿ã«ç¶ããŠçŽ°èæ¯çŽ ããã®çŽ°èå
æšçã«ã¢ã¯ã»ã¹ãããã³é è¡çŽ°èæ»ãåªä»ãåŸãããã§ããã现èã€ã³ã¿ãŒããªãŒãŒã·ã§ã³æäœãŸãã¯ãã®æåçµåæ§æçã«ã³ã³ãžã¥ã²ãŒãããããä»»æã®æ°ã®çŽ°èæ¯çŽ ãæCD117æäœã«çµåãããããšãã§ããäŸã¯ã1ã2ã3ã4ã5ã6ã7ããŸãã¯8ã§ããã
ããã«èšèŒã®çµæç©ããã³æ¹æ³ãšå
±ã«äœ¿çšããã®ã«é©ãã现èæ¯çŽ ã«ã¯ãDNAã€ã³ã¿ãŒã«ã¬ãŒã·ã§ã³å€ïŒæ¿å
¥å€ãªã©ãšãèšãïŒãïŒäŸã¯ãã¢ã³ãã©ãµã€ã¯ãªã³ïŒãæ糞åè£çŽ¡éåšå®ïŒmitotic spindle apparatusã玡éäœè£
眮ãªã©ãšãèšãïŒãç Žå£ããããšãå¯èœã§ããè¬å€ïŒäŸã¯ããã³ã«ã¢ã«ã«ãã€ãããã€ã¿ã³ã·ã³ããã€ã¿ã³ã·ãã€ããããã³ãããã®èªå°äœïŒãRNAããªã¡ã©ãŒãŒæå¶ç©è³ªïŒäŸã¯ãã¢ãããã·ã³ãäŸã¯ãα-ã¢ãããã³ãããã³ãããã®èªå°äœïŒãããã³ã¿ã³ãã¯è³ªçåæãç Žå£ããããšãå¯èœãªè¬å€ïŒäŸã¯ãrRNA N-ã°ãªã³ã·ããŒãŒæŽ»æ§ãèŠããè¬å€ãäŸãã°ããµããªã³ããã³ãªã·ã³AéïŒãªã©ãã»ãã«ãããããåœæè¡ã«ãããŠç¥ããããã®ãå«ãŸããã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯åŸ®å°ç®¡çµåå€ïŒäŸãšããŠããã€ã¿ã³ã·ã³ãŸãã¯ãã€ã¿ã³ã·ãã€ãïŒãã¢ãããã·ã³ãã·ã¥ãŒãã¢ãã¹å€æ¯çŽ AãdeBouganinïŒãããŒã¬ãã³ïŒããžãããªã¢æ¯çŽ ããµããªã³ãã¢ãŠãªã¹ã¿ãã³ãã¢ã³ãã©ãµã€ã¯ãªã³ãã«ãªã±ã¢ãã€ã·ã³ãã€ãªããã«ã³ãSN-38ããã¥ãªã«ã«ãã€ã·ã³ãããããã³ãŸãžã¢ãŒãã³ãããããã³ãŸãžã¢ãŒãã³äºéäœãã€ã³ããªããã³ãŸãžã¢ãŒãã³ãã€ã³ããªããã³ãŸãžã¢ãŒãã³äºéäœããŸãã¯ãã®å€çš®ããããã¯ããã«èšèŒã®ãŸãã¯åœæè¡ã§æ¢ç¥ã®å¥ã®çŽ°èå·å®³æ§ååç©ã§ããã
ããã«èšèŒã®æCD117æäœãããã³ãã®æåçµåæ§æçã¯åŸ®å°ç®¡çµåå€ã§ãã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããããšãã§ãããããã§çšããããããã«ãã埮å°ç®¡çµåå€ããšããçšèªã¯çŽ°èã«ãããæ糞åè£ããã³éæ现èæ©èœïŒinterphase cellular functionïŒã«ã€ããŠäžå¯æ¬ ã§ãã埮å°ç®¡ãããã¯ãŒã¯ãç Žå£ããããšã«ãã£ãŠäœçšããååç©ã«èšåããã埮å°ç®¡çµåå€ã®äŸã«ã¯ãå¶éãããªããããã€ã¿ã·ã³ããã€ã¿ã³ã·ãã€ããããã³ãããã®èªå°äœãäŸãã°ãããã«èšèŒãããŸãã¯åœæè¡ã«ãããŠæ¢ç¥ãªã©ã®ãããªãã®ããã³ã«ã¢ã«ã«ãã€ããäŸãã°ããã³ãã©ã¹ãã³ãç¡«é
žãã³ãã©ã¹ãã³ããã³ã¯ãªã¹ãã³ãç¡«é
žãã³ã¯ãªã¹ãã³ããã³ãã·ã³ãããã³ããã¬ã«ãã³ãªã©ã®ãããªãã®ãã¿ããµã³é¡ãäŸãã°ããã»ã¿ãã»ã«ããã³ãã¯ãªã¿ãã»ã«ãªã©ã®ãããªãã®ããã¯ãã©ã€ãé¡ãäŸãã°ããã£ã¹ã³ãã«ã¢ãªããã³ããã³ïŒcochicineïŒãããã³ãšãããã³é¡ããªãã³ã«ãã®èªå°äœãäŸãã°ããšãããã³BãŸãã¯ãã®èªå°äœãªã©ã®ãããªãã®ãå«ãŸããã
ãã€ã¿ã³ã·ãã€ãé¡
ãã€ã¿ã³ã·ãã€ãé¡
ããã«èšèŒã®æäœããã³ãã®æåçµåæ§æçã¯ãã€ã¿ã³ã·ãã€ãã§ãã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããããšãã§ãããããããã®å®æœæ
æ§ã§ã¯ã埮å°ç®¡çµåå€ã¯ãã€ã¿ã³ã·ã³ããã€ã¿ã³ã·ãã€ããŸãã¯ãã€ã¿ã³ã·ãã€ãé¡çžäœã§ããããã€ã¿ã³ã·ãã€ãã¯åŸ®å°ç®¡ã«çµåãããã¥ãŒããªã³ã®éåãæå¶ããããšã«ãã£ãŠäœçšããæ糞åè£æå¶ç©è³ªã§ããããã€ã¿ã³ã·ã³ïŒã¡ã€ã¿ã³ã·ã³ãšãèšãïŒã¯æ±ã¢ããªã«ã®äœæšMaytenus serrataïŒã¡ã€ããã¹ã»ã»ã©ã¿ïŒããåããŠåé¢ãããïŒç±³åœç¹èš±ç¬¬3,896,111å·ïŒãã®ã¡ã«ãäžå®ã®åŸ®çç©ããã€ã¿ã³ã·ãã€ãïŒã¡ã€ã¿ã³ã·ãã€ããšãèšãïŒãäŸãã°ãã¡ã€ã¿ã³ã·ããŒã«ããã³C-3ã¡ã€ã¿ã³ã·ããŒã«ãšã¹ãã«ãªã©ã®ãããªãã®ãç£çããããšãçºèŠãããïŒç±³åœç¹èš±ç¬¬4,151,042å·ïŒãåæã¡ã€ã¿ã³ã·ããŒã«ããã³ãããã®èªå°äœããã³é¡çžäœã¯äŸãã°ãç±³åœç¹èš±ç¬¬4,137,230å·ïŒç¬¬4,248,870å·ïŒç¬¬4,256,746å·ïŒç¬¬4,260,608å·ïŒç¬¬4,265,814å·ïŒç¬¬4,294,757å·ïŒç¬¬4,307,016å·ïŒç¬¬4,308,268å·ïŒç¬¬4,308,269å·ïŒç¬¬4,309,428å·ïŒç¬¬4,313,946å·ïŒç¬¬4,315,929å·ïŒç¬¬4,317,821å·ïŒç¬¬4,322,348å·ïŒç¬¬4,331,598å·ïŒç¬¬4,361,650å·ïŒç¬¬4,364,866å·ïŒç¬¬4,424,219å·ïŒç¬¬4,450,254å·ïŒç¬¬4,362,663å·ïŒããã³ç¬¬4,371,533å·æ现æžã«ãããŠé瀺ããããã¡ã€ã¿ã³ã·ãã€ãè¬ç©ã¢ã€ãšãã£ã¯æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒè€åäœãšãèšãïŒã«ãããŠé
åçãªè¬ç©ã¢ã€ãšãã£ã§ããããã®çç±ã¯ãããã以äžã®ãã®ã ããã§ããïŒïŒiïŒçºé
µãŸãã¯ååŠä¿®é£Ÿãçºé
µç£ç©ã®èªå°äœåã«ãã£ãŠèª¿è£œããããšãæ¯èŒç容æã§ãããïŒiiïŒæäœãžã®éãžã¹ã«ãã£ããªã³ã«ãŒãéããã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ããå®èœåºã«ããèªå°äœåãåãæããïŒiiiïŒè¡ãããäžã§å®å®ã§ãããããã³ïŒivïŒæ§ã
ã®è
«ç现èç³»ã«å¯ŸããŠæå¹ã§ããã
é©åãªã¡ã€ã¿ã³ã·ãã€ãã®äŸã«ã¯ãã¡ã€ã¿ã³ã·ããŒã«ã®ãšã¹ãã«ãåæã¡ã€ã¿ã³ã·ããŒã«ãããã³ã¡ã€ã¿ã³ã·ããŒã«é¡çžäœããã³èªå°äœãå«ãŸãããããã«å«ãŸããã®ã¯åŸ®å°ç®¡åœ¢æãæå¶ããããã³åºä¹³é¡çŽ°èã«å¯ŸããŠé«åºŠã«æ¯æ§ã§ããä»»æã®çŽ°èæ¯çŽ ã§ããããã®ãŸãŸã¡ã€ã¿ã³ã·ãã€ããã¡ã€ã¿ã³ã·ããŒã«ãããã³ã¡ã€ã¿ã³ã·ããŒã«é¡çžäœããªãã³ã«èªå°äœã§ããã
奜é©ãªã¡ã€ã¿ã³ã·ããŒã«ãšã¹ãã«ã®äŸã«ã¯ã修食ãããè³éŠç°ãæãããã®ããã³ä»ã®äœçœ®ã«ãŠä¿®é£Ÿãæãããã®ãå«ãŸããããã®ãããªå¥œé©ãªã¡ã€ã¿ã³ã·ãã€ãã¯ç±³åœç¹èš±ç¬¬4,137,230å·ïŒç¬¬4,151,042å·ïŒç¬¬4,248,870å·ïŒç¬¬4,256,746å·ïŒç¬¬4,260,608å·ïŒç¬¬4,265,814å·ïŒç¬¬4,294,757å·ïŒç¬¬4,307,016å·ïŒç¬¬4,308,268å·ïŒç¬¬4,308,269å·ïŒç¬¬4,309,428å·ïŒç¬¬4,313,946å·ïŒç¬¬4,315,929å·ïŒç¬¬4,317,821å·ïŒç¬¬4,322,348å·ïŒç¬¬4,331,598å·ïŒç¬¬4,361,650å·ïŒç¬¬4,362,663å·ïŒç¬¬4,364,866å·ïŒç¬¬4,424,219å·ïŒç¬¬4,450,254å·ïŒç¬¬4,322,348å·ïŒç¬¬4,362,663å·ïŒç¬¬4,371,533å·ïŒç¬¬5,208,020å·ïŒç¬¬5,416,064å·ïŒç¬¬5,475,092å·ïŒç¬¬5,585,499å·ïŒç¬¬5,846,545å·ïŒç¬¬6,333,410å·ïŒç¬¬7,276,497å·ïŒããã³ç¬¬7,473,796å·æ现æžã«é瀺ããããããã®åã
ã®é瀺ã¯ããããã¡ã€ã¿ã³ã·ãã€ãããã³ãããã®èªå°äœã«é¢ãããã®ãšããŠåç
§ã«ãã£ãŠããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã§ã¯ãæ¬é瀺ã®æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCsïŒã¯å«ããªãŒã«ã¡ã€ã¿ã³ã·ãã€ãïŒDM1ïŒãæ£åŒã«ã¯N2â²-ãã¢ã»ãã«-N2â²-(3-ã¡ã«ã«ãã-1-ãªããœãããã«)-ã¡ã€ã¿ã³ã·ã³ã现èå·å®³æ§è¬å€ãšããŠæŽ»çšãããDM1ã¯æ§é åŒïŒVïŒã«ãã£ãŠä»£è¡šãããïŒ
å¥ã®å®æœæ
æ§ã§ã¯ãæ¬é瀺ã®ã³ã³ãžã¥ã²ãŒãã¯å«ããªãŒã«ã¡ã€ã¿ã³ã·ãã€ãN2â²-ãã¢ã»ãã«-N2â²(4-ã¡ãã«-4-ã¡ã«ã«ãã-1-ãªããœãã³ãã«)-ã¡ã€ã¿ã³ã·ã³ïŒäŸã¯ãDM4ïŒã现èå·å®³æ§è¬å€ãšããŠæŽ»çšãããDM4ã¯æ§é åŒïŒVIïŒã«ãã£ãŠä»£è¡šãããïŒ
ç«äœé害ããªãŒã«çµåãå«ãåŽéãå«ãŸããå¥ã®ã¡ã€ã¿ã³ã·ãã€ãã¯N2â²-ãã¢ã»ãã«-N-2â²(4-ã¡ã«ã«ãã-1-ãªããœãã³ãã«)-ã¡ã€ã¿ã³ã·ã³ïŒDM3ãšç§°ããïŒã§ãããæ§é åŒïŒVIIïŒã«ãã£ãŠä»£è¡šãããïŒ
ç±³åœç¹èš±ç¬¬ç¬¬5,208,020å·ããã³ç¬¬7,276,497å·æ现æžã«æ瀺ãããã¡ã€ã¿ã³ã·ãã€ãã®åã
ã¯ãŸããæ¬é瀺ã®ã³ã³ãžã¥ã²ãŒãã«ãããŠäœ¿çšããããšãã§ããããã®ç¹ã«é¢ããŠã5,208,020ããã³7,276,697ã®é瀺å
šäœã¯åç
§ã«ããããã«çµã¿èŸŒãŸããã
ã¡ã€ã¿ã³ã·ãã€ãäžã®å€ãã®äœçœ®ã¯é£çµã¢ã€ãšãã£ãååŠçã«é£çµããäœçœ®ãšããŠæ©èœããããšãã§ãããäŸãã°ãããããã·ã«åºãæããC-3äœçœ®ãããããã·ã¡ãã«ã«ãã修食ãããC-14äœçœ®ãããããã·ã«ãã修食ãããC-15äœçœ®ããã³ããããã·åºãæããC-20äœçœ®ã¯ãã¹ãŠæçšã§ãããšäºæ³ããããããããã®å®æœæ
æ§ã«ãããŠãC-3äœçœ®ã¯é£çµã¢ã€ãšãã£ãååŠçã«é£çµããäœçœ®ãšããŠæ©èœããããã³ããããã®ç¹å®ã®å®æœæ
æ§ã«ãããŠãã¡ã€ã¿ã³ã·ããŒã«ã®C-3äœçœ®ã¯é£çµã¢ã€ãšãã£ãååŠçã«é£çµããäœçœ®ãšããŠæ©èœãããæäœ-ã¡ã€ã¿ã³ã·ãã€ãã³ã³ãžã¥ã²ãŒããäœæããããã«åœæè¡ã§ç¥ãããŠããå€ãã®é£çµåºããããäŸãã°ãç±³åœç¹èš±ç¬¬5,208,020å·ã第6,441,163å·ãããã³EPç¹èš±ç¬¬0425235B1å·ïŒChariïŒã·ã£ãªïŒã, Cancer ResearchïŒãã£ã³ãµãŒã»ãªãµãŒãïŒ52ïŒ127-131ïŒ1992ïŒïŒããã³ç±³åœç¹èš±åºé¡å
¬é第2005/0169933 A1å·ã«é瀺ããããã®ãå«ãŸãããããã®é瀺ã¯åç
§ã«ããããã«æ瀺çã«çµã¿èŸŒãŸãããè¿œå ã®é£çµåºã¯ããã«èšèŒãããããã³äŸèšŒãããã
æ¬é瀺ã¯ãŸããã¡ã€ã¿ã³ã·ãã€ãããã³ã³ã³ãžã¥ã²ãŒãã®çš®ã
ã®ç°æ§äœããã³æ··åç©ãå«ããæ¬é瀺ã®äžå®ã®ååç©ããã³ã³ã³ãžã¥ã²ãŒãã¯çš®ã
ã®ç«äœç°æ§äœããšãã³ããªããŒãããã³ãžã¢ã¹ãã¬ãªããŒåœ¢æ
ã«ãããŠååšãåŸãããã®ãããªæäœ-ã¡ã€ã¿ã³ã·ãã€ãã³ã³ãžã¥ã²ãŒããçç£ããããã®ããã€ãã®èšèŒã¯ç±³åœç¹èš±ç¬¬5,208,020å·ã第5,416,064å·ã第6,333,410å·ã第6,441,163å·ã第6,716,821å·ãããã³ç¬¬7,368,565å·æ现æžã«æäŸããããããã®åã
ã¯ãã®å
šäœãããã«çµã¿èŸŒãŸããã
æäœååãããçµåããæ²»çäžæå¹ãªæ°ã®ã¡ã€ã¿ã³ã·ãã€ãååã¯252nmããã³280nmã§ã®åžå
床ã®æ¯ãåå
å
床æ³ã§æž¬å®ããããšã«ãã£ãŠæ±ºå®ããããšãã§ãããäžå®ã®å®æœæ
æ§ã§ã¯ãæäœ1ååãããå¹³å3ãã4åãŸã§ã³ã³ãžã¥ã²ãŒã·ã§ã³ããã¡ã€ã¿ã³ã·ãã€ãååã¯ã1ååã®æ¯çŽ /æäœãæäœåç¬ããã现èå·å®³æ§ãé«ããããšãã§ããããæäœã®æ©èœãŸãã¯æº¶è§£æ§ã«æªåœ±é¿ãäžããããšãªãæšç现èã®çŽ°èå·å®³æ§ãé«ãåŸããã¡ã€ã¿ã³ã·ãã€ãåå/æäœãŸãã¯ãã®æåçµåæ§æçã®å¹³åæ°ã¯äŸãã°ã1-10åãŸãã¯2-5åã§ããããšãã§ããã
ã¢ã³ãã©ãµã€ã¯ãªã³é¡
ã¢ã³ãã©ãµã€ã¯ãªã³é¡
ä»ã®å®æœæ
æ§ã§ã¯ãããã«èšèŒã®æäœããã³ãã®æåçµåæ§æçã¯ã¢ã³ãã©ãµã€ã¯ãªã³ååã§ãã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒããããããšãã§ãããã¢ã³ãã©ãµã€ã¯ãªã³ã¯çŽ°èå·å®³æ§æŽ»æ§ãèŠããæçç©è³ªååç©ã§ãããç 究ã¯ã¢ã³ãã©ãµã€ã¯ãªã³ã以äžãå«ããŠå€ãã®ç°ãªãã¡ã«ããºã ã«ãã£ãŠçŽ°èã殺ãããã«åäœãåŸããšæã瀺ãïŒ1ïŒçŽ°èã®DNAãžã®è¬ç©ååã®å·®ã蟌ã¿ãããã«ããDNAäŸåæ§ã®æ žé
žåæã®æå¶ïŒ2ïŒè¬ç©ã«ããããªãŒã©ãžã«ã«ã®çæã§ãããããã¯çŽ°èã®é«ååãšåå¿ããŠçŽ°èã«æå·ãäžããããŸãã¯3ïŒè¬ç©ååããã³çŽ°èèã®çžäºäœçšïŒ»äŸã¯ãC. PetersonïŒããŒã¿ãŒãœã³ïŒãããTransport And Storage Of Anthracycline In Experimental Systems And Human LeukemiaïŒå®éšç³»ããã³ããçœè¡ç
ã«ãããã¢ã³ãã©ãµã€ã¯ãªã³ã®èŒžéããã³è²¯èµïŒãin Anthracycline Antibiotics In Cancer TherapyïŒçæ²»çã«ãããã¢ã³ãã©ãµã€ã¯ãªã³ç³»æçç©è³ªïŒïŒN.R. BachurïŒãã¯ãŒã«ïŒããFree Radical DamageïŒããªãŒã©ãžã«ã«æå·ïŒãid.ïŒåäžïŒã97-102é åç
§ïŒœããããã®çŽ°èæ¯æ§èœã®ããã«ãã¢ã³ãã©ãµã€ã¯ãªã³ã¯å€æ°ã®ã¬ã³ãäŸãã°ãçœè¡ç
ãèžéšã¬ã³è
«ãèºã¬ã³è
«ãåµå·£è
ºã¬ã³ããã³èè
«ãªã©ã®ãããªãã®ã®åŠçœ®ã«ãããŠäœ¿çšãããŠããäŸã¯ãP.H- WiernikïŒããšã«ãã¯ïŒ, in Anthracycline: Current Status And New DevelopmentsïŒã¢ã³ãã©ãµã€ã¯ãªã³ïŒçŸç¶ããã³æ°ããªå±éïŒ11é åç
§ïŒœãæ®éã«çšããããã¢ã³ãã©ãµã€ã¯ãªã³ã«ã¯ããããœã«ãã·ã³ããšãã«ãã·ã³ãã€ãã«ãã·ã³ããã³ããŠããã€ã·ã³ãå«ãŸãããããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯ããŠãã«ãã·ã³ããããœã«ãã·ã³ããšãã«ãã·ã³ãããã³ã€ãã«ãã·ã³ãããªã矀ããéžã°ããã¢ã³ãã©ãµã€ã¯ãªã³ã§ãããã¢ã³ãã©ãµã€ã¯ãªã³ã®ä»£è¡šäŸã«ã¯ãå¶éãããªãããããŠãã«ãã·ã³ïŒCerubidineïŒã»ã«ããžã³ïŒïŒBedford LaboratoriesïŒããããã©ãŒãç 究æïŒããããœã«ãã·ã³ïŒAdriamycinïŒã¢ããªã¢ãã€ã·ã³ïŒïŒBedford LaboratoriesïŒãŸãå¡©é
žãããœã«ãã·ã³ãããããã·ããŠã«ãã·ã³ãããã³RubexïŒã«ããã¯ã¹ïŒãšãèšåãããïŒããšãã«ãã·ã³ïŒEllenceïŒãšã¬ã³ã¹ïŒïŒPfizerïŒãã¡ã€ã¶ãŒïŒïŒãã€ãã«ãã·ã³ïŒIdamycinïŒã€ããã€ã·ã³ïŒïŒPfizer Inc.ïŒãã¡ã€ã¶ãŒç€ŸïŒïŒãå«ãŸããã
ã¢ã³ãã©ãµã€ã¯ãªã³é¡çžäœããããœã«ãã·ã³ïŒADRIAMYCINOïŒã¢ããªã¢ãã€ã·ã³OïŒïŒã¯ã転åã®ããã«DNAãå·»ãæ»ãé
µçŽ ããã€ãœã¡ã©ãŒãŒIIã®ã€ã³ã¿ãŒã«ã¬ãŒã·ã§ã³ããã³é²è¡ã®æå¶ã«ãã£ãŠDNAãšçžäºäœçšãããšèããããããããœã«ãã·ã³ã¯è€è£œã®ããã«DNAéãåæããåŸã®ããã€ãœã¡ã©ãŒãŒIIè€åäœãå®å®åãããDNAäºéãããã®å°ãçŽããé²ããããã³ããã«ãã£ãŠè€è£œã®éçšãåæ¢ãããããããœã«ãã·ã³ããã³ããŠãã«ãã·ã³ïŒDAUNOMYCINïŒããŠããã€ã·ã³ïŒïŒã¯ãããã¿ã€ãã®çŽ°èå·å®³æ§èªç¶çç£ç©ã¢ã³ãã©ãµã€ã¯ãªã³ååŠæ²»çè¬ïŒprototype cytotoxic natural product anthracycline chemotherapeuticsïŒã§ããïŒSessaïŒã»ããµïŒã, ïŒ2007ïŒCardiovasc. Toxicol.ïŒã«ãŒãã£ãªãã¹ãã¥ã©ãŒã»ãã¯ã·ã³ããžãŒïŒ7:75-79ïŒã
ããã§çšããããã®ã«é©ããã¢ã³ãã©ãµã€ã¯ãªã³ã®1ã€ã®éå¶éçãªäŸã¯ãPNU-159682ïŒãPNUãïŒã§ãããPNUã¯èŠªãã¢ã«ãã·ã³ã«é¢ããŠ3000åãè¶
ãã现èå·å®³æ§ãèŠããïŒQuintieriïŒãã³ãã£ãšãªïŒã, Clinical Cancer ResearchïŒã¯ãªãã«ã«ã»ãã£ã³ãµãŒã»ãªãµãŒãïŒ2005ã11ã1608-1617ïŒãPNUã¯æ¬¡ã®æ§é åŒã§ä»£è¡šãããïŒ
ã¢ã³ãã©ãµã€ã¯ãªã³ãäŸãã°ãPNUãªã©ã®ãããªãã®ã®äžã®è€æ°ã®äœçœ®ã¯ãé£çµã¢ã€ãšãã£ãããã³ããããã«ããã«èšèŒã®ãããªæCD117æäœãŸãã¯ãã®æåçµåæ§æçãå
±æçµåããäœçœ®ãšããŠæ©èœããããšãã§ãããäŸãã°ããªã³ã«ãŒã¯ããããã·ã¡ãã«ã±ãã³åŽéãžã®ä¿®é£ŸãéããŠå°å
¥ããåŸãã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯æ¬¡ã®æ§é åŒã«ãã£ãŠä»£è¡šãããPNUèªå°äœã§ããïŒ
åŒäžãæ³¢ç·ã¯ããã«èšèŒã®ããã«ADCã®ãªã³ã«ãŒãžã®å
±æçµåçãªä»çã®ãã€ã³ããæã瀺ãã
ããããã®å®æœæ
æ§ã«ãããŠããµã€ãããã·ã³ã¯æ¬¡ã®æ§é åŒã§ä»£è¡šãããPNUèªå°äœã§ããïŒ
åŒäžãæ³¢ç·ã¯ããã«èšèŒã®ãããªADCã®ãªã³ã«ãŒãžã®å
±æçµåçä»çã®ç¹ãæã瀺ãã
ãã³ãŸãžã¢ãŒãã³ç³»çŽ°èæ¯çŽ é¡ïŒäŸã¯ãããããã³ãŸãžã¢ãŒãã³é¡ïŒPBDsïŒïŒ
ãã³ãŸãžã¢ãŒãã³ç³»çŽ°èæ¯çŽ é¡ïŒäŸã¯ãããããã³ãŸãžã¢ãŒãã³é¡ïŒPBDsïŒïŒ
ä»ã®å®æœæ
æ§ã§ã¯ãããã«èšèŒã®æCD117æäœãŸãã¯ãã®æåçµåæ§æçã¯ããããã³ãŸãžã¢ãŒãã³ïŒPBDïŒã§ãã现èæ¯çŽ ãŸãã¯PBDãå«ã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããããšãã§ãããPBDsã¯äžå®ã®æŸç·èã«ãã£ãŠçç£ãããèªç¶çç£ç©ã§ãããããã³é
åéžæçãªDNAã¢ã«ãã«åååç©ã§ããããšã瀺ãããŠãããPBD现èæ¯çŽ ã«ã¯ãå¶éãããªãããã¢ã³ãã©ãã€ã·ã³ãäºéäœPBDsãããã³äŸãã°ãHartleyïŒããŒããªãŒïŒïŒJ. A. (2011). ãThe development of pyrrolobenzodiazepines as antitumour agentsïŒæè
«çå€ãšããŠã®ããããã³ãŸãžã¢ãŒãã³ã®éçºïŒã. Expert Opin. Inv. DrugïŒãšãã¹ããŒãã»ãªãããªã³ã»ãªã³ã»ã€ã³ãã¹ãã£ã²ãŒã·ã§ãã«ã»ãã©ãã°ãºïŒ, 20(6), 733-744ïŒããã³AntonowïŒã¢ã³ãããŠïŒ, D.; ThurstonïŒãµãŒã¹ãã³ïŒ, D.E. (2011)ãSynthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)ïŒDNAçžäºäœçšæ§ããã[2,1-c][1,4]ãã³ãŸãžã¢ãŒãã³(PBDs)ã®åæïŒã. Chem. Rev.ïŒã±ãã«ã«ã»ã¬ãã¥ãŒãºïŒ111: 2815-2864ã«é瀺ããããã®ãå«ãŸããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯æ¬¡ã®åŒã§ä»£è¡šãããããããã³ãŸãžã¢ãŒãã³äºéäœã§ããåŸãïŒ
åŒäžãæ³¢ç·ã¯ãªã³ã«ãŒã®ä»çç¹ãæã瀺ãã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯ãã¬ã€ããã«ããã€ã«ãªã³ã«ãŒã«ãã£ãŠãæäœãŸãã¯ãã®æåçµåæ§æçã«ã³ã³ãžã¥ã²ãŒããããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããããããªãªãŽç³ã-(CH2)p-ã-(CH2CH2O)q-ã-(C=O)(CH2)r-ã-(C=O)(CH2CH2O)t-ã-(NHCH2CH2)u-ã-PABãVal-Cit-PABãVal-Ala-PABãVal-Lys(Ac)-PABãPhe-Lys-PABãPhe-Lys(Ac)-PABãD-Val-Leu-LysãGly-Gly-ArgãAla-Ala-Asn-PABããŸãã¯Ala-PABãããªã1以äžã®ãã®ãå«ã¿ãããåã
ã®pãqãrãtãããã³uã¯1-12ããã®æŽæ°ã§ãããåçºçã«ã€ããŠç¡é¢ä¿ã«éžã°ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯æ¬¡ã®åŒã®æ§é ãæããïŒ
åŒäžãR1ã¯CH3(Ala)ãŸãã¯(CH2)3NH(CO)NH2(Cit)ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãæäœãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«å
ç«ã¡ãããã³åå¿æ§çœ®æåºZ'ãå«ããŠãL-Z'ãšããŠäžç·ã«èãããïŒtaken together as L-Z'ïŒã次ã®æ§é ãæããïŒ
åŒäžãæ³¢ç·ã¯çŽ°èæ¯çŽ ïŒäŸã¯ãPBDïŒãžã®ä»çç¹ãæã瀺ããäžå®ã®å®æœæ
æ§ã«ãããŠãR1ã¯CH3ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ -ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã¯ãæäœãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«å
ç«ã¡ãããã³åå¿æ§çœ®æåºZ'ãå«ããŠãCy-L-Z'ãšããŠäžç·ã«èãããã次ã®åŒã®æ§é ãæããïŒ
ãã®äžå®ã®çŽ°èæ¯çŽ -ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã¯ãã·ãªã³ïŒSG3249ïŒãšããŠç¥ãããããã³äŸãã°ãHowardïŒãã¯ãŒãïŒã, ACS Med. Chem. Lett.ïŒACSã¡ãã£ã·ãã«ã»ã±ãã¹ããªãŒã»ã¬ã¿ãŒãºïŒ2016, 7(11), 983-987ã«èšèŒãããŠããããã®é瀺å
容ã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯æ¬¡ã®åŒã§ä»£è¡šãããããããã³ãŸãžã¢ãŒãã³äºéäœã§ããåŸãïŒ
åŒäžãæ³¢ç·ã¯ãªã³ã«ãŒã®ä»çç¹ãæã瀺ãã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ -ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã¯ãæäœãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«å
ç«ã¡ãããã³åå¿æ§çœ®æåºZ'ãå«ããŠãCy-L-Z'ãšããŠäžç·ã«èãããã次ã®åŒã®æ§é ãæããïŒ
ãã®ç¹å®ã®çŽ°èæ¯çŽ -ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã¯ã¿ãªãªã³ïŒtalirineïŒãšããŠç¥ããããããã³äŸãã°ãADC Vadastuximab talirineïŒADCããã¹ããã·ããã¿ãªãªã³ïŒ(SGN-CD33A), MantajïŒãã³ã¿ã€ïŒã, Angewandte Chemie International Edition EnglishïŒã¢ã³ã²ãŽã¡ã³ãã»ã±ããŒã»ã€ã³ã¿ãŒãã·ã§ãã«ã»ãšãã£ã·ã§ã³ã»ã€ã³ã°ãªãã·ã¥ïŒ2017,56, 462-488ã«é¢é£ããŠèšèŒããããã®é瀺ã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯æ¬¡ã®åŒã®æ§é ãæããã€ã³ããªããã³ãŸãžã¢ãŒãã³æ¬äºéäœã§ããåŸãïŒ
åŒäžãæ³¢ç·ã¯ãªã³ã«ãŒã®ä»çç¹ãæã瀺ãã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ -ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã¯ãæäœãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³åã®ãããã³åå¿æ§çœ®æåºZ'ãå«ããCy-L-Z'ãšããŠäžç·ã«èãããã次ã®åŒã®æ§é ãæããïŒ
ããã¯ADC IMGN632ãå«ã¿ãäŸãã°ãåœéç¹èš±åºé¡å
¬é第WO2017004026ã«é瀺ãããããã¯åç
§ã«ããããã«çµã¿èŸŒãŸããã
ã«ãªã±ã¢ãã€ã·ã³
ã«ãªã±ã¢ãã€ã·ã³
ä»ã®å®æœæ
æ§ã§ã¯ãããã«èšèŒã®æäœããã³ãã®æåçµåæ§æçã¯ãšã³ãžã€ã³æè
«çæçç©è³ªïŒäŸã¯ãã«ãªã±ã¢ãã€ã·ã³é¡ããªãŸã¬ãã€ã·ã³ïŒã§ãã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããããšãã§ãããã«ãªã±ã¢ãã€ã·ã³ãã¡ããªãŒã®æçç©è³ªã¯ãµããã³ã¢ã«æ¿åºŠã«ãŠäºæ¬éDNAåæãçæããããšãå¯èœã§ãããã«ãªã±ã¢ãã·ã³ãã¡ããªãŒã®ã³ã³ãžã¥ã²ãŒãã®èª¿è£œã«ã€ããŠU.S. Pat. 第5,712,374ïŒ5,714,586ïŒ5,739,116ïŒ5,767,285ïŒ5,770,701ïŒ5,770,710ïŒ5,773,001ïŒããã³5,877,296å·ãåç
§ïŒãã¹ãŠã¯American Cyanamid CompanyïŒã¢ã¡ãªã«ã³ã»ã·ã¢ããã瀟ïŒã«å¯ŸããïŒã䜿çšãåŸãã«ãªã±ã¢ãã€ã·ã³ã®æ§é é¡çžäœã«ã¯ãå¶éãããªãããäŸãã°ãHinmanïŒãã³ãã³ïŒã, Cancer Research 53:3336-3342ïŒ1993ïŒãLodeïŒããŒãïŒã, Cancer Research 58:2925-2928ïŒ1998ïŒãããã³American Cyanamidã«å¯Ÿããåè¿°ã®ç±³åœç¹èš±ã«é瀺ããããã®ãå«ãŸããã
æš¡ç¯çãªã«ãªã±ã¢ãã€ã·ã³ã¯Î³1ãšåœåãããããã¯ããã«ãããŠåã«ã¬ã³ããšããŠåç
§ãããããã³æ¬¡ã®æ§é åŒãæããïŒ
ããããã®å®æœæ
æ§ã«ãããŠãã«ãªã±ã¢ãã€ã·ã³ã¯ã¬ã³ã-ã«ãªã±ã¢ãã€ã·ã³èªå°äœãŸãã¯N-ã¢ã»ãã«ã¬ã³ã-ã«ãªã±ã¢ãã€ã·ã³èªå°äœã§ãã£ãŠãããã䜿çšããåŸãã«ãªã±ã¢ãã€ã·ã³ã®æ§é é¡çžäœã«ã¯ãå¶éãããªãããäŸãã°ãHinmanã, Cancer Research 53:3336-3342ïŒ1993ïŒãLodeã, Cancer Research 58:2925-2928ïŒ1998ïŒãããã³åè¿°ã®ç±³åœç¹èš±ã«é瀺ããããã®ãå«ãŸãããã«ãªã±ã¢ãã€ã·ã³ã¯ã¡ãã«ããªã¹ã«ãã£ãã¢ã€ãšãã£ãå«ã¿ãããã¯ãžã¹ã«ãã£ãã圢æããããã«é©åãªããªãŒã«ãšåå¿ãããããšãã§ãããšåæã«ããªã³ã«ãŒãä»ããŠãã«ãªã±ã¢ãã€ã·ã³èªå°äœãããã«èšèŒã®æCD117æäœãŸãã¯ãã®æåçµåæ§æçã«ä»çãããã®ã«æçšãªå®èœåºãå°å
¥ããããã«ãªã±ã¢ãã€ã·ã³ãã¡ããªãŒã®ã³ã³ãžã¥ã²ãŒãã®èª¿è£œã«ã€ããŠãU.S. Pat. 第5,712,374å·ïŒç¬¬5,714,586å·ïŒç¬¬5,739,116å·ïŒç¬¬5,767,285å·ïŒç¬¬5,770,701å·ïŒç¬¬5,770,710å·ïŒç¬¬5,773,001å·ïŒããã³ç¬¬5,877,296å·ãåç
§ïŒãã¹ãŠAmerican Cyanamid Companyã«å¯ŸããŠïŒã䜿çšããåŸãã«ãªã±ã¢ãã€ã·ã³ã®æ§é é¡çžäœã«ã¯ãå¶éãããªãããäŸãã°ãHinmanã, Cancer Research 53:3336-3342ïŒ1993ïŒãLodeã, Cancer Research 58:2925-2928ïŒ1998ïŒãããã³American Cyanamidã«å¯Ÿããåè¿°ã®ç±³åœç¹èš±ã«é瀺ããããã®ãå«ãŸããã
äžå®æœæ
æ§ã«ãããŠãããã«é瀺ããããããªADCã®çŽ°èæ¯çŽ ã¯æ¬¡ã®åŒã§ä»£è¡šãããã«ãªã±ã¢ãã€ã·ã³ãžã¹ã«ãã£ãèªå°äœã§ããåŸãïŒ
åŒäžãæ³¢ç·ã¯ãªã³ã«ãŒã®ä»çç¹ãæã瀺ãã
ãªããœãŒã äžæŽ»æ§åã¿ã³ãã¯è³ªïŒRIPsïŒ
ãªããœãŒã äžæŽ»æ§åã¿ã³ãã¯è³ªïŒRIPsïŒ
ããããã®å®æœæ
æ§ã«ãããŠãæCD117æäœã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãã现èæ¯çŽ ã¯ãªããœãŒã äžæŽ»æ§åã¿ã³ãã¯è³ªïŒRIPïŒã§ããããªããœãŒã äžæŽ»æ§åã¿ã³ãã¯è³ªã¯éåžžäžå¯éçã«ãªããœãŒã ã«äœçšããã¿ã³ãã¯è³ªåææå¶ç©è³ªã§ãããRIPsã¯æ€ç©ããªãã³ã«çŽ°èã«ãèŠåºããããRIPsã®äŸã«ã¯ãå¶éãããªããããµããªã³ããªã·ã³ãã¢ããªã³ãã²ããã³ãã·ã¥ãŒãã¢ãã¹å€æ¯çŽ ïŒãŸãã¯å€æ¯çŽ AïŒãããªã³ãµã³ãã³ãã«ãã£ã³ãã¢ã°ã«ããã³ïŒåéçŽ ïŒããã³ãžãããªã¢æ¯çŽ ãå«ãŸããã
ããã«é瀺ãããADCsããã³æ¹æ³ã«ãããŠäœ¿çšããåŸãRIPã®å¥ã®äŸã¯ãå¿è³æ¯çŽ ïŒShiga toxinïŒïŒStxïŒãŸãã¯å¿è³æ¯çŽ æ§æ¯çŽ ïŒShiga-like toxinsïŒïŒSLTïŒã§ãããå¿è³æ¯çŽ ïŒStxïŒã¯Shigella dysenteriae 1ïŒã·ã²ã©ã»ãã£ã»ã³ããªã¢ãš1ïŒããã³Escherichia coliïŒãšã·ã§ãªãã¢ã»ã³ãªã倧è
žèãªã©ãšãèšãïŒã®ããããã®è¡æž
矀ïŒè¡æž
åO157ïŒH7ãããã³O104ïŒH4ãå«ãïŒã«èŠããã匷åãªçŽ°èæ¯çŽ ã§ããïŒE. coliã§ã¯Stx1ãšåŒã°ããïŒãStx1ã«å ããããããã®E. coliæ ªã¯Stx/Stx1ãšåãäœçšã®ã¢ãŒããæã€ãæåçã«å¥åã®ç¬¬2ã¿ã€ãã®StxïŒStx2ïŒãçç£ããããã®æ¯çŽ ã¯å¿è³æœïŒKiyoshi ShigaïŒã«ã¡ãªãã§åœåããã圌ã¯Shigella dysenteriaeã«ãã£ãŠåŒãèµ·ããããèµ€ç¢ã®çŽ°èåŠçèµ·æºãæåã«å ±åãããSLTã¯å€§è
žèãçç£ããé¡çžãããã¯åäžã®æ¯çŽ ã«ã€ããŠã®æŽå²çãªçšèªã§ãããåæ¯çŽ ã®äºåãèå¥ãããŠãããããåœæãåã°ã«ãŒãã«ã€ããŠã®ååã®æ¯çŽ ãStx1aãŸãã¯Stx2aãšç§°ãããStx1aããã³Stx2aã¯ãçš®ã
ã®çŽ°èåã«å¯Ÿãã现èå·å®³æ§ã«ãããéããèŠããå容äœé¡çžäœãŸãã¯æš¡å£ç©ã«åæ§ã§ãªãïŒdissimilarly toïŒçµåããå·®åã±ã¢ã«ã€ã³å¿çãèªå°ããããã³ããã€ãã®ç¹åŸŽçãªæ§é ç¹æ§ãæããã
å¿è³æ¯çŽ ãã¡ããªãŒã®ã¡ã³ããŒã¯æ§é çããã³æ©èœçã«é¢é£ããèªç¶ã«çºçããã¿ã³ãã¯è³ªæ¯çŽ ãç¹ã«ãS. dysenteriaeããã³å€§è
žèããåé¢ãããæ¯çŽ ã®ãã¡ããªãŒã®ä»»æã®ã¡ã³ããŒã«èšåããïŒJohannesïŒãšããã¹ïŒL, RomerïŒã¬ãŒã¡ã«ïŒW, Nat Rev MicrobiolïŒãã€ãã£ãŒã»ã¬ãã¥ãŒãºïŒãã€ã¯ããã€ãªããžãŒïŒ8: 105-16 (2010)ïŒãäŸãã°ãå¿è³æ¯çŽ ãã¡ããªãŒã¯S. dysenteriaeè¡æž
å1ããåé¢ãããçã®å¿è³æ¯çŽ ïŒStxïŒãè
žç®¡åºè¡æ§å€§è
žèã®è¡æž
åããåé¢ãããå¿è³æ¯çŽ æ§æ¯çŽ 1å€çš®ïŒSLT1ãŸãã¯Stx1ãŸãã¯SLT-1ãŸãã¯Slt-IïŒãããã³è
žç®¡åºè¡æ§å€§è
žèã®è¡æž
åããåé¢ãããå¿è³æ¯çŽ æ§æ¯çŽ 2å€çš®ïŒSLT2ãŸãã¯Stx2ãŸãã¯SLT-2ïŒãå
å«ãããSLT1ã¯Stxãã1æ®åºã ãã§ç°ãªããããã³äž¡è
ã¯VerocytotoxinsïŒãããµã€ãæ¯çŽ ïŒãŸãã¯ããæ¯çŽ ïŒVTsïŒãšç§°ãããïŒO'BrienïŒãªãã©ã€ãšã³ïŒAã, Curr Top Microbiol ImmunolïŒã«ã¬ã³ãã»ãããã¯ã¹ã»ã€ã³ã»ãã€ã¯ããã€ãªããžãŒã»ã¢ã³ãã»ã€ã ãããžãŒïŒ180: 65-94 (1992)ïŒãSLT1ããã³SLT2å€çš®ã¯ã¢ããé
žé
åã¬ãã«ã§ã¯äºãã«çŽ53-60ïŒ
ããé¡äŒŒããŠããªããããããã¯å¿è³æ¯çŽ ãã¡ããªãŒã®ã¡ã³ããŒãšå
±éã®é
µçŽ 掻æ§ããã³çŽ°èå·å®³æ§ã®ã¡ã«ããºã ãå
±æããïŒJohannes, Nat Rev Microbiol 8: 105-16 (2010)ïŒã
å¿è³æ¯çŽ ãã¡ããªãŒã®ã¡ã³ããŒã¯2ã€ã®ãµããŠãããïŒAãµããŠãããããã³BãµããŠããããæãããBãµããŠãããã¯ç³è質ã°ããããªã¢ãªã·ã«ã»ã©ããïŒGb3ïŒãšããŠç¥ããã现èèã®æåã«çµåãããGb3ãžã®ãµããŠãããBã®çµåã¯ã现ã管ç¶ã®èåµå
¥ã®èªå°ãåŒãèµ·ããããããã¯çŽ°èã现èäžã«åã蟌ãŸããããã®å
åãèã®ç®¡ã®åœ¢æãæšé²ãããå¿è³æ¯çŽ ïŒé现å圢ææ§æ¯çŽ ïŒã¯ãŽã«ãžãããã¯ãŒã¯ããã³ERïŒå°èäœïŒãä»ããŠçŽ°è質ãžç§»è¡ããããŽã«ãžäœããæ¯çŽ ã¯ERãžèŒžéãããïŒtraffickedïŒãå¿è³æ¯çŽ ã¯ãªã·ã³ãšåæ§ã®ã¡ã«ããºã ã«ãã£ãŠæšç现èå
ã®ã¿ã³ãã¯è³ªåæãæå¶ããïŒSandvigïŒãµã³ããã°ïŒããã³van DeursïŒãã¡ã³ã»ããŠã«ã¹ïŒ(2000) EMBO JïŒEMBOãžã£ãŒãã«ïŒ19(220:5943)ïŒã现èã«äŸµå
¥ããåŸãæ¯çŽ ã®AãµããŠãããã¯ãªããœãŒã ã®60SãµããŠãããã®28S RNAããç¹å®ã®ã¢ããã³æ žé
žå¡©åºãéè£ãããããã«ãã£ãŠã¿ã³ãã¯è³ªåæãåæ¢ãããïŒDonohue-RolfeïŒãããã¥ãŒ-ãã«ãïŒãïŒ2010ïŒReviews of Infectious DiseasesïŒã¬ãã¥ãŒãºã»ãªãã»ã€ã³ãã§ã¯ã·ã£ã¹ã»ãã£ãžãŒãºïŒ13 Suppl.ïŒãµãã«ã¡ã³ãïŒ4(7): S293-297ïŒã
ããã§çšããããããã«ãå¿è³ãã¡ããªãŒæ¯çŽ ãžã®èšåã¯ãèªç¶çºçæ§ã¿ã³ãã¯è³ªæ¯çŽ ã®å¿è³æ¯çŽ ãã¡ããªãŒã®ä»»æã®ã¡ã³ããŒïŒäŸã¯ãS. dysenteriaeããã³å€§è
žèããåé¢ãããæ¯çŽ ïŒã«èšåãããããã¯æ§é çããã³æ©èœçã«é¢é£ãããäŸãã°ãå¿è³æ¯çŽ ãã¡ããªãŒã¯S. dysenteriaeè¡æž
å1ããåé¢ãããçã®å¿è³æ¯çŽ ïŒStxïŒãè
žç®¡åºè¡æ§å€§è
žèã®è¡æž
åããåé¢ãããå¿è³æ¯çŽ æ§æ¯çŽ 1å€çš®ïŒSLT1ãŸãã¯Stx1ãŸãã¯SLT-1ãŸãã¯Slt-IïŒãããã³è
žç®¡åºè¡æ§å€§è
žèã®è¡æž
åããåé¢ãããå¿è³æ¯çŽ æ§æ¯çŽ 2å€çš®ïŒSLT2ãŸãã¯Stx2ãŸãã¯SLT-2ïŒãå
å«ãããããã§çšããããããã«ããå¿è³ãã¡ããªãŒæ¯çŽ ããã®ãµããŠãããAããŸãã¯ãå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAãã¯å¿è³æ¯çŽ ãã¡ããªãŒã®ä»»æã®ã¡ã³ããŒãå¿è³æ¯çŽ ãŸãã¯å¿è³æ¯çŽ æ§æ¯çŽ ãå«ãããããããã®ãµããŠãããAã«èšåããã
äžå®æœæ
æ§ã§ã¯ãæCD117 ADCã¯ãå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAããŸãã¯çŽ°èæ¯æ§æŽ»æ§ãå³ã¡ããªããœãŒã æå¶æŽ»æ§ãæããå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã®äžéšã«ã³ã³ãžã¥ã²ãŒãããæCD117æäœãå«ããå¿è³æ¯çŽ ãµããŠãããA现èå·å®³æ§æŽ»æ§ã«ã¯ãäŸãã°ããªããœãŒã äžæŽ»æ§åãã¿ã³ãã¯è³ªåææå¶ãN-ã°ãªã³ã·ããŒãŒæŽ»æ§ãããªãã¯ã¬ãªããïŒã¢ããã·ã³ã°ãªã³ã·ããŒãŒæŽ»æ§ãRNAaseïŒRNã¢ãŒãŒïŒæŽ»æ§ãããã³DNAaseïŒDNã¢ãŒãŒïŒæŽ»æ§ãå«ãŸãããå¿è³æ¯çŽ ãšãã§ã¯ã¿ãŒæŽ»æ§ã«ã€ããŠã®ã¢ãã»ã€ã®éå¶éçãªäŸã¯ãã¿ã³ãã¯è³ªåææå¶æŽ»æ§ãè±ããªã³æŽ»æ§ã现èå¢æ®ã®æå¶ã现èå·å®³æ§ãã¹ãŒããŒã³ã€ã«DNAç·©å掻æ§ïŒrelaxation activityïŒãããã³ãã¯ã¬ã¢ãŒãŒæŽ»æ§ã枬å®ããã
äžå®ã®å®æœæ
æ§ã«ãããŠãæCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯ãå¿è³ãã¡ããªãŒæ¯çŽ AãµããŠãããããŸãã¯ãªããœãŒã æå¶æŽ»æ§ãæãããã®æçã«ã³ã³ãžã¥ã²ãŒããããå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã®äŸã¯å¿è³æ¯çŽ æ§æ¯çŽ ãµããŠãããAïŒSLT-1AïŒã§ããããã®ã¢ããé
žé
åã¯ä»¥äžã«æäŸããã
KEFTLDFSTAKTYVDSLNVIRSAIGTPLQTISSGGTSLLMIDSGSGDNLFAVDVRGIDPEEGRFNNLRLIVERNNLYVTGFVNRTNNVFYRFADFSHVTFPGTTAVTLSGDSSYTTLQRVAGISRTGMQINRHSLTTSYLDLMSHSGTSLTQSVARAMLRFVTVTAEALRFRQIQRGFRTTLDDLSGRSYVMTAEDVDLTLNWGRLSSVLPDYHGQDSVRVGRISFGSINAILGSVALILNCHHHASRVARMASDEFPSMCPADGRVRGITHNKILWDSSTLGAILMRRTISS
(é åçªå·42)ã
KEFTLDFSTAKTYVDSLNVIRSAIGTPLQTISSGGTSLLMIDSGSGDNLFAVDVRGIDPEEGRFNNLRLIVERNNLYVTGFVNRTNNVFYRFADFSHVTFPGTTAVTLSGDSSYTTLQRVAGISRTGMQINRHSLTTSYLDLMSHSGTSLTQSVARAMLRFVTVTAEALRFRQIQRGFRTTLDDLSGRSYVMTAEDVDLTLNWGRLSSVLPDYHGQDSVRVGRISFGSINAILGSVALILNCHHHASRVARMASDEFPSMCPADGRVRGITHNKILWDSSTLGAILMRRTISS
(é åçªå·42)ã
å¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã®å¥ã®äŸã¯å¿è³æ¯çŽ ãµããŠãããAïŒStxAïŒã§ããããã®ã¢ããé
žé
åã¯ä»¥äžã«æäŸããã
KEFTLDFSTAKTYVDSLNVIRSAIGTPLQTISSGGTSLLMIDSGTGDNLFAVDVRGIDPEEGRFNNLRLIVERNNLYVTGFVNRTNNVFYRFADFSHVTFPGTTAVTLSGDSSYTTLQRVAGISRTGMQINRHSLTTSYLDLMSHSGTSLTQSVARAMLRFVTVTAEALRFRQIQRGFRTTLDDLSGRSYVMTAEDVDLTLNWGRLSSVLPDYHGQDSVRVGRISFGSINAILGSVALILNCHHHASRVARMASDEFPSMCPADGRVRGITHNKILWDSSTLGAILMRRTISS
(é åçªå·43)ã
KEFTLDFSTAKTYVDSLNVIRSAIGTPLQTISSGGTSLLMIDSGTGDNLFAVDVRGIDPEEGRFNNLRLIVERNNLYVTGFVNRTNNVFYRFADFSHVTFPGTTAVTLSGDSSYTTLQRVAGISRTGMQINRHSLTTSYLDLMSHSGTSLTQSVARAMLRFVTVTAEALRFRQIQRGFRTTLDDLSGRSYVMTAEDVDLTLNWGRLSSVLPDYHGQDSVRVGRISFGSINAILGSVALILNCHHHASRVARMASDEFPSMCPADGRVRGITHNKILWDSSTLGAILMRRTISS
(é åçªå·43)ã
å¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã®å¥ã®äŸã¯å¿è³æ¯çŽ æ§æ¯çŽ 2ãµããŠãããAïŒSLT-2AïŒã§ããããã®ã¢ããé
žé
åã¯ä»¥äžã«æäŸããã
DEFTVDFSSQKSYVDSLNSIRSAISTPLGNISQGGVSVSVINHVLGGNYISLNVRGLDPYSERFNHLRLIMERNNLYVAGFINTETNIFYRFSDFSHISVPDVITVSMTTDSSYSSLQRIADLERTGMQIGRHSLVGSYLDLMEFRGRSMTRASSRAMLRFVTVIAEALRFRQIQRGFRPALSEASPLYTMTAQDVDLTLNWGRISNVLPEYRGEEGVRIGRISFNSLSAILGSVAVILNCHSTGSYSVRSVSQKQKTECQIVGDRAAIKVNNVLWEANTIAALLNRKPQDLTEPNQ
(é åçªå·44)ã
DEFTVDFSSQKSYVDSLNSIRSAISTPLGNISQGGVSVSVINHVLGGNYISLNVRGLDPYSERFNHLRLIMERNNLYVAGFINTETNIFYRFSDFSHISVPDVITVSMTTDSSYSSLQRIADLERTGMQIGRHSLVGSYLDLMEFRGRSMTRASSRAMLRFVTVIAEALRFRQIQRGFRPALSEASPLYTMTAQDVDLTLNWGRISNVLPEYRGEEGVRIGRISFNSLSAILGSVAVILNCHSTGSYSVRSVSQKQKTECQIVGDRAAIKVNNVLWEANTIAALLNRKPQDLTEPNQ
(é åçªå·44)ã
äžå®ã®ç¶æ³ã«ãããŠãèªç¶ã«çºçããå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã¯çŽ22ã¢ããé
žã®ã·ã°ãã«é
åããããã®ã¢ããæ«ç«¯ã«ãŠå«ãŸããåé§äœåœ¢æ
ãå«ã¿åŸããããã¯æçå¿è³ãã¡ããªãŒæ¯çŽ AãµããŠããããçæããããã«é€å»ãããããã³åœæè¡ã«ãããçç·Žäœæ¥è
ã«èªèå¯èœã§ãããå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã®çŽ°èå·å®³æ§æçãŸãã¯åè©°ãåïŒtruncated versionsïŒããŸããããã«é瀺ãããADCsããã³æ¹æ³ã«ãããŠäœ¿çšããåŸãã
äžå®ã®å®æœæ
æ§ã§ã¯ãå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã¯ãèªç¶ã«çºçããå¿è³æ¯çŽ AãµããŠããããšæ倧ã§1ã2ã3ã4ã5ã6ã7ã8ã9ã10ã15ã20ã25ã30ã35ïŒ40åãŸãã¯ããããããå€ãã®ã¢ããé
žæ®åºã«ãã£ãŠïŒãã ããå°ãªããšãçŽ85ïŒ
ãå°ãªããšãçŽ90ïŒ
ãå°ãªããšãçŽ95ïŒ
ãå°ãªããšãçŽ96ïŒ
ãå°ãªããšãçŽ97ïŒ
ãå°ãªããšãçŽ98ïŒ
ãå°ãªããšãçŽ99ïŒ
ããŸãã¯ããããããå€ãã®ã¢ããé
žé
ååäžæ§ãä¿æãããã®ãè¶
ããªããã®ã«ãã£ãŠïŒç°ãªããããããã®å®æœæ
æ§ã§ã¯ãå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã¯ãèªç¶ã«çºçããå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAãšæ倧ã§1ã2ã3ã4ã5ã6ã7ã8ã9ã10ã15ã20ã25ã30ã35ã40åãŸãã¯ããããããå€ãã®ã¢ããé
žæ®åºã«ãã£ãŠïŒãã ããå°ãªããšãçŽ85ïŒ
ãå°ãªããšãçŽ90ïŒ
ãå°ãªããšãçŽ95ïŒ
ãå°ãªããšãçŽ96ïŒ
ãå°ãªããšãçŽ97ïŒ
ãå°ãªããšãçŽ98ïŒ
ãå°ãªããšãçŽ99ïŒ
ãŸãã¯ããããããå€ãã®ã¢ããé
žé
ååäžæ§ãä¿æãããã®ãè¶
ããªããã®ã«ãã£ãŠïŒç°ãªããããããã«ãå¿è³æ¯çŽ ãã¡ããªãŒã®ã¡ã³ããŒã®AãµããŠãããããå°ãåºãããããªããããé åã¯èªç¶ã«çºçããå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã«å¯ŸããŠå°ãªããšãçŽ85ïŒ
ãå°ãªããšãçŽ90ïŒ
ãå°ãªããšãçŽ95ïŒ
ãå°ãªããšãçŽ96ïŒ
ãå°ãªããšãçŽ97ïŒ
ãå°ãªããšãçŽ98ïŒ
ãå°ãªããšãçŽ99ïŒ
ãŸãã¯ããããããå€ãã®ã¢ããé
žé
ååäžæ§ãç¶æãããéããå
ã®é
åããã®ä»å ãæ¬ å€±ãåè©°ãããŸãã¯ä»ã®æ¹å€ãå«ã¿åŸãã
ãããã£ãŠãäžå®ã®å®æœæ
æ§ã«ãããŠãå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAã¯ãèªç¶ã«çºçããå¿è³ãã¡ããªãŒæ¯çŽ ãµããŠãããAãäŸãã°ãSLT-1AïŒé
åçªå·42ïŒãStxAïŒé
åçªå·43ïŒãããã³/ãŸãã¯SLT-2AïŒé
åçªå·44ïŒãªã©ã®ãããªãã®ãšå°ãªããšãçŽ55ïŒ
ãå°ãªããšãçŽ60ïŒ
ãå°ãªããšãçŽ65ïŒ
ãå°ãªããšãçŽ70ïŒ
ãå°ãªããšãçŽ75ïŒ
ãå°ãªããšãçŽ80ïŒ
ãå°ãªããšãçŽ85ïŒ
ãå°ãªããšãçŽ90ïŒ
ãå°ãªããšãçŽ95ïŒ
ãå°ãªããšãçŽ96ïŒ
ãå°ãªããšãçŽ97ïŒ
ãå°ãªããšãçŽ98ïŒ
ãå°ãªããšãçŽ99ïŒ
ãå°ãªããšãçŽ99.5ïŒ
ãå°ãªããšãçŽ99.6%ãå°ãªããšãçŽ99.7%ãå°ãªããšãçŽ99.8%ãå°ãªããšãçŽ99.9%ãŸãã¯ããããããå€ãã®å
šäœã®é
ååäžæ§ã®ã¢ããé
žé
åãå«ããããŸãã¯æ¬è³ªçã«ãªãã
现èæ¯ãšããŠå¥œé©ãªå¿è³æ¯çŽ ããã³RIPsã¯äŸãã°ãUS20180057544ã«é瀺ãããŠãããããã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸããã
ã¢ãŠãªã¹ã¿ãã³é¡
ã¢ãŠãªã¹ã¿ãã³é¡
ããã«èšèŒã®æCD117æäœãããã³ãã®æåçµåæ§æçã¯ã¢ãŠãªã¹ã¿ãã³ã§ãã现èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒãããããšãã§ããïŒç±³åœç¹èš±ç¬¬5,635,483å·ïŒç¬¬5,780,588å·ïŒãã¢ãŠãªã¹ã¿ãã³ã¯åŸ®å°ç®¡ãã€ããã¯ã¹ãGTPå æ°Žå解ããªãã³ã«æ žããã³çŽ°èåè£ãå¹²æžããææ糞åè£æ§è¬å€ã§ããïŒWoykeïŒãŠã©ã€ã±ïŒã (2001) Antimicrob. Agents and Chemother.ïŒã¢ã³ããã€ã¯ããã€ã¢ã«ã»ãšãŒãžã§ã³ãã»ã¢ã³ãã»ã±ã¢ã»ã©ããŒïŒ45(12):3580-3584ïŒãããã³æã¬ã³æŽ»æ§ïŒç±³åœç¹èš±ç¬¬5,663,149å·ïŒãããã³æçè掻æ§ïŒPettitïŒããã£ããïŒã (1998) Antimicrob. Agents Chemother. 42:2961-2965)ãæãããïŒç±³åœç¹èš±ç¬¬5,635,483å·ïŒå第5,780,588å·ïŒãã¢ãŠãªã¹ã¿ãã³è¬ç©ã¢ã€ãšãã£ã¯ããããè¬ç©ã¢ã€ãšãã£ã®N-ïŒã¢ããïŒæ«ç«¯ãŸãã¯C-ïŒã«ã«ããã·ã«ïŒæ«ç«¯ãéããŠæäœã«ä»çãåŸãïŒWO 02/088172ïŒã
æš¡ç¯çãªã¢ãŠãªã¹ã¿ãã³ã®å®æœæ
æ§ã¯SenterïŒã»ã³ã¿ãŒïŒã, Proceedings of the American Association for Cancer ResearchïŒããã·ãŒãã£ã³ã°ãºã»ãªãã»ãžã»ã¢ã¡ãªã«ã³ã»ã¢ãœã·ãšãŒã·ã§ã³ã»ãã©ãŒã»ãã£ã³ãµãŒã»ãªãµãŒãïŒ, Volume 45, Abstract Number 623, presented Mar. 28, 2004ïŒç¬¬45å·»ãæé²çªå·623ã2004幎3æ28æ¥ïŒã«çºè¡šãããNæ«ç«¯é£çµã¢ãã¡ãã«ã¢ãŠãªã¹ã¿ãã³è¬ç©ã¢ã€ãšãã£DEããã³DFãå«ã¿ããã®é瀺å
容ã¯åç
§ã«ãããã®å
šäœãæ瀺çã«çµã¿èŸŒãã
æš¡ç¯çãªã¢ãŠãªã¹ã¿ãã³ã®å®æœæ
æ§ã¯ä»¥äžã®MMAEã§ãããïŒ
åŒäžãæ³¢ç·ã¯æäœ-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãïŒ-L-Z-Abãããã«èšèŒã®ãããªãã®ïŒã®ãªã³ã«ãŒãžã®å
±æçµåçä»çã®ç¹ãæã瀺ãã
å¥ã®æš¡ç¯çãªã¢ãŠãªã¹ã¿ãã³ã®å®æœæ
æ§ã¯MMAFïŒ
ã§ãããåŒäžãæ³¢ç·ã¯US 2005/0238649ã«é瀺ãããŠããããã«ãæäœ-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã®ãªã³ã«ãŒãžã®å
±æçµåçä»çã®ç¹ãæã瀺ãïŒ-L-Z-Abãããã«èšèŒã®ãããªãã®ïŒ
ã¢ãŠãªã¹ã¿ãã³ã¯ä»¥äžã®æ¹æ³ã«åŸã£ãŠèª¿è£œãåŸãïŒç±³åœç¹èš±ç¬¬5,635,483å·ïŒç±³åœç¹èš±ç¬¬5,780,588å·ïŒPettitã (1989) J. Am. Chem. Soc.ïŒãžã£ãŒãã«ã»ãªãã»ãžã»ã¢ã¡ãªã«ã³ã»ã±ãã«ã«ã»ãœãµãšãã£ïŒ111:5463-5465ïŒPettitã (1998) Anti-Cancer Drug DesignïŒã¢ã³ã-ãã£ã³ãµãŒã»ãã©ãã°ã»ãã¶ã€ã³ïŒ13:243-277ïŒPettit, G. R.,ã SynthesisïŒã·ã³ã»ã·ã¹ïŒ, 1996, 719-725ïŒPettitã (1996) J. Chem. Soc. Perkin Trans.ïŒãžã£ãŒãã«ã»ãªãã»ã¶ã»ã±ãã«ã«ã»ãœãµãšãã£-ããŒãã³ã»ãã©ã³ã¶ã¯ã·ã§ã³ãºïŒ15:859-863ïŒããã³DoroninaïŒããããïŒ (2003) Nat. Biotechnol. 21(7):778-784.
ã¢ãããã·ã³é¡
ã¢ãããã·ã³é¡
ããããã®å®æœæ
æ§ã§ã¯ãæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã®çŽ°èæ¯çŽ ã¯RNAããªã¡ã©ãŒãŒæå¶ç©è³ªã§ãããããããã®å®æœæ
æ§ã§ã¯ãRNAããªã¡ã©ãŒãŒæå¶ç©è³ªã¯ã¢ãããã·ã³ãŸãã¯ãã®èªå°äœã§ããã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯ã¢ãããã·ã³ãŸãã¯ãã®èªå°äœãäŸãã°ãα-ã¢ãããã³ãβ-ã¢ãããã³ãγ-ã¢ãããã³ãε-ã¢ãããã³ãã¢ããã³ãã¢ããã³ã¢ãããã¢ãããªã³ãã¢ãããªã³é
žãããã³ããã¢ãããªã³ãªã©ã®ãããªãã®ã§ãããçš®ã
ã®èªç¶ã«çºçããã¢ãããã·ã³ã®æ§é ã¯åŒIIIã«ãã£ãŠä»£è¡šãããäŸã¯ãZanottiïŒã¶ãããã£ïŒã, Int. J. Peptide Protein Res.ïŒã€ã³ã¿ãŒãã·ã§ãã«ã»ãžã£ãŒãã«ã»ãªãã»ããããã»ã¢ã³ãã»ãããã€ã³ã»ãªãµãŒãïŒ30, 1987, 450-459ã«é瀺ããããäžå®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯ã¢ãããã³ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯åŒIIIãIIIAãIIIBããŸãã¯IIICã®ã¢ãããã·ã³ã§ãããäŸãšããŠãããã«èšèŒã®æäœããŸãã¯æåçµåæ§æçã¯åŒAb-Z-L-Amã«ãã£ãŠä»£è¡šãããã³ã³ãžã¥ã²ãŒãã圢æããããã«ãã¢ãããã·ã³ã«çµåãåŸãåŒäžAbã¯æäœããŸãã¯ãã®æåçµåæ§æçãLã¯ãªã³ã«ãŒãZã¯ååŠçã¢ã€ãšãã£ããã³Amã¯ã¢ãããã³ã§ãããã¢ãããã·ã³ãŸãã¯ãã®èªå°äœäžã®å€ãã®äœçœ®ã¯ãé£çµã¢ã€ãšãã£Lãããã³ããã«æäœãŸãã¯ãã®æåçµåæ§æçãå
±æçµåããäœçœ®ãšããŠæ©èœããããšãã§ãããããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯æ¬¡ã®åŒïŒIïŒã§ä»£è¡šããã
ã§ãããåŒäžãR1ã¯HãOHãORAããŸãã¯ORCã§ããïŒ
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåããéæã«çœ®æããã5å¡ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãRCããŸãã¯RDã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCãORDãNHRCããŸãã¯NRCRDã§ããïŒ
R9ã¯HãOHãORCããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒ
RCã¯-L-Zã§ããïŒ
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããïŒ
Lã¯ãªã³ã«ãŒãäŸãã°ãéæã«çœ®æãããã¢ã«ãã¬ã³ïŒäŸã¯ãC1-C6ã¢ã«ãã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ãã¬ã³ïŒC1-C6ãããã¢ã«ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æããããžããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ãžããã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ããã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ãããã¢ã«ããã¬ã³ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æãããã¢ãªã¬ã³ãéæã«çœ®æããããããã¢ãªã¬ã³ãããããããžããããã-(C=O)-ããžã¹ã«ãã£ããããªãšãŒãã«ãããã©ãŸã³ããŸãã¯ãããã®çµåãã§ããïŒããã³
Zã¯Läžã«ååšããåå¿æ§çœ®æåºïŒsubstituentïŒããã³CD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ã€ãšãã£ã§ããã
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåããéæã«çœ®æããã5å¡ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãRCããŸãã¯RDã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCãORDãNHRCããŸãã¯NRCRDã§ããïŒ
R9ã¯HãOHãORCããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒ
RCã¯-L-Zã§ããïŒ
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããïŒ
Lã¯ãªã³ã«ãŒãäŸãã°ãéæã«çœ®æãããã¢ã«ãã¬ã³ïŒäŸã¯ãC1-C6ã¢ã«ãã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ãã¬ã³ïŒC1-C6ãããã¢ã«ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æããããžããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ãžããã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ããã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ãããã¢ã«ããã¬ã³ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æãããã¢ãªã¬ã³ãéæã«çœ®æããããããã¢ãªã¬ã³ãããããããžããããã-(C=O)-ããžã¹ã«ãã£ããããªãšãŒãã«ãããã©ãŸã³ããŸãã¯ãããã®çµåãã§ããïŒããã³
Zã¯Läžã«ååšããåå¿æ§çœ®æåºïŒsubstituentïŒããã³CD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ã€ãšãã£ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãAmã¯1ã€ã®RC眮æåºãæ£ç¢ºã«å«ãã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH)2n-åäœãå«ã¿ãããã§nã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((CH2)nãå«ã¿ãããã§nã¯6ã§ãããããããã®å®æœæ
æ§ã§ã¯ãL-Zã¯
ã§ãããåŒäžãSã¯CD117ãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšããåå¿æ§çœ®æåºã代衚ããç¡«é»ååã§ããïŒäŸã¯ãã·ã¹ãã€ã³æ®åºã®-SHåºããïŒã
ããããã®å®æœæ
æ§ã«ãããŠãL-Zã¯
ã§ãããåŒäžãSã¯CD117ãçµåããæäœãŸãã¯ãã®æåçµåæ§æçå
ã«ååšããåå¿æ§çœ®æåºã代衚ããç¡«é»ååã§ããïŒäŸã¯ãã·ã¹ãã€ã³æ®åºã®-SHåºããïŒã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Z-Abã¯ä»¥äžã®ãã¡ã®1ã€ã§ããïŒ
åŒäžãXã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ãããããã³Abã¯Abä»çã®ç¹ãæã瀺ãããã«çŸããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Z-Abã¯åŒïŒIAïŒã«ãã£ãŠä»£è¡šãããã
ã§ãããåŒäžãR1ã¯HãOHãORAããŸãã¯ORCã§ããïŒ
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåããéæã«çœ®æããã5å¡ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãRCããŸãã¯RDã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCãORDãNHRCããŸãã¯NRCRDã§ããïŒ
R9ã¯HãOHãORCããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒ
RCã¯-L-Zã§ããïŒ
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããïŒ
Lã¯ãªã³ã«ãŒãäŸãã°ãéæã«çœ®æãããã¢ã«ãã¬ã³ïŒäŸã¯ãC1-C6ã¢ã«ãã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ãã¬ã³ïŒC1-C6ãããã¢ã«ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æããããžããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ãžããã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ããã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ãããã¢ã«ããã¬ã³ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æãããã¢ãªã¬ã³ãéæã«çœ®æããããããã¢ãªã¬ã³ãããããããžããããã-(C=O)-ããžã¹ã«ãã£ããããªãšãŒãã«ãããã©ãŸã³ããŸãã¯ãããã®çµåãã§ããïŒ
Zã¯Läžã«ååšããåå¿æ§çœ®æåºïŒsubstituentïŒããã³CD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ã€ãšãã£ã§ããïŒããã³
ããã§Amã¯1ã€ã®RC眮æåºãæ£ç¢ºã«å«ãã
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåããéæã«çœ®æããã5å¡ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãRCããŸãã¯RDã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCãORDãNHRCããŸãã¯NRCRDã§ããïŒ
R9ã¯HãOHãORCããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒ
RCã¯-L-Zã§ããïŒ
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããïŒ
Lã¯ãªã³ã«ãŒãäŸãã°ãéæã«çœ®æãããã¢ã«ãã¬ã³ïŒäŸã¯ãC1-C6ã¢ã«ãã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ãã¬ã³ïŒC1-C6ãããã¢ã«ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æããããžããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ãžããã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ããã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ãããã¢ã«ããã¬ã³ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æãããã¢ãªã¬ã³ãéæã«çœ®æããããããã¢ãªã¬ã³ãããããããžããããã-(C=O)-ããžã¹ã«ãã£ããããªãšãŒãã«ãããã©ãŸã³ããŸãã¯ãããã®çµåãã§ããïŒ
Zã¯Läžã«ååšããåå¿æ§çœ®æåºïŒsubstituentïŒããã³CD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ã€ãšãã£ã§ããïŒããã³
ããã§Amã¯1ã€ã®RC眮æåºãæ£ç¢ºã«å«ãã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒã¯-((CH2)nãå«ã¿ãããã§nã¯6ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯åŒïŒIBïŒã«ãã£ãŠä»£è¡šãããã
ã§ãããåŒäžãR1ã¯HãOHãORAããŸãã¯ORCã§ããïŒ
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåããéæã«çœ®æããã5å¡ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãRCããŸãã¯RDã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCãORDãNHRCããŸãã¯NRCRDã§ããïŒ
R9ã¯HãOHãORCããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒ
RCã¯-L-Zã§ããïŒ
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããïŒ
Lã¯ãªã³ã«ãŒãäŸãã°ãéæã«çœ®æãããã¢ã«ãã¬ã³ïŒäŸã¯ãC1-C6ã¢ã«ãã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ãã¬ã³ïŒC1-C6ãããã¢ã«ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æããããžããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ãžããã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ããã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ãããã¢ã«ããã¬ã³ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æãããã¢ãªã¬ã³ãéæã«çœ®æããããããã¢ãªã¬ã³ãããããããžããããã-(C=O)-ããžã¹ã«ãã£ããããªãšãŒãã«ãããã©ãŸã³ããŸãã¯ãããã®çµåãã§ããïŒ
Zã¯Läžã«ååšããåå¿æ§çœ®æåºïŒsubstituentïŒããã³CD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ã€ãšãã£ã§ããïŒããã³
ããã§Amã¯1ã€ã®RC眮æåºãæ£ç¢ºã«å«ãã
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåããéæã«çœ®æããã5å¡ãããã·ã¯ãã¢ã«ãã«åºã圢æããããã«çµã¿åãããïŒ
R3ã¯HãRCããŸãã¯RDã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCãORDãNHRCããŸãã¯NRCRDã§ããïŒ
R9ã¯HãOHãORCããŸãã¯ORDã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒ
RCã¯-L-Zã§ããïŒ
RDã¯ãéæã«çœ®æãããã¢ã«ãã«ïŒäŸã¯ãC1-C6ã¢ã«ãã«ïŒãéæã«çœ®æããããããã¢ã«ãã«ïŒäŸã¯ãC1-C6ãããã¢ã«ãã«ïŒãéæã«çœ®æãããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã«ïŒãéæã«çœ®æããããããã¢ã«ã±ãã«ïŒäŸã¯ãC2-C6ãããã¢ã«ã±ãã«ïŒãéæã«çœ®æãããã¢ã«ããã«ïŒäŸã¯ãC2-C6ã¢ã«ããã«ïŒãéæã«çœ®æããããããã¢ã«ããã«ïŒäŸã¯ãC2-C6ãããã¢ã«ããã«ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ããŸãã¯éæã«çœ®æããããããã¢ãªãŒã«ã§ããïŒ
Lã¯ãªã³ã«ãŒãäŸãã°ãéæã«çœ®æãããã¢ã«ãã¬ã³ïŒäŸã¯ãC1-C6ã¢ã«ãã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ãã¬ã³ïŒC1-C6ãããã¢ã«ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æããããžããã¢ã«ã±ãã¬ã³ïŒäŸã¯ãC2-C6ãžããã¢ã«ã±ãã¬ã³ïŒãéæã«çœ®æãããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ã¢ã«ããã¬ã³ïŒãéæã«çœ®æããããããã¢ã«ããã¬ã³ïŒäŸã¯ãC2-C6ãããã¢ã«ããã¬ã³ïŒãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã¬ã³ãéæã«çœ®æãããã¢ãªã¬ã³ãéæã«çœ®æããããããã¢ãªã¬ã³ãããããããžããããã-(C=O)-ããžã¹ã«ãã£ããããªãšãŒãã«ãããã©ãŸã³ããŸãã¯ãããã®çµåãã§ããïŒ
Zã¯Läžã«ååšããåå¿æ§çœ®æåºïŒsubstituentïŒããã³CD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ã€ãšãã£ã§ããïŒããã³
ããã§Amã¯1ã€ã®RC眮æåºãæ£ç¢ºã«å«ãã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯ãL-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ãorãâããŸãã¯ã
ããããã®å®æœæ
æ§ã§ã¯ãRAããã³RBã¯é
žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãã次ã®åŒã®5å¡ãããã·ã¯ãã¢ã«ãã«åºã圢æããŠåœ¢æããããã«ïŒto form to formïŒãçµã¿åãããïŒ
åŒäžãYã¯-(C=O)-ã-(C=S)-ã-(C=NRE)-ããŸãã¯-(CRERE')-ã§ããïŒããã³
REããã³RE'ã¯ããããç¡é¢ä¿ã«ãéæã«çœ®æãããC1-C6ã¢ã«ãã¬ã³-RCãéæã«çœ®æãããC1-C6ãããã¢ã«ãã¬ã³-RCãéæã«çœ®æãããC2-C6ã¢ã«ã±ãã¬ã³-RCãéæã«çœ®æãããC2-C6ãããã¢ã«ã±ãã¬ã³-RCãéæã«çœ®æãããC2-C6ã¢ã«ããã¬ã³-Rcãéæã«çœ®æãããC2-C6ãããã¢ã«ããã¬ã³-RCãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³-RCãéæã«çœ®æããããžããã·ã¯ãã¢ã«ãã¬ã³-RCãéæã«çœ®æãããã¢ãªã¬ã³-RCããŸãã¯éæã«çœ®æããããžããã¢ãªã¬ã³-RCã§ããã
REããã³RE'ã¯ããããç¡é¢ä¿ã«ãéæã«çœ®æãããC1-C6ã¢ã«ãã¬ã³-RCãéæã«çœ®æãããC1-C6ãããã¢ã«ãã¬ã³-RCãéæã«çœ®æãããC2-C6ã¢ã«ã±ãã¬ã³-RCãéæã«çœ®æãããC2-C6ãããã¢ã«ã±ãã¬ã³-RCãéæã«çœ®æãããC2-C6ã¢ã«ããã¬ã³-Rcãéæã«çœ®æãããC2-C6ãããã¢ã«ããã¬ã³-RCãéæã«çœ®æãããã·ã¯ãã¢ã«ãã¬ã³-RCãéæã«çœ®æããããžããã·ã¯ãã¢ã«ãã¬ã³-RCãéæã«çœ®æãããã¢ãªã¬ã³-RCããŸãã¯éæã«çœ®æããããžããã¢ãªã¬ã³-RCã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯åŒïŒIAïŒãŸãã¯åŒïŒIBïŒã«ãã£ãŠä»£è¡šããã
åŒäžãR1ã¯HãOHãORAããŸãã¯ORCã§ããïŒ
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãã次ã®ïŒ
ã圢æããããã«çµã¿åããã
R3ã¯HãŸãã¯RCã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCããŸãã¯NHRCã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
ããã§RCããã³RDã¯ããããäžèšã§èŠå®ãããããã§ããã
åŒäžãR1ã¯HãOHãORAããŸãã¯ORCã§ããïŒ
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãã次ã®ïŒ
R3ã¯HãŸãã¯RCã§ããïŒ
R4ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R5ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R6ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R7ã¯HãOHãORCãORDãRCããŸãã¯RDã§ããïŒ
R8ã¯OHãNH2ãORCããŸãã¯NHRCã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
ããã§RCããã³RDã¯ããããäžèšã§èŠå®ãããããã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯åŒïŒIAïŒãŸãã¯åŒïŒIBïŒã«ãã£ãŠä»£è¡šããã
åŒäžãR1ã¯HãOHãORAããŸãã¯ORCã§ããïŒ
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãã次ã®ïŒ
ã圢æããããã«çµã¿åããã
R3ã¯HãŸãã¯RCã§ããïŒ
R4ããã³R5ã¯ããããç¡é¢ä¿ã«HãOHãORCãRCããŸãã¯ORDã§ããïŒ
R6ããã³R7ã¯ããããHã§ããïŒ
R8ã¯OHãNH2ãORCããŸãã¯NHRCã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
ããã§RCã¯äžèšã§èŠå®ãããããã§ããã
åŒäžãR1ã¯HãOHãORAããŸãã¯ORCã§ããïŒ
R2ã¯HãOHãORBããŸãã¯ORCã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãã次ã®ïŒ
R3ã¯HãŸãã¯RCã§ããïŒ
R4ããã³R5ã¯ããããç¡é¢ä¿ã«HãOHãORCãRCããŸãã¯ORDã§ããïŒ
R6ããã³R7ã¯ããããHã§ããïŒ
R8ã¯OHãNH2ãORCããŸãã¯NHRCã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
ããã§RCã¯äžèšã§èŠå®ãããããã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯åŒïŒIAïŒãŸãã¯åŒïŒIBïŒã«ãã£ãŠä»£è¡šããã
åŒäžãR1ã¯HãOHããŸãã¯ORAã§ããïŒ
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãã次ã®ïŒ
ã圢æããããã«çµã¿åããã
R3ãR4ãR6ãããã³R7ã¯ããããHã§ããïŒ
R5ã¯ORCã§ããïŒ
R8ã¯OHãŸãã¯NH2ã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
ããã§ãRCã¯äžèšã§ãèŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸã¯ãç±³åœç¹èš±åºé¡å ¬é第2016/0002298å·ã«èšèŒããããã®é瀺ã¯åç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
åŒäžãR1ã¯HãOHããŸãã¯ORAã§ããïŒ
R2ã¯HãOHããŸãã¯ORBã§ããïŒ
RAããã³RBã¯ãååšãããšããé žçŽ ååãšäžç·ã«ãªã£ãŠããã«ããããçµåãã次ã®ïŒ
R3ãR4ãR6ãããã³R7ã¯ããããHã§ããïŒ
R5ã¯ORCã§ããïŒ
R8ã¯OHãŸãã¯NH2ã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒ
Xã¯-S-ã-S(O)-ããŸãã¯-SO2-ã§ããïŒããã³
ããã§ãRCã¯äžèšã§ãèŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸã¯ãç±³åœç¹èš±åºé¡å ¬é第2016/0002298å·ã«èšèŒããããã®é瀺ã¯åç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯åŒïŒIAïŒãŸãã¯åŒïŒIBïŒã«ãã£ãŠä»£è¡šããã
åŒäžãR1ããã³R2ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R3ã¯RCã§ããïŒ
R4ãR6ãããã³R7ã¯ããããHã§ããïŒ
R5ã¯HãOHããŸãã¯OC1-C6ã¢ã«ãã«ã§ããïŒ
R8ã¯OHãŸãã¯NH2ã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒããã³
ããã§ãRCã¯äžèšã§èŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸãã°ãç±³åœç¹èš±åºé¡å ¬é第2014/0294865å·ã«èšèŒããããã®é瀺ã¯åç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
åŒäžãR1ããã³R2ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R3ã¯RCã§ããïŒ
R4ãR6ãããã³R7ã¯ããããHã§ããïŒ
R5ã¯HãOHããŸãã¯OC1-C6ã¢ã«ãã«ã§ããïŒ
R8ã¯OHãŸãã¯NH2ã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒããã³
ããã§ãRCã¯äžèšã§èŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸãã°ãç±³åœç¹èš±åºé¡å ¬é第2014/0294865å·ã«èšèŒããããã®é瀺ã¯åç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯åŒïŒIAïŒãŸãã¯åŒïŒIBïŒã«ãã£ãŠä»£è¡šããã
åŒäžãR1ããã³R2ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R3ãR6ãããã³R7ã¯ããããHã§ããïŒ
R4ããã³R5ã¯ããããç¡é¢ä¿ã«HãOHãORCããŸãã¯RCã§ããïŒ
R8ã¯OHãŸãã¯NH2ã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒããã³
ããã§ãRCã¯äžèšã§èŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸãã°ãç±³åœç¹èš±åºé¡å ¬é第2015/0218220å·ã«èšèŒããããã®é瀺ã¯åç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
åŒäžãR1ããã³R2ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R3ãR6ãããã³R7ã¯ããããHã§ããïŒ
R4ããã³R5ã¯ããããç¡é¢ä¿ã«HãOHãORCããŸãã¯RCã§ããïŒ
R8ã¯OHãŸãã¯NH2ã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒããã³
ããã§ãRCã¯äžèšã§èŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸãã°ãç±³åœç¹èš±åºé¡å ¬é第2015/0218220å·ã«èšèŒããããã®é瀺ã¯åç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Zã¯åŒïŒIAïŒãŸãã¯åŒïŒIBïŒã«ãã£ãŠä»£è¡šããã
åŒäžãR1ããã³R2ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R3ãR6ãããã³R7ã¯ããããHã§ããïŒ
R4ããã³R5ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R8ã¯OHãNH2ãORCããŸãã¯NHRCã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒããã³
ããã§ãRCã¯äžèšã§èŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸãã°ãç±³åœç¹èš±ç¬¬9,233,173å·ããã³ç¬¬9,399,681å·ããªãã³ã«US2016/0089450ã«èšèŒããããããã®åã ã®é瀺ã¯ãã®å šäœãåç §ã«ããããã«çµã¿èŸŒãŸããã
åŒäžãR1ããã³R2ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R3ãR6ãããã³R7ã¯ããããHã§ããïŒ
R4ããã³R5ã¯ããããç¡é¢ä¿ã«HãŸãã¯OHã§ããïŒ
R8ã¯OHãNH2ãORCããŸãã¯NHRCã§ããïŒ
R9ã¯HãŸãã¯OHã§ããïŒããã³
ããã§ãRCã¯äžèšã§èŠå®ãããããã§ããããã®ãããªã¢ãããã·ã³ã³ã³ãžã¥ã²ãŒãã¯ãäŸãã°ãç±³åœç¹èš±ç¬¬9,233,173å·ããã³ç¬¬9,399,681å·ããªãã³ã«US2016/0089450ã«èšèŒããããããã®åã ã®é瀺ã¯ãã®å šäœãåç §ã«ããããã«çµã¿èŸŒãŸããã
ããã«èšèŒã®çµæç©ããã³æ¹æ³ã«åŸã£ãŠãæäœããŸãã¯ãã®æåçµåæ§æçãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«ã€ããŠäœ¿çšããåŸãè¿œå ã®ã¢ãããã·ã³ã¯ãäŸãã°ãWO2016/142049ïŒWO2016/071856ïŒWO2017/046658ïŒããã³WO2018/115466ã«èšèŒããããããã®åã
ã®é瀺ã¯åç
§ã«ãããããã®å
šäœãšããŠããã«çµã¿èŸŒãŸããã
ããå®æœæ
æ§ã§ã¯ãAm-L-Zã¯åŒïŒIIïŒãåŒIIAããŸãã¯åŒIIBã«ãã£ãŠä»£è¡šãã
åŒäžãXã¯SãSOããŸãã¯SO2ã§ããïŒR1ã¯HãŸãã¯ãªã³ã«ãŒäžã«ååšããåå¿æ§çœ®æåºããã³æäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ãšã€ãã£ãŒïŒchemical moeityïŒZãéããŠæäœãŸãã¯ãã®æåçµåæ§æçã«å
±æçµåãããªã³ã«ãŒã§ããïŒR2ã¯HãŸãã¯ãªã³ã«ãŒäžã«ååšããåå¿æ§çœ®æåºããã³æäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšããåå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ãšã€ãã£ãŒZãä»ããŠæäœãŸãã¯ãã®æåçµåæ§æçã«å
±æçµåãããªã³ã«ãŒã§ããïŒããã§R1ãHã®ãšããR2ã¯ãªã³ã«ãŒã§ãããããã³R2ãHã®ãšããR1ã¯ãªã³ã«ãŒã§ããã
ããããã®å®æœæ
æ§ã§ã¯ãR1ã¯ãªã³ã«ãŒã§ãããããã³R2ã¯Hã§ããããªãã³ã«ãªã³ã«ãŒããã³ååŠçã¢ã€ãšãã£ã¯L-ZãšããŠäžç·ã«ãªã£ãŠã以äžãã®ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ãR1ã¯ãªã³ã«ãŒã§ãããããã³R2ã¯Hã§ããããªãã³ã«ãªã³ã«ãŒããã³ååŠçã¢ã€ãšãã£ã¯L-ZãšããŠäžç·ã«ãªã£ãŠã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãAm-L-Z-Abåé§äœïŒå³ã¡ãAm-L-Z'ïŒã¯ä»¥äžã®ãã¡ã®1ã€ïŒ
ã§ããïŒ
åŒäžããã¬ã€ããã¯æäœã«ãããã·ã¹ãã€ã³äžã«èŠåºãããããªãŒã«åºãšåå¿ããã
åŒäžããã¬ã€ããã¯æäœã«ãããã·ã¹ãã€ã³äžã«èŠåºãããããªãŒã«åºãšåå¿ããã
ããããã®å®æœæ
æ§ã§ã¯ã现èæ¯çŽ ã¯Î±-ã¢ãããã³ã§ãããããããã®å®æœæ
æ§ã§ã¯ãα-ã¢ãããã³ã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®Î±-ã¢ãããã³ã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAãIIBãIVãIVAãŸãã¯IVBã®Î±-ã¢ãããã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®èããããäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ããããã§åŒIIIã®Î±-ã¢ãããã³ã«ä»çããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯R1äœçœ®ã§ä»çãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ããŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžãnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n)-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯Î²-ã¢ãããã³ã§ãããããããã®å®æœæ
æ§ã§ã¯ãβ-ã¢ãããã³ã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®Î²-ã¢ãããã³ã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®Î²-ã¢ãããã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®1ã€ã«ãŠåŒIIIã®Î²-ã¢ãããã³ã«ä»çããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯Î³-ã¢ãããã³ã§ãããããããã®å®æœæ
æ§ã§ã¯ãγ-ã¢ãããã³ã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®Î³-ã¢ãããã³ã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®Î³-ã¢ãããã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®1ã€ã«ãŠåŒIIIã®Î³-ã¢ãããã³ã«ä»çããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžãnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯Îµ-ã¢ãããã³ã§ãããããããã®å®æœæ
æ§ã§ã¯ãε-ã¢ãããã³ã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®Îµ-ã¢ãããã³ã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®Î³-ã¢ãããã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®1ã€ã«ãŠåŒIIIã®Îµ-ã¢ãããã³ã«ä»çããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžãnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯ã¢ããã³ã§ãããããããã®å®æœæ
æ§ã§ã¯ãã¢ããã³ã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®ã¢ããã³ã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®ã¢ããã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®1ã€ã«ãŠåŒIIIã®ã¢ããã³ã«ä»çããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯ã¢ããã³ã¢ããã§ãããããããã®å®æœæ
æ§ã§ã¯ãã¢ããã³ã¢ããã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®ã¢ããã³ã¢ããã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®ã¢ããã³ã¢ãã-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®äžã€ã«ãŠåŒIIIã®ã¢ããã³ã¢ããã«ä»çããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯ã¢ãããªã³ã§ãããããããã®å®æœæ
æ§ã§ã¯ãã¢ãããªã³ã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®ã¢ãããªã³ã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®ã¢ãããªã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®äžã€ã«ãŠåŒIIIã®ã¢ãããªã³ã«çµåããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ãããI
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯ã¢ãããªã³é
žã§ãããããããã®å®æœæ
æ§ã§ã¯ãã¢ãããªã³é
žã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®ã¢ãããªã³é
žã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®ã¢ãããªã³é
ž-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®äžã€ã«ãŠåŒIIIã®ã¢ãããªã³é
žã«ä»çãåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠã现èæ¯çŽ ã¯ããã¢ãããªã³ã§ãããããããã®å®æœæ
æ§ã§ã¯ãããã¢ãããªã³ã¯åŒIIIã®ååç©ã§ãããããããã®å®æœæ
æ§ã§ã¯ãåŒIIIã®ããã¢ãããªã³ã¯ãªã³ã«ãŒLãä»ããŠæCD117æäœã«ä»çãããããªã³ã«ãŒLã¯åŒIãIAãIBãIIãIIAããŸãã¯IIBã®ããã¢ãããªã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããæäŸããããã«ããã€ãã®å¯èœãªäœçœ®ïŒäŸã¯ãä»»æã®R1-R9ïŒã®ä»»æã®äžã€ã«ãŠåŒIIIã®ããã¢ãããªã³ã«ä»çããåŸããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R1ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R2ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R3ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R4ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R5ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R6ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R7ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R8ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äœçœ®R9ã«ä»çããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èãããã次ã®ãã®ã§ããã
ã¢ãããã·ã³ãäœæããåææ¹æ³ã¯ç±³åœç¹èš±ç¬¬9,676,702å·ã«èšèŒãããããã¯åç
§ã«ããããã«çµã¿èŸŒãŸããã
ããã«èšèŒã®çµæç©ããã³æ¹æ³ãšå
±ã«äœ¿çšããããã®æäœããŸãã¯æåçµåæ§æçã¯åœæè¡ã§ç¥ããããŸãã¯ããã«èšèŒã®ã³ã³ãžã¥ã²ãŒã·ã§ã³æè¡ã䜿çšããŠãã¢ãããã·ã³ãäŸãã°ãα-ã¢ãããã³ãŸãã¯ãã®å€çš®ãªã©ã®ãããªãã®ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ããããšãã§ãããäŸãšããŠãCD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãèªèãããã³çµåããæäœããŸãã¯ãã®æåçµåæ§æçã¯ãã¢ãããã·ã³ãäŸãã°ãα-ã¢ãããã³ãŸãã¯ãã®å€çš®ãªã©ã®ãããªãã®ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ããããšãã§ããããã¯US 2015/0218220ã«èšèŒãããããã§ããããã®é瀺ã¯ããããäŸãã°ãã¢ãããã·ã³ãäŸãã°ãα-ã¢ãããã³ããã³ãã®å€çš®ãªã©ã®ãããªãã®ããªãã³ã«å
±æçµçã³ã³ãžã¥ã²ãŒã·ã§ã³ã«ã€ããŠäœ¿çšããããšãã§ããå
±æçµåçãªã³ã«ãŒã«é¢ãããã®ãšããŠãåç
§ã«ããããã«çµã¿èŸŒãã
ããã«èšèŒã®æ¹æ³ãšé¢é£ããŠæçšãªæš¡ç¯çãªæäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã¯æäœããŸãã¯ãã®æåçµåæ§æçãšãæäœããŸãã¯ãã®æåçµåæ§æçäžã®åå¿æ§æ®åºãšã®åå¿ã«é©ãã眮æåãå«ããªã³ã«ãŒã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ããã¢ãããã·ã³ãšã®åå¿ã«ãã£ãŠåœ¢æããåŸããããã«èšèŒãããæäœããŸãã¯ãã®æåçµåæ§æçäžã®åå¿æ§æ®åºãšã®åå¿ã«é©ãã眮æåãå«ããªã³ã«ãŒã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ããã¢ãããã·ã³ã«ã¯ãå¶éã䌎ããªããã7'C-(4-(6-(ãã¬ã€ãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ããã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(3-ã«ã«ããã·ãããã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(2-ããã¢ã¢ã»ãã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(3-(ããªãžã³-2-ã€ã«ãã¹ãã¡ãã«)ãããã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(4-(ãã¬ã€ãã)ãã¿ã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(ãã¬ã€ãã)ã¢ã»ãã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(3-(ãã¬ã€ãã)ããããã€ã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(4-(ãã¬ã€ãã)ãã¿ã³ã¢ã€ã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ã7'C-(4-(2-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(3-((6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ã¡ãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(3-((6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµãã¢ãã)ã¡ãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(3-((4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ã¡ãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(3-(6-((4-(ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ã¡ãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(6-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãããµãã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(4-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãã¿ã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(4-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãã¿ãã€ã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(6-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-((4-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(6-(ãã¬ã€ãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ(R)-7'C-((3-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ(S)-7'C-((3-((6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(6-(ãã¬ã€ãã)ãããµãã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµã³ã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ããã·ã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµã³ã¢ãã)-S-ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµãã¢ãã)-R-ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)-S-ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)-R-ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(3-ã«ã«ããã·ãããã³ã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(ãã¬ã€ãã)ã¢ã»ãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(3-(ãã¬ã€ãã)ããããã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(4-(ãã¬ã€ãã)ãã¿ãã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(2-(ãã¬ã€ãã)ã¢ã»ãã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(4-(ãã¬ã€ãã)ãã¿ã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ã¡ãã«)ã¢ãŒããžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-(2-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãšãã«)ã¢ãŒããžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ã¡ãã«)ã¢ãŒããžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-(2-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãšãã«)ã¢ãŒããžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-(2-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ãšãã«)ã¢ãŒããžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-(((2-(6-(ãã¬ã€ãã)-N-ã¡ãã«ãããµã³ã¢ãã)ãšãã«)(ã¡ãã«)ã¢ãã)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-(((4-(6-(ãã¬ã€ãã)-N-ã¡ãã«ãããµã³ã¢ãã)ããã«)(ã¡ãã«)ã¢ãã)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((2-(2-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãšãã«)ã¢ãžãªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((2-(2-(6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)ãšãã«)ã¢ãžãªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(6-(6-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãããµã³ã¢ãã)ãããµãã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(1-(ã¢ãããªãã·)-2-ãªããœ-6,9,12,15-ããã©ãªããµ-3-ã¢ã¶ããã¿ãã«ã³-17-ãªã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ã¢ã»ãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(3-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ããããã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(4-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãã¿ãã€ã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(6-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãããµã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(2-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ã¢ã»ãã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(4-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)ãã¿ã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(20-(ã¢ãããªãã·)-4,19-ãžãªããœ-6,9,12,15-ããã©ãªãã¶3,18-ãžã¢ã¶ã€ã³ã·ã«ïŒdiazaicosylïŒ)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-(((2-(6-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)-N-ã¡ãã«ãããµã³ã¢ãã)ãšãã«)(ã¡ãã«)ã¢ãã)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-(((4-(6-(2-(ã¢ãããªãã·)ã¢ã»ãã¢ãã)-N-ã¡ãã«ãããµã³ã¢ãã)ããã«)(ã¡ãã«)ã¢ãã)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((3-((6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµããã)ã¡ãã«)ãããªãžã³-1-ã€ã«)-S-ã¡ãã«)-ã¢ãããã·ã³ã7'C-((3-((6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãããµã³ã¢ãã)-R-ã¡ãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(2-ããã¢ã¢ã»ãã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(2-ããã¢ã¢ã»ãã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ7'C-((4-(2-(3-ããªãžã³-2-ã€ã«ãžã¹ã«ãã¡ãã«)ãããã³ã¢ãã)ãšãã«)ãããªãžã³-1-ã€ã«)ã¡ãã«)-ã¢ãããã·ã³ïŒ6'O-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ããã·ã«)-ã¢ãããã·ã³ïŒ6'O-(5-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ãããµãã)ãã³ãã«)-ã¢ãããã·ã³ïŒ6'O-(2-((6-(ãã¬ã€ãã)ããã·ã«)ãªãã·)-2-ãªããœãšãã«)-ã¢ãããã·ã³ïŒ6'O-((6-(ãã¬ã€ãã)ããã·ã«)ã«ã«ãã¢ã€ã«)-ã¢ãããã·ã³ïŒ6'O-((6-(4-((ãã¬ã€ãã)ã¡ãã«)ã·ã¯ããããµã³ã«ã«ããã·ã¢ãã)ããã·ã«)ã«ã«ãã¢ã€ã«)-ã¢ãããã·ã³ïŒ6'O-(6-(2-ããã¢ã¢ã»ãã¢ãã)ããã·ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(6-(ã¢ãžã)ãããµã³ã¢ãã)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(ãããµïŒhexïŒ-5-ãšãã€ã«ã¢ããïŒynoylaminoïŒ)ãããªãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ7'C-(4-(2-(6-(6-(ãã¬ã€ãã)ãããµã³ã¢ãã)ãããµã³ã¢ãã)ãšãã«)ããã©ãžã³-1-ã€ã«)-ã¢ãããã·ã³ïŒ6'O-(6-(6-(11,12-ãžãããã-5,6-ãžããã-ãžãã³ãº[b,f]ã¢ãŸã·ã³-5-ã€ã«)-6-ãªããœãããµã³ã¢ãã)ããã·ã«)-ã¢ãããã·ã³ïŒ6'O-(6-(ãããµ-5-ãšãã€ã«ã¢ãã)ããã·ã«)-ã¢ãããã·ã³ïŒ6'O-(6-(2-(ã¢ãããªãã·)ã¢ã»ãã«ã¢ãã)ããã·ã«)-ã¢ãããã·ã³ïŒ6'O-((6-ã¢ãããªãã·)ããã·ã«)-ã¢ãããã·ã³ïŒããã³ 6'O-(6-(2-ãšãŒãã¢ã»ãã¢ãã)ããã·ã«)-ã¢ãããã·ã³ãå«ãŸãããåè¿°ã®ãªã³ã«ãŒã¯ãããã«èšèŒã®çµæç©ããã³æ¹æ³ãšé¢é£ããŠæçšãªä»ã®ãã®ãããããäŸãã°ãç±³åœç¹èš±åºé¡å
¬é第2015/0218220å·ã«èšèŒãããŠããããã®é瀺ã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸããã
CD117ãèªèããããã³çµåããæäœããŸãã¯ãã®æåçµåæ§æçã«ã³ã³ãžã¥ã²ãŒãããããšãã§ããè¿œå ã®çŽ°èæ¯çŽ ïŒäŸãã°ãã¬ã³ããªãŒããã€ã³ïŒautommineïŒç¶æ
ãçŽæ¥åŠçœ®ããããšã§ã®ããŸãã¯ãã€ã·ã§ã³ãïŒäŸã¯ããããã€ã·ã§ã³ãïŒãé è¡å¹¹çŽ°è移æ€çæ³ã®æºåã«ãããã³ã³ãã£ã·ã§ãã³ã°ïŒèª¿æŽãšãèšãïŒã®ããã«äœ¿çšããããã®GNNK+CD117ãªã©ã®ãããªãã®ã¯ãå¶éãããªããã5-ãšããã«ãŠã©ã·ã«ãã¢ãã©ããã³ãã¢ã·ã«ãã«ãã³ãã¢ãã·ãããŒã«ãã¢ããŒã¬ã·ã³ãã¢ã«ãã¹ãã€ãã³ãã¢ã«ãã¬ã¿ãã³ãã¢ã³ãã ã¹ãã³ãã¢ãããã¯ã¹ãã¢ããã¹ãã³ãã¢ããã¬ããªã³é
žãã¢ã ã«ãã·ã³ãã¢ã ãµã¯ãªã³ãã¢ãã°ã¬ãªããã¢ãã¹ãããŸãŒã«ãã¢ã³ããã°ã©ããªããè¡ç®¡æ°çæå¶ç©è³ªãã¢ã³ã¿ã¬ãªã¯ã¹ãæèåŽå圢æ
圢æã¿ã³ãã¯è³ªïŒanti-dorsalizing morphogenetic proteinïŒ-1ãæã¢ã³ããã²ã³ãåç«è
ºã¬ã³è
«ãæãšã¹ããã²ã³ãæããªãã©ã¹ãã³ïŒantineoplastonãææ°çç©è¬ïŒãã¢ã³ãã»ã³ã¹ãªãªãŽãã¯ã¬ãªãããã¢ãã£ãžã³ãªã³ã°ãªã·ããŒããã¢ãããŒã·ã¹éºäŒåã¢ãžã¥ã¬ãŒã¿ãŒãã¢ãããŒã·ã¹ã¬ã®ã¥ã¬ãŒã¿ãŒãã¢ããªã³é
žãã¢ã¹ã©ã¯ãªã³ãã¢ã¿ã¡ã¹ã¿ã³ãã¢ããªã ã¹ãã³ãã¢ãã·ãã¹ã¿ãã³1ãã¢ãã·ãã¹ã¿ãã³2ãã¢ãã·ãã¹ã¿ãã³3ãã¢ã¶ã»ããã³ãã¢ã¶ããã·ã³ãã¢ã¶ããã·ã³ãããã«ãã³IIIèªå°äœããã©ããŒã«ããããã¹ã¿ãããBCR/ABLæ®æç©è³ªããã³ãŸã¯ããªã³ããã³ãŸã€ã«ã¹ã¿ãŠãã¹ããªã³ãããŒã¿ã©ã¯ã¿ã èªå°äœãããŒã¿-ã¢ã¬ãã³ããã¿ã¯ã©ãã€ã·ã³Bããããªã³é
žãbFGFæå¶ç©è³ªããã«ã«ã¿ãããããµã³ãã¬ã³ããã¹ã¢ãžãªãžãã«ã¹ãã«ãã³ïŒbisaziridinylspermineïŒããã¹ããã£ãããã¹ãã©ãã³AãããŒã¬ã·ã³ããã¬ãã©ãŒãããã¬ãªãã€ã·ã³A2ããã¬ãªãã€ã·ã³B2ãããããªãã³ããããã¿ã³ïŒbudotitaneïŒããããªãã³ã¹ã«ããã·ãã³ãã«ã«ã·ãããªãªãŒã«ãã«ã«ãã¹ãã³Cãã«ã³ããã»ã·ã³èªå°äœïŒäŸã¯ã10-ããããã·-ã«ã³ããã»ã·ã³ïŒãã«ãã·ã¿ãã³ãã«ã«ãã¢ãã-ã¢ãã-ããªã¢ãŸãŒã«ïŒcarboxamide-amino-triazoleïŒãã«ã«ããã·ã¢ããããªã¢ãŸãŒã«ïŒcarboxyamidotriazoleïŒãã«ã«ãŒã¬ã·ã³ãã«ãŒã€ã³ãããŒãŒæå¶ç©è³ªãã«ã¹ã¿ãã¹ãã«ãã³ãã»ã¯ããã³Bãã»ããã¬ãªãã¯ã¹ãå¡©çŽ ãã¯ããããããµãªã³ã¹ã«ãã³ã¢ãããã·ã«ããã¹ããã·ã¹ãã«ãã£ãªã³ãã¯ã©ããªãã³ãã¯ãããã§ã³ããã³ãã®é¡çžç©ãã¯ãããªããŸãŒã«ãã³ãªã¹ãã€ã·ã³Aãã³ãªã¹ãã€ã·ã³Bãã³ã³ãã¬ã¿ã¹ã¿ãã³A4ãã³ã³ãã¬ã¿ã¹ã¿ãã³é¡çžäœãã³ãã²ãã³ãã¯ã©ã³ãã·ãžã³816ãã¯ãªã¹ãããŒã«ãã¯ãªãããã£ã·ã³8ãã¯ãªãããã£ã·ã³Aèªå°äœãã¯ã©ã·ã³Aãã·ã¯ããã³ã¿ã¢ã³ãã©ããã³ïŒcyclopentanthraquinonesïŒãã·ã¯ããã©ã¿ã ïŒcycloplatamïŒãã·ããã€ã·ã³ãã·ã¿ã©ãã³ãªã¯ãã¹ãã¡ãŒãã现è溶解å åïŒcytolytic factorïŒãã·ãã¹ã¿ãã³ããã¯ãªãã·ããïŒdacliximabïŒããã·ã¿ãã³ããããããžãã ãã³Bã2'ããªãã·ã³ãã«ãã€ã·ã³ïŒDCFïŒããã¹ãã¬ãªã³ãããã·ãã¹ãã¡ããïŒdexifosfamideïŒãããã¹ã©ãŸããµã³ããã¯ã¹ãã©ããã«ããžã¢ãžã¯ãªã³ããžãã ãã³Bããžããã¯ã¹ããžãšãã«ãã«ã¹ãã«ãã³ããžããã-5-ã¢ã¶ã·ããžã³ããžãããã¿ããœãŒã«ããžãªããµãã€ã·ã³ããžãã§ãã«ã¹ããã ã¹ãã³ããžã¹ã³ãã«ã¢ãªãããã³ãµããŒã«ããã©ã»ããã³ãããã·ãã«ãªãžã³ãããããã·ãã§ã³ãããããããŒã«ããã¥ãªã«ã«ãã€ã·ã³SAããšãã»ã¬ã³ããšã³ã ã¹ãã³ããšãã«ãã·ã³ããšãã¬ã³ãããããšãã«ããã³ããšã¬ã¡ã³ããšãããã«ããšãããã³ããšãããã³ïŒepithilonesïŒããšããªã¹ããªãããšã¹ãã©ã ã¹ãã³ããã³ãã®é¡çžäœããšããã·ãããšããã·ã4'-ãã¹ãã¡ãŒãïŒãŸããšãããã©ã¹ïŒetopofosïŒãšã称ããïŒããšãã»ã¡ã¹ã¿ã³ããã¡ãããŸãŒã«ããã¡ã¶ã©ãã³ããã§ã³ã¬ãããããã£ã«ã°ã©ã¹ãã ããã£ãã¹ããªãããã©ãããªããŒã«ããã¬ãŒã©ã¹ãã³ããã«ã¢ã¹ããã³ããã«ãã©ãã³ãå¡©é
žãããªããã«ãã·ã³ïŒfluorodaunorunicin hydrochlorideïŒããã«ãã§ãã¡ãã¯ã¹ããã«ã¡ã¹ã¿ã³ããã©ã¹ããªãšã·ã³ããã©ãã ã¹ãã³ãã¬ããªããŠã ãããµãã£ãªã³ãç¡é
žã¬ãªãŠã ãã¬ãã·ã¿ãã³ãã¬ãã¬ãªãã¯ã¹ããŒã©ãããŒãŒæå¶ç©è³ªãã²ã ã·ã¿ãã³ãã°ã«ã¿ããªã³æå¶ç©è³ªãããã¹ã«ãã¡ã ããã¢ããªã³ããã³ïŒHHTïŒããã€ããªã·ã³ãã€ãã³ããã³é
žãã€ããã·ãã§ã³ãã€ãã©ãã³ãã³ãã€ã«ã¢ãã·ã³ãã€ããã¹ã¿ãããã€ãããŸã¢ã¯ãªãã³ãã€ããã¢ããå
ç«è³ŠæŽ»è¬ããããïŒimmunostimulant peptidesïŒãã€ãªãã³ã°ã¢ã³ïŒiobenguaneïŒããšãŒããããœã«ãã·ã³ïŒiododoxorubicinïŒãã€ãã¡ã¢ããŒã«ãã€ãªããã«ã³ãã€ããã©ã¯ããã€ã«ãœã°ã©ãžã³ãã€ãœãã³ã¬ãŸãŒã«ããžã£ã¹ãã©ããã©ã€ããã«ãã©ã©ã€ãFãã©ã¡ã©ãªã³Nããªã¢ã»ããŒããã©ã³ã¬ãªã¿ã€ããã¬ã€ããã€ã·ã³ãã¬ãã°ã©ã¹ãã ãã¬ã³ããã³ç¡«é
žãã¬ããã«ã¹ã¿ãã³ãã¬ãããŸãŒã«ã芪油æ§çœéååç©ããªãœã¯ãªã³ã¢ãã7ããããã©ãã³ããã¡ãã¬ããœãŒã«ãããããã³ãããœããµã³ããã³ããããœãªãã³ãã«ã«ããã«ã³ãã«ãããŠã ãããµãã£ãªã³ããªãŸãã£ãªã³ãããœããã³ãŒã«ããã¹ãã³ããããªãã¯ã¹ã¡ã¿ããããã¢ãŒãŒæå¶ç©è³ªãã¡ãã¬ãªã«ãã«ãããã³ãã¡ãã¬ãªã³ãã¡ããªãããŒãŒãã¡ãã³ãã©ãããMIFæå¶ç©è³ªãã€ãã§ããªã¹ãã³ããã«ããã©ã·ã³ãããªã¢ã¹ãã£ã ãããã©ã·ã³ãããã°ã¢ãŸã³ãããã©ã¯ãã«ããã€ããã€ã·ã³ããã³ãã®é¡çžäœãããããã¡ã€ããããããµã³ããã³ãã¢ãã¡ããŒãã³ãã¢ã«ã°ã©ã¢ã¹ãã ããã€ã«ããããµã€ãBãããªã¢ããã³ãN-ã¢ã»ãã«ãžããªã³ãN-眮æãã³ãºã¢ãããããã¡ã¬ãªã³ããã°ã¬ãžããããããã³ããããã«ãã³ããã«ãã°ã©ã¹ãã ããããã©ãã³ããã¢ã«ãã·ã³ãããªããã³é
žããã«ã¿ãããããµãã€ã·ã³ãããã«ãªã³ããªã¯ãã¬ãªããããªãã»ãã³ããªãããªã¹ãã³ããªã³ãã³ã»ããã³ããªã©ã·ã³ããªã«ããã©ãã³ããªããµãªãã©ãã³ããªããµãŠããã·ã³ããã¯ãªã¿ãã»ã«ããã³ãã®é¡çžäœããã©ãŠã¢ãã³ïŒpalauamineïŒããã«ããã€ã«ãªãŸãã·ã³ãããããã³é
žããããã·ããªãªãŒã«ãããããã§ã³ããã©ãã¯ãã³ãããŒãªããã³ããã¬ã¹ãã«ã¬ãŒãŒããã«ãã·ã³ããã³ããµã³ããªç¡«é
žãããªãŠã ããã³ãã¹ã¿ãã³ããã³ãããŸãŒã«ïŒpentrozoleïŒããã«ãã«ããã³ããã«ãã©ã¹ãã¡ããããã§ããžããã€ã·ã³ããã·ãããŒã«ããã©ã«ãã·ã³ãããªãã¬ãã·ã ããããã£ãããã·ã³ããã«ãã£ããã€ã·ã³ãããªã³ãã¯ã¬ãªã·ããã¹ããªã©ãŒãŒæå¶ç©è³ªãã©ã«ããã¬ãã»ãããªãŸãã·ã³ããã°ã¬ããããããããã³ãã«ãã®ãã³B1ãã«ããã·ã«ããµãã£ã³ãŽãŒã«ããµã³ããã³ããµã«ã³ãã£ããŒã«Aããµã«ã°ã©ã¢ã¹ãã ããœããŸããµã³ããœããŒãã³ïŒsonerminïŒãã¹ãã«ãã©ã·ã³é
žïŒsparfosic acidïŒãã¹ãã«ãã€ã·ã³Dãã¹ããã ã¹ãã³ïŒspiromustineïŒãã¹ããã¢ãããã¹ã«ãã£ãã·ã³ãã¿ãªã ã¹ãã³ããã¬ããŒã«ããã¢ãŸãããããããã·ããã¿ãªãã©ã¹ãã³ãããªã³ã©ãªã³ããã©ãã¶ãã³ããããã«ã³ãããã»ã³ãã³ãããªã·ãªãã³ãããªã¡ãã¬ããµãŒãããã©ãã³ãããã¬ã«ãã³ããã³ããµã«ãã³ïŒvinxaltineïŒããããŸãŒã«ããŒããã©ãã³ïŒzeniplatinïŒãããã³ãžã©ã¹ã³ã«ãããªã©ä»ã«ããããå«ãŸããã
ååŠçã³ã³ãžã¥ã²ãŒã·ã§ã³çšãªã³ã«ãŒ
ååŠçã³ã³ãžã¥ã²ãŒã·ã§ã³çšãªã³ã«ãŒ
æ§ã
ãªãªã³ã«ãŒã¯ãããã«èšèŒã®ããã«ãæäœããŸãã¯æåçµåæ§æçïŒäŸã¯ãCD117ïŒäŸã¯ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãèªèãããã³çµåããæäœããŸãã¯ãã®æåçµåæ§æçïŒã现èå·å®³æ§ååãšã³ã³ãžã¥ã²ãŒã·ã§ã³ãããããã«ã䜿çšããããšãã§ããã
ããã§çšããããçšèªããªã³ã«ãŒãã¯ãæäœãŸãã¯ãã®æçïŒAbïŒãæ¬é瀺ã®æäœ-è¬å€ã³ã³ãžã¥ã²ãŒãïŒADCsïŒAb-Z-L-DãåŒäžDã¯çŽ°èæ¯çŽ ã§ããïŒã圢æããããã«è¬ç©ã¢ã€ãšãã£ïŒDïŒã«å
±æçµåã§ä»çãããå
±æçµåãŸãã¯ååã®éãå«ãäºäŸ¡ã®ååŠçã¢ã€ãšãã£ãæå³ãããé©åãªãªã³ã«ãŒã¯äºã€ã®åå¿æ§æ«ç«¯ãäžæ¹ã¯æäœãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³çšãä»æ¹ã¯çŽ°èæ¯çŽ ãžã®ã³ã³ãžã¥ã²ãŒã·ã§ã³çšãæããããªã³ã«ãŒã®æäœã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿æ§æ«ç«¯ïŒåå¿æ§ã¢ã€ãšãã£ãZïŒã¯å
žåçã«ãæäœäžã®ã·ã¹ãã€ã³ããªãŒã«ãŸãã¯ãªãžã³ã¢ãã³åºãéããŠæäœã«ã³ã³ãžã¥ã²ãŒã·ã§ã³å¯èœãªéšäœã§ãããããã³ããã§å
žåçã«ã¯ãããªãŒã«åå¿åºãäŸãã°ãäºéçµåãªã©ã®ãããªãã®ïŒãã¬ã€ããã«ãããããã«ïŒããŸãã¯è±é¢åºãäŸã¯ãã¯ãããããã¢ããšãŒãããŸãã¯R-ã¹ã«ãã¡ãã«åºãªã©ã®ãããªãã®ããŸãã¯ã¢ãã³åå¿æ§åºãäŸãã°ãã«ã«ããã·ã«åºãªã©ã®ãããªãã®ã§ããïŒãã®äžæ¹ããªã³ã«ãŒã®æäœã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿æ§æ«ç«¯ã¯å
žåçã«ã现èæ¯çŽ äžã®å¡©åºæ§ã¢ãã³ãŸãã¯ã«ã«ããã·ã«åºãšã®ã¢ããçµåã®åœ¢æãéããŠçŽ°èæ¯çŽ ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³å¯èœãªéšäœã§ãããããã³ããã§å
žåçã«ã¯ãã«ã«ããã·ã«åºãŸãã¯å¡©åºæ§ã¢ãã³åºã§ãããçšèªããªã³ã«ãŒããã³ã³ãžã¥ã²ãŒã·ã§ã³åœ¢æ
ã«ããããªã³ã«ãŒã説æããéã«çšãããããšããåå¿æ§æ«ç«¯ã®äžæ¹ãŸãã¯åæ¹ã¯ãªã³ã«ãŒããã³/ãŸãã¯çŽ°èæ¯çŽ éããªãã³ã«ãªã³ã«ãŒããã³/ãŸãã¯æäœãããã¯ãã®æåçµåæ§æçéã®çµåã®åœ¢æã®ããã«ãäžååšã§ããïŒäŸãã°ãåå¿æ§ã¢ã€ãšãã£ZãååŠçã¢ã€ãšãã£Zã«å€æããããã®ãªã©ã®ãããªãã®ïŒãããŸãã¯äžå®å
šã§ããïŒäŸãã°ãã«ã«ãã³é
žã®ã«ã«ããã«ã ãã§ãããªã©ã®ãããªãã®ïŒããã®ãããªã³ã³ãžã¥ã²ãŒã·ã§ã³åå¿ã¯ããã«ãããŠä»¥äžã«ããã«èª¬æããã
æŠããŠãæ¬é瀺ã«é©ãããªã³ã«ãŒã¯åŸªç°ã«ãããŠå®è³ªå®å®ã§ãã£ãŠãããããæšç现èå
ãŸãã¯ãã®è¿åã§ã®çŽ°èæ¯çŽ ïŒäŸã¯ãããã«é瀺ããããããªã¢ãããã·ã³ïŒã®æŸåºã蚱容ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯äžå®ã®çŽ°èå
æ¡ä»¶äžã§éè£å¯èœã§ããããªã³ã«ãŒã®éè£ã¯çŽ°èå
ç°å¢ã«ãããŠæäœããã®è¬ç©ãŠããããæŸåºãåŸãããã«ãããããã«ä»ã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒåäœã¯éè£å¯èœã§ã¯ãªããããã³è¬ç©ã¯äŸãã°ãæäœã®å解ã«ãã£ãŠæŸåºããåŸãã倧æµã¯ãéè£å¯èœãªãªã³ã«ãŒã¯çççç°å¢ã«å¿çããŠéè£ããã1以äžã®å®èœåºãå«ããäŸãã°ãéè£å¯èœãªãªã³ã«ãŒã¯çŽ°èå
é
µçŽ ïŒäŸã¯ãã«ããã·ã³BïŒã®ååšäžã§å解ããé
µçŽ åºè³ªïŒäŸã¯ãããªã³-ã¢ã©ãã³ïŒã现èåºç»ã®é
žæ§ç°å¢ã§å解ããé
žå解æ§åºïŒäŸã¯ãããããŸã³ïŒhydrozoneïŒïŒããŸãã¯çŽ°èå
ã®éå
ç°å¢ã§å解ããéå
æ§åºïŒäŸã¯ããžã¹ã«ãã£ãïŒãå«ã¿åŸãã察ç
§çã«ïŒBy contastïŒã倧æµã¯ãééè£å¯èœãªã³ã«ãŒã¯æšç现èå
ã®ADCã®æäœã¢ã€ãšãã£ã®å解ïŒäŸã¯ããªãœãŸãŒã å解ïŒäžã«ADCããæŸåºããããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯æšç现èå€ã§å®è³ªå®å®ã§ããåŸãããã³çŽ°èå
ã§ããããã®æå¹ãªé床ã«ãŠéè£ããåŸããããããã®å®æœæ
æ§ã§ã¯ãæå¹ãªãªã³ã«ãŒã¯ä»¥äžã§ããåŸãïŒïŒiïŒæäœã®ç¹ç°ççµåç¹æ§ãç¶æãïŒïŒiiïŒã³ã³ãžã¥ã²ãŒããŸãã¯è¬ç©ã¢ã€ãšãã£ã®çŽ°èå
ããªããªãŒãå¯èœã«ãïŒïŒiiiïŒã³ã³ãžã¥ã²ãŒãããã®æšçãšãããéšäœã«éãããŸãã¯èŒžéããããŸã§ãå®å®ã§ããã³ç¡å·ã§ãå³ã¡ãéè£ãããªããŸãŸã§ããïŒããã³ïŒivïŒçŽ°èæ¯æ§ã现è殺å·å¹æãŸãã¯çŽ°èæ¯æ§ã¢ã€ãšãã£ã®çŽ°èåè£åæ¢å¹æãç¶æããããšã§ãããADCã®å®å®æ§ã¯æšæºçãªåææè¡ãäŸãã°ã質éåæãHPLCãããã³åé¢/åææè¡LC/MSãªã©ã®ãããªãã®ã«ãã£ãŠæž¬å®ããåŸããããããã®å®æœæ
æ§ã§ã¯ãæäœããã³è¬ç©ã¢ã€ãšãã£ã®å
±æçµåçä»çã¯ãªã³ã«ãŒã2ã€ã®åå¿æ§å®èœåºãæããããšãå³ã¡ãåå¿æ§ã®æå³ã§ã®äºäŸ¡æ§ãæããããšãå¿
èŠãšãããäºä»¥äžã®æ©èœçãŸãã¯çç©åŠçã«æŽ»æ§ãªã¢ã€ãšãã£ãäŸãã°ããããããæ žé
žãè¬ç©ãæ¯çŽ ãæäœããããã³ãããã³ã¬ããŒã¿ãŒåºãªã©ã®ãããªãã®ãä»çãããã®ã«æçšãªäºäŸ¡ã®ãªã³ã«ãŒè©Šè¬ãç¥ãããããã³ããããã®æ¹æ³ã¯ãããã®çµæãšããŠåŸãããã³ã³ãžã¥ã²ãŒããèšèŒãããŠããïŒHermansonïŒããŒãã³ãœã³ïŒ, G. T. (1996) Bioconjugate TechniquesïŒãã€ãªã³ã³ãžã¥ã²ãŒãæè¡ïŒïŒAcademic PressïŒã¢ã«ãããã¯ã»ãã¬ã¹ïŒ: New YorkïŒãã¥ãŒãšãŒã¯ïŒ, p.234-242ïŒã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒã¯äŸãšããŠãé
µçŽ çå æ°Žå解ãå
å解ãé
žæ§æ¡ä»¶äžã§ã®å æ°Žå解ãå¡©åºæ§æ¡ä»¶äžã§ã®å æ°Žå解ãé
žåããžã¹ã«ãã£ãéå
ãæ±æ žæ§éè£ããŸãã¯ææ©éå±éè£ã«ãã£ãŠéè£ããåŸããã®ãå«ãïŒäŸãã°ãLericheã, Bioorg. Med. Chem., 20:571-582, 2012ããã®é瀺ã¯å
±æçµåçã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ãããªã³ã«ãŒã«é¢ãããã®ãšããŠãåç
§ã«ããããã«çµã¿èŸŒãŸããïŒã
é
žæ§æ¡ä»¶äžã§å æ°Žå解å¯èœãªãªã³ã«ãŒã«ã¯äŸãã°ãããã©ãŸã³ãã»ãã«ã«ããŸã³ãããªã»ãã«ã«ããŸã³ãã·ã¹-ã¢ã³ãããã¢ããããªã«ããšã¹ãã«ãã¢ã»ã¿ãŒã«ãã±ã¿ãŒã«ããŸãã¯ãã®çš®ã®ä»ã®ãã®ãªã©ãå«ãŸãããïŒäŸã¯ãç±³åœç¹èš±ç¬¬5,122,368å·ïŒç¬¬5,824,805å·ïŒç¬¬5,622,929å·ïŒDubowchikïŒãã¥ããŠãã¯ïŒããã³WalkerïŒãŠã©ãŒã«ãŒïŒïŒ1999ïŒPharm. TherapeuticsïŒãã¡ãŒãã³ããžãŒïŒã»ã©ãã¥ãŒãã£ã¯ã¹ïŒ83:67-123ïŒNevilleïŒããŽã£ã«ïŒã, 1989ãBiol. Chem.ïŒã¶ã»ãžã£ãŒãã«ã»ãªãã»ãã€ãªããžã«ã«ã»ã±ãã¹ããªãŒïŒ264:14653-14661ããããã®åã
ã®é瀺ã¯ãããå
±æçµåçã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ãããªã³ã«ãŒã«é¢ãããã®ãšããŠãã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸããããã®ãããªãªã³ã«ãŒã¯äžæ§pHæ¡ä»¶ãäŸãã°ãè¡æ¶²ã«ããããã®ãªã©ã®ãããªãã®ã§ã¯æ¯èŒçå®å®ã§ããããpH5.5ãŸãã¯5.0æªæºãã©ã€ãœãŸãŒã ã®ããããã®pHã§ã¯äžå®å®ã§ããã
éå
æ¡ä»¶äžã§éè£å¯èœãªãªã³ã«ãŒã«ã¯äŸãã°ããžã¹ã«ãã£ããå«ãŸãããæ§ã
ãªãžã¹ã«ãã£ããªã³ã«ãŒãåœæè¡ã§ç¥ãããŠãããäŸãã°ãSATAïŒN-ã¹ã¯ã·ã³ã€ããžã«-S-ã¢ã»ãã«ããªã¢ã»ã¿ãŒãïŒãSPDPïŒN-ã¹ã¯ã·ã³ã€ããžã«-3-(2-ããªãžã«ãžããª)ããããªããŒãïŒãSPDBïŒN-ã¹ã¯ã·ã³ã€ããžã«-3-(2-ããªãžã«ãžããª)ããã©ãŒãïŒããã³SMPTïŒN-ã¹ã¯ã·ã³ã€ããžã«-ãªãã·ã«ã«ããã«-α-ã¡ãã«-α-(2-ããªãžã«ãžããª)ãã«ãšã³ïŒãçšããŠåœ¢æããããšãã§ãããã®ãå«ãŸããSPDBããã³SMPTïŒäŸã¯ãThorpeïŒãœãŒãïŒã, 1987ãCancer Res.47ïŒ5924-5931ïŒWawrzynczakïŒã¯ããžã³ãã£ã¯ïŒã, In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of CancerïŒã€ã ãã³ã³ãžã¥ã²ãŒãïŒã¬ã³ã®æŸå°ç·ç»åããã³çæ³ã«ãããæäœã³ã³ãžã¥ã²ãŒãã«ãããŠïŒïŒC. W. VogelïŒãŽã©ãŒã²ã«ïŒed., Oxford U. PressïŒãªãã¯ã¹ãã©ãŒã倧åŠãã¬ã¹ïŒ, 1987ãåç
§ïŒããŸããU.S. Pat. No. 4,880,935å·ãåç
§ããããã®åã
ã®é瀺ã¯ãããå
±æçµåçãªã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ãããªã³ã«ãŒã«é¢ãããã®ãšããŠãã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸããã
é
µçŽ çå æ°Žå解ã«æåæ§ããããªã³ã«ãŒã¯ãäŸã¯ãå¶éãããªããããªãœãœãŒã ãŸãã¯ãšã³ããœãŒã ãããã¢ãŒãŒãå«ãã现èå
ãããããŒãŒãŸãã¯ãããã¢ãŒãŒé
µçŽ ã«ãã£ãŠéè£ãããããããå«æãªã³ã«ãŒã§ããããšãã§ãããæ²»ççšè¬å€ã®çŽ°èå
ã¿ã³ãã¯è³ªå解æŸåºã䜿çšããããšã®1ã€ã®å©çã¯è¬å€ãã³ã³ãžã¥ã²ãŒãããããšå
žåçã«æžè¡°ããããã³ã³ã³ãžã¥ã²ãŒãã®è¡æž
å®å®æ§ãå
žåçã«é«ãããšã§ãããããããã®å®æœæ
æ§ã§ã¯ãããããžã«ãªã³ã«ãŒã¯å°ãªããšã2åã®ã¢ããé
žé·ãŸãã¯å°ãªããšã3åã®ã¢ããé
žé·ã§ãããæš¡ç¯çãªã¢ããé
žãªã³ã«ãŒã«ã¯ããžãããããããªãããããããã©ããããããŸãã¯ãã³ã¿ãããããå«ãŸããã奜é©ãªããããã®äŸã«ã¯ãã¢ããé
žãäŸãã°ãããªã³ãã¢ã©ãã³ãã·ãã«ãªã³ïŒCitïŒããã§ãã«ã¢ã©ãã³ããªãžã³ããã€ã·ã³ãããã³ã°ãªã·ã³ãªã©ã®ãããªãã®ãå«ããã®ãå«ãŸãããã¢ããé
žãªã³ã«ãŒæåãæ§æããã¢ããé
žæ®åºãšããŠã¯èªç¶ã«çºçãããã®ã®ä»ããã€ããŒãªã¢ããé
žããã³éèªç¶ã«çºçããã¢ããé
žé¡çžäœãäŸãã°ãã·ãã«ãªã³ãªã©ã®ãããªãã®ãå«ãŸãããæš¡ç¯çãªãžãããããšããŠã¯ããªã³-ã·ãã«ãªã³ïŒvcãŸãã¯val-citïŒããã³ã¢ã©ãã³-ãã§ãã«ã¢ã©ãã³ïŒafãŸãã¯ala-pheïŒãªã©ãå«ãŸãããæš¡ç¯çãªããªããããã«ã¯ãã°ãªã·ã³-ããªã³-ã·ãã«ãªã³ïŒgly-val-citïŒããã³ã°ãªã·ã³-ã°ãªã·ã³-ã°ãªã·ã³ïŒgly-gly-glyïŒãå«ãŸãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã«ã¯ããžãããããäŸãã°ãVal-CitãAla-ValããŸãã¯Phe-LysãVal-LysãAla-LysãPhe-CitãLeu-CitãIle-CitãPhe-ArgããŸãã¯Trp-Citãªã©ã®ãããªãã®ãå«ãŸããããžãããããäŸãã°ãVal-CitãŸãã¯Phe-Lysãªã©ã®ãããªãã®ãå«ããªã³ã«ãŒã¯äŸãã°ãç±³åœç¹èš±ç¬¬6ïŒ214ïŒ345å·ã«é瀺ãããŠããããã®é瀺ã¯ãããå
±æçµåçã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ãããªã³ã«ãŒã«é¢ãããã®ãšããŠãã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯Val-Alaããã³Val-Citããéžã°ãããžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããžããããã¯èªå·±å
ç«æ§ãªã³ã«ãŒãšçµã¿åãããŠçšããããã
ããã«èšèŒã®è¬ç©-æäœã³ã³ãžã¥ã²ãŒãã®åæã«é©ããè¿œå ã®ãªã³ã«ãŒã«ã¯ã1ïŒ6-è±é¢ããã»ã¹ïŒelimination processïŒã«ãã£ãŠçŽ°èæ¯çŽ ãæŸåºå¯èœãªãã®ïŒãèªå·±å
ç«æ§ãåºïŒãäŸãã°ãp-ã¢ãããã³ãžã«ã¢ã«ã³ãŒã«ïŒPABCïŒãp-ã¢ãããã³ãžã«ïŒPABïŒã6-ãã¬ã€ãããããµãé
žãpHæåæ§çé
žå¡©ããã³JainïŒãžã§ã€ã³ïŒã, Pharm. Res.ïŒãã¡ãŒãã¹ãŒãã£ã«ã«ã»ãªãµãŒãïŒ32:3526-3540, 2015ã«èšèŒããããã®ãªã©ã®ãããªãã®ãå«ãŸãããã®é瀺ã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯èªå·±ç ç²ã°ã«ãŒãïŒself-immolative groupïŒãäŸãã°ãåè¿°ã®PABãŸãã¯PABCïŒãã©ã¢ãããã³ãžã«ãªãã·ã«ã«ããã«ïŒãªã©ã®ãããªãã®ãå«ã¿ããããã¯äŸãã°ãCarlïŒã«ãŒã«ïŒã, J. Med. Chem.ïŒãžã£ãŒãã«ã»ãªãã»ã¡ãã£ã·ãã«ã»ã±ãã¹ããªãŒïŒ(1981) 24:479-480ïŒChakravartyïŒãã£ã¯ã©ãã«ãã£ãŒïŒã (1983) J. Med. Chem. 26:638-644ïŒUS 6214345ïŒUS20030130189ïŒUS20030096743ïŒUS6759509ïŒUS20040052793ïŒUS6218519ïŒUS6835807ïŒUS6268488ïŒUS20040018194ïŒWO98/13059ïŒUS20040052793ïŒUS6677435ïŒUS5621002ïŒUS20040121940ïŒWO2004/032828) ã«é瀺ãããããã®ããã»ã¹ãå¯èœãªä»ã®ååŠçã¢ã€ãšãã£ïŒãèªå·±ç ç²ãªã³ã«ãŒãïŒã«ã¯ãã¡ãã¬ã³ã«ã«ãããŒãããã³ãããã¢ãªãŒã«åºãäŸãã°ãã¢ãããã¢ãŸãŒã«ãã¢ããã€ãããŸãŒã«ãã¢ããããªããžã³ãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ã®ãããªãã®ãå«ãŸããããã®ãããªè€çŽ ç°åŒèªå·±ç ç²åºãå«ããªã³ã«ãŒã¯äŸãã°ãç±³åœç¹èš±åºé¡å
¬é第20160303254å·ããã³å第20150079114å·ããªãã³ã«ç±³åœç¹èš±ç¬¬7,754,681å·ïŒHayïŒãã€ïŒã, ïŒ1999ïŒBioorg. Med. Chem. Lett.ïŒãã€ãªãªãŒã¬ããã¯ïŒã¡ãã£ã·ãã«ã»ã±ãã¹ããªãŒã»ã¬ã¿ãŒãºïŒ9:2237ïŒUS 2005/0256030ïŒde GrootïŒãã»ãããŒãïŒã (2001) J. Org. Chem.ïŒã¶ã»ãžã£ãŒãã«ã»ãªãã»ãªãŒã¬ããã¯ã»ã±ãã¹ããªãŒïŒ66:8815-8830ïŒããã³US 7223837ã«é瀺ãããŠããã
ããã§ã®äœ¿çšã«é©ãããªã³ã«ãŒã¯C1-C6ã¢ã«ãã¬ã³ãC1-C6ãããã¢ã«ãã¬ã³ãC2-C6ã¢ã«ã±ãã¬ã³ãC2-C6ãããã¢ã«ã±ãã¬ã³ãC2-C6ã¢ã«ããã¬ã³ãC3-C6ã·ã¯ãã¢ã«ãã¬ã³ããããã·ã¯ãã¢ã«ãã¬ã³ãã¢ãªãŒã¬ã³ããããã¢ãªãŒã¬ã³ãããã³ãããã®çµåãããéžã°ãã1以äžã®åºãããã«å«ã¿åŸãåã
ã®ãããã¯éæã«çœ®æãããŠããŠãããããã®ãããªåºã®éå¶éçãªäŸãšããŠã¯(CH2)nã(CH2CH2O)nãããã³-(C=O)(CH2)n-åäœãå«ãŸããåŒäžnã¯åå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ããã1-6ããã®æŽæ°ã§ããã
奜é©ãªãªã³ã«ãŒã¯æº¶è§£æ§åäžç¹æ§ãæããåºãå«ã¿åŸãã (CH2CH2O)påäœïŒããªãšãã¬ã³ã°ãªã³ãŒã«ãPEGïŒãå«ããªã³ã«ãŒã¯äŸãã°ãã¢ãããã¹ã«ãã³é
žããã¹ãã³é
žãŸãã¯ãªã³é
žæ®åºã§çœ®æãããã¢ã«ãã«éã§ããããšãã§ããã®ãšåæ§ã«ã溶解æ§ãé«ããããšãã§ããããã®ãããªã¢ã€ãšãã£ãå«ããªã³ã«ãŒã¯ãäŸãã°ãç±³åœç¹èš±ç¬¬8,236,319å·ããã³ç¬¬9,504,756å·ã«é瀺ãããŠããããããã®åã
ã®é瀺ã¯ãããå
±æçµåçã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ãããªã³ã«ãŒã«é¢ãããã®ãšããŠããã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸããããããªã溶解æ§åäžåºã«ã¯ãäŸãã°ã次ã®æ§é ãæããã¢ã·ã«ããã³ã«ã«ãã¢ã€ã«ã¹ã«ãã¡ããåºãå«ãŸããïŒ
åŒäžaã¯0ãŸãã¯1ã§ããïŒããã³
R10ã¯æ°ŽçŽ ãC1-C24ã¢ã«ãã«åºãC3-C24ã·ã¯ãã¢ã«ãã«åºãC1-C24 (ããã)ã¢ãªãŒã«åºãC1-C24ã¢ã«ãã«(ããã)ã¢ãªãŒã«åºããã³C1-C24(ããã)ã¢ãªãŒã«ã¢ã«ãã«åºããã®C1-C24ã¢ã«ãã«åºãC3-C24ã·ã¯ãã¢ã«ãã«åºãC2-C24 (ããã)ã¢ãªãŒã«åºãC3-C24ã¢ã«ãã«(ããã)ã¢ãªãŒã«åºããã³C3-C24 (ããã)ã¢ãªãŒã«ã¢ã«ãã«åºãããªã矀ããéžã°ãããããã®åã ã¯OãSããã³NR11R12ããéžã°ãã1以äžã®ãããååã«ãã£ãŠéæã«çœ®æãããŠããããããã³/ãŸãã¯éæã«äžæãããŠããããããã§R11ããã³R12ã¯æ°ŽçŽ ããã³C1-C4ã¢ã«ãã«åºãããªã矀ããç¡é¢ä¿ã«éžã°ãïŒãŸãã¯R10ã¯çŽ°èæ¯çŽ ã§ãããããã§çŽ°èæ¯çŽ ã¯ã¹ããŒãµãŒã¢ã€ãšãã£ãä»ããŠNã«éæã«æ¥ç¶ãããŠããããã®ãããªåºãå«ããªã³ã«ãŒã¯äŸãã°ãç±³åœç¹èš±ç¬¬9,636,421å·ããã³ç±³åœç¹èš±åºé¡å ¬é第2017/0298145å·ã«èšèŒãããŠããããããã®é瀺ã¯ãããã现èæ¯çŽ ããã³æäœãŸãã¯ãã®æåçµåæ§æçãžã®å ±æçµåçã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ãããªã³ã«ãŒã«é¢ãããã®ãšããŠãåç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
R10ã¯æ°ŽçŽ ãC1-C24ã¢ã«ãã«åºãC3-C24ã·ã¯ãã¢ã«ãã«åºãC1-C24 (ããã)ã¢ãªãŒã«åºãC1-C24ã¢ã«ãã«(ããã)ã¢ãªãŒã«åºããã³C1-C24(ããã)ã¢ãªãŒã«ã¢ã«ãã«åºããã®C1-C24ã¢ã«ãã«åºãC3-C24ã·ã¯ãã¢ã«ãã«åºãC2-C24 (ããã)ã¢ãªãŒã«åºãC3-C24ã¢ã«ãã«(ããã)ã¢ãªãŒã«åºããã³C3-C24 (ããã)ã¢ãªãŒã«ã¢ã«ãã«åºãããªã矀ããéžã°ãããããã®åã ã¯OãSããã³NR11R12ããéžã°ãã1以äžã®ãããååã«ãã£ãŠéæã«çœ®æãããŠããããããã³/ãŸãã¯éæã«äžæãããŠããããããã§R11ããã³R12ã¯æ°ŽçŽ ããã³C1-C4ã¢ã«ãã«åºãããªã矀ããç¡é¢ä¿ã«éžã°ãïŒãŸãã¯R10ã¯çŽ°èæ¯çŽ ã§ãããããã§çŽ°èæ¯çŽ ã¯ã¹ããŒãµãŒã¢ã€ãšãã£ãä»ããŠNã«éæã«æ¥ç¶ãããŠããããã®ãããªåºãå«ããªã³ã«ãŒã¯äŸãã°ãç±³åœç¹èš±ç¬¬9,636,421å·ããã³ç±³åœç¹èš±åºé¡å ¬é第2017/0298145å·ã«èšèŒãããŠããããããã®é瀺ã¯ãããã现èæ¯çŽ ããã³æäœãŸãã¯ãã®æåçµåæ§æçãžã®å ±æçµåçã³ã³ãžã¥ã²ãŒã·ã§ã³ã«é©ãããªã³ã«ãŒã«é¢ãããã®ãšããŠãåç §ã«ãããã®å šäœãããã«çµã¿èŸŒãŸããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ããžãããããp-ã¢ãããã³ãžã«ïŒPABïŒåºãè€çŽ ç°èªå·±ç ç²åºãéæã«çœ®æãããC1-C6ã¢ã«ãã«ãéæã«çœ®æãããC1-C6ãããã¢ã«ãã«ãéæã«çœ®æãããC2-C6ã¢ã«ã±ãã«ãéæã«çœ®æãããC2-C6ãžããã¢ã«ã±ãã«ãéæã«çœ®æãããC2-C6ã¢ã«ããã«ãéæã«çœ®æãããC2-C6ãããã¢ã«ããã«ãéæã«çœ®æãããC3-C6ã·ã¯ãã¢ã«ãã«ãéæã«çœ®æããããããã·ã¯ãã¢ã«ãã«ãéæã«çœ®æãããã¢ãªãŒã«ãéæã«çœ®æããããããã¢ãªãŒã«ãã¢ã·ã«ã-(C=O)-ãŸãã¯-(CH2CH2O)n-åºã§åŒäžnã¯1-6ããã®æŽæ°ã§ãããã®ã®1以äžãå«ãŸãåŸããåœæè¡ã«ãããŠçç·Žã®è
ã§ããã°ãåæããåºã®1以äžãäºäŸ¡ïŒãžã©ãžã«ã«ïŒçš®ãäŸã¯ãC1-C6ã¢ã«ãã¬ã³ããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ã®åœ¢æ
ã§ååšããŠãããããšãèªèããã§ãããã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLã¯ã¢ã€ãšãã£*-L1L2-**ãå«ã¿ãåŒäžïŒ
L1ã¯ååšããªããããŸãã¯-(CH2)mNR13C(=O)-ã-(CH2)mNR13-ã-(CH2)mX3(CH2)m-ã
ã§ããïŒ
L2ã¯ååšããªããããŸãã¯-(CH2)m-ã-NR13(CH2)m-ã-(CH2)mNR13C(=O)(CH2)m-ã-X4ã-(CH2)mNR13C(=O)X4ã- (CH2)mNR13C(=O)-ã-((CH2)mO)n(CH2)m-ã-((CH2)mO)n(CH2)mX3(CH2)m-ã- NR13((CH2)mO)nX3(CH2)m-ã-NR13((CH2)mO)n(CH2)mX3(CH2)m-ã-X1X2C(=O)(CH2)m-ã- (CH2)m(O(CH2)m)n-ã-(CH2)mNR13(CH2)m-ã-(CH2)mNR13C(=O)(CH2)mX3(CH2)m-ã- (CH2)mC(=O)NR13(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)-ã- (CH2)mNR13(CH2)mC(=O)X2X1C(=O)-ã-(CH2)mX3(CH2)mC(=O)X2X1C(=O)-ã- (CH2)mC(=O)NR13(CH2)m-ã-(CH2)mC(=O)NR13(CH2)mX3(CH2)m-ã-(CH2)mX3(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mX3(CH2)mC(=O)NR13(CH2)m-ã- (CH2)mO)n(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)NR13(CH2)m(O(CH2)m)n-ã- (CH2)m(O(CH2)m)nC(=O)-ã-(CH2)mNR13(CH2)mC(=O)-ã -(CH2)mC(=O)NR13(CH2)mNR13C(=O)-ã-(CH2)m(O(CH2)m)nX3(CH2)m-ã- (CH2)mX3((CH2)mO)n(CH2)m-ã-(CH2)mX3(CH2)mC(=O)-ã- (CH2)mC(=O)NR13(CH2)mO)n(CH2)mX3(CH2)m-ã- (CH2)mX3(CH2)m(O(CH2)m)nNR13C(=O)(CH2)m-ã-(CH2)mX3(CH2)m(O(CH2)m)nC(=O)-ã-(CH2)mX3(CH2)m(O(CH2)m)n-ã-(CH2)mC(=O)NR13(CH2)mC(=O)-ã-(CH2)mC(=O)NR13(CH2)m(O(CH2)m)nC(=O)-ã-((CH2)mO)n(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)NR13(CH2)mC(=O)NR13(CH2)m-ã-(CH2)mNR13C(=O)(CH2)mNR13C(=O)(CH2) -(CH2)mX3(CH2)mC(=O)NR13-ã-(CH2)mC(=O)NR13-ã-(CH2)mX3-ã-C(R13)2(CH2)m-ã-(CH2)mC(R13)2NR13-ã-(CH2)mC(=O)NR13(CH2)mNR13-ã- (CH2)mC(=O)NR13(CH2)mNR13C(=O)NR13-ã-(CH2)mC(=O)X2X1C(=O)-ã- C(R13)2(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)NR13(CH2)mC(R13)2NR13-ã- C(R13)2(CH2)mX3(CH2)m-ã-(CH2)mX3(CH2)mC(R13)2NR13-ã-C(R13)2(CH2)mOC(=O)NR13(CH2)m-ã-(CH2)mNR13C(=O)O(CH2)mC(R13)2NR13-ã-(CH2)mX3(CH2)mNR13-ã-(CH2)mX3(CH2)m(O(CH2)m)nNR13-ã-(CH2)mNR13-ã-(CH2)mC(=O)NR13(CH2)m(O(CH2)m)nNR13-ã-(CH2)m(O(CH2)m)nNR13-ã-(CH2CH2O)n(CH2)m-ã-(CH2)m(OCH2CH2)n;-(CH2)mO(CH2)m-ã-(CH2)mS(=O)2-ã- (CH2)mC(=O)NR13(CH2)mS(=O)2-ã-(CH2)mX3(CH2)mS(=O)2-ã-(CH2)mX2X1C(=O)-ã-(CH2)m(O(CH2)m)nC(=O)X2X1C(=O)-ã-(CH2)m(O(CH2)m)nX2X1C(=O)-ã- (CH2)mX3(CH2)mX2X1C(=O)-ã-(CH2)mX3(CH2)m(O(CH2)m)nX2X1C(=O)-ã- (CH2)mX3(CH2)mC(=O)NR13(CH2)mNR13C(=O)-ã-(CH2)mX3(CH2)mC(=O)NR13(CH2)mC(=O)-ã-(CH2)mX3(CH2)mC(=O)NR13(CH2)m(O(CH2)m)nC(=O)-ã-(CH2)mC(=O)X2X1C(=O)NR13(CH2)m-ã-(CH2)mX3(O(CH2)m)nC(=O)-ã-(CH2)mNR13C(=O)((CH2)mO)n(CH2)m-ã-(CH2)m(O(CH2)m)nC(=O)NR13(CH2)m-ã-(CH2)mNR13C(=O)NR13(CH2)m-ãŸãã¯-(CH2)mX3(CH2)mNR13C(=O)-ã§ããïŒ
åŒäž
X1ã¯æ¬¡ã®ãã®ã§ãã
X2ã¯æ¬¡ã®ãã®ã§ãã
X3ã¯æ¬¡ã®ãã®
ã§ããïŒããã³
X4ã¯ä»¥äžã®
ã§ããïŒ
åŒäž
R13ã¯Hããã³C1-C6ã¢ã«ãã«ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
mã¯1ã2ã3ã4ã5ã6ã7ã8ã9ããã³10ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
nã¯1ã2ã3ã4ã5ã6ã7ã8ã9ã10ã11ã12ã13ããã³14ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒããã³
ããã§åäžã®ã¢ã¹ã¿ãªã¹ã¯ïŒ*ïŒã¯çŽ°èæ¯çŽ ïŒäŸã¯ãã¢ãããã·ã³ïŒãžã®ä»çç¹ãæã瀺ããäºéã¢ã¹ã¿ãªã¹ã¯ïŒ**ïŒã¯åå¿æ§çœ®æåºZ'ãŸãã¯ååŠçã¢ã€ãšãã£Zãžã®ä»çç¹ãæã瀺ãããã ãL1ããã³L2ãäž¡æ¹ãšããªãããã§ã¯ãªããšããæ¡ä»¶ãä»ãã
L1ã¯ååšããªããããŸãã¯-(CH2)mNR13C(=O)-ã-(CH2)mNR13-ã-(CH2)mX3(CH2)m-ã
L2ã¯ååšããªããããŸãã¯-(CH2)m-ã-NR13(CH2)m-ã-(CH2)mNR13C(=O)(CH2)m-ã-X4ã-(CH2)mNR13C(=O)X4ã- (CH2)mNR13C(=O)-ã-((CH2)mO)n(CH2)m-ã-((CH2)mO)n(CH2)mX3(CH2)m-ã- NR13((CH2)mO)nX3(CH2)m-ã-NR13((CH2)mO)n(CH2)mX3(CH2)m-ã-X1X2C(=O)(CH2)m-ã- (CH2)m(O(CH2)m)n-ã-(CH2)mNR13(CH2)m-ã-(CH2)mNR13C(=O)(CH2)mX3(CH2)m-ã- (CH2)mC(=O)NR13(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)-ã- (CH2)mNR13(CH2)mC(=O)X2X1C(=O)-ã-(CH2)mX3(CH2)mC(=O)X2X1C(=O)-ã- (CH2)mC(=O)NR13(CH2)m-ã-(CH2)mC(=O)NR13(CH2)mX3(CH2)m-ã-(CH2)mX3(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mX3(CH2)mC(=O)NR13(CH2)m-ã- (CH2)mO)n(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)NR13(CH2)m(O(CH2)m)n-ã- (CH2)m(O(CH2)m)nC(=O)-ã-(CH2)mNR13(CH2)mC(=O)-ã -(CH2)mC(=O)NR13(CH2)mNR13C(=O)-ã-(CH2)m(O(CH2)m)nX3(CH2)m-ã- (CH2)mX3((CH2)mO)n(CH2)m-ã-(CH2)mX3(CH2)mC(=O)-ã- (CH2)mC(=O)NR13(CH2)mO)n(CH2)mX3(CH2)m-ã- (CH2)mX3(CH2)m(O(CH2)m)nNR13C(=O)(CH2)m-ã-(CH2)mX3(CH2)m(O(CH2)m)nC(=O)-ã-(CH2)mX3(CH2)m(O(CH2)m)n-ã-(CH2)mC(=O)NR13(CH2)mC(=O)-ã-(CH2)mC(=O)NR13(CH2)m(O(CH2)m)nC(=O)-ã-((CH2)mO)n(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)NR13(CH2)mC(=O)NR13(CH2)m-ã-(CH2)mNR13C(=O)(CH2)mNR13C(=O)(CH2) -(CH2)mX3(CH2)mC(=O)NR13-ã-(CH2)mC(=O)NR13-ã-(CH2)mX3-ã-C(R13)2(CH2)m-ã-(CH2)mC(R13)2NR13-ã-(CH2)mC(=O)NR13(CH2)mNR13-ã- (CH2)mC(=O)NR13(CH2)mNR13C(=O)NR13-ã-(CH2)mC(=O)X2X1C(=O)-ã- C(R13)2(CH2)mNR13C(=O)(CH2)m-ã-(CH2)mC(=O)NR13(CH2)mC(R13)2NR13-ã- C(R13)2(CH2)mX3(CH2)m-ã-(CH2)mX3(CH2)mC(R13)2NR13-ã-C(R13)2(CH2)mOC(=O)NR13(CH2)m-ã-(CH2)mNR13C(=O)O(CH2)mC(R13)2NR13-ã-(CH2)mX3(CH2)mNR13-ã-(CH2)mX3(CH2)m(O(CH2)m)nNR13-ã-(CH2)mNR13-ã-(CH2)mC(=O)NR13(CH2)m(O(CH2)m)nNR13-ã-(CH2)m(O(CH2)m)nNR13-ã-(CH2CH2O)n(CH2)m-ã-(CH2)m(OCH2CH2)n;-(CH2)mO(CH2)m-ã-(CH2)mS(=O)2-ã- (CH2)mC(=O)NR13(CH2)mS(=O)2-ã-(CH2)mX3(CH2)mS(=O)2-ã-(CH2)mX2X1C(=O)-ã-(CH2)m(O(CH2)m)nC(=O)X2X1C(=O)-ã-(CH2)m(O(CH2)m)nX2X1C(=O)-ã- (CH2)mX3(CH2)mX2X1C(=O)-ã-(CH2)mX3(CH2)m(O(CH2)m)nX2X1C(=O)-ã- (CH2)mX3(CH2)mC(=O)NR13(CH2)mNR13C(=O)-ã-(CH2)mX3(CH2)mC(=O)NR13(CH2)mC(=O)-ã-(CH2)mX3(CH2)mC(=O)NR13(CH2)m(O(CH2)m)nC(=O)-ã-(CH2)mC(=O)X2X1C(=O)NR13(CH2)m-ã-(CH2)mX3(O(CH2)m)nC(=O)-ã-(CH2)mNR13C(=O)((CH2)mO)n(CH2)m-ã-(CH2)m(O(CH2)m)nC(=O)NR13(CH2)m-ã-(CH2)mNR13C(=O)NR13(CH2)m-ãŸãã¯-(CH2)mX3(CH2)mNR13C(=O)-ã§ããïŒ
åŒäž
X1ã¯æ¬¡ã®ãã®ã§ãã
X4ã¯ä»¥äžã®
åŒäž
R13ã¯Hããã³C1-C6ã¢ã«ãã«ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
mã¯1ã2ã3ã4ã5ã6ã7ã8ã9ããã³10ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
nã¯1ã2ã3ã4ã5ã6ã7ã8ã9ã10ã11ã12ã13ããã³14ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒããã³
ããã§åäžã®ã¢ã¹ã¿ãªã¹ã¯ïŒ*ïŒã¯çŽ°èæ¯çŽ ïŒäŸã¯ãã¢ãããã·ã³ïŒãžã®ä»çç¹ãæã瀺ããäºéã¢ã¹ã¿ãªã¹ã¯ïŒ**ïŒã¯åå¿æ§çœ®æåºZ'ãŸãã¯ååŠçã¢ã€ãšãã£Zãžã®ä»çç¹ãæã瀺ãããã ãL1ããã³L2ãäž¡æ¹ãšããªãããã§ã¯ãªããšããæ¡ä»¶ãä»ãã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒã¯p-ã¢ãããã³ãžã«åºïŒPABïŒãå«ããäžå®æœæ
æ§ã§ã¯ãp-ã¢ãããã³ãžã«åºã¯çŽ°èå·å®³æ§è¬ç©ããã³ãªã³ã«ãŒã«ããããããã¢ãŒãŒéè£éšäœéã«é
眮ããããäžå®æœæ
æ§ã§ã¯ãp-ã¢ãããã³ãžã«åºã¯p-ã¢ãããã³ãžã«ãªãã·ã«ã«ããã«åäœã®äžéšåã§ãããäžå®æœæ
æ§ã§ã¯ãp-ã¢ãããã³ãžã«åºã¯p-ã¢ãããã³ãžã«ã¢ããåäœã®äžéšåã§ããã
ããå®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯PABãVal-Cit-PABãVal-Ala-PABãVal-Lys(Ac)-PABãPhe-Lys-PABãPhe-Lys(Ac)-PABãD-Val-Leu-LysãGly-Gly-ArgãAla-Ala-Asn-PABããŸãã¯Ala-PABãå«ãã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ããããããªãªãŽç³ã-(CH2)n-ã-(CH2CH2O)n-ãPABãVal-Cit-PABãVal-Ala-PABãVal-Lys(Ac)-PABãPhe-Lys-PABãPhe-Lys(Ac)-PABãD-Val-Leu-LysãGly-Gly-ArgãAla-Ala-Asn-PABããŸãã¯Ala-PABã®1以äžã®çµåããå«ãã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒã¯-(C=O)(CH2)n-åäœãå«ã¿ãnã¯1-6ããã®æŽæ°ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãnã¯2ãã6ãŸã§ã®æŽæ°ã§ããã
ããå
·äœçãªå®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯æ¬¡ã®æ§é ãå«ã¿ïŒ
åŒäžãæ³¢ç·ã¯çŽ°èæ¯çŽ ããã³åå¿æ§ã¢ã€ãšãã£Zã«å¯Ÿããä»çç¹ãæã瀺ããå¥ã®å
·äœçãªå®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯æ¬¡ã®æ§é ãå«ã¿ïŒ
åŒäžãæ³¢ç·ã¯çŽ°èæ¯çŽ ããã³åå¿æ§ã¢ã€ãšãã£Zâ²ã«å¯Ÿããä»çç¹ãæã瀺ãããã®ãããªPAB-ãžãããã-ããããªãã«ãªã³ã«ãŒã¯äŸã¯ãç¹èš±åºé¡å
¬éçªå·WO2017/149077ã«é瀺ãããŠãããããã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸãããããã«ãWO2017/149077ã«é瀺ããã现èæ¯çŽ ã¯åç
§ã«ããããã«çµã¿èŸŒãŸããã
äžå®ã®å®æœæ
æ§ã§ã¯ãADCã®ãªã³ã«ãŒã¯ãã¬ã€ããã«ããã€ã«-Val-Ala-ãã©-ã¢ãããã³ãžã«(mc-Val-Ala-PABïŒã§ããã
äžå®ã®å®æœæ
æ§ã«ãããŠãADCã®ãªã³ã«ãŒã¯ãã¬ã€ããã«ããã€ã«-Val-Cit-ãã©-ã¢ãããã³ãžã«(mc-vc-PABïŒã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯MCC(4-[N-ãã¬ã€ããã¡ãã«]ã·ã¯ããããµã³-1-ã«ã«ããã·ã©ãŒãïŒãå«ãã
æäœããŸãã¯ãã®æåçµåæ§æçã现èå·å®³æ§è¬å€ã«ã³ã³ãžã¥ã²ãŒãããããã«äœ¿çšããããšãã§ãããªã³ã«ãŒã«ã¯ããªã³ã«ãŒã®äžç«¯ã«ãããŠçŽ°èå·å®³æ§è¬å€ã«å
±æçµåããããã³ãªã³ã«ãŒã®ä»ç«¯ã«ãããŠããªã³ã«ãŒäžã«ååšããåå¿æ§çœ®æåºãšCD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãçµåããæäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšããåå¿æ§çœ®æåºãšã®éã®ã«ãããªã³ã°åå¿ãã圢æãããååŠçã¢ã€ãšãã£ãå«ããã®ãå«ãŸãããCD117ïŒäŸãã°ãGNNK+CD117ãªã©ã®ãããªãã®ïŒãšçµåããæäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšãåŸãåå¿æ§çœ®æåºã«ã¯ãå¶éã䌎ããªãããã»ãªã³ãã¹ã¬ãªãã³ãããã³ããã·ã³æ®åºã®ããããã·ã«ã¢ã€ãšãã£ïŒãªãžã³æ®åºã®ã¢ããã¢ã€ãšãã£ïŒã¢ã¹ãã©ã®ã³é
žããã³ã°ã«ã¿ãã³é
žæ®åºã®ã«ã«ããã·ã«ã¢ã€ãšãã£ïŒãªãã³ã«ã·ã¹ãã€ã³æ®åºã®ããªãŒã«éšäœããªãã³ã«ãããã«ã®ã«ãã¢ãžããããã¢ãªãŒã«ïŒäŸã¯ããã«ãªãã¢ãªãŒã«ïŒããããããã¢ãªãŒã«ïŒäŸã¯ããã«ãªããããã¢ãªãŒã«ïŒãããã¢ã«ãã«ãããã³ãããããã¢ã«ãã«ã¢ã€ãšãã£ã®éèªç¶çºçã¢ããé
žãå«ãŸããã
è¬ç©-æäœã³ã³ãžã¥ã²ãŒãè€åäœïŒdrug-antibody conjugates conjugatesïŒã®åæã«æçšãªãªã³ã«ãŒã®äŸã«ã¯ã芪é»åç©è³ªãäŸãã°ããã€ã±ã«ã¢ã¯ã»ãã¿ãŒïŒäŸã¯ããã¬ã€ããïŒã掻æ§åãšã¹ãã«ãé»åäžè¶³ã«ã«ããã«ååç©ãããã³ã¢ã«ããããã»ãã«ãããããã®ãããªãã®ã§ãæäœãŸãã¯æåçµåæ§æçå
ã«ååšããæ±æ žæ§çœ®æåºãšã®åå¿ã«é©ãããã®ãäŸãã°ãã¢ãã³ããã³ããªãŒã«ã¢ã€ãšãã£ãªã©ã®ãããªãã®ãå«ããã®ãå«ãŸãããäŸãšããŠãè¬ç©-æäœã³ã³ãžã¥ã²ãŒãã®åæã«é©ãããªã³ã«ãŒã«ã¯ãå¶éã䌎ããã«ãã¹ã¯ã·ã³ã€ããžã«4-(N-ãã¬ã€ããã¡ãã«)-ã·ã¯ããããµã³-L-ã«ã«ããã·ã©ãŒãïŒSMCCïŒãN-ã¹ã¯ã·ã³ã€ããžã«ãšãŒãã¢ã»ã¿ãŒãïŒSIAïŒãã¹ã«ãSMCCãm-ãã¬ã€ãããã³ãŸã€ã«-N-ããããã·ã¹ã¯ã·ã³ã€ããžã«ãšã¹ãã«ïŒMBSïŒãã¹ã«ãMBSãããã³ã¹ã¯ã·ã³ã€ããžã«ãšãŒãã¢ã»ã¿ãŒããã»ãã«ãããããäŸãšããŠãLiuïŒãªã¥ãŒïŒãã18:690-697, 1979ã«èšèŒãããŠãããã®ãªã©ã®ãããªãã®ãå«ãŸãããã®é瀺ã¯ãããååŠçã³ã³ãžã¥ã²ãŒã·ã§ã³ã®ããã®ãªã³ã«ãŒã«é¢ãããã®ãšããŠåç
§ã«ããããã«çµã¿èŸŒãŸãããè¿œå çãªãªã³ã«ãŒã«ã¯ãéåæå¯èœãªãã¬ã€ããã«ããã€ã«ãªã³ã«ãŒãå«ãŸããããã¯åŸ®å°ç®¡ç Žå£æ§è¬å€ïŒmicrotubule-disrupting agentsïŒãäŸãã°ãã¢ãŠãªã¹ã¿ãã³ãªã©ã®ãããªãã®ã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«ç¹ã«æçšã§ãããDoroninaã, Bioconjugate Chem.ïŒãã€ãªã³ã³ãžã¥ã²ãŒãã»ã±ãã¹ããªãŒïŒ17:14-24, 2006ã«èšèŒãããŠããããã®é瀺ã¯ãããååŠçã³ã³ãžã¥ã²ãŒã·ã§ã³ã®ããã®ãªã³ã«ãŒã«é¢ãããã®ãšããŠåç
§ã«ããããã«çµã¿èŸŒãŸããã
ããã«é瀺ãããååŠçåºãã¢ã€ãšãã£ïŒã¢ã€ãšãã£ã¯åããããäžéšãäžéšåã®ããšãèšãïŒããã³ç¹é·ã®ä»»æã®äžä»¥äžã¯ãããã«é瀺ããããããªæäœããã³çŽ°èæ¯çŽ ã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«æçšãªãªã³ã«ãŒã圢æããããã«ããŸããŸãªæ¹æ³ã§çµã¿åããåŸãããšã¯åœæè¡ã«ãããŠçç·Žã®è
ã«ãã£ãŠèªèãããã§ããããããã«èšèŒãããçµæç©ããã³æ¹æ³ãšé¢é£ããŠæçšãªãããªããªã³ã«ãŒã¯äŸãã°ãç±³åœç¹èš±åºé¡å
¬é第2015/0218220å·ã«èšèŒãããŠããããã®é瀺ã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸããã
ããã«èšèŒãããæäœè¬ç©ãšé¢é£ããŠæçšãªãªã³ã«ãŒã«ã¯ãå¶éã䌎ããã«ã以äžã®è¡š1ã«æããããããªã«ãããªã³ã°åå¿ã«ãã£ãŠåœ¢æãããååŠçã¢ã€ãšãã£ãå«ããªã³ã«ãŒãå«ãŸãããæ²ç·ã¯æäœããŸãã¯æåçµåæ§æçãããã³çŽ°èå·å®³æ§ååãžã®ä»çç¹ãããããæå®ããã
åœæè¡ã«ãããŠçç·Žã®è
ã¯ããªã³ã«ãŒã«ä»çããåå¿æ§çœ®æåºZ'ããã³æäœãŸãã¯ãã®æåçµåæ§æçã§ã®åå¿æ§çœ®æåºãååŠçã¢ã€ãšãã£Zãçæããããã«å
±æçµåçã«ãããªã³ã°åå¿ã«ãããŠé¢äžããããã³åå¿æ§çœ®æåºZ'ãèªèããã§ãããããããã£ãŠãããã«èšèŒã®æ¹æ³ãšé¢é£ããŠæçšãªæäœè¬ç©ã³ã³ãžã¥ã²ãŒãã¯æäœããŸãã¯ãã®æåçµåæ§æçãšãããã«èšèŒã®ããã«ããªã³ã«ãŒãŸãã¯çŽ°èæ¯çŽ ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒããšã®åå¿ã«ãã£ãŠãååŠéšäœZã圢æãããããã«åœ¢æãããŠãããããã®ãªã³ã«ãŒãŸãã¯çŽ°èæ¯çŽ ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã¯æäœããŸãã¯ãã®æåçµåæ§æçäžã®åå¿æ§çœ®æåºãšã®åå¿ã«é©ããåå¿æ§çœ®æåºZ'ãå«ãã
ããããã®å®æœæ
æ§ã«ãããŠãZ'ã¯-NR13C(=O)CH=CH2ã-N3ã-SHã-S(=O)2(CH=CH2)ã-(CH2)2S(=O)2(CH=CH2)ã-NR13S(=O)2(CH=CH2)ã-NR13C(=O)CH2R14ã-NR13C(=O)CH2Brã-NR13C(=O)CH2Iã-NHC(=O)CH2Brã-NHC(=O)CH2Iã-ONH2ã-C(O)NHNH2ã-CO2Hã-NH2ã-NH(C=O)ã-NC(=S)ã
åŒäž
R13ã¯Hããã³C1-C6ã¢ã«ãã«ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
R14ã¯-S(CH2)nCHR15NHC(=O)R13ã§ããïŒ
R15ã¯R13ãŸãã¯-C(=O)OR13ã§ããïŒ
R16ã¯HãC1-C6ã¢ã«ãã«ãFãClãããã³-OHããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
R17ã¯HãC1-C6ã¢ã«ãã«ãFãClã-NH2ã-OCH3ã-OCH2CH3ã-N(CH3)2ã-CNã-NO2ããã³-OHããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒããã³
R18ã¯HãC1-C6ã¢ã«ãã«ãFã-C(=O)OHã«ãã眮æããããã³ãžã«ãªãã·ã-C(=O)OHã«ãã眮æããããã³ãžã«ã-C(=O)OHã«ãã眮æãããC1-C4ã¢ã«ã³ãã·ãããã³-C(=O)OHã«ãã眮æãããC1-C4ã¢ã«ãã«ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ããã
R13ã¯Hããã³C1-C6ã¢ã«ãã«ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
R14ã¯-S(CH2)nCHR15NHC(=O)R13ã§ããïŒ
R15ã¯R13ãŸãã¯-C(=O)OR13ã§ããïŒ
R16ã¯HãC1-C6ã¢ã«ãã«ãFãClãããã³-OHããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒ
R17ã¯HãC1-C6ã¢ã«ãã«ãFãClã-NH2ã-OCH3ã-OCH2CH3ã-N(CH3)2ã-CNã-NO2ããã³-OHããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ãïŒããã³
R18ã¯HãC1-C6ã¢ã«ãã«ãFã-C(=O)OHã«ãã眮æããããã³ãžã«ãªãã·ã-C(=O)OHã«ãã眮æããããã³ãžã«ã-C(=O)OHã«ãã眮æãããC1-C4ã¢ã«ã³ãã·ãããã³-C(=O)OHã«ãã眮æãããC1-C4ã¢ã«ãã«ããåå Žé¢ã«ã€ããŠç¡é¢ä¿ã«éžã°ããã
è¡š1ã«æãããããã«ããªã³ã«ãŒããã³æäœãŸãã¯ãã®æåçµåæ§æçäžã®å¥œé©ãªåå¿æ§çœ®æåºã®äŸã«ã¯ãæ±æ žå€/æ±é»åå€å¯ŸïŒäŸã¯ïŒããªãŒã«/ããã¢ã«ãã«å¯Ÿãã¢ãã³/ã«ã«ããã«å¯ŸããŸãã¯ããªãŒã«/αãβ-äžé£œåã«ã«ããã«å¯Ÿãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ïŒããžãšã³/æ±ãžãšã³äœå¯ŸïŒäŸã¯ãã¢ãžã/ã¢ã«ãã³å¯ŸããŸãã¯ãžãšã³/αãβ-äžé£œåã«ã«ããã«å¯Ÿãã»ãã«ããããïŒãããã³ãã®ä»åçš®é¡ã®ãã®ãªã©ãå«ãŸãããååŠçã¢ã€ãšãã£Zã圢æããããã®åå¿æ§çœ®æåºéã®ã«ãããªã³ã°åå¿ã«ã¯ãå¶éãããªãããããªãŒã«ã¢ã«ãã«åãããããã·ã«ã¢ã«ãã«åãã¢ãã³ã¢ã«ãã«åãã¢ãã³ãŸãã¯ããããã·ã«ã¢ãã³çž®åãããã©ãžã³åœ¢æãã¢ããåããšã¹ãã«åããžã¹ã«ãã£ã圢æãä»å ç°åïŒäŸã¯ã4+2ãã£ãŒã«ã¹-ã¢ã«ããŒä»å ç°åã3+2ãã¥ã¹ã²ã³ä»å ç°åãã»ãã«ããããïŒãæ±æ žæ§è³éŠæ眮æãæ±é»åæ§è³éŠæ眮æãããã³åœæè¡ã§ç¥ãããŠãããããŸãã¯ããã«èšèŒãããŠããä»ã®åå¿æ§æ§åŒãå«ãŸããããªãã¹ããªãããªã³ã«ãŒã¯æäœããŸãã¯ãã®æåçµåæ§æçã§ã®æ±æ žæ§å®èœåºãšã®åå¿ã®ããã®æ±é»åæ§å®èœåºãå«ãã
ããã«é瀺ãããããã«ãæäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšãåŸãåå¿æ§çœ®æåºã«ã¯ãå¶éãããªãããæ±æ žæ§åºãäŸãã°ãïŒiïŒNæ«ç«¯ã¢ãã³åºãïŒiiïŒåŽéã¢ãã³åºãäŸã¯ããªãžã³ãïŒiiiïŒåŽéããªãŒã«åºãäŸã¯ãã·ã¹ãã€ã³ãããã³ïŒivïŒæäœãã°ãªã³ã·ã«åãããç³ããããã·ã«åºãŸãã¯ã¢ããåºãªã©ã®ãããªãã®ãå«ãŸãããããã«é瀺ãããããã«ãæäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšãåŸãåå¿æ§çœ®æåºã«ã¯ãå¶éãããªãããã»ãªã³ãã¹ã¬ãªãã³ãããã³ããã·ã³æ®åºã®ããããã·ã«ã¢ã€ãšãã£ïŒãªãžã³æ®åºã®ã¢ããã¢ã€ãšãã£ïŒã¢ã¹ãã©ã®ã³é
žããã³ã°ã«ã¿ãã³é
žæ®åºã®ã«ã«ããã·ã«ã¢ã€ãšãã£ïŒããã³ã·ã¹ãã€ã³æ®åºã®ããªãŒã«ã¢ã€ãšãã£ããªãã³ã«ãããã«ã®ã«ãã¢ãžããããã¢ãªãŒã«ïŒäŸã¯ããã«ãªãã¢ãªãŒã«ïŒããããããã¢ãªãŒã«ïŒäŸã¯ããã«ãªããããã¢ãªãŒã«ïŒãããã¢ã«ãã«ãããã³ãããããã¢ã«ãã«ã¢ã€ãšãã£ã®éèªç¶çºçã¢ããé
žãå«ãŸãããããããã®å®æœæ
æ§ã§ã¯ãããã«é瀺ããããããªæäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšããåå¿æ§çœ®æåºã«ã¯ãã¢ãã³ãŸãã¯ããªãŒã«ã¢ã€ãšãã£ãå«ãŸãããããã§ãããäžå®ã®æäœã¯éå
å¯èœãªééãžã¹ã«ãã£ããå³ã¡ãã·ã¹ãã€ã³ããªããžãæãããæäœã¯éå
å€ãäŸãã°ãDTTïŒãžããªã¹ã¬ã€ããŒã«ïŒãªã©ã®ãããªãã®ã§åŠçããããšã«ãã£ãŠãªã³ã«ãŒè©Šè¬ãšã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«å¯ŸããŠåå¿æ§ã«ãåŸããåã·ã¹ãã€ã³ããªããžã¯ããããã«çè«çã«ã¯ã2ã€ã®åå¿æ§ããªãŒã«æ±æ žå€ã圢æããã§ããããè¿œå çãªæ±æ žæ§åºã¯ããªãžã³ãš2-ã€ããããªã©ã³ïŒãã©ãŠãè©Šè¬ïŒTraut's reagentïŒïŒã®åå¿ãéããŠæäœã«å°å
¥ãããããšãã§ããã¢ãã³ã®ããªãŒã«ãžã®å€æããããããããåå¿æ§ããªãŒã«åºã¯ã1ã2ã3ã4ããŸãã¯ããããããå€ãã®ã·ã¹ãã€ã³æ®åºãå°å
¥ããããšã«ãã£ãŠæäœïŒãŸãã¯ãã®æçïŒã«å°å
¥ãåŸãïŒäŸã¯ã1以äžã®éãã€ãã£ãã·ã¹ãã€ã³ã¢ããé
žæ®åºãå«ãå€çš®æäœã®èª¿è£œïŒãç±³åœç¹èš±ç¬¬7,521,541å·ã¯åå¿æ§ã·ã¹ãã€ã³ã¢ããé
žã®å°å
¥ã«ããæäœã®ãšã³ãžãã¢ãªã³ã°ãæ瀺ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã«ä»çããåå¿æ§ã¢ã€ãšãã£Zã¯æäœã«ãŠååšããæ±é»åæ§åºãšåå¿ããæ±æ žæ§åºã§ãããæäœã§ã®æçšãªæ±é»åæ§åºã«ã¯ãå¶éãããªãããã¢ã«ãããåºããã³ã±ãã³ã«ã«ããã«åºãå«ãŸãããæ±æ žæ§åºã®ãããååã¯æäœã§ã®æ±é»åæ§åºãšåå¿ããããã³æäœãšã®å
±æçµåã圢æããããšãã§ãããæçšãªæ±æ žæ§åºã«ã¯ãå¶éãããªãããããã©ãžãããªãã·ã ãã¢ãããããããã·ã«ãããã©ãžã³ãããªã»ãã«ã«ããŸã³ãããã©ãžã³ã«ã«ããã·ã©ãŒããããã³ã¢ãªãŒã«ããã©ãžããå«ãŸããã
ããããã®å®æœæ
æ§ã§ã¯ãZã¯æäœããŸãã¯ãã®æåçµåæ§æçå
ã«ååšããåå¿æ§æ±æ žæ§çœ®æåºãäŸãã°ãã¢ãã³ããã³ããªãŒã«ã¢ã€ãšãã£ãªã©ã®ãããªãã®ãšãåå¿æ§æ±é»åæ§çœ®æåºZãšã®éã®åå¿ã®çç£ç©ã§ãããäŸãšããŠãZã¯ããã€ã±ã«å容äœïŒäŸã¯ããã¬ã€ããïŒã掻æ§åãšã¹ãã«ãé»åäžè¶³ã«ã«ããã«ååç©ããŸãã¯ã¢ã«ããããã»ãã«ãããããã§ããåŸãã
ããããã®å®æœæ
æ§ã§ã¯ãADCã¯ããã«é瀺ããããããªåŒIIIãIIIAãIIIBããŸãã¯IIICã®ããããã®ã¢ãããã·ã³ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ããæCD117æäœãå«ã¿ããªã³ã«ãŒããã³ååŠçã¢ã€ãšãã£Zãä»ããŠãåã
ããã«é瀺ãããããã«ãåŒIãIAãIBãIIãIIAããŸãã¯IIBã®ããããã®ãªã³ã«ãŒ-ã¢ãããã·ã³ãŸãã¯æäœè¬ç©ã³ã³ãžã¥ã²ãŒãã圢æããããããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒã¯ããã©ãžã³ããžã¹ã«ãã£ããããªãšãŒãã«ãŸãã¯ãžãããããå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã«ã¯ãVal-Alaããã³Val-Citããéžã°ãããžãããããå«ãŸãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ãã©ã¢ãããã³ãžã«åºïŒPABïŒãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Cit-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯ã¢ã€ãšãã£PAB-Ala-Valãå«ããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((C=O)(CH2)n-åäœãå«ã¿ãåŒäžãnã¯1-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ããã
ããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-åäœãå«ã¿ãåŒäžnã¯2-6ããã®æŽæ°ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Cit-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-PAB-Ala-Val-((C=O)(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-(CH2)n-ã§ãããããããã®å®æœæ
æ§ã§ã¯ããªã³ã«ãŒã¯-((CH2)n-ã§ãããåŒäžnã¯6ã§ããã
ããããã®å®æœæ
æ§ã«ãããŠãååŠçã¢ã€ãšãã£Zã¯è¡š1ããéžã°ãããããããã®å®æœæ
æ§ã«ãããŠãååŠçéšåZã¯
ã§ããã
åŒäžãSã¯CD117ãšçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºã代衚ããç¡«é»ååã§ããïŒäŸã¯ãã·ã¹ãã€ã³æ®åºã®-SHåºããïŒã
åŒäžãSã¯CD117ãšçµåããæäœããŸãã¯ãã®æåçµåæ§æçå ã«ååšããåå¿æ§çœ®æåºã代衚ããç¡«é»ååã§ããïŒäŸã¯ãã·ã¹ãã€ã³æ®åºã®-SHåºããïŒã
ããããã®å®æœæ
æ§ã«ãããŠããªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£Zã¯L-ZãšããŠäžç·ã«èããŠã次ã®ãã®ã§ããã
åœæè¡ã«ãããŠçç·Žã®è
ã§ããã°ãæäœãŸãã¯ãã®æåçµåæ§æçãšã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«å
ç«ã¡ãªã³ã«ãŒåå¿æ§çœ®æåºæ§é ãåºZãšããŠãã¬ã€ãããå«ãããšãèªèããã§ããããããããã®å®æœæ
æ§ã§ã¯ãæäœãŸãã¯ãã®æåçµåæ§æçãšã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã«å
ç«ã¡ãªã³ã«ãŒåå¿æ§çœ®æåºæ§é L-Z'ã¯æ¬¡ã®ãã®ã§ãããïŒ
ããããã®å®æœæ
æ§ã«ãããŠãããã«é瀺ããããããªã¢ãããã·ã³ã¯ä»¥äžã®åŒãæãããªã³ã«ãŒåå¿æ§ã¢ã€ãšãã£-L-Zâ²ã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããïŒ
ããããã®å®æœæ
æ§ã«ãããŠãããã«é瀺ããããããªã¢ãããã·ã³ã¯ä»¥äžã®åŒãæãããªã³ã«ãŒåå¿æ§éšå-L-Zâ²ãšã³ã³ãžã¥ã²ãŒã·ã§ã³ãããïŒ
ããã«èšèŒã®çµæç©ããã³æ¹æ³ãšé¢é£ããŠæçšãªåè¿°ã®ãªã³ã«ãŒã¢ã€ãšãã£ããã³ã¢ãããã·ã³-ãªã³ã«ãŒã³ã³ãžã¥ã²ãŒãã¯ãã»ãã«ããããäŸãã°ãç±³åœç¹èš±åºé¡å
¬é第2015/0218220å·ããã³ç¹èš±åºé¡å
¬éçªå·WO2017/149077ã«èšèŒãããŠããããããã®åã
ã®é瀺ã¯åç
§ã«ãããã®å
šäœãããã«çµã¿èŸŒãŸããã
æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã®èª¿è£œ
æäœ-è¬ç©ã³ã³ãžã¥ã²ãŒãã®èª¿è£œ
ããã«é瀺ãããããªåŒIã®ADCsã«ãããŠãæCD117æäœãŸãã¯ãã®æåçµåæ§æçã¯ãããã«é瀺ãããããªãªã³ã«ãŒLããã³ååŠçã¢ã€ãšãã£ZãéããŠã1以äžã®çŽ°èå·å®³æ§è¬ç©ã¢ã€ãšãã£ïŒDïŒãäŸã¯ãæäœãããçŽ1ããçŽ20ãŸã§ã®è¬ç©ã¢ã€ãšãã£ã«ã³ã³ãžã¥ã²ãŒãããããæ¬é瀺ã®ADCsã¯åœæè¡ã«ãããŠçç·Žã®è
ã«æ¢ç¥ã®ææ©ååŠåå¿ãæ¡ä»¶ãããã³è©Šè¬ãæ¡çšããããã€ãã®çµè·¯ã«ãã£ãŠèª¿è£œãåŸãããããã«ã¯æ¬¡ã®ãã®ãå«ãŸããïŒïŒ1ïŒæäœãŸãã¯ãã®æåçµåæ§æçã®åå¿æ§çœ®æåºã®ãäžèšã®ããã«Ab-Z-Lã圢æããããã®äºäŸ¡ã®ãªã³ã«ãŒè©Šè¬ãšã®åå¿ã次ãã§è¬ç©ã¢ã€ãšãã£Dãšã®åå¿ïŒãŸãã¯ïŒ2ïŒè¬ç©ã¢ã€ãšãã£ã®åå¿æ§çœ®æåºã®ãD-L-Zã圢æããããã®äºäŸ¡ã®ãªã³ã«ãŒè©Šè¬ãšã®åå¿ã次ãã§åŒD-L-Z-Abã®ADCãäŸãã°ãAm-Z-L-Abãªã©ã®ãããªãã®ã圢æãããããã«äžèšã®ãããªæäœãŸãã¯ãã®æåçµåæ§æçã®åå¿æ§çœ®æåºãšã®åå¿ã§ãããADCã調補ããããã®è¿œå ã®æ¹æ³ã¯ããã«èšèŒããã
å¥ã®æ
æ§ã§ã¯ãæCD117æäœãŸãã¯ãã®æåçµåæ§æçã¯1以äžã®ã¹ã«ããããªã«åºãå°å
¥ããããã«ååŠçã«ä¿®é£Ÿããããšãã§ãã1以äžã®ãªãžã³æ®åºãæããã次ãã§ãADCã¯ããã«ãããŠäžè¿°ããããã«ãã¹ã«ããããªã«åºã®ç¡«é»ååãéããã³ã³ãžã¥ã²ãŒã·ã§ã³ã«ãã£ãŠåœ¢æãããããªãžã³ã修食ããããã«äœ¿çšããããšãã§ããè©Šè¬ã«ã¯ãå¶éãããªãããN-ã¹ã¯ã·ã³ã€ããžã«S-ã¢ã»ãã«ããªã¢ã»ã¿ãŒãïŒSATAïŒããã³å¡©é
ž2-ã€ããããªã©ã³ïŒãã©ãŠãè©Šè¬ïŒãå«ãŸããã
å¥ã®æ
æ§ã§ã¯ãæCD117æäœãŸãã¯ãã®æåçµåæ§æçã¯1以äžã®ã¹ã«ããããªã«åºãæããããã«ååŠçã«ä¿®é£Ÿãããããšãã§ãã1以äžã®çæ°Žåç©åºãæããããšãã§ããã次ãã§ãADCã¯ããã«ãããŠäžè¿°ããããã«ãã¹ã«ããããªã«åºã®ç¡«é»ååãéããã³ã³ãžã¥ã²ãŒã·ã§ã³ã«ãã£ãŠåœ¢æãããã
ããã«å¥ã®æ
æ§ã§ã¯ãæCD117æäœã¯ã¢ã«ãããïŒ-CHOïŒåºãæäŸããããã«é
žåãããããšãã§ãã1以äžã®çæ°Žåç©åºãæããããšãã§ããïŒäŸã¯ãLaguzzaïŒã©ã°ã¶ïŒããJ. Med. Chem. 1989, 32(3), 548-55ã«ã€ããŠåç
§ïŒã次ãã§ãADCã¯ããã«ãããŠäžè¿°ããããã«ã察å¿ããã¢ã«ããããéããã³ã³ãžã¥ã²ãŒã·ã§ã³ã«ãã£ãŠåœ¢æãããã现èæ¯çŽ ã®ä»çãŸãã¯é¢é£ã«ã€ããŠã®ã¿ã³ãã¯è³ªã®ä¿®é£Ÿã®ããã®ä»ã®ãããã³ã«ã¯ColiganïŒã³ãªã¬ã³ïŒã, Current Protocols in Protein ScienceïŒã¿ã³ãã¯è³ªç§åŠã«ãããã«ã¬ã³ããããã³ã«ãºïŒãvol. 2, John Wiley & SonsïŒãžã§ã³ã»ã¯ã€ãªãŒã»ã¢ã³ãã»ãµã³ãºç€ŸïŒ(2002)ã«èšèŒãããŠãããåç
§ã«ããããã«çµã¿èŸŒãŸããã
现èæšçã¿ã³ãã¯è³ªãäŸãã°ãæäœãå
ç«ã°ãããªã³ãŸãã¯ãããã®æçãªã©ã®ãããªãã®ãžã®ãªã³ã«ãŒè¬ç©ã¢ã€ãšãã£ã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã®ããã®æ¹æ³ã¯äŸãã°ãç±³åœç¹èš±ç¬¬5,208,020å·ïŒç±³åœç¹èš±6,441,163å·ïŒWO2005037992ïŒWO2005081711ïŒããã³WO2006/034488ã«èšèŒãããŠããããããã®ãã¹ãŠã¯åç
§ã«ãããã®å
šäœãããã«æ瀺çã«çµã¿èŸŒãŸããã
ãããã¯ãŸããæCD117æäœãšçŽ°èå·å®³æ§è¬å€ãããªãèåã¿ã³ãã¯è³ªã¯ãäŸã¯ãçµæãæè¡ãŸãã¯ããããåæã«ãã£ãŠäœæãåŸããDNAã®é·ãã¯ã³ã³ãžã¥ã²ãŒãã®2ã€ã®éšåãã³ãŒãããããããã®é åãäºãã«é£æ¥ãããŸãã¯ã³ã³ãžã¥ã²ãŒãã®æãŸããç¹æ§ãç Žå£ããªããªã³ã«ãŒãããããã³ãŒãããé åã«ãã£ãŠåãããããã®ããããã§ãå«ãŸãåŸãã
åŠçœ®ã®æ¹æ³
åŠçœ®ã®æ¹æ³
ããã«èšèŒãããããã«ãé è¡å¹¹çŽ°è移æ€çæ³ã¯1以äžã®è¡æ¶²çŽ°èåãéåïŒpopulateïŒãŸãã¯åå¢æ®ããïŒre-populateïŒããã«ãåŠçœ®ãå¿
èŠãªå¯Ÿè±¡ã«æœãããšãã§ãããé è¡å¹¹çŽ°èã¯æŠããŠå€èœæ§ãèŠããããã³ãããããå€æ§ãªç°ãªãè¡æ¶²ç³»çµ±ã«ååããããšãã§ããå¶éãããªãããé¡ç²çïŒäŸã¯ãå骚é«çã奜äžçã奜é
žçã奜塩åºçïŒãèµ€è¡çïŒäŸã¯ã網ç¶èµ€è¡çãèµ€è¡çïŒãæ çïŒäŸã¯ãå·šæ žèœçãè¡å°æ¿ç£çå·šæ žçãè¡å°æ¿ïŒãåçïŒäŸã¯ãåçããã¯ããã¡ãŒãžïŒãæš¹ç¶çŽ°èããã¯ãã°ãªã¢çŽ°èãç ŽéªšçŽ°èãããã³ãªã³ãçïŒäŸã¯ãNK现èãB现èããã³T现èïŒãå«ãŸãããé è¡å¹¹çŽ°èã¯è¿œå çã«èªå·±åçã®èœåããããããã³ããããã«æ¯çŽ°èãšåçã®èœåãæããåšçŽ°èãçã¿åºãããšãã§ããããã³ãŸã移æ€ã¬ã·ããšã³ãã«åå°å
¥ãããèœåãç¹è²ãšãããã®ããã§ãããã¯é è¡å¹¹çŽ°èãããã«åž°å·£ããããã³çç£çã§ããã³æç¶çãªé è¡ãå確ç«ããã
ãã®ããã«ãé è¡å¹¹çŽ°èã¯é è¡ç³»çµ±ã®1以äžã®çŽ°èåã«ãããŠæ¬ æãããŸãã¯æ¬ ä¹æ§ããããã€ã·ã§ã³ãã«å¯ŸããŠãæ¬ æãããŸãã¯æ¬ ä¹æ§ã®çŽ°èã®éå£ãã€ã³ããã§åæ§æããããã«æœãããšãã§ããããã«ãã£ãŠå
å æ§è¡æ¶²çŽ°èéå£ã«ãããæ¬ æãŸãã¯æ¶èã«é¢ä¿ããç
ç¶ãåŠçœ®ããããããããã«ãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯ãéæªæ§ç°åžžãã¢ã°ããã³çïŒäŸã¯ãéç¶èµ€è¡ç貧è¡ããµã©ã»ãã¢ããã¡ã³ã³ããŒè²§è¡ãåçäžè¯æ§è²§è¡ãããã³ãŠã£ã¹ã³ãã-ã¢ã«ããªããçå矀ãããªã矀ããéžã°ããç°åžžãã¢ã°ããã³çïŒãåŠçœ®ããããã«çšããããšãã§ãããè¿œå çã«ãŸãã¯ä»£æ¿çã«ãããã«èšèŒã®çµæç©ãŸãã¯æ¹æ³ã¯ãå
ç«äžå
šãäŸãã°ãå
倩æ§å
ç«äžå
šãªã©ã®ãããªãã®ãåŠçœ®ããããã«çšããããšãã§ãããè¿œå çã«ãŸãã¯ä»£æ¿çã«ãããã«èšèŒã®çµæç©ãŸãã¯æ¹æ³ã¯ãåŸå€©æ§å
ç«äžå
šïŒäŸã¯ãHIVããã³AIDSãããªã矀ããéžã°ããåŸå€©æ§å
ç«äžå
šïŒãåŠçœ®ããããã«çšããããšãã§ãããããã«èšèŒã®çµæç©ãŸãã¯æ¹æ³ã¯ã代è¬é害ïŒäŸã¯ãç³åç
ãã ã³å€ç³çããŽãŒã·ã§ç
ãããŒã©ãŒç
ãã¹ãã£ã³ãŽãªããçãããã³ç°ææ§çœè³ªãžã¹ãããã£ãŒãããªã矀ããéžã°ãã代è¬é害ïŒãåŠçœ®ããããã«çšããããšãã§ããã
è¿œå çã«ãŸãã¯ä»£æ¿çã«ãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯æªæ§è
«çãŸãã¯å¢æ®æ§çŸæ£ãäŸãã°ãè¡æ¶²ã¬ã³ã骚é«å¢æ®æ§çŸæ£ãªã©ã®ãããªãã®ãåŠçœ®ããããã«äœ¿çšããããšãã§ãããã¬ã³åŠçœ®ã®å Žåãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯ãé è¡å¹¹çŽ°è移æ€çæ³ã«å
ç«ã¡å
å æ§é è¡å¹¹çŽ°èã®éå£ãæžå°ãããããã«ããã€ã·ã§ã³ãã«æœããŠããããã®å Žåã移æ€çŽ°èã¯å
å æ§çŽ°èæžå°ã¹ãããã«ãã£ãŠäœãåºããããããã«åž°å·£ããããã³çç£çé è¡ã確ç«ããããšãå¯èœã§ããããã®å Žåã移æ€ããã现èã¯å
å æ§çŽ°èé€å»ã®éçšã§çãããããã«å®çããçç£çãªé è¡ã確ç«ããããšãã§ããããã®ããšã¯æ¬¡ã«ãã¬ã³çŽ°èæ ¹çµ¶ã®éãäŸãã°ãå
šèº«ååŠçæ³éãªã©ã®ãããªãã®ã§æžå°ãã现èéå£ãåã³æ§æããããšãã§ãããããã«ïŒheeinïŒèšèŒã®çµæç©ããã³æ¹æ³ãçšããŠåŠçœ®ããããšãã§ããæš¡ç¯çãªè¡æ¶²åŠçã¬ã³ã«ã¯ãå¶éãããªãããæ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«ãããã³éããžãã³ãªã³ãè
«ããªãã³ã«ç¥çµèœè
«ãå«ããŠä»ã®ã¬ã³æ§ç
æ
ãå«ãŸããã
ããã«èšèŒã®çµæç©ããã³æ¹æ³ã«ããåŠçœ®ããããšãã§ããè¿œå çãªçŸæ£ã«ã¯ãå¶éãããªãããã¢ããã·ã³ãã¢ãããŒãŒæ¬ æçããã³éçè€åå
ç«äžå
šãé«å
ç«ã°ãããªã³Mçå矀ããã§ãã£ã¢ãã¯-æ±ç
ãéºäŒæ§ãªã³ãçµç¹ççã倧çç³éªšç
ã骚圢æäžå
šãèç©çããµã©ã»ãã¢ã¡ãžã£ãŒãå
šèº«æ§ç¡¬åçãå
šèº«æ§ãšãªããããŒãã¹ãå€çºæ§ç¡¬åçãããã³è¥å¹Žæ§é¢ç¯ãªã¥ãŠãããå«ãŸããã
ããã«èšèŒã®æCD117æäœããã®æåçµåæ§æçãããã³ã³ã³ãžã¥ã²ãŒãïŒå³ã¡ãADCsïŒã¯åºåœ¢åšå®ç§»æ€å¯å®¹ïŒsolid organ transplant toleranceïŒãèªå°ããããã«äœ¿çšããããšãã§ãããäŸãšããŠãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯æšççµç¹ãã现èã®éå£ãæžå°ãããããŸãã¯åé€ããããã«ïŒäŸã¯ã骚é«å¹¹çŽ°èãããããé è¡å¹¹çŽ°èãæžå°ãããããã«ïŒäœ¿çšããåŸããæšççµç¹ããã®çŽ°èã®ãã®ãããªæžå°ã«ç¶ããŠãåšå®ãããŒããã®å¹¹çŽ°èãŸãã¯åé§çŽ°èã®éå£ïŒäŸã¯ãåšå®ãããŒããã®é è¡å¹¹çŽ°èïŒã¯ç§»æ€ã¬ã·ããšã³ãã«æœããåŸãããã³æ¬¡ãã§ãã®ãããªå¹¹çŽ°èãŸãã¯åé§çŽ°èã®ççã«ç¶ããŠãäžæçãŸãã¯å®å®ããæ··åãã¡ã©ãéæãããããã«ãã£ãŠããããªãå
ç«æå¶æ§è¬å€ã«ã€ããŠã®å¿
èŠæ§ãªãé·æã®ç§»æ€åšå®èæ§ãå¯èœã«ãåŸããäŸãã°ãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯åºåœ¢åšå®ç§»æ€ã¬ã·ããšã³ãã«ããã移æ€èæ§ãèªå°ããããã«äœ¿çšããåŸãïŒäŸã¯ãè
è移æ€ãèºç§»æ€ãèè移æ€ãããã³å¿è移æ€ãã»ãã«ããããïŒãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯ãäŸãšããŠã移æ€ãããåšå®ã®é·æçãªå¯å®¹ãèªå°ããããã«ã¯ãäœãå²åã®äžæçãŸãã¯å®å®ãããããŒççã§ååã§ãããããåºåœ¢åšå®ç§»æ€å¯å®¹ã®èªå°ã«é¢é£ããŠäœ¿çšããã®ã«ããé©ããŠããã
å ããŠãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯ãã¬ã³ãçŽæ¥ãäŸãã°ãCD117+ã§ãã现èã«ãã£ãŠç¹åŸŽä»ããããã¬ã³ãªã©ã®ãããªãã®ãåŠçœ®ããããã«äœ¿çšããããšãã§ãããäŸãšããŠãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯ãçœè¡ç
åŠçœ®ãããç¹ã«CD117+çœè¡ç
现èãèŠãããã€ã·ã§ã³ãã«ãããŠè¡ãããã«äœ¿çšããããšãã§ãããCD117+ã¬ã³çŽ°èãäŸãã°ãçœè¡ç
现èãªã©ã®ãããªãã®ãæžå°ãããããšã«ãã£ãŠãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯ãçš®ã
ã®ã¬ã³ãçŽæ¥åŠçœ®ããããã«äœ¿çšããããšãã§ããããã®ä»æ¹ã«ãããŠåŠçœ®ããåŸãæš¡ç¯çãªã¬ã³ã«ã¯ãè¡æ¶²åŠçã¬ã³ãäŸãã°ãæ¥æ§éªšé«æ§çœè¡ç
ãæ¥æ§ãªã³ãæ§çœè¡ç
ãæ
¢æ§éªšé«æ§çœè¡ç
ãæ
¢æ§ãªã³ãæ§çœè¡ç
ãå€çºæ§éªšé«è
«ãã³ãŸãæ§å€§çŽ°èåB现èãªã³ãè
«ãããã³éããžãã³ãªã³ãè
«ãªã©ã®ãããªãã®ãå«ãŸããã
æ¥æ§éªšé«æ§çœè¡ç
ïŒAMLïŒã¯éªšé«ç³»ã®è¡æ¶²çŽ°èã®ã¬ã³ã§ããã骚é«ã«éãŸãããã³æ£åžžãªè¡æ¶²çŽ°èã®çç£ã劚ããç°åžžãªçœè¡çãæ¥éã«å¢æ®ããããšã«ãã£ãŠç¹åŸŽä»ãããããAMLã¯æ人ã«åœ±é¿ããæãæ®éã®æ¥æ§çœè¡ç
ã§ãããããã³ãã®çºççã¯å¹Žéœ¢ãšãšãã«å¢å ãããAMLã®çç¶ã¯æ£åžžãªéªšé«ãçœè¡ç
现èãšçœ®ãæããããšã«ãã£ãŠåŒãèµ·ãããããããèµ€è¡çãè¡å°æ¿ãããã³æ£åžžãªçœè¡çã«ãããäœäžãèµ·ãããæ¥æ§çœè¡ç
ãšããŠãAMLã¯æ¥éã«é²è¡ããããã³åŠçœ®ããã«æŸçœ®ãããšæ°é±éãŸãã¯æ°ãæå
ã§èŽåœçãšãªãåŸããäžå®æœæ
æ§ã§ã¯ãããã«èšèŒã®æCD117 ADCsã¯ãã®å¿
èŠããããããã€ã·ã§ã³ãã«ãããŠAMLãåŠçœ®ããããã«çšãããããäžå®ã®å®æœæ
æ§ã§ã¯ãæCD117 ADCåŠçœ®ã¯åŠçœ®ããã察象ã«ãããŠAML现èãæžå°ããããããããã®å®æœæ
æ§ã§ã¯ãçŽ50ïŒ
以äžã®AML现èã¯æžå°ãããä»ã®å®æœæ
æ§ã§ã¯ãçŽ60ïŒ
以äžã®AML现èãæžå°ãããŸãã¯çŽ70ïŒ
以äžã®AML现èãæžå°ãããŸãã¯çŽ80ïŒ
以äžè¥ããã¯çŽ90ïŒ
以äžããŸãã¯çŽ95ïŒ
以äžã®AML现èãæžå°ãããäžå®ã®å®æœæ
æ§ã§ã¯ãæCD117 ADCåŠçœ®ã¯åäžçšéåŠçœ®ã§ãããäžå®ã®å®æœæ
æ§ã§ã¯ãåäžçšéã®æCD117 ADCåŠçœ®ã¯AML现èã®çŽ60ïŒ
ãçŽ70ïŒ
ãçŽ80ïŒ
ãçŽ90ïŒ
ãçŽ95ïŒ
ããŸãã¯ããããããå€ããæžå°ãããã
å ããŠãããã«èšèŒãããçµæç©ããã³æ¹æ³ã¯èªå·±å
ç«çŸæ£ãåŠçœ®ããããã«äœ¿çšããããšãã§ãããäŸãšããŠãæCD117æäœãŸãã¯ãã®æåçµåæ§æçã¯CD117+å
ç«çŽ°èã殺ãããã«ã察象ãäŸãã°ãèªå·±å
ç«é害ãæ£ã£ãŠãããããã€ã·ã§ã³ããªã©ã®ãããªãã®ã«æœãããšãã§ãããCD117+å
ç«çŽ°èã¯èªå·±åå¿æ§ãªã³ãçãäŸãã°ãèªå·±æåãšç¹ç°çã«çµåããããã³èªå·±æåã«å¯Ÿããå
ç«å¿çãããŠã³ãããT现èå容äœãçºçŸããT现èãªã©ã®ãããªãã®ã§ããåŸããèªå·±åå¿æ§ãCD117+现èãæžå°ãããããšã«ãã£ãŠãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯èªå·±å
ç«ç
æ
ãäŸãã°ã以äžã«èšèŒããããã®ãªã©ã®ãããªãã®ãåŠçœ®ããããã«äœ¿çšããããšãã§ãããå ããŠãŸãã¯ä»£æ¿çã«ãããã«èšèŒã®çµæç©ããã³æ¹æ³ã¯ãé è¡å¹¹çŽ°è移æ€çæ³ã®åã«å
å æ§é è¡å¹¹çŽ°èã®éå£ãæžå°ãããããšã«ãã£ãŠèªå·±å
ç«çŸæ£ãåŠçœ®ããããã«äœ¿çšããããšãã§ãããã®å Žåã移æ€ããã现èã¯å
å æ§çŽ°èæžå°ã¹ãããã«ãã£ãŠäœãåºããããããã«åž°å·£ããããã³çç£çé è¡ã確ç«ããããšãã§ããããã®ããšã¯æ¬¡ã«ãèªå·±å
ç«çŽ°èã®æ ¹çµ¶ã®éã«æžå°ãã现èéå£ãåã³æ§æããããšãã§ããã
ããã«èšèŒã®çµæç©ããã³æ¹æ³ãçšããŠåŠçœ®ããããšãã§ããèªå·±å
ç«çŸæ£ã«ã¯ãå¶éãããªããã也ç¬ã也ç¬æ§é¢ç¯çã1åçæ§ç³å°¿ç
ïŒ1åç³å°¿ç
ïŒãé¢ç¯ãªãŠããïŒRAïŒãããå
šèº«æ§ãšãªããããŒãã¹ïŒSLEïŒãå€çºæ§ç¡¬åçïŒMSïŒãççæ§è
žçŸæ£ïŒIBDïŒããªã³ãçæ§å€§è
žçãæ¥æ§æ£åšæ§è³èé«çïŒADEMïŒãã¢ãžãœã³ç
ïŒAddison's diseaseïŒãæ±çºæ§è±æ¯çã匷çŽæ§èæ€çïŒankylosing spondylitisisïŒãæãªã³è質æäœçå矀ïŒAPSïŒãåçäžè¯æ§è²§è¡ãèªå·±å
ç«æ§æº¶è¡æ§è²§è¡ãèªå·±å
ç«æ§èçãèªå·±å
ç«æ§å
è³çŸæ£ïŒAIEDïŒãèªå·±å
ç«æ§ãªã³ãå¢æ®çå矀ïŒautoimmune Iymphoproliferative syndromeïŒïŒALPSïŒãèªå·±å
ç«æ§åµå·£çïŒautoimmune oophoritisïŒããããŒç
ïŒBalo diseaseïŒãããŒãã§ããç
ïŒBehcet's diseaseïŒãæ°Žç±æ§é¡å€©ç±ç¡ãå¿ççãã·ã£ã¬ã¹ç
ïŒChagas' diseaseïŒãæ
¢æ§ç²åŽå
ç«æ©èœäžå
šçå矀ïŒchronic fatigue immune dysfunction syndromeïŒïŒCFIDSïŒãæ
¢æ§ççæ§è±é«æ§å€çºãã¥ãŒããããŒãã¯ããŒã³ç
ãç¢çæ§é¡å€©ç±ç¡ïŒcicatrical pemphigoidïŒãã»ãªã¢ãã¯ã¹ãã«ãŒç±ç¹ç¶ç®èçïŒcoeliac sprue-dermatitis herpetiformisïŒãå¯å·åéçŽ ç
ãã¯ã¬ã¹ãçå矀ïŒCREST syndromeïŒãããŽã¹ç
ïŒDegos diseaseïŒãåæ¿ç¶ãšãªããããŒãã¹ïŒdiscoid lupusïŒãèªåŸç¥çµé害ãåå®®å
èçãæ¬æ
æ§æ··ååã¯ãªãªã°ãããªã³è¡çïŒessential mixed cryoglobulinemiaïŒãç·ç¶ççç-ç·ç¶ççïŒfibromyalgia-fibromyositisïŒãã°ãããã¹ãã£ãŒçå矀ãã°ã¬ãŒãŽãºç
ãã®ã©ã³-ãã¬ãŒçå矀ïŒGBSïŒãæ©æ¬ç²ç¶è
ºçïŒHashimoto's thyroiditisïŒãåè¿æ§æ±è
ºçïŒåè¿æ§æ±è
ºçïŒãç¹çºæ§ããã³/ãŸãã¯æ¥æ§è¡å°æ¿æžå°æ§çŽ«æç
ïŒidiopathic and/or acute thrombocytopenic purpuraïŒãç¹çºæ§èºç·ç¶çãIgAç¥çµé害ãé質æ§èè±çãè¥å¹Žæ§é¢ç¯çãå·åŽç
ãæå¹³èç¬ãã©ã€ã ç
ãã¡ããšãŒã«ç
ãæ··åæ§çµåçµç¹ç
ïŒMCTDïŒãéççç¡åçãç¥çµæ§ç匷çŽãçŒçã¯ããŒãã¹ããªã¯ããŒãã¹çå矀ïŒOMSïŒãèŠç¥çµçããªãŒãç²ç¶è
ºçïŒOrd's thyroiditisïŒãå°åžžæ§å€©ç±ç¡ãæªæ§è²§è¡ãå€çºæ§è»éªšçãå€çºæ§ççããã³ç®èççãåçºæ§èæ±æ§è硬å€ãçµç¯æ§å€çºåèçãå€è
ºæ§çå矀ïŒpolyglandular syndromesïŒããªãŠããæ§å€çºççãåçºæ§ç¡ã¬ã³ãã°ãããªã³è¡çïŒprimary agammaglobulinemiaïŒãã¬ã€ããŒçŸè±¡ïŒRaynaud phenomenonïŒãã©ã€ã¿ãŒçå矀ïŒReiter's syndromeïŒããªãŠããç±ãé¡èè
«çã硬ç®çãã·ã§ãŒã°ã¬ã³çå矀ïŒSjogren's syndromeïŒãå
šèº«ç¡¬çŽçå矀ïŒstiff person syndromeïŒãé«å®åèçïŒTakayasu's arteritisïŒãåŽé åèçïŒãŸããã巚现èæ§åèçããšããŠãç¥ãããïŒã朰çæ§å€§è
žçãã³ã©ãŒã²ã³æ§å€§è
žçãã¶ã©ãèçãè管çãçœæãå€é°éšçïŒãå€é°éšååºçãïŒãããã³ãŠã§ã²ããŒèèœè
«çïŒWegener's granulomatosisïŒãå«ãŸããã
æäžçµè·¯ããã³æè¬
æäžçµè·¯ããã³æè¬
ADCsãæäœããŸãã¯ãããã®æåçµåæ§æçããŸãã¯ããã«èšèŒããããã®ã¯æ§ã
ãªå€åœ¢ã«ãããŠãã€ã·ã§ã³ãïŒäŸã¯ãã¬ã³ãèªå·±å
ç«çŸæ£ãæ£ã£ãŠããããŸãã¯é è¡å¹¹çŽ°è移æ€çæ³ã®å¿
èŠããããããã€ã·ã§ã³ãïŒã«æœãããšãã§ãããäŸãšããŠãããã«èšèŒã®æäœãŸãã¯ãã®æåçµåæ§æçã¯æ°Žæº¶æ¶²ãäŸãã°ã1以äžã®è¬åŠçã«èš±å®¹å¯èœãªè³Šåœ¢å€ãå«ã氎溶液ãªã©ã®ãããªãã®ã®åœ¢æ
ã«ãããŠãã¬ã³ãèªå·±å
ç«çŸæ£ãæ£ã£ãŠããããŸãã¯é è¡å¹¹çŽ°è移æ€çæ³ã®å¿
èŠããããã€ã·ã§ã³ãã«æœãããšãã§ãããããã«èšèŒã®çµæç©ããã³æ¹æ³ãšå
±ã«äœ¿çšããããã®è¬åŠçã«èš±å®¹å¯èœãªè³Šåœ¢å€ã«ã¯ãç²åºŠä¿®é£Ÿæ§è¬å€ãå«ãŸããã氎溶液ã¯åœæè¡ã§æ¢ç¥ã®æè¡ã䜿çšããŠæ»
èãåŸãã
ããã«èšèŒã®ããã«æCD117 ADCãŸãã¯æäœãå«ã補è¬èª¿å€ç©ã¯ããã®ãããªADCãŸãã¯æCD117æäœã1以äžã®éæã®è¬åŠçã«èš±å®¹å¯èœãªæ
äœãšæ··åããããšã«ãã£ãŠïŒRemington's Pharmaceutical SciencesïŒã¬ãã³ãã³ã®è¬ç§åŠïŒ16th edition, OsolïŒãªãœã«ïŒ, A. Ed. (1980)ïŒãåçµä¹Ÿç¥èª¿å€ç©ãŸãã¯æ°Žæº¶æ¶²ã®åœ¢æ
ã«ãããŠèª¿è£œããããè¬åŠçã«èš±å®¹å¯èœãªæ
äœã¯æ¡çšãããæçšéããã³æ¿åºŠã«ãããŠæŠããŠã¬ã·ããšã³ãã«å¯ŸããŠç¡æ¯ã§ãããããã³ããã«ã¯ãå¶éãããªããã以äžãå«ãïŒç·©è¡å€ãäŸãã°ããªã³é
žå¡©ãã¯ãšã³é
žå¡©ãããã³ä»ã®ææ©é
žãªã©ã®ãããªãã®ïŒæé
žåå€ãäŸãã°ãã¢ã¹ã³ã«ãã³é
žããã³ã¡ããªãã³ãªã©ã®ãããªãã®ïŒä¿åæïŒäŸãã°ããªã¯ã¿ãã·ã«ãžã¡ãã«ãã³ãžã«ã¢ã³ã¢ããŠã ã¯ããªãïŒãããµã¡ãããŠã ã¯ããªãïŒãã³ã¶ã«ã³ããŠã ã¯ããªããå¡©åãã³ãŒãããŠã ïŒãã§ããŒã«ãããã«ãŸãã¯ãã³ãžã«ã¢ã«ã³ãŒã«ïŒã¢ã«ãã«ãã©ãã³ãäŸãã°ãã¡ãã«ãŸãã¯ãããã«ãã©ãã³ãªã©ã®ãããªãã®ïŒã«ãã³ãŒã«ïŒã¬ãŸã«ã·ããŒã«ïŒã·ã¯ããããµããŒã«ïŒ3-ãã³ã¿ããŒã«ïŒããã³m-ã¯ã¬ãŸãŒã«ïŒïŒäœååéïŒçŽ10æ®åºæªæºïŒããªãããããã¿ã³ãã¯è³ªãäŸãã°ãè¡æž
ã¢ã«ããã³ããŒã©ãã³ããŸãã¯å
ç«ã°ãããªã³ãªã©ã®ãããªãã®ïŒèŠªæ°Žæ§ããªããŒãäŸãã°ãããªããã«ãããªãã³ãªã©ã®ãããªãã®ïŒã¢ããé
žãäŸãã°ãã°ãªã·ã³ãã°ã«ã¿ãã³ãã¢ã¹ãã©ã®ã³ããã¹ããžã³ãã¢ã«ã®ãã³ããŸãã¯ãªãžã³ãªã©ã®ãããªãã®ïŒåç³é¡ãäºç³é¡ãããã³ä»ã®çæ°Žåç©ã§ã°ã«ã³ãŒã¹ããã³ããŒã¹ããŸãã¯ããã¹ããªã³ãå«ããã®ïŒãã¬ãŒãå€ãäŸãã°ãEDTAãªã©ã®ãããªãã®ïŒç³é¡ãäŸãã°ãã¹ã¯ããŒã¹ããã³ãããŒã«ããã¬ãããŒã¹ãŸãã¯ãœã«ãããŒã«ãªã©ã®ãããªãã®ïŒå¡©åœ¢æ察ã€ãªã³ãäŸãã°ããããªãŠã ãªã©ã®ãããªãã®ïŒéå±è€åäœïŒäŸã¯ãZn-ã¿ã³ãã¯è³ªè€åäœïŒïŒããã³/ãŸãã¯éã€ãªã³æ§çé¢æŽ»æ§å€ãäŸãã°ãããªãšãã¬ã³ã°ãªã³ãŒã«ïŒPEGïŒãªã©ã®ãããªãã®ã§ããã
ããã«èšèŒã®ãæCD117 ADCsãæäœããŸãã¯æåçµåæ§æçã¯æ§ã
ãªçµè·¯äŸãã°ãçµå£ãçµç®ãç®äžãçµéŒ»ãéèå
ãçèå
ãçŒå
ããŸãã¯éçµå£ãªã©ã®ãããªãã®ã«ãã£ãŠæœãããšãã§ããããããªãå Žåã«ãããŠããæãé©ããæäžçµè·¯ã¯æäžãããç¹å®ã®æäœããŸãã¯æåçµåæ§æçããã€ã·ã§ã³ãã補å€æ³ãæäžæ¹æ³ïŒäŸã¯ãæäžæéããã³æäžçµè·¯ïŒããã€ã·ã§ã³ãã®éœ¢ãäœéãæ§å¥ãåŠçœ®ãããçŸæ£ã®éç床ããã€ã·ã§ã³ãã®é£é€ãããã³ãã€ã·ã§ã³ãã®ææ³çã«äŸåããã
ããã«èšèŒã®ãæCD117 ADCãæäœããŸãã¯ãããã®æåçµåæ§æçã®æå¹éã¯äŸãã°ãååïŒäŸã¯ãããŒã©ã¹ïŒæäžãè€æ°åæäžããŸãã¯é£ç¶æäžãããçŽ0.001ããçŽ100 mg/kgãŸã§ã®äœéããŸãã¯æäœããã®æåçµåæ§æçã®è³é©è¡æž
æ¿åºŠïŒäŸã¯ã0.0001-5000ÎŒg/mLã®è¡æž
æ¿åºŠïŒãéæããããã«åã¶ããšãã§ãããæCD117 ADCã®çšéã¯ã¬ã³ãèªå·±å
ç«çŸæ£ãæ£ã£ãŠããããŸãã¯é è¡å¹¹çŽ°è移æ€ãåããããã®æºåãšããŠã³ã³ãã£ã·ã§ãã³ã°çæ³ãåããŠãã察象ïŒäŸã¯ãããïŒã«å¯ŸããŠã1æ¥ã1é±éããŸãã¯1ã¶æã«1å以äžïŒäŸã¯ã2-10åïŒæäžããåŸããé è¡å¹¹çŽ°è移æ€ã«å
ç«ã€ã³ã³ãã£ã·ã§ãã³ã°æé ã®å ŽåãæCD117 ADCãæäœããŸãã¯ãããã®æåçµåæ§æçã¯ãå€å æ§é è¡å¹¹çŽ°èã®ççãæé©ã«ä¿é²ããæéãäŸãšããŠãå€å æ§é è¡å¹¹çŽ°è移æ€ã®æœäžã«å
ç«ã¡ãçŽ1æéããçŽ1é±éãŸã§ïŒäŸã¯ãçŽ1æéãçŽ2æéãçŽ3æéãçŽ4æéãçŽ5æéãçŽ6æéãçŽ7æéãçŽ8æéãçŽ9æéãçŽ10æéãçŽ11æéãçŽ12æéãçŽ13æéãçŽ14æéãçŽ15æéãçŽ16æéãçŽ17æéãçŽ18æéãçŽ19æéãçŽ20æéãçŽ21æéãçŽ22æéãçŽ23æéãçŽ24æéãçŽ2æ¥ãçŽ3æ¥ãçŽ4æ¥ãçŽ5æ¥ãçŽ6æ¥ããŸãã¯çŽ7æ¥ïŒãŸãã¯ããããããå€ãã«ãŠãã€ã·ã§ã³ãã«æœãããããšãã§ããã
ããã«é瀺ãããæ¹æ³ãçšããŠãåœæè¡ã«ãããŠçç·Žã®å»åž«ã¯é è¡å¹¹çŽ°è移æ€çæ³ãå¿
èŠãšãããããã€ã·ã§ã³ãã«ãé è¡å¹¹çŽ°èã«ãã£ãŠçºçŸããæåCD117ãšçµåããæäœãŸãã¯ãããã®æåçµåæ§æçïŒäŸãã°ãGNNK+CD117ãšçµåããæäœãŸãã¯ãã®æåçµåæ§æçïŒãªã©ã®ãããªãã®ãçµåå¯èœãªæCD117 ADCãæäœãŸãã¯ãããã®æåçµåæ§æçãæäžããããšãã§ããããã®ããã«ããŠãå
å æ§é è¡å¹¹çŽ°èã®éå£ã¯ãé è¡å¹¹çŽ°è移æ€çã®ççãä¿é²ããããã«ãå€å æ§é è¡å¹¹çŽ°è移æ€çã®æäžã«å
ç«ã¡æžå°ãããããšãã§ããã
äžè¿°ããããã«ãæäœã¯æ¯çŽ ãäŸãã°ãããã«èšèŒããããŸãã¯åœæè¡ã§æ¢ç¥ã®çŽ°èå·å®³æ§ååãªã©ã®ãããªãã®ã«å
±æçµåçã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ããåŸããäŸãšããŠãæCD117æäœãŸãã¯ãã®æåçµåæ§æçïŒäŸãã°ãæGNNKïŒCD117æäœãŸãã¯ãã®æåçµåæ§æçãªã©ã®ãããªãã®ïŒã¯çŽ°èæ¯çŽ ãäŸãã°ãã·ã¥ãŒãã¢ãã¹å€æ¯çŽ AããããŒã¬ãã³ïŒdeBouganinïŒããžãããªã¢æ¯çŽ ãã¢ãããã·ã³ãäŸãã°ãγ-ã¢ãããã³ãα-ã¢ãããã³ããµããªã³ããã€ã¿ã³ã·ã³ãªã©ã®ãããªãã®ããã€ã¿ã³ã·ãã€ããã¢ãŠãªã¹ã¿ãã³ãã¢ã³ãã©ãµã€ã¯ãªã³ãã«ãªã±ã¢ãã€ã·ã³ãã€ãªããã«ã³ãSN-38ããã¥ãªã«ã«ãã€ã·ã³ãå¿è³æ¯çŽ ãããããã³ãŸãžã¢ãŒãã³ãããããã³ãŸãžã¢ãŒãã³ãã€ããŒãã€ã³ããªããã³ãŸãžã¢ãŒãã³ãã€ã³ããªããã³ãŸãžã¢ãŒãã³ãã€ããŒããŸãã¯ãããã®å€çš®ãªã©ã®ãããªãã®ãšå
±æçµåçã«ã³ã³ãžã¥ã²ãŒã·ã§ã³ãããããšãã§ããããã®ã³ã³ãžã¥ã²ãŒã·ã§ã³ã¯ããã«èšèŒããããŸãã¯åœæè¡ã§æ¢ç¥ã®å
±æçµå圢ææè¡ã䜿çšããŠå®è¡ããããšãã§ãããæäœããã®æåçµåæ§æçããŸãã¯è¬ç©-æäœã³ã³ãžã¥ã²ãŒãã¯ãã®åŸããã€ã·ã§ã³ããžã®å€å æ§é è¡å¹¹çŽ°èïŒäŸãã°ãèªå®¶ãåç³»ããŸãã¯åçš®é è¡å¹¹çŽ°èãªã©ã®ãããªãã®ïŒã®ç§»æ€ã«å
ç«ã¡ãäŸãã°ãéèå
æäžã«ãã£ãŠãã€ã·ã§ã³ãã«æäžããããšãã§ããã
æCD117ïŒäŸã¯ãæGNNK+CD117ïŒæäœããã®æåçµåæ§æçããŸãã¯è¬å€-æäœã³ã³ãžã¥ã²ãŒãã¯ãé è¡å¹¹çŽ°è移æ€çæ³ã«å
ç«ã£ãŠãå
å æ§é è¡å¹¹çŽ°èã®åéããäŸãã°ãçŽ10ïŒ
ãçŽ20ïŒ
ãçŽ30ïŒ
ãçŽ40ïŒ
ãçŽ50ïŒ
ãçŽ60ïŒ
ãçŽ70ïŒ
ãçŽ80ïŒ
ãçŽ90ïŒ
ãçŽ95ïŒ
ããŸãã¯ããããããå€ãæžå°ãããããã«ååãªéã«ãããŠæœãããšãã§ãããé è¡å¹¹çŽ°èèšæ°ã§ã®æžå°ã¯åœæè¡ã§ç¥ãããæ
£ç¿çãªæè¡ãäŸãã°ãã³ã³ãã£ã·ã§ãã³ã°çæ³äžã«æ§ã
ãªééã§ãã€ã·ã§ã³ãããåãåºããè¡æ¶²ãµã³ãã«ã«ãããç¹åŸŽçãªé è¡å¹¹çŽ°èè¡šé¢æåãçºçŸãã现èã®FACSåæã«ãã£ãŠãªã©ã®ãããªãã®ãçšããŠç£èŠããããšãã§ãããäŸãšããŠãåœæè¡ã«ãããŠçç·Žã®å»åž«ã¯ã³ã³ãã£ã·ã§ãã³ã°çæ³äžã®æ§ã
ãªæç¹ã§ãã€ã·ã§ã³ãããè¡æ¶²ãµã³ãã«ãåãåºããããã³é è¡å¹¹çŽ°èããŒã«ãŒæåã«çµåããæäœãçšããŠãµã³ãã«äžã®é è¡å¹¹çŽ°èã®çžå¯Ÿæ¿åºŠã解æããããã«FACSåæãè¡ãããšã«ãã£ãŠãå
å æ§é è¡å¹¹çŽ°èã®æžå°ã®çšåºŠã決å®ããããšãã§ãããããããã®å®æœæ
æ§ã«ããã°ãæCD117ïŒäŸã¯ãæGNNK+CD117ïŒæäœããã®æåçµåæ§æçããŸãã¯è¬å€-æäœã³ã³ãžã¥ã²ãŒããçšããã³ã³ãã£ã·ã§ãã³ã°çæ³ã«å¿çããŠé è¡å¹¹çŽ°èã®æ¿åºŠãæå°å€ã«éãããšããå»åž«ã¯ã³ã³ãã£ã·ã§ãã³ã°çæ³ãçµäºãåŸãããã³é è¡å¹¹çŽ°è移æ€çæ³ã«å¯Ÿãããã€ã·ã§ã³ãã®æºåãéå§ãåŸãã
æCD117ïŒäŸã¯ãæGNNK+CD117ïŒæäœããã®æåçµåæ§æçããŸãã¯è¬ç©-æäœã³ã³ãžã¥ã²ãŒãã¯1以äžã®è¬åŠçã«èš±å®¹ã§ãã賊圢å€ãäŸãã°ãç²åºŠä¿®é£Ÿæ§è¬å€ãªã©ã®ãããªãã®ãå«ã氎溶液ã«ãããŠãã€ã·ã§ã³ãã«æäžããããšãã§ããã氎溶液ã¯ããã«èšèŒãããæè¡ãŸãã¯åœæè¡ã«ãããŠæ¢ç¥ã®æè¡ãçšããŠæ»
èãåŸããæäœããã®æåçµåæ§æçããŸãã¯è¬ç©-æäœã³ã³ãžã¥ã²ãŒãã¯ããã€ã·ã§ã³ããžã®é è¡å¹¹çŽ°è移æ€çã®æäžã«å
ç«ã¡ãäŸãã°ã0.001mg/kgãã100mg/kgãŸã§ã®æè¬éã«ãŠãã€ã·ã§ã³ãã«æäžããããšãã§ãããæäœããã®æåçµåæ§æçããŸãã¯è¬ç©-æäœã³ã³ãžã¥ã²ãŒãã¯ãå€å æ§é è¡å¹¹çŽ°èã®ççãæé©ã«ä¿é²ããæéãäŸãšããŠãå€å æ§é è¡å¹¹çŽ°è移æ€ã®æœäžã«å
ç«ã¡çŽ1æéããçŽ1é±éãŸã§ïŒäŸã¯ãçŽ1æéãçŽ2æéãçŽ3æéãçŽ4æéãçŽ5æéãçŽ6æéãçŽ7æéãçŽ8æéãçŽ9æéãçŽ10æéãçŽ11æéãçŽ12æéãçŽ13æéãçŽ14æéãçŽ15æéãçŽ16æéãçŽ17æéãçŽ18æéãçŽ19æéãçŽ20æéãçŽ21æéãçŽ22æéãçŽ23æéãçŽ24æéãçŽ2æ¥ãçŽ3æ¥ãçŽ4æ¥ãçŽ5æ¥ãçŽ6æ¥ããŸãã¯çŽ7æ¥ïŒãŸãã¯ããããããå€ãã«ãŠãã€ã·ã§ã³ãã«æœãããšãã§ããã
ã³ã³ãã£ã·ã§ãã³ã°çæ³ã®çµäºåŸããã€ã·ã§ã³ãã¯æ¬¡ã«ãäŸãã°ãã³ã³ãã£ã·ã§ãã³ã°çæ³ãè¡ã£ãå»åž«ãšåãå»åž«ããããŸãã¯ç°ãªãå»åž«ãããªã©ã®ãããªãã®ã§ãå€å æ§é è¡å¹¹çŽ°èã®æ³šå
¥ïŒäŸã¯ãéèå
泚å
¥ïŒãåãåŸããå»åž«ã¯äŸãšããŠã1Ã103ãã1Ã109ãŸã§ã®é è¡å¹¹çŽ°è/kgã®æè¬éã«ãŠãèªå·±ãåç³»ããŸãã¯åçš®é è¡å¹¹çŽ°èã®æ³šå
¥ç©ããã€ã·ã§ã³ãã«æäžãåŸããå»åž«ã¯äŸãã°ããã€ã·ã§ã³ãããè¡æ¶²ãµã³ãã«ãæ¡åããããã³é è¡å¹¹çŽ°èãŸãã¯é è¡ç³»çµ±ã®çŽ°èïŒäŸãã°ãå·šæ žçãæ çãè¡å°æ¿ãèµ€è¡çããã¹ã现èã骚é«èœçã奜塩åºçã奜äžçã奜é
žçããã¯ãã°ãªã¢ãé¡ç²çãåçãç ŽéªšçŽ°èãæåæ瀺现èããã¯ããã¡ãŒãžãæš¹ç¶çŽ°èãããã¥ã©ã«ãã©ãŒçŽ°èãTãªã³ãçãããã³Bãªã³ãçãªã©ã®ãããªãã®ïŒã®ç§»æ€ã®æœäžåŸã®æ¿åºŠã«ãããå¢å ãå®ããããšã«ãã£ãŠé è¡å¹¹çŽ°è移æ€ã®ççãç£èŠãåŸãããã®åæã¯äŸãã°ãé è¡å¹¹çŽ°è移æ€çæ³åŸãçŽ1æéããçŽ6ãæéããŸãã¯ãããããé·ãïŒäŸã¯ãçŽ1æéãçŽ2æéãçŽ3æéãçŽ4æéãçŽ5æéãçŽ6æéãçŽ7æéãçŽ8æéãçŽ9æéãçŽ10æéãçŽ11æéãçŽ12æéãçŽ13æéãçŽ14æéãçŽ15æéãçŽ16æéãçŽ17æéãçŽ18æéãçŽ19æéãçŽ20æéãçŽ21æéãçŽ22æéãçŽ23æéãçŽ24æéãçŽ2æ¥éãçŽ3æ¥éãçŽ4æ¥éãçŽ23æ¥éãçŽ4æ¥éãçŽ5æ¥ãçŽ6æ¥ãçŽ7æ¥ãçŽ2é±éãçŽ3é±éãçŽ4é±éãçŽ5é±éãçŽ6é±éãçŽ7é±éãçŽ8é±éãçŽ9é±éãçŽ10é±éãçŽ11é±éãçŽ12é±éãçŽ13é±éãçŽ14é±éãçŽ15é±éãçŽ16é±éãçŽ17é±éãçŽ18é±éãçŽ19é±éãçŽ20é±éãçŽ21é±éãçŽ22é±éãçŽ23é±éãçŽ24é±éããŸãã¯ãããããé·ãïŒè¡ãåŸããé è¡å¹¹çŽ°èãŸãã¯é è¡ç³»çµ±ã®çŽ°èã®æ¿åºŠã移æ€çæ³ã«å
ç«ã¡å¯Ÿå¿ãã现èåã®æ¿åºŠã«å¯Ÿã移æ€çæ³ã®åŸã§äžæãããšããç¥èŠïŒäŸã¯ïŒçŽ1ïŒ
ãçŽ2ïŒ
ãçŽ3ïŒ
ãçŽ4ïŒ
ãçŽ5ïŒ
ãçŽ6ïŒ
ãçŽ7ïŒ
ãçŽ8ïŒ
ãçŽ9ïŒ
ãçŽ10ïŒ
ãçŽ20ïŒ
ãçŽ30ïŒ
ãçŽ40ïŒ
ãçŽ50ïŒ
ãçŽ60ïŒ
ãçŽ70ïŒ
ãçŽ80ïŒ
ãçŽ90ïŒ
ãçŽ100ïŒ
ãçŽ200ïŒ
ãçŽ500ïŒ
ããŸãã¯ããããããå€ãïŒã¯æCD117ïŒäŸã¯ãæGNNK+CD117ïŒæäœããã®æåçµåæ§æçããŸãã¯è¬å€-æäœã³ã³ãžã¥ã²ãŒãã«ããåŠçœ®ã移æ€ãããé è¡å¹¹çŽ°è移æ€çã®ççã奜éŠå°Ÿã«ä¿é²ããããšã瀺ã1ã€ã®ææšãæäŸããã
以äžã®äŸã¯ããã«èšèŒã®çµæç©ããã³æ¹æ³ãã©ã®ããã«äœ¿çšã補é ãããã³è©äŸ¡ããåŸããã®èª¬æãåœæè¡ã«ãããéåžžã®æéã®è
ïŒåœæ¥è
ãšãèšãïŒã«æäŸããããã«æ瀺ãããããã³æ¬é瀺ãçŽç²ã«äŸç€ºããããšãæå³ããããã³æ¬çºæè
ããçºæãšã¿ãªãç¯å²ãå¶éããããšãæå³ããŠããªãã
äŸ1ïŒæCD117æäœ67(Ab67)ã®èå¥
äŸ1ïŒæCD117æäœ67(Ab67)ã®èå¥
äžæ§æCD117æäœ67ïŒå³ã¡ãAb67ïŒã®èå¥ã¯ãWO 2019/084057(PCT/US2018/057172ïŒãã®é瀺ã¯ãã®å
šäœãåç
§ã«ããããã«çµã¿èŸŒãŸããïŒã«èšèŒãããŠããããã«ãé
µæ¯ãã£ã¹ãã¬ã€ã©ã€ãã©ãªãŒããã³ããCD117ã®å€éšãã¡ã€ã³ãžã®çµåã«ã€ããŠã®ã¹ã¯ãªãŒãã³ã°ã«åºã¥ãããäžæ§æäœã¯æšçã«ãŠæŽ»æ§ããªãå©çãæäŸããã移æ€ã«é¢é£ããŠãäžæ§æäœãæ²»çäžããäžå±€å®å
šã§ããåŸãå¯èœæ§ãããããã®çç±ã¯äŸãã°ãã¢ã³ã¿ãŽãã¹ã掻æ§ããããŒã®CD117ä¿æ现èãšã®é£åãä»ããŠççãé
ãããããšã«ãã£ãŠç§»æ€çã«ãã€ãã¹ã®åœ±é¿ãäžããããã§ãããäžæ§æäœïŒãŸãã¯äžæ§ADCïŒã¯ãã®åé¡ãåé¿ããã§ãããã
PCT/US2018/057172ã«èšèŒãããŠããããã«ããã®ãããªäžæ§æäœãèå¥ããããã«ãéšåçã«ã¯ãé
µæ¯ãã£ã¹ãã¬ã€æè¡ãå©çšããããäžæ§æäœãå
·äœçã«èå¥ããããã«ãçµæãCD117å€éšãã¡ã€ã³ãèªç¶ãªãªã¬ã³ã幹现èå åïŒStem Cell FactorïŒïŒSCFïŒãšãã¬è€åäœåããããã³ãã®è€åäœã«ãããŠCD117å€éšãã¡ã€ã³ãçµåå¯èœãªæäœã ããéžã°ããããã®éžå®æ¹æ³ã«åºã¥ããåé¢ãããæäœã¯CD117ãžã®SCFã®çµåã劚ããããããã¯äžæ§ã«åé¡ãããããŸããæäœã¯ãCD117ãçºçŸããŠãã现èãäŸãã°ãé è¡å¹¹çŽ°èïŒHSCïŒãªã©ã®ãããªãã®ã«ãããŠã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ãããããã®èœåã«ã€ããŠãéžãã ããããã¯æäœè¬ç©ã³ã³ãžã¥ã²ãŒãïŒADCïŒãšããŠçšããããæäœãšããŠå¥œãŸãããè€æ°ã®ã©ãŠã³ãã®ã¹ã¯ãªãŒãã³ã°ãéããŠãéžã°ããæCD117æäœãçºçŸãããããã³æãŸããæ§é ããã³/ãŸãã¯æ©èœæŽ»æ§ãæããæCD117æäœãèå¥ããããã«ãåŸãããæäœãããã«ã¹ã¯ãªãŒãã³ã°ããïŒäŸã¯ã现èã€ã³ã¿ãŒããªãŒãŒã·ã§ã³ç¹æ§ãæããäžæ§æäœã«ã€ããŠéžå®ããã¹ã¯ãªãŒãã³ã°ïŒãæäœãã£ã¹ãã¬ã€ã©ã€ãã©ãªãŒã®çæããã³ã¹ã¯ãªãŒãã³ã°ã«ããã䜿çšã«ç¹ã«åãå
¥ãå¯èœãªæ¹æ³ããã³è©Šè¬ã®äŸã¯ãäŸãã°ãBoderïŒããŒããŒïŒ E.T.ããã³WittrupïŒãŠã£ãã«ãïŒ K.D., Yeast surface display for directed evolution of protein expression, affinity, and stabilityïŒã¿ã³ãã¯è³ªçºçŸã芪åæ§ãããã³å®å®æ§ã®æåé²åã«ã€ããŠã®é
µæ¯è¡šé¢ãã£ã¹ãã¬ã€ïŒ, Methods EnzymolïŒã¡ãœãã
ã»ã€ã³ã»ãšã³ã¶ã€ã¢ããžãŒïŒ, 328:430-44 (2000) ããã³Boder E.T.ããã³Wittrup K.D., Yeast surface display for screening combinatorial polypeptide librariesïŒçµåãã®ããªããããã©ã€ãã©ãªãŒãã¹ã¯ãªãŒãã³ã°ããããã®é
µæ¯è¡šé¢ãã£ã¹ãã¬ã€ïŒ, Nat Biotechnol. 15(6):553-7(1997幎6æ)ã«èŠåºãããšãã§ããã
Ab67ã¯ãã®ããã»ã¹ãçšããŠèå¥ããã1ã€ã®äžæ§æäœã§ãããAb67ã®ééããã³è»œéå¯å€é åïŒCDRãã¡ã€ã³ãå«ãïŒã以äžã«èšèŒããã
æäœHC-67/LC-67(Ab67)
æäœHC-67/LC-67(Ab67)
Ab67ã®ééå¯å€é åïŒVHïŒã¢ããé
žé
åã¯ãé
åçªå·2ãšããŠä»¥äžã«æäŸããããAb67ã®VH CDRã¢ããé
žé
åã¯äžã«äžç·ãåŒããããã³æ¬¡ã®ããã§ãããFTFSDADMD (VH CDR1; é
åçªå·3); RTRNKAGSYTTEYAASVKG (VH CDR2; é
åçªå·4); ããã³AREPKYWIDFDL (VH CDR3; é
åçªå·5).
Ab67ã®è»œéå¯å€é åïŒVLïŒã¢ããé
žé
åã¯é
åçªå·6ïŒSEQ ID NO 6ïŒãšããŠä»¥äžã«æäŸããããAb67ã®VL CDRã¢ããé
žé
åã¯äžã«äžç·ãåŒããããã³æ¬¡ã®ããã§ããïŒRASQSISSYLN (VL CDR1ïŒé
åçªå·7)ïŒAASSLQS (VL CDR2ïŒé
åçªå·8)ïŒããã³QQSYIAPYT (VL CDR3ïŒé
åçªå·9)ã
WO 2019/084057ã«èšèŒãããŠããããã«ãæäœæ®æäœçšã®çšåºŠã決å®ããããã«ãããã«èšèŒãããŠããå€æ°ã®èå¥æäœã¯ãããCD34+骚é«çŽ°èãçšããã€ã³ããã幹现èå åïŒSCFïŒäŸåæ§å¢æ®ã¢ãã»ã€ã«ãããŠè©å®ãããæCD117æäœïŒIgG1ïŒã®æ·»å ã«ããSCFã®ååšäžã§ã®çŽ°èã®æ»ã¯ããã®æäœãSCFã®çµåãæ··ä¹±ãããããšã瀺ãããããã£ãŠSCFã¢ã³ã¿ãŽãã¹ããšèãããããæCD117æäœCK6ã¯ããããã¢ã³ã¿ãŽãã¹ã掻æ§ãæããããšãç¥ãããŠãããããããžãã£ãã³ã³ãããŒã«ãšããŠäœ¿çšãïŒU.S. Patent No. 8,552,157åç
§ïŒãããã³ã¢ã€ãœã¿ã€ãéCD117çµåæäœã¯ãã¬ãã£ãã³ã³ãããŒã«ãšããŠäœ¿çšããããã®ã€ã³ããã现èå¢æ®ã¢ãã»ã€ã®ããã«ãããCD34+骚é«çŽ°èã¯SCFããã³æ瀺æäœã®ååšäžã§5æ¥éå¹é€ããã ç现èã«ãŠã³ãã¯ãããŒãµã€ãã¡ããªãŒã«ãã£ãŠãã¹ãŠã®çŽ°èã«ã€ããŠããŸãã¯CD34+CD90+ã²ãŒã现èã«ã€ããŠæ±ºå®ããã
å³1Aããã³1BïŒç现èïŒãªãã³ã«2Aããã³2BïŒCD34+CD90+现èïŒã«èšèŒããçµæã¯ãè©ŠéšããæäœãSCFçµåã®æå¶ãéããŠçŽ°èå¢æ®ãå¶éããããã³åŸã£ãŠã¢ã³ã¿ãŽãã¹ããšã¿ãªããããã©ãããå®èšŒãããå³1Aã1Bã2Aãããã³2Bã«èšèŒãããããã«ãæäœAb54ãAb55ãAb56ãããã³Ab57ã¯ãããããSCFäŸåæ§çŽ°èå¢æ®ã¢ãã»ã€ã«ãããŠç现èããã³CD34+CD90现èã®äž¡æ¹ã殺å·ããããã³SCFäŸåæ§å¢æ®ãé²æ¢ããããšãå¯èœã§ãã£ãã®ã§CD117æ®ææ§ã§ãããäžæ¹ãAb58ãAb61ãAb66ãAb67ãAb68ãããã³Ab69ã¯ãå¹é€äžã®ããCD34+骚é«çŽ°èã®SCFäŸåæ§å¢æ®ãæå¶ããªãäžæ§æäœã§ãããšæ±ºå®ãããã
äŸ2ïŒAb67ã®ãšãããŒã解æ
ååŠçæ¶æ©å®éš
äŸ2ïŒAb67ã®ãšãããŒã解æ
ååŠçæ¶æ©å®éš
æ¶æ©å®éšã¯High-MassïŒãã€ã»ãã¹ïŒMALDI質éåæèšã«ãã£ãŠéå
±æçµåçžäºäœçšã®çŽæ¥åæãå¯èœã«ãããéå
±æçµåæ§çžäºäœçšãå«ãã¿ã³ãã¯è³ªãµã³ãã«ãç¹å¥ã«éçºãããæ¶æ©æ§æ··åç©ãšæ··åããããšã«ãã£ãŠïŒBichïŒããïŒ, CãAnal. Chem.ïŒã¢ããªãã£ã«ã«ã»ã±ãã¹ããªãŒïŒ, 2010, 82 (1), pp 172-179)ãéå
±æçµåæ§è€åäœãé«æ床ã«ããç¹ç°çã«æ€åºããããšãå¯èœã§ãããçæãããå
±æçµåã¯çžäºäœçšçš®ããµã³ãã«èª¿è£œããã»ã¹ããã³MALDIã€ãªã³åã«èããããšã蚱容ãããç¹æ®ãªHigh-Massæ€åºã·ã¹ãã ã¯High-Massç¯å²ã§ã®çžäºäœçšãç¹åŸŽä»ããããããšãå¯èœã«ããã
Ab67ã®ãµã³ãã«ãèžçæ°Žã«ãããŠ2.7 mg/mLã®æ¿åºŠã«ãŸã§åžéããã次ã«ãåžéããAb67ã®1ÎŒLãã¢ã»ããããªã«/æ°ŽïŒ1ïŒ1ãv/vïŒãTFAïŒ0.1ïŒ
ïŒK200 MALDIãããïŒïŒã«ãããŠåçµæ¶åã·ããã³é
žãããªã¯ã¹ïŒ10mg/mLïŒããæ§æããããããªã¯ã¹ã®1ÎŒLãšæ··åããããã®æ··åç©ãCovalXïŒã³ãã«XïŒç€Ÿã®K200 MALDI MSåæããããçšããŠæ¶æ©ã«åŸããããã¿ã³ãã¯è³ªæº¶æ¶²ã¯1ÎŒlã®K200 StabilizerïŒã¹ã¿ãã©ã€ã¶ãŒïŒè©Šè¬ïŒ2mg/mlïŒãšæ··åããããã³å®€æž©ã«ãŠã€ã³ãã¥ããŒããããã€ã³ãã¥ããŒã·ã§ã³æéïŒ180åïŒåŸãMALDIåæçšã®ãµã³ãã«ã調補ããããµã³ãã«ã¯çµæ¶åçŽåŸã«å®€æž©ã«ãŠHigh-Mass MALDI MSã«ãã£ãŠåæããã
MALDI ToF MSåæã¯CovalXã®HM4çžäºäœçšã¢ãžã¥ãŒã«ãçšããŠãæšæºçªçŽ ã¬ãŒã¶ãŒãçšããããã³0ãã1500kDaãŸã§ã®ç°ãªã質éç¯å²ã«çŠç¹ãåãããŠå®è¡ããã
ãããã質éãã£ã³ã¬ãŒããªã³ãå®éš
ãããã質éãã£ã³ã¬ãŒããªã³ãå®éš
CD117ãç¹åŸŽä»ããããã«ãCD117ã®ãµã³ãã«ã¯ãããªãã·ã³ããã¢ããªãã·ã³ãAsp-Nããšã©ã¹ã¿ãŒãŒããã³ãµãŒã¢ãªã·ã³ã®ã¿ã³ãã¯è³ªå解ãåãããã次ãã§LTQ-OrbitrapïŒãªãŒããã©ããïŒè³ªéåæèšïŒThermo ScientificïŒãµãŒã¢ã»ãµã€ãšã³ãã£ãã£ãã¯ç€ŸïŒïŒã«æ²¿ã£ãŠnLC UltimateïŒã¢ã«ãã£ã¡ãŒãïŒ3000-RSLCã·ã¹ãã ãçšããŠnLC-NTQ-Orbitrap MS/MSåæãç¶ããã
10ÎŒLã®CD117ïŒ6.8ÎŒMïŒã¯å®€æž©ã«ãŠã®180åã®ã€ã³ãã¥ããŒã·ã§ã³æéã®åã«1ÎŒLã®DSS d0/d12ïŒ2mg/mL;DMFïŒãšæ··åãããã€ã³ãã¥ããŒã·ã§ã³åŸãåå¿ã¯ã1ÎŒLã®Ammonium BicarbonateïŒéçé
žã¢ã³ã¢ããŠã ïŒïŒæçµæ¿åºŠ20mMïŒãå ããããšã«ãã£ãŠå®€æž©ã«ãŠã®1æéã®ã€ã³ãã¥ããŒã·ã§ã³åã«åæ¢ããã次ãã§ã溶液ã¯ãH2O 8Må°¿çŽ æžæ¿ïŒ10ÎŒLïŒã®åã«speedvacïŒã¹ããŒãããã¯ïŒãçšããŠä¹Ÿç¥ããããæ··ååŸã1ÎŒlã®DTTïŒ500mMïŒã溶液ã«æ·»å ããã次ãã§ãæ··åç©ã37âã§1æéã€ã³ãã¥ããŒããããã€ã³ãã¥ããŒã·ã§ã³åŸã宀枩ã«ãŠãæ宀ã§ã®1æéã®ã€ã³ãã¥ããŒã·ã§ã³æéã®åã«ã1ÎŒlã®ãšãŒãã¢ã»ãã¢ããïŒ1MïŒãæ·»å ãããã€ã³ãã¥ããŒã·ã§ã³åŸã100ÎŒlã®ã¿ã³ãã¯è³ªå解緩è¡å€ãå ãããããªãã·ã³ç·©è¡å€ã¯50mM AmbicïŒã¢ã³ããã¯ïŒpH8.5ã5%ã¢ã»ããããªã«ãå«ã¿ããã¢ããªãã·ã³ç·©è¡å€ã¯TrisïŒããªã¹ïŒHCl 100mMãCaCL2 10mM pH7.8ãå«ã¿ïŒASP-Nç·©è¡å€ã¯ãã¹ãã¡ãŒãïŒPhopshateïŒç·©è¡å€50MM pH7.8ãå«ã¿ïŒãšã©ã¹ã¿ãŒãŒç·©è¡å€ã¯Tris HCl 50mM pH8.0ãå«ã¿ãããã³ãµãŒã¢ãªã·ã³ç·©è¡å€ã¯Tris HCl 50mMãCaCl20.5mM pH9.0ãå«ãã
ããªãã·ã³ã¿ã³ãã¯è³ªå解ïŒéå
/ã¢ã«ãã«åããCD117ã®100ÎŒlãããªãã·ã³ïŒRoche DiagnosticïŒãã·ã¥ã»ãã€ã¢ã°ãã¹ãã£ãã¯ïŒïŒã®1ÎŒlãš1/100ã®å²åã§æ··åããããã®ã¿ã³ãã¯è³ªå解混åç©ã37âã«ãŠå€éãã€ã³ãã¥ããŒã·ã§ã³ããã
ãã¢ããªãã·ã³ã¿ã³ãã¯è³ªå解ïŒéå
/ã¢ã«ãã«åããCD117ã®100ÎŒlããã¢ããªãã·ã³ïŒRoche DiagnosticïŒã®0.5ÎŒlãš1/200ã®å²åã§æ··åãããã¿ã³ãã¯è³ªå解混åç©ã25âã«ãŠå€éãã€ã³ãã¥ããŒã·ã§ã³ããã
ASP-Nã¿ã³ãã¯è³ªå解ïŒ100ÎŒlã®éå
/ã¢ã«ãã«åCD117ã0.5ÎŒlã®ASP-N (Roche Diagnostic)ãš1/200ã®å²åã§æ··åããããã®ã¿ã³ãã¯è³ªå解混åç©ã37âã«ãŠå€éãã€ã³ãã¥ããŒã·ã§ã³ããã
ãšã©ã¹ã¿ãŒãŒã¿ã³ãã¯è³ªå解ïŒ100ÎŒlã®éå
/ã¢ã«ãã«åCD117ã1ÎŒlã®ãšã©ã¹ã¿ãŒãŒïŒRoche DiagnosticïŒãš1/100ã®å²åã§æ··åããããã®ã¿ã³ãã¯è³ªå解混åç©ã37âã«ãŠå€éãã€ã³ãã¥ããŒã·ã§ã³ããã
ãµãŒã¢ãªã·ã³ã¿ã³ãã¯è³ªå解ïŒ100ÎŒlã®éå
/ã¢ã«ãã«åCD117ã2ÎŒlã®ãµãŒã¢ãªã·ã³ïŒRoche DiagnosticïŒãš1/50ã®å²åã§æ··åããããã®ã¿ã³ãã¯è³ªå解混åç©ã70âã«ãŠå€éãã€ã³ãã¥ããŒã·ã§ã³ããã
æ¶ååŸãè»é
ž1%ãã¡ã€ãã«ã溶液ã«æ·»å ãããã¿ã³ãã¯è³ªå解åŸãçæãããããã溶液ã®10ulããã液äœã¯ãããã°ã©ãã£ãŒã·ã¹ãã ïŒUltimate 3000-RSLCïŒã«ããŒããããæ¶æ©ãããããããã¯XquestïŒãšãã¯ã¹ã¯ãšã¹ãïŒversion 2.0ïŒããŒãžã§ã³2.0ïŒããã³StavroxïŒã¹ã¿ããã¯ã¹ïŒ3.6.ãœãããŠã§ã¢ã䜿çšããŠè§£æãããnLC Ultimate 3000-RSLCã·ã¹ãã ããã³LTQ-Orbitrap質éåæèš(Thermo Scientific)ã«æ²¿ã£ãŠnLC-LTQ-Orbitrap MS/MSåæãå®è¡ããã
çµæ
çµæ
High-Mass MALDI質éåæèšããã³ååŠçæ¶æ©ãçšããããšã§ã¯ãAb67æäœã®éå
±æçµååéäœããŸãã¯æåCD117ã®å€éäœã¯æ€åºãããªãã£ããååŠçæ¶æ©ãHigh-Mass MALDI質éåæããã³nLC-Orbitrap質éåæãçšããCD117ããã³Ab67éã®ååçé¢ã決å®ãããããã®è§£æã«åºã¥ããçžäºäœçšã«ã¯ãCD117äžã®ä»¥äžã®ã¢ããé
žãå«ãŸããïŒS236ãH238ãY244ãS273ãT277ãŸãã¯T279(å³3)ã
ä»ã®å®æœæ
æ§
ãã®æ现ã«ãããŠèšåããããã¹ãŠã®åè¡ç©ãç¹èš±ããã³ç¹èš±åºé¡ã¯ãããããåç¬ç«ããåè¡ç©ãŸãã¯ç¹èš±åºé¡ãåç
§ã«ããçµã¿èŸŒãŸããããšãå
·äœçã«ããã³åå¥ã«ç€ºãããå ŽåãšåãçšåºŠã«ãåç
§ã«ããããã«çµã¿èŸŒãŸããã
æ¬é瀺ã¯ãã®ç¹å®ã®å®æœæ
æ§ã«é¢é£ããŠèª¬æããŠããããããã«ã¯ãããªã修食ãå¯èœã§ããããšãç解ãããããã³ãã®åºé¡ã¯æŠããŠãæ¬é瀺ã®ååã«åŸãæ¬é瀺ã®ä»»æã®å€åœ¢ã䜿çšããŸãã¯é©å¿ã察象ãšããããšãæå³ãããããã³æ¬é瀺ãå±ããæè¡å
ã«ãããŠæ¢ç¥ãŸãã¯æ
£è¡ã®ç¯å²ã«å
¥ããããã³äžæã«èšèŒãããæ¬è³ªçç¹é·ã«é©çšããåŸãããã³è«æ±ã®ç¯å²ã®èŠéã«ç¶ãæ¬é瀺ããã®ãããçºå±ãå«ãŸããã
ä»ã®å®æœæ
æ§ã¯è«æ±ã®ç¯å²å
ã«å«ãŸããã
Claims (18)
- é åçªå·1ïŒCD117ïŒã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšãäºã€ã«ãŠããCD117ã«çµåãããåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšãäžã€ã«çµåãããè«æ±é 1ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšãåã€ã«çµåãããè«æ±é 1ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšãäºã€ã«çµåãããè«æ±é 1ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®ããããã«çµåãããè«æ±é 1ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·2ãšçŽ95ïŒ åäžã§ããã¢ããé žé åãæããééå¯å€é åããã³é åçªå·6ãšçŽ95ïŒ åäžã§ããã¢ããé žé åãæãã軜éå¯å€é åãå«ããå è¡ããè«æ±é ã®ããããäžé ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·2ãšçŽ96ïŒ åäžã§ããã¢ããé žé åãæããééå¯å€é åé åçªå·6ãšçŽ96ïŒ åäžã§ããã¢ããé žé åãæãã軜éå¯å€é åãå«ããå è¡ããè«æ±é ã®ããããäžé ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·2ãšçŽ97ïŒ åäžã§ããã¢ããé žé åãæããééå¯å€é åããã³é åçªå·6ãšçŽ97ïŒ åäžã§ããã¢ããé žé åãæãã軜éå¯å€é åãå«ããå è¡ããè«æ±é ã®ããããäžé ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·2ãšçŽ99ïŒ åäžã§ããã¢ããé žé åãæããééå¯å€é åããã³é åçªå·6ãšçŽ99ïŒ åäžã§ããã¢ããé žé åãæãã軜éå¯å€é åãå«ããå è¡ããè«æ±é ã®ããããäžé ã®åé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- é åçªå·ïŒ1ã®å°ãªããšãã¢ããé ž236-244ããã³273-279å ã®æ®åºãæãããšãããŒãã«çµåããCD117ã«çµåããèœåããããåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- é åçªå·1ã®CD117ã®S236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®äºã€ãäžã€ãåã€ãäºã€ããŸãã¯ãã¹ãŠã®ã¢ããé žæ®åºãå«ãCD117ã§ã®ãšãããŒãã«çµåããCD117ã«çµåããèœåããããåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçã
- æCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·2ããã³é åçªå·6ã«èŠå®ããCDRsãŸãã¯å¯å€é åãå«ãŸãªããè«æ±é 1-11ã®ããããäžé ã®æäœã
- æCD117æäœããŸãã¯ãã®æåçµåæ§æçã¯äžæ§æäœããŸãã¯ãã®æåçµåæ§æçã§ãããè«æ±é 1-12ã®ããããäžé ã®æäœã
- CD117ã«çµåãããšããæäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšãäºã€ã«çµåãããåé¢ãããæCD117æäœããŸãã¯ãã®æåçµåæ§æçãå«ãè¬å€çµæç©ã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºT67ãK69ãT71ãS81ãY83ãT114ãT119ããŸãã¯K129ã®å°ãªããšãäžã€ã«çµåãããè«æ±é 14ã®è¬å€çµæç©ã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®å°ãªããšãåã€ã«çµåãããè«æ±é 14ã®è¬å€çµæç©ã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®ã¢ããé žæ®åºT67ãK69ãT71ãS81ãY83ãT114ãT119ããŸãã¯K129ã®å°ãªããšãäºã€ã«çµåãããè«æ±é 14ã®è¬å€çµæç©ã
- æäœããŸãã¯ãã®æåçµåæ§æçã¯é åçªå·1ã«èšèŒãããCD117ã®ä»¥äžã®æ®åºS236ãH238ãY244ãS273ãT277ãŸãã¯T279ã®ããããã«çµåãããè«æ±é 14ã®è¬å€çµæç©ã
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962838255P | 2019-04-24 | 2019-04-24 | |
US62/838,255 | 2019-04-24 | ||
US201962841739P | 2019-05-01 | 2019-05-01 | |
US62/841,739 | 2019-05-01 | ||
PCT/US2020/029618 WO2020219748A2 (en) | 2019-04-24 | 2020-04-23 | Anti-cd117 antibodies and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022529727A JP2022529727A (ja) | 2022-06-23 |
JPWO2020219748A5 true JPWO2020219748A5 (ja) | 2022-09-20 |
Family
ID=72941301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021562914A Withdrawn JP2022529727A (ja) | 2019-04-24 | 2020-04-23 | ïœïœïœïŒïœïœïŒïŒïŒ ãšãã®äœ¿çš |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220177578A1 (ja) |
EP (1) | EP3959243A4 (ja) |
JP (1) | JP2022529727A (ja) |
WO (1) | WO2020219748A2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022187050A1 (en) * | 2021-03-01 | 2022-09-09 | BioLegend, Inc. | Anti-cd117 agents and compositions and methods for making and using the same |
CA3240527A1 (en) * | 2021-12-16 | 2023-06-22 | Universitat Basel | Discernible cell surface protein variants of cd117 for use in cell therapy |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
MA38396B1 (fr) * | 2013-03-15 | 2019-05-31 | Novartis Ag | Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit |
WO2015050959A1 (en) * | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
EP3065773A1 (en) * | 2013-11-05 | 2016-09-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human neutralizing anti-kit antibodies and uses thereof |
KR20230066647A (ko) * | 2016-06-17 | 2023-05-16 | ë§ì í í ëŒíší±ì€ ìžìœí¬ë ìŽí°ë | Cd117+ ìží¬ì ê³ ê°ì ìí ì¡°ì±ë¬Œ ë° ë°©ë² |
WO2019084067A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODIES AND METHODS OF USE |
EP3700540A4 (en) * | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS OF DEPRODUCTION FROM CD117 + CELLS |
WO2019234694A2 (en) * | 2018-06-07 | 2019-12-12 | Magenta Therapeutics, Inc. | Therapeutic methods using antibody drug conjugates (adcs) |
-
2020
- 2020-04-23 WO PCT/US2020/029618 patent/WO2020219748A2/en unknown
- 2020-04-23 JP JP2021562914A patent/JP2022529727A/ja not_active Withdrawn
- 2020-04-23 EP EP20794877.9A patent/EP3959243A4/en not_active Withdrawn
-
2021
- 2021-10-22 US US17/508,766 patent/US20220177578A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11958908B2 (en) | Compositions and methods for the depletion of CD117+ cells | |
US11572411B2 (en) | Anti-CD117 antibodies and conjugates | |
JP2021500375A5 (ja) | ||
US20210371524A1 (en) | Anti-cd45 antibodies and conjugates thereof | |
US20210369854A1 (en) | Compositions and methods for the depletion of cd5+ cells | |
US20220267441A1 (en) | Anti-cd45 antibodies and conjugates thereof | |
US20220177578A1 (en) | Anti-cd117 antibodies and uses thereof | |
US20220177575A1 (en) | Anti-cd117 antibodies and uses thereof | |
JPWO2020092654A5 (ja) | ||
US20230390412A1 (en) | Compositions and methods for allogeneic transplantation | |
JPWO2020219748A5 (ja) | ||
JPWO2020219770A5 (ja) | ||
JPWO2021087368A5 (ja) |